diff --git "a/data/ct_llm/ct_l1_dataset.jsonl" "b/data/ct_llm/ct_l1_dataset.jsonl"
new file mode 100644--- /dev/null
+++ "b/data/ct_llm/ct_l1_dataset.jsonl"
@@ -0,0 +1,1500 @@
+{"question_id": "CTL1-0000", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: graft versus host disease prophylaxis/therapy\nCondition: Stage III Adult Diffuse Small Cleaved Cell Lymphoma\nPhase: phase_2\nEnrollment: 20\nTermination reason: \"Study was closed to accrual for safety related to the frequency of BK infections.\"\nDetail: Study was closed to accrual for safety related to the frequency of BK infections.", "metadata": {"result_id": 59754, "source_trial_id": "NCT01044745", "intervention_name": "graft versus host disease prophylaxis/therapy", "condition_name": "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0001", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Irinotecan Liposome Injection\nCondition: Gallbladder Carcinoma\nPhase: phase_2\nEnrollment: 17\nTermination reason: \"Internal strategy change. Not related to safety concerns.\"\nDetail: Internal strategy change. Not related to safety concerns.", "metadata": {"result_id": 5141, "source_trial_id": "NCT05009953", "intervention_name": "Irinotecan Liposome Injection", "condition_name": "Gallbladder Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0002", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Caffeine citrate\nCondition: Respiratory Failure\nEnrollment: 87\nTermination reason: \"Safety\"\nDetail: Safety", "metadata": {"result_id": 38232, "source_trial_id": "NCT01751724", "intervention_name": "Caffeine citrate", "condition_name": "Respiratory Failure", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0003", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Posoleucel (ALVR105)\nDrug type: cell_therapy\nCondition: Cytomegalovirus Infections\nPhase: phase_2_3\nBlinding: QUADRUPLE\nEnrollment: 451\np-value: 0.5603\nEffect size (Mean Difference (Final Values)): 0.01\n95% CI: [-0.09, 0.1]\nInterpretation: safety_stopped", "metadata": {"result_id": 27018, "source_trial_id": "NCT05305040", "intervention_name": "Posoleucel (ALVR105)", "condition_name": "Cytomegalovirus Infections", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0004", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)\nCondition: Recurrent GBM\nPhase: phase_1_2\nEnrollment: 8\nTermination reason: \"Study is terminated due to funding challenges and not due to safety concerns.\"\nDetail: Study is terminated due to funding challenges and not due to safety concerns.", "metadata": {"result_id": 16118, "source_trial_id": "NCT05370508", "intervention_name": "SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)", "condition_name": "Recurrent GBM", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0005", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: PTK787/ZK 222584\nCondition: Multiple Myeloma\nPhase: phase_2\nEnrollment: 21\nTermination reason: \"investigator letter from drug manufacturer stating animal studies showed increased risk of cancer which was an unknown adverse event\"\nDetail: investigator letter from drug manufacturer stating animal studies showed increased risk of cancer which was an unknown adverse event", "metadata": {"result_id": 44421, "source_trial_id": "NCT00240162", "intervention_name": "PTK787/ZK 222584", "condition_name": "Multiple Myeloma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0006", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Botulinum Toxin A, bladder detrusor muscle injection\nCondition: Urinary Incontinence\nPhase: phase_3\nEnrollment: 87\nTermination reason: \"higher than anticipated rate of increased post-void residual in subjects who received botulinum toxin A injection\"\nDetail: higher than anticipated rate of increased post-void residual in subjects who received botulinum toxin A injection", "metadata": {"result_id": 52402, "source_trial_id": "NCT00373789", "intervention_name": "Botulinum Toxin A, bladder detrusor muscle injection", "condition_name": "Urinary Incontinence", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0007", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: LY3499446\nCondition: Non-Small Cell Lung Cancer\nPhase: phase_1_2\nEnrollment: 5\nTermination reason: \"The study was terminated due to an unexpected toxicity finding.\"\nDetail: The study was terminated due to an unexpected toxicity finding.", "metadata": {"result_id": 3158, "source_trial_id": "NCT04165031", "intervention_name": "LY3499446", "condition_name": "Non-Small Cell Lung Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0008", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: TAK-994\nCondition: Narcolepsy Type 2 (NT2)\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 97\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (LS Mean Difference): 26.4\n95% CI: [20.07, 32.73]\nInterpretation: safety_stopped", "metadata": {"result_id": 52695, "source_trial_id": "NCT04096560", "intervention_name": "TAK-994", "condition_name": "Narcolepsy Type 2 (NT2)", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0009", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: AlphaMedix\nDrug type: unknown\nCondition: Neuroendocrine Tumor\nPhase: phase_1\nEnrollment: 33\nTermination reason: \"Terminated for non-safety reasons.\"\nDetail: Terminated for non-safety reasons.", "metadata": {"result_id": 55534, "source_trial_id": "NCT03466216", "intervention_name": "AlphaMedix", "condition_name": "Neuroendocrine Tumor", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0010", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Yasmin\nCondition: HIV Infections\nPhase: phase_1\nEnrollment: 13\nTermination reason: \"In a Phase II study in HIV-infected patients there were a number of seizures, although exact causality could not be assessed phase 1 activity was terminated.\"\nDetail: In a Phase II study in HIV-infected patients there were a number of seizures, although exact causality could not be assessed phase 1 activity was terminated.", "metadata": {"result_id": 47064, "source_trial_id": "NCT01195974", "intervention_name": "Yasmin", "condition_name": "HIV Infections", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "fewshot"}
+{"question_id": "CTL1-0011", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Cemdisiran\nDrug type: oligonucleotide\nCondition: Berger Disease\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 31\nPrimary endpoint met: 1.0\np-value: 0.0021\nEffect size (Placebo-adjusted GM Percent Change): -45.771\n95% CI: [-60.093, -26.309]\nInterpretation: safety_stopped", "metadata": {"result_id": 22232, "source_trial_id": "NCT03841448", "intervention_name": "Cemdisiran", "condition_name": "Berger Disease", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0012", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Duragesic 25 mcg/h + Clinical Procedure 1\nCondition: Healthy\nPhase: phase_1\nEnrollment: 12\nTermination reason: \"due to multiple subjects reporting pain and burning at the phlebotomy sites after 38hr\"\nDetail: due to multiple subjects reporting pain and burning at the phlebotomy sites after 38hr", "metadata": {"result_id": 47345, "source_trial_id": "NCT00648414", "intervention_name": "Duragesic 25 mcg/h + Clinical Procedure 1", "condition_name": "Healthy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0013", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Brolucizumab 6 mg\nDrug type: monoclonal_antibody\nCondition: Central Retinal Vein Occlusion\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 493\np-value: 0.173\nEffect size (Least Square Mean Difference): -2.9\n95% CI: [-5.2, -0.5]\nSerious adverse events: 256.0\nInterpretation: safety_stopped", "metadata": {"result_id": 19652, "source_trial_id": "NCT03810313", "intervention_name": "Brolucizumab 6 mg", "condition_name": "Central Retinal Vein Occlusion", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0014", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: AR08\nCondition: Vasomotor Symptoms (VMS)\nPhase: phase_2\nEnrollment: 32\nTermination reason: \"Study stopping criteria met with regards to vital sign measurements post dose.\"\nDetail: Study stopping criteria met with regards to vital sign measurements post dose.", "metadata": {"result_id": 5207, "source_trial_id": "NCT02049164", "intervention_name": "AR08", "condition_name": "Vasomotor Symptoms (VMS)", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0015", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Bevacizumab-IRDye800CW\nCondition: Esophageal Cancer\nPhase: phase_1\nEnrollment: 25\nTermination reason: \"Dose-escalation was finished, but no clear correlation between fluorescence and tumor grade was established\"\nDetail: Dose-escalation was finished, but no clear correlation between fluorescence and tumor grade was established", "metadata": {"result_id": 37038, "source_trial_id": "NCT03558724", "intervention_name": "Bevacizumab-IRDye800CW", "condition_name": "Esophageal Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0016", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Posoleucel\nDrug type: cell_therapy\nCondition: Adenovirus Infection\nPhase: phase_3\nEnrollment: 57\nTermination reason: \"Study discontinued as DSMB determined it was futile. No safety concerns were noted.\"\nDetail: Study discontinued as DSMB determined it was futile. No safety concerns were noted.", "metadata": {"result_id": 36407, "source_trial_id": "NCT05179057", "intervention_name": "Posoleucel", "condition_name": "Adenovirus Infection", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0017", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Factor VIII concentrates\nDrug type: unknown\nCondition: Hemophilia A With Inhibitors\nEnrollment: 134\nTermination reason: \"The DSMB recommended stopping the study due to safety concerns.\"\nDetail: The DSMB recommended stopping the study due to safety concerns.", "metadata": {"result_id": 14441, "source_trial_id": "NCT00212472", "intervention_name": "Factor VIII concentrates", "condition_name": "Hemophilia A With Inhibitors", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0018", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Dovitinib lactate\nCondition: Non-small Cell Lung Cancer (NSCLC), Stage IV\nPhase: phase_1\nEnrollment: 9\nTermination reason: \"Patient safety - Unacceptable toxicity\"\nDetail: Patient safety - Unacceptable toxicity", "metadata": {"result_id": 49497, "source_trial_id": "NCT01515969", "intervention_name": "Dovitinib lactate", "condition_name": "Non-small Cell Lung Cancer (NSCLC), Stage IV", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0019", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: milatuzumab\nDrug type: monoclonal_antibody\nCondition: Myelodysplastic Syndrome\nPhase: phase_1\nEnrollment: 12\nTermination reason: \"PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD no further patients would be enrolled\"\nDetail: PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD no further patients would be enrolled", "metadata": {"result_id": 50348, "source_trial_id": "NCT01663766", "intervention_name": "milatuzumab", "condition_name": "Myelodysplastic Syndrome", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0020", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Aflibercept 2 mg\nDrug type: peptide\nCondition: Central Retinal Vein Occlusion\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 493\np-value: 0.173\nEffect size (Least Square Mean Difference): -2.9\n95% CI: [-5.2, -0.5]\nSerious adverse events: 256.0\nInterpretation: safety_stopped", "metadata": {"result_id": 19653, "source_trial_id": "NCT03810313", "intervention_name": "Aflibercept 2 mg", "condition_name": "Central Retinal Vein Occlusion", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0021", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Belatacept\nDrug type: peptide\nCondition: Renal Transplantation\nPhase: phase_2\nEnrollment: 19\nTermination reason: \"Secondary to safety concerns plus change in Campath® (alemtuzumab) availability.\"\nDetail: Secondary to safety concerns plus change in Campath® (alemtuzumab) availability.", "metadata": {"result_id": 2460, "source_trial_id": "NCT01436305", "intervention_name": "Belatacept", "condition_name": "Renal Transplantation", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0022", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: CG1940/CG8711\nCondition: Prostate Cancer\nPhase: phase_2\nEnrollment: 6\nTermination reason: \"Safety reasons, though no safety issues arose.\"\nDetail: Safety reasons, though no safety issues arose.", "metadata": {"result_id": 6906, "source_trial_id": "NCT00577356", "intervention_name": "CG1940/CG8711", "condition_name": "Prostate Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0023", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: L-citrulline\nCondition: Acute Vaso Occlusive Crisis (VOC)\nPhase: phase_1_2\nEnrollment: 30\nTermination reason: \"Impacted by viraemia resulting in higher than expected admissions\"\nDetail: Impacted by viraemia resulting in higher than expected admissions", "metadata": {"result_id": 9846, "source_trial_id": "NCT04852172", "intervention_name": "L-citrulline", "condition_name": "Acute Vaso Occlusive Crisis (VOC)", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0024", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: KVD824\nCondition: Angioedema, Hereditary, Types I and II\nPhase: phase_2\nEnrollment: 33\nTermination reason: \"Terminated by Sponsor due to adverse events reported\"\nDetail: Terminated by Sponsor due to adverse events reported", "metadata": {"result_id": 58643, "source_trial_id": "NCT05055258", "intervention_name": "KVD824", "condition_name": "Angioedema, Hereditary, Types I and II", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0025", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Tasisulam-sodium\nCondition: Melanoma\nPhase: phase_3\nBlinding: NONE\nEnrollment: 336\nPrimary endpoint met: 1.0\np-value: 0.048\nEffect size (Hazard Ratio (HR)): 1.3\nSerious adverse events: 285.0\nInterpretation: safety_stopped", "metadata": {"result_id": 2961, "source_trial_id": "NCT01006252", "intervention_name": "Tasisulam-sodium", "condition_name": "Melanoma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0026", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: RESP301\nCondition: Bronchiectasis\nPhase: phase_2\nEnrollment: 88\nTermination reason: \"Study stopping criteria were met. A safety event has occurred which was classified as an SAE and was related to the study intervention.\"\nDetail: Study stopping criteria were met. A safety event has occurred which was classified as an SAE and was related to the study intervention.", "metadata": {"result_id": 49196, "source_trial_id": "NCT04858451", "intervention_name": "RESP301", "condition_name": "Bronchiectasis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0027", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: SOBI002\nDrug type: unknown\nCondition: Healthy\nPhase: phase_1\nEnrollment: 24\nTermination reason: \"Transient adverse events observed\"\nDetail: Transient adverse events observed", "metadata": {"result_id": 7632, "source_trial_id": "NCT02083666", "intervention_name": "SOBI002", "condition_name": "Healthy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0028", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: HL 10\nCondition: Acute Respiratory Distress Syndrome\nPhase: phase_3\nEnrollment: 418\nTermination reason: \"A 300 patient safety analysis by the Data Monitoring Committee showed a trend towards higher mortality in the treatment group.\"\nDetail: A 300 patient safety analysis by the Data Monitoring Committee showed a trend towards higher mortality in the treatment group.", "metadata": {"result_id": 44798, "source_trial_id": "NCT00742482", "intervention_name": "HL 10", "condition_name": "Acute Respiratory Distress Syndrome", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0029", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Hematopoietic stem cell transplantation\nCondition: Scleroderma\nPhase: phase_1\nEnrollment: 8\nTermination reason: \"No subject enrolled since 2009\"\nDetail: No subject enrolled since 2009", "metadata": {"result_id": 14173, "source_trial_id": "NCT00282425", "intervention_name": "Hematopoietic stem cell transplantation", "condition_name": "Scleroderma", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0030", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: mycophenolate mofetil\nCondition: Kidney Transplantation\nPhase: phase_2\nBlinding: NONE\nEnrollment: 71\np-value: 0.531\nEffect size (Mean Difference (Final Values)): 4.82\n95% CI: [-10.481, 20.121]\nSerious adverse events: 134.0\nInterpretation: safety_stopped", "metadata": {"result_id": 12027, "source_trial_id": "NCT01856257", "intervention_name": "mycophenolate mofetil", "condition_name": "Kidney Transplantation", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0031", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: clevudine\nCondition: Chronic Hepatitis\nPhase: phase_3\nTermination reason: \"The study was terminated in the interest of patient safety.\"\nDetail: The study was terminated in the interest of patient safety.", "metadata": {"result_id": 16494, "source_trial_id": "NCT00496002", "intervention_name": "clevudine", "condition_name": "Chronic Hepatitis", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "fewshot"}
+{"question_id": "CTL1-0032", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Trilaciclib\nCondition: Breast Cancer\nPhase: phase_2\nBlinding: NONE\nEnrollment: 102\nPrimary endpoint met: 1.0\np-value: 0.0004\nEffect size (Adjusted hazard ratio (HR)): 0.4\n95% CI: [0.22, 0.74]\nSerious adverse events: 128.0\nInterpretation: safety_stopped", "metadata": {"result_id": 56335, "source_trial_id": "NCT02978716", "intervention_name": "Trilaciclib", "condition_name": "Breast Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0033", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Chimeric monoclonal antibody cG250\nCondition: Renal Cell Carcinoma (RCC)\nPhase: phase_1\nBlinding: NONE\nEnrollment: 8\np-value: 0.172\nSerious adverse events: 7.0\nInterpretation: safety_stopped", "metadata": {"result_id": 4122, "source_trial_id": "NCT00520533", "intervention_name": "Chimeric monoclonal antibody cG250", "condition_name": "Renal Cell Carcinoma (RCC)", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0034", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Chemotherapy\nDrug type: unknown\nCondition: Leukemia\nPhase: phase_1\nEnrollment: 30\nTermination reason: \"Withdrawn due to toxicity problems\"\nDetail: Withdrawn due to toxicity problems", "metadata": {"result_id": 61031, "source_trial_id": "NCT00124644", "intervention_name": "Chemotherapy", "condition_name": "Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0035", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: busulfan\nCondition: Stage IV Adult Lymphoblastic Lymphoma\nPhase: phase_2\nEnrollment: 20\nTermination reason: \"Study was closed to accrual for safety related to the frequency of BK infections.\"\nDetail: Study was closed to accrual for safety related to the frequency of BK infections.", "metadata": {"result_id": 59960, "source_trial_id": "NCT01044745", "intervention_name": "busulfan", "condition_name": "Stage IV Adult Lymphoblastic Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0036", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: ORG 24448\nCondition: Depression\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 9\np-value: 0.919\nEffect size (Mean Difference (Final Values)): 2.22\n95% CI: [-46.565, 51.006]\nSerious adverse events: 2.0\nInterpretation: safety_stopped", "metadata": {"result_id": 23846, "source_trial_id": "NCT00113022", "intervention_name": "ORG 24448", "condition_name": "Depression", "confidence_tier": "silver", "therapeutic_area": "psychiatry"}, "split": "fewshot"}
+{"question_id": "CTL1-0037", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: NBO (Normobaric Oxygen)\nCondition: Ischemic Stroke\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 85\np-value: 0.68\nSerious adverse events: 108.0\nInterpretation: safety_stopped", "metadata": {"result_id": 34309, "source_trial_id": "NCT00414726", "intervention_name": "NBO (Normobaric Oxygen)", "condition_name": "Ischemic Stroke", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "fewshot"}
+{"question_id": "CTL1-0038", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Tacrolimus with rapid steroid withdrawal\nCondition: Diabetes Mellitus, Adult-Onset\nPhase: phase_4\nBlinding: NONE\nEnrollment: 134\nPrimary endpoint met: 1.0\np-value: 0.02\nSerious adverse events: 51.0\nInterpretation: safety_stopped", "metadata": {"result_id": 7170, "source_trial_id": "NCT01002339", "intervention_name": "Tacrolimus with rapid steroid withdrawal", "condition_name": "Diabetes Mellitus, Adult-Onset", "confidence_tier": "silver", "therapeutic_area": "metabolic"}, "split": "fewshot"}
+{"question_id": "CTL1-0039", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: St. John's wort\nDrug type: unknown\nCondition: Breast Cancer\nPhase: phase_2\nBlinding: NONE\nEnrollment: 9\np-value: 0.1042\nEffect size (Mean Difference (Final Values)): 4.35\n95% CI: [-1.12, 9.822]\nInterpretation: safety_stopped", "metadata": {"result_id": 45443, "source_trial_id": "NCT00110136", "intervention_name": "St. John's wort", "condition_name": "Breast Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0040", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Cellulose Sulfate Vaginal Gel (Microbicide)\nCondition: HIV Infections\nPhase: phase_3\nEnrollment: 2160\nTermination reason: \"The study was halted in January 2007 due to safety concerns.\"\nDetail: The study was halted in January 2007 due to safety concerns.", "metadata": {"result_id": 45475, "source_trial_id": "NCT00120770", "intervention_name": "Cellulose Sulfate Vaginal Gel (Microbicide)", "condition_name": "HIV Infections", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "fewshot"}
+{"question_id": "CTL1-0041", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Sitaxsentan and Sildenafil\nCondition: Pulmonary Arterial Hypertension\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 131\nPrimary endpoint met: 1.0\np-value: 0.0049\nSerious adverse events: 91.0\nInterpretation: safety_stopped", "metadata": {"result_id": 3647, "source_trial_id": "NCT00796666", "intervention_name": "Sitaxsentan and Sildenafil", "condition_name": "Pulmonary Arterial Hypertension", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "fewshot"}
+{"question_id": "CTL1-0042", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: ApoTamox 10mg\nCondition: X Linked Myotubular Myopathy\nPhase: phase_1_2\nEnrollment: 6\nTermination reason: \"Study terminated due to safety concerns.\"\nDetail: Study terminated due to safety concerns.", "metadata": {"result_id": 4657, "source_trial_id": "NCT04915846", "intervention_name": "ApoTamox 10mg", "condition_name": "X Linked Myotubular Myopathy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0043", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Vorapaxar\nCondition: Myocardial Infarction\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 12944\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Cox Proportional Hazard): 1.36\n95% CI: [1.18, 1.57]\nSerious adverse events: 10012.0\nInterpretation: safety_stopped", "metadata": {"result_id": 45347, "source_trial_id": "NCT00527943", "intervention_name": "Vorapaxar", "condition_name": "Myocardial Infarction", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "fewshot"}
+{"question_id": "CTL1-0044", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: imatinib (Gleevec/ Glivec)\nCondition: Chronic Myeloid Leukemia\nPhase: phase_3\nBlinding: NONE\nEnrollment: 307\nPrimary endpoint met: 1.0\np-value: 0.001\nSerious adverse events: 158.0\nInterpretation: safety_stopped", "metadata": {"result_id": 19748, "source_trial_id": "NCT01650805", "intervention_name": "imatinib (Gleevec/ Glivec)", "condition_name": "Chronic Myeloid Leukemia", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0045", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Anti-Thymocyte Globulin (Rabbit)\nDrug type: other_biologic\nCondition: Primary Renal Allograft Candidate\nPhase: phase_2\nBlinding: NONE\nEnrollment: 71\np-value: 0.531\nEffect size (Mean Difference (Final Values)): 4.82\n95% CI: [-10.481, 20.121]\nSerious adverse events: 134.0\nInterpretation: safety_stopped", "metadata": {"result_id": 12036, "source_trial_id": "NCT01856257", "intervention_name": "Anti-Thymocyte Globulin (Rabbit)", "condition_name": "Primary Renal Allograft Candidate", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0046", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: DYN101\nCondition: Centronuclear Myopathy\nPhase: phase_1_2\nEnrollment: 14\nTermination reason: \"Based on tolerability findings at the low dose level thus far, continuation of dosing or even dose escalation is not possible.\"\nDetail: Based on tolerability findings at the low dose level thus far, continuation of dosing or even dose escalation is not possible.", "metadata": {"result_id": 49743, "source_trial_id": "NCT04033159", "intervention_name": "DYN101", "condition_name": "Centronuclear Myopathy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0047", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Buparlisib\nCondition: Non-Small Cell Lunch Cancer\nPhase: phase_1\nEnrollment: 6\nTermination reason: \"Due to DLTs/AEs safety profile considered challenging.\"\nDetail: Due to DLTs/AEs safety profile considered challenging.", "metadata": {"result_id": 14306, "source_trial_id": "NCT01820325", "intervention_name": "Buparlisib", "condition_name": "Non-Small Cell Lunch Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0048", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Eteplirsen\nDrug type: oligonucleotide\nCondition: Duchenne Muscular Dystrophy\nPhase: phase_2\nEnrollment: 15\nTermination reason: \"Participants were either transitioned to a post-trial access program or another Sarepta study, or they declined further treatment. There are no safety concerns with Eteplirsen.\"\nDetail: Participants were either transitioned to a post-trial access program or another Sarepta study, or they declined further treatment. There are no safety concerns with Eteplirsen.", "metadata": {"result_id": 13510, "source_trial_id": "NCT03985878", "intervention_name": "Eteplirsen", "condition_name": "Duchenne Muscular Dystrophy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0049", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Phenprocoumon\nCondition: Thrombosis\nPhase: phase_2\nEnrollment: 16\nTermination reason: \"safety reasons\"\nDetail: safety reasons", "metadata": {"result_id": 18344, "source_trial_id": "NCT02872649", "intervention_name": "Phenprocoumon", "condition_name": "Thrombosis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0050", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: 177Lu-3BP-227 (also called 177Lu-IPN01087)\nCondition: Colorectal Cancer\nPhase: phase_1\nEnrollment: 14\nTermination reason: \"Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns\"\nDetail: Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns", "metadata": {"result_id": 4964, "source_trial_id": "NCT03525392", "intervention_name": "177Lu-3BP-227 (also called 177Lu-IPN01087)", "condition_name": "Colorectal Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0051", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: VLX1570 and dexamethasone\nCondition: Multiple Myeloma\nPhase: phase_1_2\nEnrollment: 15\nTermination reason: \"Dose limiting tox is observed. Study put on full clinical hold.\"\nDetail: Dose limiting tox is observed. Study put on full clinical hold.", "metadata": {"result_id": 20743, "source_trial_id": "NCT02372240", "intervention_name": "VLX1570 and dexamethasone", "condition_name": "Multiple Myeloma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0052", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Mycophenolate mofetil (MMF/MPA)\nCondition: Delayed Graft Function\nPhase: phase_2_3\nEnrollment: 25\nTermination reason: \"Interim results suggested a concern for patient outcomes and safety\"\nDetail: Interim results suggested a concern for patient outcomes and safety", "metadata": {"result_id": 2129, "source_trial_id": "NCT01878786", "intervention_name": "Mycophenolate mofetil (MMF/MPA)", "condition_name": "Delayed Graft Function", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0053", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Belviq\nCondition: Overweight and Obesity\nPhase: phase_4\nBlinding: DOUBLE\nEnrollment: 32\nPrimary endpoint met: 1.0\np-value: 0.0001\nInterpretation: safety_stopped", "metadata": {"result_id": 34193, "source_trial_id": "NCT03353220", "intervention_name": "Belviq", "condition_name": "Overweight and Obesity", "confidence_tier": "silver", "therapeutic_area": "metabolic"}, "split": "fewshot"}
+{"question_id": "CTL1-0054", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Topical ABI-1968 cream\nCondition: HSIL, High-Grade Squamous Intraepithelial Lesions\nPhase: phase_1\nEnrollment: 6\nTermination reason: \"Pre-Clinical Toxicology Findings\"\nDetail: Pre-Clinical Toxicology Findings", "metadata": {"result_id": 35882, "source_trial_id": "NCT03677960", "intervention_name": "Topical ABI-1968 cream", "condition_name": "HSIL, High-Grade Squamous Intraepithelial Lesions", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0055", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: BBV87 Chikungunya vaccine\nCondition: Chikungunya\nPhase: phase_2_3\nEnrollment: 3210\nTermination reason: \"The founder has decided to discontinue the study for Part C. This decision is not related to any safety concerns, adverse event findings or manufacturing process changes. There were multiple delays in initiating part C\"\nDetail: The founder has decided to discontinue the study for Part C. This decision is not related to any safety concerns, adverse event findings or manufacturing process changes. There were multiple delays in initiating part C", "metadata": {"result_id": 18335, "source_trial_id": "NCT04566484", "intervention_name": "BBV87 Chikungunya vaccine", "condition_name": "Chikungunya", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0056", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: colestipol\nDrug type: unknown\nCondition: Healthy Volunteers\nPhase: phase_1\nEnrollment: 14\nTermination reason: \"PK time points were not being met as expected. Determination that risks outweighed benefit.\"\nDetail: PK time points were not being met as expected. Determination that risks outweighed benefit.", "metadata": {"result_id": 46723, "source_trial_id": "NCT02263547", "intervention_name": "colestipol", "condition_name": "Healthy Volunteers", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0057", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Enzalutamide\nCondition: Prostate Neoplasms\nPhase: phase_2\nEnrollment: 4\nTermination reason: \"Study was closed for toxicity.\"\nDetail: Study was closed for toxicity.", "metadata": {"result_id": 34293, "source_trial_id": "NCT03531827", "intervention_name": "Enzalutamide", "condition_name": "Prostate Neoplasms", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0058", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Conventional glycaemic control\nCondition: External Causes of Morbidity and Mortality\nEnrollment: 200\nTermination reason: \"Hypoglycaemia is significantly higher in TGC\"\nDetail: Hypoglycaemia is significantly higher in TGC", "metadata": {"result_id": 63244, "source_trial_id": "NCT01225159", "intervention_name": "Conventional glycaemic control", "condition_name": "External Causes of Morbidity and Mortality", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0059", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Posoleucel (ALVR105)\nDrug type: cell_therapy\nCondition: BK Virus Infection\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 97\np-value: 0.6253\nEffect size (Hazard Ratio (HR)): 0.92\n95% CI: [0.55, 1.55]\nInterpretation: safety_stopped", "metadata": {"result_id": 58192, "source_trial_id": "NCT04390113", "intervention_name": "Posoleucel (ALVR105)", "condition_name": "BK Virus Infection", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0060", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: rituximab\nDrug type: monoclonal_antibody\nCondition: Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\nPhase: phase_1\nEnrollment: 5\nTermination reason: \"Extreme toxicity in Phase I, study did not proceed to Phase II\"\nDetail: Extreme toxicity in Phase I, study did not proceed to Phase II", "metadata": {"result_id": 34536, "source_trial_id": "NCT01045928", "intervention_name": "rituximab", "condition_name": "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0061", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Sitaxsentan\nCondition: Pulmonary Arterial Hypertension\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 183\nPrimary endpoint met: 1.0\np-value: 0.0104\nEffect size (Mean Difference (Final Values)): 14.0\n95% CI: [3.0, 26.0]\nSerious adverse events: 56.0\nInterpretation: safety_stopped", "metadata": {"result_id": 56145, "source_trial_id": "NCT00795639", "intervention_name": "Sitaxsentan", "condition_name": "Pulmonary Arterial Hypertension", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL1-0062", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Hydroxyurea\nCondition: Hematologic Diseases\nPhase: phase_3\nBlinding: NONE\nEnrollment: 134\nPrimary endpoint met: 1.0\np-value: 0.01\nSerious adverse events: 122.0\nInterpretation: safety_stopped", "metadata": {"result_id": 9870, "source_trial_id": "NCT00122980", "intervention_name": "Hydroxyurea", "condition_name": "Hematologic Diseases", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0063", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: KW-2871\nDrug type: monoclonal_antibody\nCondition: Stage IV Melanoma\nPhase: phase_1_2\nEnrollment: 5\nTermination reason: \"Occurrence of 2 dose-limiting toxicities at the initial dose level (60 mg/m2) in Part I.\"\nDetail: Occurrence of 2 dose-limiting toxicities at the initial dose level (60 mg/m2) in Part I.", "metadata": {"result_id": 36422, "source_trial_id": "NCT00199342", "intervention_name": "KW-2871", "condition_name": "Stage IV Melanoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0064", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: AKN-028\nCondition: Acute Myeloid Leukemia\nPhase: phase_1_2\nEnrollment: 25\nTermination reason: \"During the study two patients have experienced serious liver events related to AKN-028. The risk-benefit balance was judged to be negative.\"\nDetail: During the study two patients have experienced serious liver events related to AKN-028. The risk-benefit balance was judged to be negative.", "metadata": {"result_id": 20089, "source_trial_id": "NCT01573247", "intervention_name": "AKN-028", "condition_name": "Acute Myeloid Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0065", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Topical testosterone gel 1% (active formulation)\nCondition: Hypogonadism\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 209\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (Mean Difference (Net)): 1.5\n95% CI: [0.4, 2.2]\nSerious adverse events: 52.0\nInterpretation: safety_stopped", "metadata": {"result_id": 8604, "source_trial_id": "NCT00240981", "intervention_name": "Topical testosterone gel 1% (active formulation)", "condition_name": "Hypogonadism", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0066", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Aliskiren\nCondition: Atherosclerosis\nPhase: phase_2_3\nBlinding: QUADRUPLE\nEnrollment: 71\nPrimary endpoint met: 1.0\np-value: 0.031\nEffect size (Mean Difference (Final Values)): 5.16\n95% CI: [0.85, 9.47]\nInterpretation: safety_stopped", "metadata": {"result_id": 5107, "source_trial_id": "NCT01417104", "intervention_name": "Aliskiren", "condition_name": "Atherosclerosis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0067", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Regulatory T-cells\nCondition: Acute Myelogenous Leukemia (AML)\nPhase: phase_1_2\nEnrollment: 10\nTermination reason: \"Safety\"\nDetail: Safety", "metadata": {"result_id": 38103, "source_trial_id": "NCT01050764", "intervention_name": "Regulatory T-cells", "condition_name": "Acute Myelogenous Leukemia (AML)", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0068", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Golimumab 50 mg\nCondition: Axial Spondyloarthritis\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 347\np-value: 0.669\nEffect size (Percentage difference): 2.586\n95% CI: [-9.138, 14.31]\nSerious adverse events: 32.0\nInterpretation: safety_stopped", "metadata": {"result_id": 35417, "source_trial_id": "NCT02437162", "intervention_name": "Golimumab 50 mg", "condition_name": "Axial Spondyloarthritis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0069", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: MDCO 3\nCondition: Bleeding\nPhase: phase_2\nEnrollment: 44\nTermination reason: \"Safety\"\nDetail: Safety", "metadata": {"result_id": 22554, "source_trial_id": "NCT01530399", "intervention_name": "MDCO 3", "condition_name": "Bleeding", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0070", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: B-701\nDrug type: monoclonal_antibody\nCondition: Bladder Cancer\nPhase: phase_1\nEnrollment: 1\nTermination reason: \"Terminated due to safety concerns.\"\nDetail: Terminated due to safety concerns.", "metadata": {"result_id": 12544, "source_trial_id": "NCT02925533", "intervention_name": "B-701", "condition_name": "Bladder Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0071", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: 177Lu-3BP-227 (also called 177Lu-IPN01087)\nCondition: Squamous Cell Carcinoma of the Head and Neck\nPhase: phase_1\nEnrollment: 14\nTermination reason: \"Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns\"\nDetail: Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns", "metadata": {"result_id": 4967, "source_trial_id": "NCT03525392", "intervention_name": "177Lu-3BP-227 (also called 177Lu-IPN01087)", "condition_name": "Squamous Cell Carcinoma of the Head and Neck", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0072", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Anti-thymocyte globulin, rabbit\nDrug type: unknown\nCondition: Myelodysplastic Syndrome (MDS)\nPhase: phase_1_2\nEnrollment: 10\nTermination reason: \"Safety\"\nDetail: Safety", "metadata": {"result_id": 38063, "source_trial_id": "NCT01050764", "intervention_name": "Anti-thymocyte globulin, rabbit", "condition_name": "Myelodysplastic Syndrome (MDS)", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0073", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Cyclophosphamide Dose Level 2\nCondition: Thalassemia\nPhase: phase_2\nEnrollment: 20\nTermination reason: \"Optimal dose obtained for engraftment and minimizing toxicity\"\nDetail: Optimal dose obtained for engraftment and minimizing toxicity", "metadata": {"result_id": 8645, "source_trial_id": "NCT02512679", "intervention_name": "Cyclophosphamide Dose Level 2", "condition_name": "Thalassemia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0074", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Leflunomide tablet\nCondition: Lupus Nephritis\nPhase: phase_3\nEnrollment: 84\nTermination reason: \"Due to safety concern of active control drug\"\nDetail: Due to safety concern of active control drug", "metadata": {"result_id": 10203, "source_trial_id": "NCT01342016", "intervention_name": "Leflunomide tablet", "condition_name": "Lupus Nephritis", "confidence_tier": "bronze", "therapeutic_area": "autoimmune"}, "split": "val"}
+{"question_id": "CTL1-0075", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47\nCondition: Non-Small Cell Lung Cancer\nPhase: phase_1\nEnrollment: 11\nTermination reason: \"for efficacy and safety reasons\"\nDetail: for efficacy and safety reasons", "metadata": {"result_id": 42669, "source_trial_id": "NCT00787852", "intervention_name": "Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47", "condition_name": "Non-Small Cell Lung Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0076", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: ACE-031 0.5 mg/kg q4wk\nCondition: Duchenne Muscular Dystrophy\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 24\nPrimary endpoint met: 1.0\np-value: 0.012\nInterpretation: safety_stopped", "metadata": {"result_id": 751, "source_trial_id": "NCT01099761", "intervention_name": "ACE-031 0.5 mg/kg q4wk", "condition_name": "Duchenne Muscular Dystrophy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0077", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Doripenem\nCondition: Ventilator-associated Pneumonia\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 274\np-value: 0.14\nSerious adverse events: 301.0\nInterpretation: safety_stopped", "metadata": {"result_id": 12623, "source_trial_id": "NCT00589693", "intervention_name": "Doripenem", "condition_name": "Ventilator-associated Pneumonia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0078", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Fasiglifam (TAK-875)\nCondition: Glycemic Control\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 916\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (LS Mean Difference): -0.55\n95% CI: [-0.77, -0.34]\nSerious adverse events: 68.0\nInterpretation: safety_stopped", "metadata": {"result_id": 46031, "source_trial_id": "NCT01549964", "intervention_name": "Fasiglifam (TAK-875)", "condition_name": "Glycemic Control", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0079", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: fosbretabulin\nCondition: Neoplasms, Ovarian\nPhase: phase_1_2\nEnrollment: 21\nTermination reason: \"Safety\"\nDetail: Safety", "metadata": {"result_id": 45468, "source_trial_id": "NCT02055690", "intervention_name": "fosbretabulin", "condition_name": "Neoplasms, Ovarian", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0080", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: anti-thymocyte globulin\nDrug type: other_biologic\nCondition: Contiguous Stage II Marginal Zone Lymphoma\nPhase: phase_2\nEnrollment: 20\nTermination reason: \"Study was closed to accrual for safety related to the frequency of BK infections.\"\nDetail: Study was closed to accrual for safety related to the frequency of BK infections.", "metadata": {"result_id": 59098, "source_trial_id": "NCT01044745", "intervention_name": "anti-thymocyte globulin", "condition_name": "Contiguous Stage II Marginal Zone Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0081", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Tolbutamide\nCondition: Advanced Cancer\nPhase: phase_1\nEnrollment: 4\nTermination reason: \"Terminated based on safety results from another trial\"\nDetail: Terminated based on safety results from another trial", "metadata": {"result_id": 26887, "source_trial_id": "NCT01185548", "intervention_name": "Tolbutamide", "condition_name": "Advanced Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0082", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Ponatinib\nCondition: Chronic Myeloid Leukemia\nPhase: phase_3\nBlinding: NONE\nEnrollment: 307\nPrimary endpoint met: 1.0\np-value: 0.001\nSerious adverse events: 158.0\nInterpretation: safety_stopped", "metadata": {"result_id": 19747, "source_trial_id": "NCT01650805", "intervention_name": "Ponatinib", "condition_name": "Chronic Myeloid Leukemia", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0083", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Fludarabine\nCondition: Leukemia, Acute\nPhase: phase_1_2\nEnrollment: 10\nTermination reason: \"Safety\"\nDetail: Safety", "metadata": {"result_id": 38078, "source_trial_id": "NCT01050764", "intervention_name": "Fludarabine", "condition_name": "Leukemia, Acute", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0084", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Posoleucel (ALVR105)\nDrug type: cell_therapy\nCondition: JC Virus Infection\nPhase: phase_2_3\nBlinding: QUADRUPLE\nEnrollment: 451\np-value: 0.5603\nEffect size (Mean Difference (Final Values)): 0.01\n95% CI: [-0.09, 0.1]\nInterpretation: safety_stopped", "metadata": {"result_id": 27026, "source_trial_id": "NCT05305040", "intervention_name": "Posoleucel (ALVR105)", "condition_name": "JC Virus Infection", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0085", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Estradiol Valerate\nCondition: Natural Cycle\nPhase: phase_4\nEnrollment: 362\nTermination reason: \"safety\"\nDetail: safety", "metadata": {"result_id": 52230, "source_trial_id": "NCT03976544", "intervention_name": "Estradiol Valerate", "condition_name": "Natural Cycle", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0086", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: clevudine\nCondition: Chronic Hepatitis\nPhase: phase_3\nTermination reason: \"The study was terminated in the interest of patient safety.\"\nDetail: The study was terminated in the interest of patient safety.", "metadata": {"result_id": 21445, "source_trial_id": "NCT00496158", "intervention_name": "clevudine", "condition_name": "Chronic Hepatitis", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "val"}
+{"question_id": "CTL1-0087", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Basiliximab\nDrug type: monoclonal_antibody\nCondition: Kidney Transplantation\nPhase: phase_2\nBlinding: NONE\nEnrollment: 71\np-value: 0.531\nEffect size (Mean Difference (Final Values)): 4.82\n95% CI: [-10.481, 20.121]\nSerious adverse events: 134.0\nInterpretation: safety_stopped", "metadata": {"result_id": 12029, "source_trial_id": "NCT01856257", "intervention_name": "Basiliximab", "condition_name": "Kidney Transplantation", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0088", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab\nCondition: Pancreatic Cancer Resectable\nPhase: phase_2\nBlinding: NONE\nEnrollment: 32\np-value: 0.13\nEffect size (Mean Difference (Final Values)): -0.63\n95% CI: [-1.0, -0.25]\nSerious adverse events: 73.0\nInterpretation: safety_stopped", "metadata": {"result_id": 62620, "source_trial_id": "NCT03344172", "intervention_name": "Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab", "condition_name": "Pancreatic Cancer Resectable", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0089", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Vorapaxar\nCondition: Atherosclerosis\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 12944\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Cox Proportional Hazard): 1.36\n95% CI: [1.18, 1.57]\nSerious adverse events: 10012.0\nInterpretation: safety_stopped", "metadata": {"result_id": 45345, "source_trial_id": "NCT00527943", "intervention_name": "Vorapaxar", "condition_name": "Atherosclerosis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0090", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: IMP Pioglitozone\nCondition: Asthma\nPhase: phase_4\nEnrollment: 68\nTermination reason: \"safety concerns with pioglitazone\"\nDetail: safety concerns with pioglitazone", "metadata": {"result_id": 9239, "source_trial_id": "NCT01134835", "intervention_name": "IMP Pioglitozone", "condition_name": "Asthma", "confidence_tier": "bronze", "therapeutic_area": "respiratory"}, "split": "val"}
+{"question_id": "CTL1-0091", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: MDCO 1\nCondition: Bleeding\nPhase: phase_2\nEnrollment: 44\nTermination reason: \"Safety\"\nDetail: Safety", "metadata": {"result_id": 22552, "source_trial_id": "NCT01530399", "intervention_name": "MDCO 1", "condition_name": "Bleeding", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0092", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Anti-Thymocyte Globulin (Rabbit)\nDrug type: other_biologic\nCondition: Kidney Transplantation\nPhase: phase_2\nBlinding: NONE\nEnrollment: 71\np-value: 0.531\nEffect size (Mean Difference (Final Values)): 4.82\n95% CI: [-10.481, 20.121]\nSerious adverse events: 134.0\nInterpretation: safety_stopped", "metadata": {"result_id": 12030, "source_trial_id": "NCT01856257", "intervention_name": "Anti-Thymocyte Globulin (Rabbit)", "condition_name": "Kidney Transplantation", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0093", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Rosiglitazone therapy\nCondition: Dilated Cardiomyopathy\nTermination reason: \"concern over safety of rosiglitazone in heart failure\"\nDetail: concern over safety of rosiglitazone in heart failure", "metadata": {"result_id": 61105, "source_trial_id": "NCT00466713", "intervention_name": "Rosiglitazone therapy", "condition_name": "Dilated Cardiomyopathy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0094", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: 0.9% normal saline\nCondition: Shock, Traumatic\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 895\nPrimary endpoint met: 1.0\np-value: 0.01\nSerious adverse events: 134.0\nInterpretation: safety_stopped", "metadata": {"result_id": 4041, "source_trial_id": "NCT00316017", "intervention_name": "0.9% normal saline", "condition_name": "Shock, Traumatic", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0095", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: CsA with steroid minimization\nCondition: Diabetes Mellitus, Adult-Onset\nPhase: phase_4\nBlinding: NONE\nEnrollment: 134\nPrimary endpoint met: 1.0\np-value: 0.02\nSerious adverse events: 51.0\nInterpretation: safety_stopped", "metadata": {"result_id": 7172, "source_trial_id": "NCT01002339", "intervention_name": "CsA with steroid minimization", "condition_name": "Diabetes Mellitus, Adult-Onset", "confidence_tier": "silver", "therapeutic_area": "metabolic"}, "split": "val"}
+{"question_id": "CTL1-0096", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Metformin XR\nCondition: Type 2 Diabetes Mellitus\nPhase: phase_1\nEnrollment: 4\nTermination reason: \"Release of Post Marketing Requirement for this study. Terminated November 2013.\"\nDetail: Release of Post Marketing Requirement for this study. Terminated November 2013.", "metadata": {"result_id": 12875, "source_trial_id": "NCT01525225", "intervention_name": "Metformin XR", "condition_name": "Type 2 Diabetes Mellitus", "confidence_tier": "bronze", "therapeutic_area": "metabolic"}, "split": "val"}
+{"question_id": "CTL1-0097", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Sitaxsentan and Sildenafil\nCondition: Pulmonary Hypertension\nPhase: phase_3\nEnrollment: 3\nTermination reason: \"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury\"\nDetail: Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury", "metadata": {"result_id": 20798, "source_trial_id": "NCT00796510", "intervention_name": "Sitaxsentan and Sildenafil", "condition_name": "Pulmonary Hypertension", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL1-0098", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: TKI258\nCondition: Acute Myeloid Leukemia\nPhase: phase_1\nEnrollment: 34\nTermination reason: \"Study was stopped due to time dependent drug accumulation\"\nDetail: Study was stopped due to time dependent drug accumulation", "metadata": {"result_id": 7400, "source_trial_id": "NCT00279773", "intervention_name": "TKI258", "condition_name": "Acute Myeloid Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0099", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: MEDI-575\nDrug type: monoclonal_antibody\nCondition: Non-Small Cell Lung Cancer\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 99\nPrimary endpoint met: 1.0\np-value: 0.027\nEffect size (Hazard Ratio (HR)): 2.205\n95% CI: [1.1, 4.5]\nSerious adverse events: 190.0\nInterpretation: safety_stopped", "metadata": {"result_id": 24787, "source_trial_id": "NCT01268059", "intervention_name": "MEDI-575", "condition_name": "Non-Small Cell Lung Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0100", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection\nCondition: Chronic Phase-Chronic Myeloid Leukemia\nPhase: phase_1_2\nEnrollment: 9\nTermination reason: \"The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2 patients.\"\nDetail: The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2 patients.", "metadata": {"result_id": 15008, "source_trial_id": "NCT04793399", "intervention_name": "Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection", "condition_name": "Chronic Phase-Chronic Myeloid Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0101", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Sitagliptin\nCondition: Glycemic Control\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 916\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (LS Mean Difference): -0.55\n95% CI: [-0.77, -0.34]\nSerious adverse events: 68.0\nInterpretation: safety_stopped", "metadata": {"result_id": 46030, "source_trial_id": "NCT01549964", "intervention_name": "Sitagliptin", "condition_name": "Glycemic Control", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0102", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Posoleucel (ALVR105)\nDrug type: cell_therapy\nCondition: Adenovirus Infection\nPhase: phase_2_3\nBlinding: QUADRUPLE\nEnrollment: 451\np-value: 0.5603\nEffect size (Mean Difference (Final Values)): 0.01\n95% CI: [-0.09, 0.1]\nInterpretation: safety_stopped", "metadata": {"result_id": 27020, "source_trial_id": "NCT05305040", "intervention_name": "Posoleucel (ALVR105)", "condition_name": "Adenovirus Infection", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0103", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: BI 767551 inhaled\nCondition: COVID-19\nPhase: phase_2_3\nEnrollment: 5\nTermination reason: \"not due to safety reasons\"\nDetail: not due to safety reasons", "metadata": {"result_id": 13685, "source_trial_id": "NCT04822701", "intervention_name": "BI 767551 inhaled", "condition_name": "COVID-19", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "val"}
+{"question_id": "CTL1-0104", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Ipilimumab 5 MG/ML Injection [Yervoy]\nCondition: A Combination of Adoptive T Cell Therapy and Ipilimumab Could Increase the Proportion of CR Patients, and Durability of Response\nPhase: phase_2\nEnrollment: 2\nTermination reason: \"due to toxicity of cyclophosphamide\"\nDetail: due to toxicity of cyclophosphamide", "metadata": {"result_id": 46161, "source_trial_id": "NCT01988077", "intervention_name": "Ipilimumab 5 MG/ML Injection [Yervoy]", "condition_name": "A Combination of Adoptive T Cell Therapy and Ipilimumab Could Increase the Proportion of CR Patients, and Durability of Response", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0105", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: fosbretabulin\nCondition: Ovarian Neoplasms\nPhase: phase_1_2\nEnrollment: 21\nTermination reason: \"Safety\"\nDetail: Safety", "metadata": {"result_id": 45466, "source_trial_id": "NCT02055690", "intervention_name": "fosbretabulin", "condition_name": "Ovarian Neoplasms", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0106", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: immunosuppressive therapy\nCondition: Recurrent Adult T-cell Leukemia/Lymphoma\nPhase: phase_2\nEnrollment: 20\nTermination reason: \"Study was closed to accrual for safety related to the frequency of BK infections.\"\nDetail: Study was closed to accrual for safety related to the frequency of BK infections.", "metadata": {"result_id": 59392, "source_trial_id": "NCT01044745", "intervention_name": "immunosuppressive therapy", "condition_name": "Recurrent Adult T-cell Leukemia/Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0107", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Intravenous Fat Emulsions\nCondition: Hypertriglyceridemia\nBlinding: NONE\nEnrollment: 19\nPrimary endpoint met: 1.0\np-value: 0.011\nInterpretation: safety_stopped", "metadata": {"result_id": 24558, "source_trial_id": "NCT01096446", "intervention_name": "Intravenous Fat Emulsions", "condition_name": "Hypertriglyceridemia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0108", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Nucleoside/nucleotide (NUC) analogue inhibitors\nCondition: Hepatitis B, Chronic\nPhase: phase_2\nEnrollment: 64\nTermination reason: \"Safety\"\nDetail: Safety", "metadata": {"result_id": 6503, "source_trial_id": "NCT04023721", "intervention_name": "Nucleoside/nucleotide (NUC) analogue inhibitors", "condition_name": "Hepatitis B, Chronic", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "val"}
+{"question_id": "CTL1-0109", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Cyclophosphamide Dose Level 3\nCondition: Stem Cell Transplantation\nPhase: phase_2\nEnrollment: 20\nTermination reason: \"Optimal dose obtained for engraftment and minimizing toxicity\"\nDetail: Optimal dose obtained for engraftment and minimizing toxicity", "metadata": {"result_id": 8642, "source_trial_id": "NCT02512679", "intervention_name": "Cyclophosphamide Dose Level 3", "condition_name": "Stem Cell Transplantation", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0110", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: LY3499446\nCondition: Colorectal Cancer\nPhase: phase_1_2\nEnrollment: 5\nTermination reason: \"The study was terminated due to an unexpected toxicity finding.\"\nDetail: The study was terminated due to an unexpected toxicity finding.", "metadata": {"result_id": 3163, "source_trial_id": "NCT04165031", "intervention_name": "LY3499446", "condition_name": "Colorectal Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0111", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: GSK1014802 low dose\nCondition: Pain, Neuropathic\nPhase: phase_1\nEnrollment: 16\nTermination reason: \"During treatment session 3, a subject had a pattern of AEs of severe intensity, suggestive of brainstem toxicity/encephalopathy during lidocaine/saline infusion\"\nDetail: During treatment session 3, a subject had a pattern of AEs of severe intensity, suggestive of brainstem toxicity/encephalopathy during lidocaine/saline infusion", "metadata": {"result_id": 40263, "source_trial_id": "NCT00964288", "intervention_name": "GSK1014802 low dose", "condition_name": "Pain, Neuropathic", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0112", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Vorapaxar\nCondition: Myocardial Ischemia\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 12944\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Cox Proportional Hazard): 1.36\n95% CI: [1.18, 1.57]\nSerious adverse events: 10012.0\nInterpretation: safety_stopped", "metadata": {"result_id": 45343, "source_trial_id": "NCT00527943", "intervention_name": "Vorapaxar", "condition_name": "Myocardial Ischemia", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL1-0113", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Gemcitabine and Capecitabine and Avastin\nCondition: Breast Cancer\nPhase: phase_2\nEnrollment: 18\nTermination reason: \"DSMB determined toxicity of regimen more than originally thought. Slow accrual.\"\nDetail: DSMB determined toxicity of regimen more than originally thought. Slow accrual.", "metadata": {"result_id": 7234, "source_trial_id": "NCT00462865", "intervention_name": "Gemcitabine and Capecitabine and Avastin", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0114", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Lacosamide oral\nCondition: Electroencephalographic Neonatal Seizures\nPhase: phase_2\nEnrollment: 29\nTermination reason: \"Study stopped after agreed PIP modification, not linked to safety reasons.\"\nDetail: Study stopped after agreed PIP modification, not linked to safety reasons.", "metadata": {"result_id": 47272, "source_trial_id": "NCT04519645", "intervention_name": "Lacosamide oral", "condition_name": "Electroencephalographic Neonatal Seizures", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "val"}
+{"question_id": "CTL1-0115", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: DFMO\nCondition: Diffuse Midline Glioma, H3 K27M-Mutant\nPhase: phase_1_2\nEnrollment: 15\nTermination reason: \"Required re-formulation of DFMO from IV to capsule to maintain safety\"\nDetail: Required re-formulation of DFMO from IV to capsule to maintain safety", "metadata": {"result_id": 42103, "source_trial_id": "NCT05500508", "intervention_name": "DFMO", "condition_name": "Diffuse Midline Glioma, H3 K27M-Mutant", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0116", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: GW873140\nCondition: HIV Infection\nPhase: phase_3\nTermination reason: \"The study was terminated due to hepatoxicity of compound\"\nDetail: The study was terminated due to hepatoxicity of compound", "metadata": {"result_id": 12837, "source_trial_id": "NCT00123890", "intervention_name": "GW873140", "condition_name": "HIV Infection", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "val"}
+{"question_id": "CTL1-0117", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Expanded autologous adipose-derived adult stem cells (eASCs)\nCondition: Crohn Disease\nPhase: phase_3\nEnrollment: 56\nTermination reason: \"After the investigators and experts in the field imput it became apparent that the protocol was not reflective of clinical reality. No safety issues reported.\"\nDetail: After the investigators and experts in the field imput it became apparent that the protocol was not reflective of clinical reality. No safety issues reported.", "metadata": {"result_id": 22024, "source_trial_id": "NCT01378390", "intervention_name": "Expanded autologous adipose-derived adult stem cells (eASCs)", "condition_name": "Crohn Disease", "confidence_tier": "bronze", "therapeutic_area": "autoimmune"}, "split": "val"}
+{"question_id": "CTL1-0118", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: IMG-007\nDrug type: peptide\nCondition: Atopic Dermatitis\nPhase: phase_1_2\nEnrollment: 13\nTermination reason: \"Cohort 1 was completed. Cohort 2 was cancelled because data from Cohort 1 provided sufficient information for further development decision. No safety concerns were noted.\"\nDetail: Cohort 1 was completed. Cohort 2 was cancelled because data from Cohort 1 provided sufficient information for further development decision. No safety concerns were noted.", "metadata": {"result_id": 9397, "source_trial_id": "NCT05984784", "intervention_name": "IMG-007", "condition_name": "Atopic Dermatitis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0119", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Tasisulam\nCondition: Advanced Cancer\nPhase: phase_1\nEnrollment: 11\nTermination reason: \"Terminated based on safety results from another trial\"\nDetail: Terminated based on safety results from another trial", "metadata": {"result_id": 13149, "source_trial_id": "NCT01209832", "intervention_name": "Tasisulam", "condition_name": "Advanced Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0120", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: BI 1265162\nCondition: Cystic Fibrosis\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 52\np-value: 0.3039\nEffect size (Adjuste means difference): 2.1\n95% CI: [-2.4, 6.5]\nSerious adverse events: 5.0\nInterpretation: safety_stopped", "metadata": {"result_id": 44965, "source_trial_id": "NCT04059094", "intervention_name": "BI 1265162", "condition_name": "Cystic Fibrosis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0121", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Botulinum Toxin A, bladder detrusor muscle injection\nCondition: Urinary Urgency\nPhase: phase_3\nEnrollment: 87\nTermination reason: \"higher than anticipated rate of increased post-void residual in subjects who received botulinum toxin A injection\"\nDetail: higher than anticipated rate of increased post-void residual in subjects who received botulinum toxin A injection", "metadata": {"result_id": 52408, "source_trial_id": "NCT00373789", "intervention_name": "Botulinum Toxin A, bladder detrusor muscle injection", "condition_name": "Urinary Urgency", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0122", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Cyclophosphamide\nCondition: Stage III Small Lymphocytic Lymphoma\nPhase: phase_2\nEnrollment: 20\nTermination reason: \"Study was closed to accrual for safety related to the frequency of BK infections.\"\nDetail: Study was closed to accrual for safety related to the frequency of BK infections.", "metadata": {"result_id": 59874, "source_trial_id": "NCT01044745", "intervention_name": "Cyclophosphamide", "condition_name": "Stage III Small Lymphocytic Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0123", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: XL999\nCondition: Multiple Myeloma\nPhase: phase_2\nEnrollment: 4\nTermination reason: \"Study was terminated due to cardiac toxicities in the subjects\"\nDetail: Study was terminated due to cardiac toxicities in the subjects", "metadata": {"result_id": 18775, "source_trial_id": "NCT00304590", "intervention_name": "XL999", "condition_name": "Multiple Myeloma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0124", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Topical ABI-1968 cream\nCondition: Anus Neoplasm\nPhase: phase_1\nEnrollment: 6\nTermination reason: \"Pre-Clinical Toxicology Findings\"\nDetail: Pre-Clinical Toxicology Findings", "metadata": {"result_id": 35883, "source_trial_id": "NCT03677960", "intervention_name": "Topical ABI-1968 cream", "condition_name": "Anus Neoplasm", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0125", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Valaciclovir\nCondition: EBV\nPhase: phase_2\nEnrollment: 85\nTermination reason: \"In light of the evolving Covid19 pandemic ongoing study recruitment was felt to pose an unacceptable risk to patient safety.\"\nDetail: In light of the evolving Covid19 pandemic ongoing study recruitment was felt to pose an unacceptable risk to patient safety.", "metadata": {"result_id": 37015, "source_trial_id": "NCT03699904", "intervention_name": "Valaciclovir", "condition_name": "EBV", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0126", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Lithium\nCondition: Depressive Disorder\nPhase: phase_2_3\nBlinding: QUADRUPLE\nEnrollment: 519\np-value: 0.22\nEffect size (Cox Proportional Hazard): 1.61\n95% CI: [0.75, 3.43]\nSerious adverse events: 522.0\nInterpretation: safety_stopped", "metadata": {"result_id": 17478, "source_trial_id": "NCT01928446", "intervention_name": "Lithium", "condition_name": "Depressive Disorder", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0127", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: ustekinumab 90 mg\nCondition: Axial Spondyloarthritis\nPhase: phase_3\nEnrollment: 315\nTermination reason: \"This study was stopped because ustekinumab did not achieve key endpoints in a related study. The safety profile was consistent with past ustekinumab studies.\"\nDetail: This study was stopped because ustekinumab did not achieve key endpoints in a related study. The safety profile was consistent with past ustekinumab studies.", "metadata": {"result_id": 35422, "source_trial_id": "NCT02438787", "intervention_name": "ustekinumab 90 mg", "condition_name": "Axial Spondyloarthritis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0128", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: FOLFOX\nCondition: Peritoneal Neoplasms\nPhase: phase_2\nEnrollment: 18\nTermination reason: \"after interim analysis it was determined that the risks were too great in comparision to the results\"\nDetail: after interim analysis it was determined that the risks were too great in comparision to the results", "metadata": {"result_id": 27584, "source_trial_id": "NCT00352755", "intervention_name": "FOLFOX", "condition_name": "Peritoneal Neoplasms", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0129", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: DLI\nCondition: Solid Tumors\nPhase: phase_1_2\nEnrollment: 9\nTermination reason: \"toxicity\"\nDetail: toxicity", "metadata": {"result_id": 14884, "source_trial_id": "NCT00582816", "intervention_name": "DLI", "condition_name": "Solid Tumors", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0130", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: PF-04455242\nCondition: Depression\nPhase: phase_1\nEnrollment: 12\nTermination reason: \"This study was terminated on January 6, 2010, due to toxicology findings in animals exposed to PF-04455242 for three months.\"\nDetail: This study was terminated on January 6, 2010, due to toxicology findings in animals exposed to PF-04455242 for three months.", "metadata": {"result_id": 51905, "source_trial_id": "NCT00939887", "intervention_name": "PF-04455242", "condition_name": "Depression", "confidence_tier": "bronze", "therapeutic_area": "psychiatry"}, "split": "test"}
+{"question_id": "CTL1-0131", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Hydromorphone 4 mcg/kg\nCondition: Pain Control\nPhase: phase_4\nEnrollment: 27\nTermination reason: \"Study participant #27 had a related adverse event that prompted interim data analysis and additional study participants were not sought.\"\nDetail: Study participant #27 had a related adverse event that prompted interim data analysis and additional study participants were not sought.", "metadata": {"result_id": 46066, "source_trial_id": "NCT05552443", "intervention_name": "Hydromorphone 4 mcg/kg", "condition_name": "Pain Control", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0132", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: THE-630\nCondition: Neoplasms, Connective Tissue\nPhase: phase_1_2\nEnrollment: 32\nTermination reason: \"The Sponsor terminated the study due to early dose-limiting toxicities.\"\nDetail: The Sponsor terminated the study due to early dose-limiting toxicities.", "metadata": {"result_id": 58701, "source_trial_id": "NCT05160168", "intervention_name": "THE-630", "condition_name": "Neoplasms, Connective Tissue", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0133", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: 0.06% Resiquimod Gel - C\nCondition: Nodular Basal Cell Carcinoma\nPhase: phase_1_2\nEnrollment: 4\nTermination reason: \"safety issues\"\nDetail: safety issues", "metadata": {"result_id": 53624, "source_trial_id": "NCT01808950", "intervention_name": "0.06% Resiquimod Gel - C", "condition_name": "Nodular Basal Cell Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0134", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: BAY2413555 Dose 1\nCondition: Chronic Heart Failure\nPhase: phase_1\nEnrollment: 22\nTermination reason: \"Due to new preclinical findings in a chronic toxicology study.\"\nDetail: Due to new preclinical findings in a chronic toxicology study.", "metadata": {"result_id": 12606, "source_trial_id": "NCT05532046", "intervention_name": "BAY2413555 Dose 1", "condition_name": "Chronic Heart Failure", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0135", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Duvelisib\nCondition: Chronic Lymphocytic Leukemia (CLL)\nPhase: phase_2\nEnrollment: 3\nTermination reason: \"Due to unexpected sudden death on study.\"\nDetail: Due to unexpected sudden death on study.", "metadata": {"result_id": 7936, "source_trial_id": "NCT04209621", "intervention_name": "Duvelisib", "condition_name": "Chronic Lymphocytic Leukemia (CLL)", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0136", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Tozadenant\nCondition: Idiopathic Parkinson Disease\nPhase: phase_3\nEnrollment: 66\nTermination reason: \"New Safety Information\"\nDetail: New Safety Information", "metadata": {"result_id": 45765, "source_trial_id": "NCT03051607", "intervention_name": "Tozadenant", "condition_name": "Idiopathic Parkinson Disease", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0137", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Dextromethorphan 30 mg\nCondition: Ulcerative Colitis\nPhase: phase_1\nEnrollment: 28\nTermination reason: \"The study was stopped as all post-marketing commitments had been fulfilled or released\"\nDetail: The study was stopped as all post-marketing commitments had been fulfilled or released", "metadata": {"result_id": 46426, "source_trial_id": "NCT03358706", "intervention_name": "Dextromethorphan 30 mg", "condition_name": "Ulcerative Colitis", "confidence_tier": "bronze", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL1-0138", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Mitoxantrone\nCondition: Myeloid Neoplasm\nPhase: phase_1\nEnrollment: 13\nTermination reason: \"Terminated due to unfavorable risk-benefit ratio of investigational regimen.\"\nDetail: Terminated due to unfavorable risk-benefit ratio of investigational regimen.", "metadata": {"result_id": 1759, "source_trial_id": "NCT04196010", "intervention_name": "Mitoxantrone", "condition_name": "Myeloid Neoplasm", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0139", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Inotuzumab Ozogamicin\nDrug type: antibody_drug_conjugate\nCondition: Lymphoma, Non-Hodgkin\nPhase: phase_3\nBlinding: NONE\nEnrollment: 338\np-value: 0.142\nEffect size (Hazard Ratio (HR)): 0.76\n95% CI: [0.47, 1.25]\nSerious adverse events: 351.0\nInterpretation: safety_stopped", "metadata": {"result_id": 27516, "source_trial_id": "NCT01232556", "intervention_name": "Inotuzumab Ozogamicin", "condition_name": "Lymphoma, Non-Hodgkin", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0140", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Platinum based chemotherapy\nCondition: Carcinoma, Non-Small-Cell Lung\nPhase: phase_1_2\nEnrollment: 19\nTermination reason: \"Increased SAE occurrence per PI\"\nDetail: Increased SAE occurrence per PI", "metadata": {"result_id": 18024, "source_trial_id": "NCT03663166", "intervention_name": "Platinum based chemotherapy", "condition_name": "Carcinoma, Non-Small-Cell Lung", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0141", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: sorafenib (Nexavar®), thalidomide (Thado®)\nCondition: Hepatocellular Carcinoma\nPhase: phase_1_2\nEnrollment: 3\nTermination reason: \"Two patients in the first dose level be counted as reaching DLT. DSMB recommend terminated early this trial.\"\nDetail: Two patients in the first dose level be counted as reaching DLT. DSMB recommend terminated early this trial.", "metadata": {"result_id": 15265, "source_trial_id": "NCT00971126", "intervention_name": "sorafenib (Nexavar®), thalidomide (Thado®)", "condition_name": "Hepatocellular Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0142", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: pemetrexed, carboplatin, sorafenib\nCondition: Carcinoma, Non-Small-Cell Lung\nPhase: phase_1_2\nEnrollment: 12\nTermination reason: \"Sorafenib administered in the combination with pemetrexed-carboplatin appears to enhance thrombocytopenia compared to historical data.\"\nDetail: Sorafenib administered in the combination with pemetrexed-carboplatin appears to enhance thrombocytopenia compared to historical data.", "metadata": {"result_id": 26947, "source_trial_id": "NCT00473486", "intervention_name": "pemetrexed, carboplatin, sorafenib", "condition_name": "Carcinoma, Non-Small-Cell Lung", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0143", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Metformin IR\nCondition: Type 2 Diabetes Mellitus\nPhase: phase_1\nEnrollment: 4\nTermination reason: \"Release of Post Marketing Requirement for this study. Terminated November 2013.\"\nDetail: Release of Post Marketing Requirement for this study. Terminated November 2013.", "metadata": {"result_id": 12874, "source_trial_id": "NCT01525225", "intervention_name": "Metformin IR", "condition_name": "Type 2 Diabetes Mellitus", "confidence_tier": "bronze", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-0144", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: CLR457\nCondition: Advanced Solid Tumor\nPhase: phase_1\nEnrollment: 31\nTermination reason: \"Novartis decided to terminate the study considering safety and tolerability concerns and limited clinical activity with CLR457 study drug administered once daily (qd).\"\nDetail: Novartis decided to terminate the study considering safety and tolerability concerns and limited clinical activity with CLR457 study drug administered once daily (qd).", "metadata": {"result_id": 54576, "source_trial_id": "NCT02189174", "intervention_name": "CLR457", "condition_name": "Advanced Solid Tumor", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0145", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Decitabine 50 MG [Dacogen]\nCondition: Pancreatic Adenocarcinoma Recurrent\nPhase: phase_2\nEnrollment: 7\nTermination reason: \"Unexpected toxicity events were documented during interim safety evaluations of the investigational drug.\"\nDetail: Unexpected toxicity events were documented during interim safety evaluations of the investigational drug.", "metadata": {"result_id": 41896, "source_trial_id": "NCT05360264", "intervention_name": "Decitabine 50 MG [Dacogen]", "condition_name": "Pancreatic Adenocarcinoma Recurrent", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0146", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Intrathecal Morphine\nCondition: Intrathecal Morphine\nPhase: phase_4\nEnrollment: 14\nTermination reason: \"The study was stopped early based on the anecdotal evidence from a surgeon who felt one group was experiencing more side effects than the other. Exposing pediatric patients who would be assigned to the inferior arm was difficult to justify ethically.\"\nDetail: The study was stopped early based on the anecdotal evidence from a surgeon who felt one group was experiencing more side effects than the other. Exposing pediatric patients who would be assigned to the inferior arm was difficult to justify ethically.", "metadata": {"result_id": 40765, "source_trial_id": "NCT05506930", "intervention_name": "Intrathecal Morphine", "condition_name": "Intrathecal Morphine", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0147", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: EMA401\nCondition: Painful Diabetic Neuropathy\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 142\np-value: 0.1\nEffect size (Odds Ratio (OR)): 2.8\n95% CI: [0.8, 9.6]\nSerious adverse events: 16.0\nInterpretation: safety_stopped", "metadata": {"result_id": 39612, "source_trial_id": "NCT03297294", "intervention_name": "EMA401", "condition_name": "Painful Diabetic Neuropathy", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0148", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Belatacept\nDrug type: peptide\nCondition: Kidney Transplantation\nPhase: phase_2\nBlinding: NONE\nEnrollment: 71\np-value: 0.531\nEffect size (Mean Difference (Final Values)): 4.82\n95% CI: [-10.481, 20.121]\nSerious adverse events: 134.0\nInterpretation: safety_stopped", "metadata": {"result_id": 12028, "source_trial_id": "NCT01856257", "intervention_name": "Belatacept", "condition_name": "Kidney Transplantation", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0149", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: St. John's wort\nDrug type: unknown\nCondition: Hot Flashes\nPhase: phase_2\nBlinding: NONE\nEnrollment: 9\np-value: 0.1042\nEffect size (Mean Difference (Final Values)): 4.35\n95% CI: [-1.12, 9.822]\nInterpretation: safety_stopped", "metadata": {"result_id": 45444, "source_trial_id": "NCT00110136", "intervention_name": "St. John's wort", "condition_name": "Hot Flashes", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0150", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Oleylphosphocholine\nCondition: Leishmaniasis\nPhase: phase_1\nEnrollment: 13\nTermination reason: \"The risk-benefit ratio changed\"\nDetail: The risk-benefit ratio changed", "metadata": {"result_id": 44503, "source_trial_id": "NCT06124144", "intervention_name": "Oleylphosphocholine", "condition_name": "Leishmaniasis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0151", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: THE-630\nCondition: Neoplasms, Connective and Soft Tissue\nPhase: phase_1_2\nEnrollment: 32\nTermination reason: \"The Sponsor terminated the study due to early dose-limiting toxicities.\"\nDetail: The Sponsor terminated the study due to early dose-limiting toxicities.", "metadata": {"result_id": 58702, "source_trial_id": "NCT05160168", "intervention_name": "THE-630", "condition_name": "Neoplasms, Connective and Soft Tissue", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0152", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Mixtard 30:70 Novonordisk® twice daily\nCondition: Type 2 Diabetes Mellitus\nPhase: phase_4\nEnrollment: 72\nTermination reason: \"Safety reasons\"\nDetail: Safety reasons", "metadata": {"result_id": 24340, "source_trial_id": "NCT02333851", "intervention_name": "Mixtard 30:70 Novonordisk® twice daily", "condition_name": "Type 2 Diabetes Mellitus", "confidence_tier": "bronze", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-0153", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Ponatinib 15 mg QD\nCondition: Chronic Phase Chronic Myeloid Leukemia\nPhase: phase_3\nEnrollment: 44\nTermination reason: \"The study was stopped due to operational feasibility and not due to any safety concerns\"\nDetail: The study was stopped due to operational feasibility and not due to any safety concerns", "metadata": {"result_id": 51468, "source_trial_id": "NCT02627677", "intervention_name": "Ponatinib 15 mg QD", "condition_name": "Chronic Phase Chronic Myeloid Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0154", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2\nCondition: Healthy\nPhase: phase_1\nEnrollment: 12\nTermination reason: \"due to multiple subjects reporting pain and burning at the phlebotomy sites after 38hr\"\nDetail: due to multiple subjects reporting pain and burning at the phlebotomy sites after 38hr", "metadata": {"result_id": 47343, "source_trial_id": "NCT00648414", "intervention_name": "Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2", "condition_name": "Healthy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0155", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Fluorouracil\nCondition: Anal Cancer\nPhase: phase_2\nEnrollment: 16\nTermination reason: \"Inadequate toxicity\"\nDetail: Inadequate toxicity", "metadata": {"result_id": 23125, "source_trial_id": "NCT00955240", "intervention_name": "Fluorouracil", "condition_name": "Anal Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0156", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Cyclophosphamide Dose Level 3\nCondition: Chronic Granulomatous Disease\nPhase: phase_2\nEnrollment: 20\nTermination reason: \"Optimal dose obtained for engraftment and minimizing toxicity\"\nDetail: Optimal dose obtained for engraftment and minimizing toxicity", "metadata": {"result_id": 8666, "source_trial_id": "NCT02512679", "intervention_name": "Cyclophosphamide Dose Level 3", "condition_name": "Chronic Granulomatous Disease", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0157", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: ustekinumab 45 mg\nCondition: Axial Spondyloarthritis\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 347\np-value: 0.669\nEffect size (Percentage difference): 2.586\n95% CI: [-9.138, 14.31]\nSerious adverse events: 32.0\nInterpretation: safety_stopped", "metadata": {"result_id": 35419, "source_trial_id": "NCT02437162", "intervention_name": "ustekinumab 45 mg", "condition_name": "Axial Spondyloarthritis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0158", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Conventional Glycemic Control\nCondition: Hyperglycemia\nEnrollment: 56\nTermination reason: \"potential harm of insulin infusion outweights the benefit.\"\nDetail: potential harm of insulin infusion outweights the benefit.", "metadata": {"result_id": 53909, "source_trial_id": "NCT00487162", "intervention_name": "Conventional Glycemic Control", "condition_name": "Hyperglycemia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0159", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Room Air\nCondition: Ischemic Stroke\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 85\np-value: 0.68\nSerious adverse events: 108.0\nInterpretation: safety_stopped", "metadata": {"result_id": 34308, "source_trial_id": "NCT00414726", "intervention_name": "Room Air", "condition_name": "Ischemic Stroke", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0160", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Raptiva\nDrug type: monoclonal_antibody\nCondition: Sjogren's Syndrome\nPhase: phase_2\nEnrollment: 10\nTermination reason: \"Increased risk of PML associated with raptiva in other studies\"\nDetail: Increased risk of PML associated with raptiva in other studies", "metadata": {"result_id": 57047, "source_trial_id": "NCT00344448", "intervention_name": "Raptiva", "condition_name": "Sjogren's Syndrome", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0161", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: IV Cyclophosphamide 500-700mg/m2\nCondition: Nausea and Vomiting, Chemotherapy-Induced\nPhase: phase_1\nEnrollment: 25\nTermination reason: \"compound terminated\"\nDetail: compound terminated", "metadata": {"result_id": 32604, "source_trial_id": "NCT00334646", "intervention_name": "IV Cyclophosphamide 500-700mg/m2", "condition_name": "Nausea and Vomiting, Chemotherapy-Induced", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0162", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: 25% human albumin\nCondition: Subarachnoid Hemorrhage\nBlinding: NONE\nEnrollment: 47\nPrimary endpoint met: 1.0\np-value: 0.05\nEffect size (Odds Ratio (OR)): 3.05\n95% CI: [0.65, 14.1]\nSerious adverse events: 33.0\nInterpretation: safety_stopped", "metadata": {"result_id": 22693, "source_trial_id": "NCT00283400", "intervention_name": "25% human albumin", "condition_name": "Subarachnoid Hemorrhage", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0163", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Prednisolone\nCondition: Hemangioma of Infancy\nPhase: phase_2\nBlinding: SINGLE\nEnrollment: 19\np-value: 0.77\nEffect size (Mean Difference (Net)): 0.06\nSerious adverse events: 14.0\nInterpretation: safety_stopped", "metadata": {"result_id": 26630, "source_trial_id": "NCT00967226", "intervention_name": "Prednisolone", "condition_name": "Hemangioma of Infancy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0164", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: myo-Inositol 5% Injection\nCondition: Retinopathy of Prematurity (ROP)\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 638\nPrimary endpoint met: 1.0\np-value: 0.0095\nEffect size (Risk Ratio (RR)): 1.41\n95% CI: [1.08, 1.83]\nSerious adverse events: 798.0\nInterpretation: safety_stopped", "metadata": {"result_id": 15657, "source_trial_id": "NCT01954082", "intervention_name": "myo-Inositol 5% Injection", "condition_name": "Retinopathy of Prematurity (ROP)", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0165", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: DFMO\nCondition: Head and Neck Cancer\nPhase: phase_1_2\nEnrollment: 15\nTermination reason: \"Required re-formulation of DFMO from IV to capsule to maintain safety\"\nDetail: Required re-formulation of DFMO from IV to capsule to maintain safety", "metadata": {"result_id": 42091, "source_trial_id": "NCT05500508", "intervention_name": "DFMO", "condition_name": "Head and Neck Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0166", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Brolucizumab 6 mg solution for intravitreal injection\nCondition: Neovascular Age-related Macular Degeneration\nPhase: phase_4\nEnrollment: 16\nTermination reason: \"due to safety letter beovu from Novartis\"\nDetail: due to safety letter beovu from Novartis", "metadata": {"result_id": 26848, "source_trial_id": "NCT04287348", "intervention_name": "Brolucizumab 6 mg solution for intravitreal injection", "condition_name": "Neovascular Age-related Macular Degeneration", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0167", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Proellex 25 mg\nCondition: Endometriosis\nPhase: phase_2\nEnrollment: 67\nTermination reason: \"Clinical hold for safety\"\nDetail: Clinical hold for safety", "metadata": {"result_id": 4841, "source_trial_id": "NCT00556075", "intervention_name": "Proellex 25 mg", "condition_name": "Endometriosis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0168", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Pioglitazone and Azilsartan\nCondition: Type 2 Diabetes\nPhase: phase_3\nEnrollment: 96\nTermination reason: \"Combination formulation concerns\"\nDetail: Combination formulation concerns", "metadata": {"result_id": 6931, "source_trial_id": "NCT00376181", "intervention_name": "Pioglitazone and Azilsartan", "condition_name": "Type 2 Diabetes", "confidence_tier": "bronze", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-0169", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine\nCondition: Pancreatic Cancer Resectable\nPhase: phase_2\nBlinding: NONE\nEnrollment: 32\np-value: 0.13\nEffect size (Mean Difference (Final Values)): -0.63\n95% CI: [-1.0, -0.25]\nSerious adverse events: 73.0\nInterpretation: safety_stopped", "metadata": {"result_id": 62621, "source_trial_id": "NCT03344172", "intervention_name": "Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine", "condition_name": "Pancreatic Cancer Resectable", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0170", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Vudalimab\nDrug type: monoclonal_antibody\nCondition: Stage IVB Prostate Cancer AJCC v8\nPhase: phase_1\nEnrollment: 4\nTermination reason: \"To review the safety data.\"\nDetail: To review the safety data.", "metadata": {"result_id": 49458, "source_trial_id": "NCT05733351", "intervention_name": "Vudalimab", "condition_name": "Stage IVB Prostate Cancer AJCC v8", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0171", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: pegfilgrastim\nDrug type: peptide\nCondition: HER2-negative Breast Cancer\nPhase: phase_2\nEnrollment: 15\nTermination reason: \"drug toxicity\"\nDetail: drug toxicity", "metadata": {"result_id": 4517, "source_trial_id": "NCT00679029", "intervention_name": "pegfilgrastim", "condition_name": "HER2-negative Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0172", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: P276-00\nCondition: Mantle Cell Lymphoma\nPhase: phase_2\nEnrollment: 13\nTermination reason: \"The study was terminated based on interim results and all subjects were off study at that time. No major safety or tolerability concerns\"\nDetail: The study was terminated based on interim results and all subjects were off study at that time. No major safety or tolerability concerns", "metadata": {"result_id": 55180, "source_trial_id": "NCT00843050", "intervention_name": "P276-00", "condition_name": "Mantle Cell Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0173", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Atenolol\nCondition: Hypertension\nPhase: phase_3\nBlinding: NONE\nEnrollment: 200\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Hazard Ratio (HR)): 2.36\n95% CI: [1.36, 4.23]\nSerious adverse events: 390.0\nInterpretation: safety_stopped", "metadata": {"result_id": 61386, "source_trial_id": "NCT00582114", "intervention_name": "Atenolol", "condition_name": "Hypertension", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0174", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Intravenous Fat Emulsions\nCondition: Hyperglycemia\nBlinding: NONE\nEnrollment: 19\nPrimary endpoint met: 1.0\np-value: 0.011\nInterpretation: safety_stopped", "metadata": {"result_id": 24559, "source_trial_id": "NCT01096446", "intervention_name": "Intravenous Fat Emulsions", "condition_name": "Hyperglycemia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0175", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: QBM076\nCondition: COPD\nPhase: phase_2\nEnrollment: 48\nTermination reason: \"Part 1 was completed. Part 2 was terminated for safety reasons.\"\nDetail: Part 1 was completed. Part 2 was terminated for safety reasons.", "metadata": {"result_id": 55556, "source_trial_id": "NCT01972776", "intervention_name": "QBM076", "condition_name": "COPD", "confidence_tier": "bronze", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-0176", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: IRX-101\nCondition: Glaucoma/Closed Angle Glaucoma\nPhase: phase_3\nEnrollment: 5\nTermination reason: \"Adverse event\"\nDetail: Adverse event", "metadata": {"result_id": 11131, "source_trial_id": "NCT05127525", "intervention_name": "IRX-101", "condition_name": "Glaucoma/Closed Angle Glaucoma", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0177", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: BG00011\nCondition: Idiopathic Pulmonary Fibrosis\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 109\np-value: 0.112\nEffect size (Hazard Ratio (HR)): 2.01\n95% CI: [0.85, 4.73]\nSerious adverse events: 56.0\nInterpretation: safety_stopped", "metadata": {"result_id": 40772, "source_trial_id": "NCT03573505", "intervention_name": "BG00011", "condition_name": "Idiopathic Pulmonary Fibrosis", "confidence_tier": "silver", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-0178", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Combination AZD1775 with AraC\nCondition: Myelodysplastic Syndromes\nPhase: phase_2\nEnrollment: 6\nTermination reason: \"Safety concerns\"\nDetail: Safety concerns", "metadata": {"result_id": 14208, "source_trial_id": "NCT03718143", "intervention_name": "Combination AZD1775 with AraC", "condition_name": "Myelodysplastic Syndromes", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0179", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: TAK-559\nCondition: Diabetes Mellitus\nPhase: phase_3\nEnrollment: 316\nTermination reason: \"Hepatic safety signal identified.\"\nDetail: Hepatic safety signal identified.", "metadata": {"result_id": 57663, "source_trial_id": "NCT00762112", "intervention_name": "TAK-559", "condition_name": "Diabetes Mellitus", "confidence_tier": "bronze", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-0180", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Cyclophosphamide Dose Level 2\nCondition: Pediatrics\nPhase: phase_2\nEnrollment: 20\nTermination reason: \"Optimal dose obtained for engraftment and minimizing toxicity\"\nDetail: Optimal dose obtained for engraftment and minimizing toxicity", "metadata": {"result_id": 8649, "source_trial_id": "NCT02512679", "intervention_name": "Cyclophosphamide Dose Level 2", "condition_name": "Pediatrics", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0181", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: 10 mg Obeticholic Acid (OCA)\nCondition: Alcoholic Hepatitis\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 19\np-value: 0.1758\nEffect size (Mean Difference (Net)): 1.5\nSerious adverse events: 40.0\nInterpretation: safety_stopped", "metadata": {"result_id": 58633, "source_trial_id": "NCT02039219", "intervention_name": "10 mg Obeticholic Acid (OCA)", "condition_name": "Alcoholic Hepatitis", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-0182", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Aripiprazole\nCondition: Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features\nPhase: phase_3\nEnrollment: 524\nTermination reason: \"The trial was terminated early as the objective of the Aripiprazole Pediatric Investigational Plan was met and provided 2 years of safety data.\"\nDetail: The trial was terminated early as the objective of the Aripiprazole Pediatric Investigational Plan was met and provided 2 years of safety data.", "metadata": {"result_id": 19030, "source_trial_id": "NCT01122927", "intervention_name": "Aripiprazole", "condition_name": "Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features", "confidence_tier": "bronze", "therapeutic_area": "psychiatry"}, "split": "test"}
+{"question_id": "CTL1-0183", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Cyclophosphamide Dose Level 2\nCondition: Metabolic Diseases\nPhase: phase_2\nEnrollment: 20\nTermination reason: \"Optimal dose obtained for engraftment and minimizing toxicity\"\nDetail: Optimal dose obtained for engraftment and minimizing toxicity", "metadata": {"result_id": 8669, "source_trial_id": "NCT02512679", "intervention_name": "Cyclophosphamide Dose Level 2", "condition_name": "Metabolic Diseases", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0184", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy\nCondition: Non-Small Cell Lung Cancer\nPhase: phase_1_2\nEnrollment: 7\nTermination reason: \"High incidence of severe radiation pneumonia\"\nDetail: High incidence of severe radiation pneumonia", "metadata": {"result_id": 58778, "source_trial_id": "NCT04958993", "intervention_name": "Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy", "condition_name": "Non-Small Cell Lung Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0185", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: ETBX-011\nCondition: Pancreatic Cancer\nPhase: phase_1_2\nEnrollment: 3\nTermination reason: \"The study was terminated before any dose escalation occurred in order to pursue other studies designed to more extensively evaluate the combination of ETBX-011 and N-803 along with other immunotherapy agents.\"\nDetail: The study was terminated before any dose escalation occurred in order to pursue other studies designed to more extensively evaluate the combination of ETBX-011 and N-803 along with other immunotherapy agents.", "metadata": {"result_id": 12580, "source_trial_id": "NCT03127098", "intervention_name": "ETBX-011", "condition_name": "Pancreatic Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0186", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Vitamin K 10 mg\nCondition: Crohn Disease\nPhase: phase_1\nEnrollment: 28\nTermination reason: \"The study was stopped as all post-marketing commitments had been fulfilled or released\"\nDetail: The study was stopped as all post-marketing commitments had been fulfilled or released", "metadata": {"result_id": 46432, "source_trial_id": "NCT03358706", "intervention_name": "Vitamin K 10 mg", "condition_name": "Crohn Disease", "confidence_tier": "bronze", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL1-0187", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: DFMO\nCondition: Advanced Cancer\nPhase: phase_1_2\nEnrollment: 15\nTermination reason: \"Required re-formulation of DFMO from IV to capsule to maintain safety\"\nDetail: Required re-formulation of DFMO from IV to capsule to maintain safety", "metadata": {"result_id": 42087, "source_trial_id": "NCT05500508", "intervention_name": "DFMO", "condition_name": "Advanced Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0188", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: adefovir\nCondition: Chronic Hepatitis\nPhase: phase_3\nTermination reason: \"The study was terminated in the interest of patient safety.\"\nDetail: The study was terminated in the interest of patient safety.", "metadata": {"result_id": 16493, "source_trial_id": "NCT00496002", "intervention_name": "adefovir", "condition_name": "Chronic Hepatitis", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-0189", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: TAK-875\nCondition: Diabetes Mellitus, Type 2\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 2454\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Odds Ratio (OR)): 0.13\n95% CI: [0.09, 0.18]\nSerious adverse events: 360.0\nInterpretation: safety_stopped", "metadata": {"result_id": 48232, "source_trial_id": "NCT01481116", "intervention_name": "TAK-875", "condition_name": "Diabetes Mellitus, Type 2", "confidence_tier": "silver", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-0190", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Cemdisiran\nDrug type: oligonucleotide\nCondition: IgA Nephropathy (IgAN)\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 31\nPrimary endpoint met: 1.0\np-value: 0.0021\nEffect size (Placebo-adjusted GM Percent Change): -45.771\n95% CI: [-60.093, -26.309]\nInterpretation: safety_stopped", "metadata": {"result_id": 22228, "source_trial_id": "NCT03841448", "intervention_name": "Cemdisiran", "condition_name": "IgA Nephropathy (IgAN)", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0191", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Micronized progesterone\nCondition: Preimplantation Genetic Screening\nPhase: phase_4\nEnrollment: 362\nTermination reason: \"safety\"\nDetail: safety", "metadata": {"result_id": 52233, "source_trial_id": "NCT03976544", "intervention_name": "Micronized progesterone", "condition_name": "Preimplantation Genetic Screening", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0192", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Pafuramidine maleate (DB289)\nCondition: Pneumocystis Carinii Pneumonia\nPhase: phase_3\nEnrollment: 48\nTermination reason: \"FDA Clinical Hold as of 12/21/07 due to safety concerns\"\nDetail: FDA Clinical Hold as of 12/21/07 due to safety concerns", "metadata": {"result_id": 439, "source_trial_id": "NCT00302341", "intervention_name": "Pafuramidine maleate (DB289)", "condition_name": "Pneumocystis Carinii Pneumonia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0193", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: CeraLyte 90\nCondition: Burn Any Degree Involving 30-39 Percent of Body Surface\nPhase: phase_1\nEnrollment: 3\nTermination reason: \"Intervention appeared to be associated with increased nausea in some patients.\"\nDetail: Intervention appeared to be associated with increased nausea in some patients.", "metadata": {"result_id": 14074, "source_trial_id": "NCT02124265", "intervention_name": "CeraLyte 90", "condition_name": "Burn Any Degree Involving 30-39 Percent of Body Surface", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0194", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Moxetumomab Pasudotox\nDrug type: antibody_drug_conjugate\nCondition: Leukemia\nPhase: phase_1\nEnrollment: 16\nTermination reason: \"Ph I Exempt as it did not proceed to the Phase II terminated early by the supporter\"\nDetail: Ph I Exempt as it did not proceed to the Phase II terminated early by the supporter", "metadata": {"result_id": 49278, "source_trial_id": "NCT01891981", "intervention_name": "Moxetumomab Pasudotox", "condition_name": "Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0195", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Dronedarone\nCondition: Atrial Fibrillation\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 3236\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (Hazard Ratio (HR)): 1.947\n95% CI: [1.448, 2.617]\nSerious adverse events: 442.0\nInterpretation: safety_stopped", "metadata": {"result_id": 21884, "source_trial_id": "NCT01151137", "intervention_name": "Dronedarone", "condition_name": "Atrial Fibrillation", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0196", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Montelukast or equivalent\nCondition: Immune System Disorder\nPhase: phase_1_2\nEnrollment: 23\nTermination reason: \"Terminated due to non-safety reasons\"\nDetail: Terminated due to non-safety reasons", "metadata": {"result_id": 13825, "source_trial_id": "NCT04294459", "intervention_name": "Montelukast or equivalent", "condition_name": "Immune System Disorder", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0197", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Lacosamide intravenous\nCondition: Electroencephalographic Neonatal Seizures\nPhase: phase_2\nEnrollment: 29\nTermination reason: \"Study stopped after agreed PIP modification, not linked to safety reasons.\"\nDetail: Study stopped after agreed PIP modification, not linked to safety reasons.", "metadata": {"result_id": 47271, "source_trial_id": "NCT04519645", "intervention_name": "Lacosamide intravenous", "condition_name": "Electroencephalographic Neonatal Seizures", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0198", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Atenolol\nCondition: Left Ventricular Hypertrophy\nPhase: phase_3\nBlinding: NONE\nEnrollment: 200\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Hazard Ratio (HR)): 2.36\n95% CI: [1.36, 4.23]\nSerious adverse events: 390.0\nInterpretation: safety_stopped", "metadata": {"result_id": 61388, "source_trial_id": "NCT00582114", "intervention_name": "Atenolol", "condition_name": "Left Ventricular Hypertrophy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0199", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Folic/folinic acid\nCondition: Rheumatoid Arthritis\nPhase: phase_2\nEnrollment: 16\nTermination reason: \"Due to delay in the study and the impact on the development timelines, not due to any identified safety concerns\"\nDetail: Due to delay in the study and the impact on the development timelines, not due to any identified safety concerns", "metadata": {"result_id": 42575, "source_trial_id": "NCT01217814", "intervention_name": "Folic/folinic acid", "condition_name": "Rheumatoid Arthritis", "confidence_tier": "bronze", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL1-0200", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Topical testosterone gel 1% (active formulation)\nCondition: Muscular Diseases\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 209\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (Mean Difference (Net)): 1.5\n95% CI: [0.4, 2.2]\nSerious adverse events: 52.0\nInterpretation: safety_stopped", "metadata": {"result_id": 8606, "source_trial_id": "NCT00240981", "intervention_name": "Topical testosterone gel 1% (active formulation)", "condition_name": "Muscular Diseases", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0201", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Leflunomide\nCondition: Melanoma\nPhase: phase_1\nEnrollment: 3\nTermination reason: \"Adverse Events\"\nDetail: Adverse Events", "metadata": {"result_id": 33165, "source_trial_id": "NCT01611675", "intervention_name": "Leflunomide", "condition_name": "Melanoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0202", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Sitaxsentan\nCondition: Pulmonary Arterial Hypertension\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 131\nPrimary endpoint met: 1.0\np-value: 0.0049\nSerious adverse events: 91.0\nInterpretation: safety_stopped", "metadata": {"result_id": 3646, "source_trial_id": "NCT00796666", "intervention_name": "Sitaxsentan", "condition_name": "Pulmonary Arterial Hypertension", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0203", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Naproxen-n-butyl nitrate\nCondition: Prostate Cancer\nPhase: phase_2\nEnrollment: 20\nTermination reason: \"Extreme toxicity\"\nDetail: Extreme toxicity", "metadata": {"result_id": 54095, "source_trial_id": "NCT00383487", "intervention_name": "Naproxen-n-butyl nitrate", "condition_name": "Prostate Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0204", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Melphalan\nCondition: Acute Myeloid Leukemia\nPhase: phase_1\nEnrollment: 5\nTermination reason: \"Toxicity. Only enrolled patients in phase I portion of trial.\"\nDetail: Toxicity. Only enrolled patients in phase I portion of trial.", "metadata": {"result_id": 53788, "source_trial_id": "NCT02750254", "intervention_name": "Melphalan", "condition_name": "Acute Myeloid Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0205", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: vorinostat (suberoylanilide hydroxamic acid)\nCondition: Non-small-cell Lung Carcinoma\nPhase: phase_1\nEnrollment: 12\nTermination reason: \"closed due to toxicity\"\nDetail: closed due to toxicity", "metadata": {"result_id": 17211, "source_trial_id": "NCT00565227", "intervention_name": "vorinostat (suberoylanilide hydroxamic acid)", "condition_name": "Non-small-cell Lung Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0206", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Xeloda,\nCondition: Gastric Cancer\nPhase: phase_1\nEnrollment: 3\nTermination reason: \"Unafavourable toxicity profile\"\nDetail: Unafavourable toxicity profile", "metadata": {"result_id": 50064, "source_trial_id": "NCT02720926", "intervention_name": "Xeloda,", "condition_name": "Gastric Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0207", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Neupogen\nDrug type: peptide\nCondition: AL Amyloidosis\nPhase: phase_3\nEnrollment: 3\nTermination reason: \"Enrollment held for toxicity evaluation; then closed due to competing trial\"\nDetail: Enrollment held for toxicity evaluation; then closed due to competing trial", "metadata": {"result_id": 52593, "source_trial_id": "NCT02489500", "intervention_name": "Neupogen", "condition_name": "AL Amyloidosis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0208", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Dutasteride/Tamsulosin\nCondition: Prostatic Hyperplasia\nPhase: phase_4\nBlinding: NONE\nEnrollment: 59\nPrimary endpoint met: 1.0\np-value: 0.001\nSerious adverse events: 2.0\nInterpretation: safety_stopped", "metadata": {"result_id": 33494, "source_trial_id": "NCT01673490", "intervention_name": "Dutasteride/Tamsulosin", "condition_name": "Prostatic Hyperplasia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0209", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: TGC\nCondition: External Causes of Morbidity and Mortality\nEnrollment: 200\nTermination reason: \"Hypoglycaemia is significantly higher in TGC\"\nDetail: Hypoglycaemia is significantly higher in TGC", "metadata": {"result_id": 63243, "source_trial_id": "NCT01225159", "intervention_name": "TGC", "condition_name": "External Causes of Morbidity and Mortality", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0210", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: immunosuppressive therapy\nCondition: Stage III Cutaneous T-cell Non-Hodgkin Lymphoma\nPhase: phase_2\nEnrollment: 20\nTermination reason: \"Study was closed to accrual for safety related to the frequency of BK infections.\"\nDetail: Study was closed to accrual for safety related to the frequency of BK infections.", "metadata": {"result_id": 59808, "source_trial_id": "NCT01044745", "intervention_name": "immunosuppressive therapy", "condition_name": "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0211", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Vudalimab\nDrug type: monoclonal_antibody\nCondition: Castration-Sensitive Prostate Carcinoma\nPhase: phase_1\nEnrollment: 4\nTermination reason: \"To review the safety data.\"\nDetail: To review the safety data.", "metadata": {"result_id": 49468, "source_trial_id": "NCT05733351", "intervention_name": "Vudalimab", "condition_name": "Castration-Sensitive Prostate Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0212", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: TAK-994\nCondition: Narcolepsy Type 1 (NT1)\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 97\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (LS Mean Difference): 26.4\n95% CI: [20.07, 32.73]\nInterpretation: safety_stopped", "metadata": {"result_id": 52693, "source_trial_id": "NCT04096560", "intervention_name": "TAK-994", "condition_name": "Narcolepsy Type 1 (NT1)", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0213", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: rituximab +bendamustine\nCondition: Lymphoma, Non-Hodgkin\nPhase: phase_3\nBlinding: NONE\nEnrollment: 338\np-value: 0.142\nEffect size (Hazard Ratio (HR)): 0.76\n95% CI: [0.47, 1.25]\nSerious adverse events: 351.0\nInterpretation: safety_stopped", "metadata": {"result_id": 27518, "source_trial_id": "NCT01232556", "intervention_name": "rituximab +bendamustine", "condition_name": "Lymphoma, Non-Hodgkin", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0214", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: DHA-piperaquine\nCondition: Malaria\nEnrollment: 231\nTermination reason: \"Medication safety concern\"\nDetail: Medication safety concern", "metadata": {"result_id": 22010, "source_trial_id": "NCT01624337", "intervention_name": "DHA-piperaquine", "condition_name": "Malaria", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-0215", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: 7.5% hypertonic saline (HS)\nCondition: Shock, Traumatic\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 895\nPrimary endpoint met: 1.0\np-value: 0.01\nSerious adverse events: 134.0\nInterpretation: safety_stopped", "metadata": {"result_id": 4043, "source_trial_id": "NCT00316017", "intervention_name": "7.5% hypertonic saline (HS)", "condition_name": "Shock, Traumatic", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0216", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Topical testosterone gel 1% (active formulation)\nCondition: Sarcopenia\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 209\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (Mean Difference (Net)): 1.5\n95% CI: [0.4, 2.2]\nSerious adverse events: 52.0\nInterpretation: safety_stopped", "metadata": {"result_id": 8602, "source_trial_id": "NCT00240981", "intervention_name": "Topical testosterone gel 1% (active formulation)", "condition_name": "Sarcopenia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0217", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: immunosuppressive therapy\nCondition: Contiguous Stage II Adult Diffuse Large Cell Lymphoma\nPhase: phase_2\nEnrollment: 20\nTermination reason: \"Study was closed to accrual for safety related to the frequency of BK infections.\"\nDetail: Study was closed to accrual for safety related to the frequency of BK infections.", "metadata": {"result_id": 58989, "source_trial_id": "NCT01044745", "intervention_name": "immunosuppressive therapy", "condition_name": "Contiguous Stage II Adult Diffuse Large Cell Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0218", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Proellex 50 mg\nCondition: Uterine Fibroids\nPhase: phase_3\nEnrollment: 56\nTermination reason: \"Repros stopped study for safety and FDA put study on hold because of safety.\"\nDetail: Repros stopped study for safety and FDA put study on hold because of safety.", "metadata": {"result_id": 5768, "source_trial_id": "NCT00702702", "intervention_name": "Proellex 50 mg", "condition_name": "Uterine Fibroids", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0219", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Hydroxyurea\nCondition: Cerebrovascular Accident\nPhase: phase_3\nBlinding: NONE\nEnrollment: 134\nPrimary endpoint met: 1.0\np-value: 0.01\nSerious adverse events: 122.0\nInterpretation: safety_stopped", "metadata": {"result_id": 9862, "source_trial_id": "NCT00122980", "intervention_name": "Hydroxyurea", "condition_name": "Cerebrovascular Accident", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0220", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Gd-DOTA\nCondition: Renal Insufficiency, Chronic\nPhase: phase_1_2\nEnrollment: 166\nTermination reason: \"The study was suspended after a suspected unexpected serious adverse event.\"\nDetail: The study was suspended after a suspected unexpected serious adverse event.", "metadata": {"result_id": 57349, "source_trial_id": "NCT02286258", "intervention_name": "Gd-DOTA", "condition_name": "Renal Insufficiency, Chronic", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0221", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Cohort 1 Not Previously Treated\nCondition: Head and Neck Cancer\nPhase: phase_2\nEnrollment: 1\nTermination reason: \"Sponsor terminated study due to higher incidence of pulmonary toxicity than expected, including death\"\nDetail: Sponsor terminated study due to higher incidence of pulmonary toxicity than expected, including death", "metadata": {"result_id": 54859, "source_trial_id": "NCT03938337", "intervention_name": "Cohort 1 Not Previously Treated", "condition_name": "Head and Neck Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0222", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Proellex 50 mg\nCondition: Uterine Fibroids\nPhase: phase_2\nEnrollment: 10\nTermination reason: \"Repros stopped the study for safety and FDA put the study on hold for safety.\"\nDetail: Repros stopped the study for safety and FDA put the study on hold for safety.", "metadata": {"result_id": 60588, "source_trial_id": "NCT00683917", "intervention_name": "Proellex 50 mg", "condition_name": "Uterine Fibroids", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0223", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Parathyroid Hormone (teriparatide)\nDrug type: peptide\nCondition: Myelofibrosis\nPhase: phase_2\nEnrollment: 13\nTermination reason: \"Study stopped because of toxicity concerns.\"\nDetail: Study stopped because of toxicity concerns.", "metadata": {"result_id": 39826, "source_trial_id": "NCT00393380", "intervention_name": "Parathyroid Hormone (teriparatide)", "condition_name": "Myelofibrosis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0224", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: EMA401\nCondition: Post-herpetic Neuralgia\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 130\np-value: 0.225\nEffect size (LS mean difference): 0.6\n95% CI: [-0.4, 1.6]\nSerious adverse events: 16.0\nInterpretation: safety_stopped", "metadata": {"result_id": 16747, "source_trial_id": "NCT03094195", "intervention_name": "EMA401", "condition_name": "Post-herpetic Neuralgia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0225", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: ADCT-502\nDrug type: monoclonal_antibody\nCondition: GastroEsophageal Cancer\nPhase: phase_1\nEnrollment: 21\nTermination reason: \"Safety\"\nDetail: Safety", "metadata": {"result_id": 26694, "source_trial_id": "NCT03125200", "intervention_name": "ADCT-502", "condition_name": "GastroEsophageal Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0226", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: PLX3397\nCondition: V600-mutated BRAF Metastatic Melanoma\nPhase: phase_1\nEnrollment: 13\nTermination reason: \"No activity was observed. BRAFi-naïve participants should have received triple combination treatment (including MEK inhibitor). Continuation was not justified.\"\nDetail: No activity was observed. BRAFi-naïve participants should have received triple combination treatment (including MEK inhibitor). Continuation was not justified.", "metadata": {"result_id": 33761, "source_trial_id": "NCT01826448", "intervention_name": "PLX3397", "condition_name": "V600-mutated BRAF Metastatic Melanoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0227", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Elenbecestat\nCondition: Alzheimer's Disease\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 2212\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (LS Mean Difference): -12.83\n95% CI: [-18.79, -6.88]\nSerious adverse events: 616.0\nInterpretation: safety_stopped", "metadata": {"result_id": 44876, "source_trial_id": "NCT02956486", "intervention_name": "Elenbecestat", "condition_name": "Alzheimer's Disease", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0228", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: MDCO 4\nCondition: Bleeding\nPhase: phase_2\nEnrollment: 44\nTermination reason: \"Safety\"\nDetail: Safety", "metadata": {"result_id": 22555, "source_trial_id": "NCT01530399", "intervention_name": "MDCO 4", "condition_name": "Bleeding", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0229", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: BPX-601\nDrug type: cell_therapy\nCondition: Metastatic Castration-resistant Prostate Cancer\nPhase: phase_1\nEnrollment: 52\nTermination reason: \"Due to a Dose Limiting Toxicity.\"\nDetail: Due to a Dose Limiting Toxicity.", "metadata": {"result_id": 56604, "source_trial_id": "NCT02744287", "intervention_name": "BPX-601", "condition_name": "Metastatic Castration-resistant Prostate Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0230", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Seladelpar\nCondition: NASH - Nonalcoholic Steatohepatitis\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 181\np-value: 0.0874\nEffect size (LS Mean of Difference): 11.02\n95% CI: [-1.63, 23.67]\nSerious adverse events: 21.0\nInterpretation: safety_stopped", "metadata": {"result_id": 24052, "source_trial_id": "NCT03551522", "intervention_name": "Seladelpar", "condition_name": "NASH - Nonalcoholic Steatohepatitis", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-0231", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Proellex 50 mg\nCondition: Uterine Fibroids\nPhase: phase_3\nEnrollment: 8\nTermination reason: \"Repros stopped the study for safety and FDA put the study on hold for safety.\"\nDetail: Repros stopped the study for safety and FDA put the study on hold for safety.", "metadata": {"result_id": 26831, "source_trial_id": "NCT00785356", "intervention_name": "Proellex 50 mg", "condition_name": "Uterine Fibroids", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0232", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: LEO 32731\nCondition: Psoriasis Vulgaris\nPhase: phase_1\nEnrollment: 12\nTermination reason: \"Due to tolerability issues related to the dose titration, unexpected withdrawals were observed and it was unlikely for the trial to meet its objectives\"\nDetail: Due to tolerability issues related to the dose titration, unexpected withdrawals were observed and it was unlikely for the trial to meet its objectives", "metadata": {"result_id": 15345, "source_trial_id": "NCT02753218", "intervention_name": "LEO 32731", "condition_name": "Psoriasis Vulgaris", "confidence_tier": "bronze", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL1-0233", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981\nCondition: Stage IVB Prostate Cancer AJCC v8\nPhase: phase_2\nEnrollment: 10\nTermination reason: \"The study was closed to accrual on 3/1/21 due to safety concerns since 2 patients experienced CVA events.\"\nDetail: The study was closed to accrual on 3/1/21 due to safety concerns since 2 patients experienced CVA events.", "metadata": {"result_id": 32208, "source_trial_id": "NCT04159896", "intervention_name": "Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981", "condition_name": "Stage IVB Prostate Cancer AJCC v8", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0234", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Gliadel\nCondition: Glioblastoma Multiforme\nPhase: phase_2\nEnrollment: 41\nTermination reason: \"Study ended early due to toxicity\"\nDetail: Study ended early due to toxicity", "metadata": {"result_id": 37142, "source_trial_id": "NCT01186406", "intervention_name": "Gliadel", "condition_name": "Glioblastoma Multiforme", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0235", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Sitaxsentan and Sildenafil\nCondition: Pulmonary Hypertension\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 131\nPrimary endpoint met: 1.0\np-value: 0.0049\nSerious adverse events: 91.0\nInterpretation: safety_stopped", "metadata": {"result_id": 3645, "source_trial_id": "NCT00796666", "intervention_name": "Sitaxsentan and Sildenafil", "condition_name": "Pulmonary Hypertension", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0236", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: rituximab + gemcitabine\nCondition: Lymphoma, Non-Hodgkin\nPhase: phase_3\nBlinding: NONE\nEnrollment: 338\np-value: 0.142\nEffect size (Hazard Ratio (HR)): 0.76\n95% CI: [0.47, 1.25]\nSerious adverse events: 351.0\nInterpretation: safety_stopped", "metadata": {"result_id": 27517, "source_trial_id": "NCT01232556", "intervention_name": "rituximab + gemcitabine", "condition_name": "Lymphoma, Non-Hodgkin", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0237", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: PF-06952229\nCondition: Colorectal Neoplasms\nPhase: phase_1\nEnrollment: 49\nTermination reason: \"The decision to stop enrollment was due to strategic considerations and not due to any specific safety reasons or request from a regulatory authority.\"\nDetail: The decision to stop enrollment was due to strategic considerations and not due to any specific safety reasons or request from a regulatory authority.", "metadata": {"result_id": 16365, "source_trial_id": "NCT03685591", "intervention_name": "PF-06952229", "condition_name": "Colorectal Neoplasms", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0238", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Lacosamide oral\nCondition: Epilepsy\nPhase: phase_2\nEnrollment: 29\nTermination reason: \"Study stopped after agreed PIP modification, not linked to safety reasons.\"\nDetail: Study stopped after agreed PIP modification, not linked to safety reasons.", "metadata": {"result_id": 47269, "source_trial_id": "NCT04519645", "intervention_name": "Lacosamide oral", "condition_name": "Epilepsy", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0239", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: IVit Melphalan\nCondition: Retinoblastoma\nEnrollment: 10\nTermination reason: \"Sufficient findings to draw conclusions\"\nDetail: Sufficient findings to draw conclusions", "metadata": {"result_id": 55708, "source_trial_id": "NCT01558960", "intervention_name": "IVit Melphalan", "condition_name": "Retinoblastoma", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0240", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: bevacizumab (Avastin)\nDrug type: monoclonal_antibody\nCondition: Myelofibrosis\nPhase: phase_2\nEnrollment: 13\nTermination reason: \"lack of response activity in the setting of an unacceptable toxicity profile\"\nDetail: lack of response activity in the setting of an unacceptable toxicity profile", "metadata": {"result_id": 18500, "source_trial_id": "NCT00667277", "intervention_name": "bevacizumab (Avastin)", "condition_name": "Myelofibrosis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0241", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: XL999\nCondition: Non-Small-Cell Lung Cancer\nPhase: phase_1\nEnrollment: 2\nTermination reason: \"The study was stopped due to safety concerns\"\nDetail: The study was stopped due to safety concerns", "metadata": {"result_id": 11857, "source_trial_id": "NCT00491699", "intervention_name": "XL999", "condition_name": "Non-Small-Cell Lung Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0242", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: cemiplimab\nDrug type: monoclonal_antibody\nCondition: Unresectable Malignant Solid Neoplasm\nPhase: phase_1\nEnrollment: 3\nTermination reason: \"The industry supporter discontinued the study and lead drug, SAR439459, due to toxicity.\"\nDetail: The industry supporter discontinued the study and lead drug, SAR439459, due to toxicity.", "metadata": {"result_id": 4691, "source_trial_id": "NCT04729725", "intervention_name": "cemiplimab", "condition_name": "Unresectable Malignant Solid Neoplasm", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0243", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Fosmetpantotenate\nDrug type: unknown\nCondition: Pantothenate Kinase-Associated Neurodegeneration\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 84\np-value: 0.1421\nEffect size (Difference in LS Mean): 2.0\n95% CI: [-0.7, 4.78]\nSerious adverse events: 140.0\nInterpretation: safety_stopped", "metadata": {"result_id": 25098, "source_trial_id": "NCT03041116", "intervention_name": "Fosmetpantotenate", "condition_name": "Pantothenate Kinase-Associated Neurodegeneration", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0244", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: ZuraPrep Vehicle\nCondition: Surgical Site Infection\nPhase: phase_2\nEnrollment: 64\nTermination reason: \"To assess product performance (test and reference products), move into further testing.\"\nDetail: To assess product performance (test and reference products), move into further testing.", "metadata": {"result_id": 8296, "source_trial_id": "NCT02221232", "intervention_name": "ZuraPrep Vehicle", "condition_name": "Surgical Site Infection", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0245", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: KML-001\nCondition: Platinum Responsive Malignancies\nPhase: phase_1\nEnrollment: 23\nTermination reason: \"Toxicity was not felt to be acceptable for further development.\"\nDetail: Toxicity was not felt to be acceptable for further development.", "metadata": {"result_id": 32768, "source_trial_id": "NCT01110226", "intervention_name": "KML-001", "condition_name": "Platinum Responsive Malignancies", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0246", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: bevacizumab, Rituximab\nCondition: Non-Hodgkin's Lymphoma\nPhase: phase_2\nEnrollment: 7\nTermination reason: \"Toxicity and efficacy data from another trial\"\nDetail: Toxicity and efficacy data from another trial", "metadata": {"result_id": 56361, "source_trial_id": "NCT00788606", "intervention_name": "bevacizumab, Rituximab", "condition_name": "Non-Hodgkin's Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0247", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: MRX34\nCondition: Melanoma\nPhase: phase_1\nEnrollment: 155\nTermination reason: \"Five immune related serious adverse events\"\nDetail: Five immune related serious adverse events", "metadata": {"result_id": 11377, "source_trial_id": "NCT01829971", "intervention_name": "MRX34", "condition_name": "Melanoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0248", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: PF-06747775\nCondition: Non-Small Cell Lung Cancer\nPhase: phase_1_2\nEnrollment: 65\nTermination reason: \"The study was ended for strategic reasons and changes in the external environment.~The safety profile and risk benefit ratio for PF-0674775 remained unchanged.\"\nDetail: The study was ended for strategic reasons and changes in the external environment.~The safety profile and risk benefit ratio for PF-0674775 remained unchanged.", "metadata": {"result_id": 3955, "source_trial_id": "NCT02349633", "intervention_name": "PF-06747775", "condition_name": "Non-Small Cell Lung Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0249", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: imipenem-cilastatin\nCondition: Ventilator-associated Pneumonia\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 274\np-value: 0.14\nSerious adverse events: 301.0\nInterpretation: safety_stopped", "metadata": {"result_id": 12624, "source_trial_id": "NCT00589693", "intervention_name": "imipenem-cilastatin", "condition_name": "Ventilator-associated Pneumonia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0250", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: anti-CD123 CAR-T treatment\nCondition: Acute Leukemia\nPhase: phase_1\nEnrollment: 2\nTermination reason: \"adverse effect\"\nDetail: adverse effect", "metadata": {"result_id": 51527, "source_trial_id": "NCT03672851", "intervention_name": "anti-CD123 CAR-T treatment", "condition_name": "Acute Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0251", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: TAK-875\nCondition: Type 2 Diabetes Mellitus\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 393\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Least squares mean difference): -1.03\n95% CI: [-1.27, -0.78]\nSerious adverse events: 37.0\nInterpretation: safety_stopped", "metadata": {"result_id": 5128, "source_trial_id": "NCT01647542", "intervention_name": "TAK-875", "condition_name": "Type 2 Diabetes Mellitus", "confidence_tier": "silver", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-0252", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Ponatinib 30 mg QD\nCondition: Chronic Phase Chronic Myeloid Leukemia\nPhase: phase_3\nEnrollment: 44\nTermination reason: \"The study was stopped due to operational feasibility and not due to any safety concerns\"\nDetail: The study was stopped due to operational feasibility and not due to any safety concerns", "metadata": {"result_id": 51467, "source_trial_id": "NCT02627677", "intervention_name": "Ponatinib 30 mg QD", "condition_name": "Chronic Phase Chronic Myeloid Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0253", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Trilaciclib\nCondition: Triple-Negative Breast Neoplasms\nPhase: phase_2\nBlinding: NONE\nEnrollment: 102\nPrimary endpoint met: 1.0\np-value: 0.0004\nEffect size (Adjusted hazard ratio (HR)): 0.4\n95% CI: [0.22, 0.74]\nSerious adverse events: 128.0\nInterpretation: safety_stopped", "metadata": {"result_id": 56344, "source_trial_id": "NCT02978716", "intervention_name": "Trilaciclib", "condition_name": "Triple-Negative Breast Neoplasms", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0254", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: VIB9600\nCondition: Safety Issues\nPhase: phase_1\nEnrollment: 24\nTermination reason: \"Study terminated due to tolerability issues.\"\nDetail: Study terminated due to tolerability issues.", "metadata": {"result_id": 52819, "source_trial_id": "NCT03621605", "intervention_name": "VIB9600", "condition_name": "Safety Issues", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0255", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: RP4010\nCondition: Lymphoma\nPhase: phase_1\nEnrollment: 21\nTermination reason: \"Study has been stopped after reviewing PK and safety results\"\nDetail: Study has been stopped after reviewing PK and safety results", "metadata": {"result_id": 8459, "source_trial_id": "NCT03119467", "intervention_name": "RP4010", "condition_name": "Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0256", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: 7.5% hypertonic saline/6% Dextran-70 (HSD)\nCondition: Shock, Traumatic\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 895\nPrimary endpoint met: 1.0\np-value: 0.01\nSerious adverse events: 134.0\nInterpretation: safety_stopped", "metadata": {"result_id": 4042, "source_trial_id": "NCT00316017", "intervention_name": "7.5% hypertonic saline/6% Dextran-70 (HSD)", "condition_name": "Shock, Traumatic", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0257", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: LY2300559\nCondition: Migraine Headache\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 87\np-value: 0.085\nEffect size (Least squares (LS) mean difference (Net)): -1.03\n95% CI: [-2.02, -0.05]\nInterpretation: safety_stopped", "metadata": {"result_id": 37604, "source_trial_id": "NCT01184508", "intervention_name": "LY2300559", "condition_name": "Migraine Headache", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0258", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: fluid bolus\nCondition: Critical Illness\nPhase: phase_4\nEnrollment: 60\nTermination reason: \"Patient Safety\"\nDetail: Patient Safety", "metadata": {"result_id": 60528, "source_trial_id": "NCT02414555", "intervention_name": "fluid bolus", "condition_name": "Critical Illness", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0259", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Memory XL\nCondition: Mild Cognitive Impairment\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 10\np-value: 0.18\nInterpretation: safety_stopped", "metadata": {"result_id": 40818, "source_trial_id": "NCT00903695", "intervention_name": "Memory XL", "condition_name": "Mild Cognitive Impairment", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0260", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: THE-630\nCondition: Digestive System Disease\nPhase: phase_1_2\nEnrollment: 32\nTermination reason: \"The Sponsor terminated the study due to early dose-limiting toxicities.\"\nDetail: The Sponsor terminated the study due to early dose-limiting toxicities.", "metadata": {"result_id": 58703, "source_trial_id": "NCT05160168", "intervention_name": "THE-630", "condition_name": "Digestive System Disease", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0261", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Tacrolimus with steroids minimization\nCondition: Diabetes Mellitus, Adult-Onset\nPhase: phase_4\nBlinding: NONE\nEnrollment: 134\nPrimary endpoint met: 1.0\np-value: 0.02\nSerious adverse events: 51.0\nInterpretation: safety_stopped", "metadata": {"result_id": 7171, "source_trial_id": "NCT01002339", "intervention_name": "Tacrolimus with steroids minimization", "condition_name": "Diabetes Mellitus, Adult-Onset", "confidence_tier": "silver", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-0262", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Anti-TGF-beta Monoclonal Antibody SAR-439459\nCondition: Metastatic Malignant Solid Neoplasm\nPhase: phase_1\nEnrollment: 3\nTermination reason: \"The industry supporter discontinued the study and lead drug, SAR439459, due to toxicity.\"\nDetail: The industry supporter discontinued the study and lead drug, SAR439459, due to toxicity.", "metadata": {"result_id": 4690, "source_trial_id": "NCT04729725", "intervention_name": "Anti-TGF-beta Monoclonal Antibody SAR-439459", "condition_name": "Metastatic Malignant Solid Neoplasm", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0263", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Belatacept\nDrug type: peptide\nCondition: Primary Renal Allograft Candidate\nPhase: phase_2\nBlinding: NONE\nEnrollment: 71\np-value: 0.531\nEffect size (Mean Difference (Final Values)): 4.82\n95% CI: [-10.481, 20.121]\nSerious adverse events: 134.0\nInterpretation: safety_stopped", "metadata": {"result_id": 12034, "source_trial_id": "NCT01856257", "intervention_name": "Belatacept", "condition_name": "Primary Renal Allograft Candidate", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0264", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Cemdisiran\nDrug type: oligonucleotide\nCondition: Glomerulonephritis, IGA\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 31\nPrimary endpoint met: 1.0\np-value: 0.0021\nEffect size (Placebo-adjusted GM Percent Change): -45.771\n95% CI: [-60.093, -26.309]\nInterpretation: safety_stopped", "metadata": {"result_id": 22230, "source_trial_id": "NCT03841448", "intervention_name": "Cemdisiran", "condition_name": "Glomerulonephritis, IGA", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0265", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Omeprazole 20 mg\nCondition: Crohn Disease\nPhase: phase_1\nEnrollment: 28\nTermination reason: \"The study was stopped as all post-marketing commitments had been fulfilled or released\"\nDetail: The study was stopped as all post-marketing commitments had been fulfilled or released", "metadata": {"result_id": 46433, "source_trial_id": "NCT03358706", "intervention_name": "Omeprazole 20 mg", "condition_name": "Crohn Disease", "confidence_tier": "bronze", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL1-0266", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: anti-CD123 CAR-T treatment\nCondition: Acute Leukemia in Relapse\nPhase: phase_1\nEnrollment: 2\nTermination reason: \"adverse effect\"\nDetail: adverse effect", "metadata": {"result_id": 51528, "source_trial_id": "NCT03672851", "intervention_name": "anti-CD123 CAR-T treatment", "condition_name": "Acute Leukemia in Relapse", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0267", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: graft versus host disease prophylaxis/therapy\nCondition: Adult Acute Lymphoblastic Leukemia in Remission\nPhase: phase_2\nEnrollment: 20\nTermination reason: \"Study was closed to accrual for safety related to the frequency of BK infections.\"\nDetail: Study was closed to accrual for safety related to the frequency of BK infections.", "metadata": {"result_id": 60105, "source_trial_id": "NCT01044745", "intervention_name": "graft versus host disease prophylaxis/therapy", "condition_name": "Adult Acute Lymphoblastic Leukemia in Remission", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0268", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: SGI-1776\nCondition: Non-Hodgkins Lymphoma\nPhase: phase_1\nEnrollment: 14\nTermination reason: \"The dose limiting toxicity of cardiac QTc prolongation was identifiedin the phase 1 study in patients with refractory prostate and lymphoma\"\nDetail: The dose limiting toxicity of cardiac QTc prolongation was identifiedin the phase 1 study in patients with refractory prostate and lymphoma", "metadata": {"result_id": 6050, "source_trial_id": "NCT00848601", "intervention_name": "SGI-1776", "condition_name": "Non-Hodgkins Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0269", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: CS-7017\nCondition: Anaplastic Thyroid Cancer\nPhase: phase_1_2\nEnrollment: 19\nTermination reason: \"Due to low enrollment, no participant had a dose limiting toxicity, therefore a maximum tolerated dose could not be established\"\nDetail: Due to low enrollment, no participant had a dose limiting toxicity, therefore a maximum tolerated dose could not be established", "metadata": {"result_id": 50419, "source_trial_id": "NCT00603941", "intervention_name": "CS-7017", "condition_name": "Anaplastic Thyroid Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0270", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Posoleucel (ALVR105)\nDrug type: cell_therapy\nCondition: Epstein-Barr Virus Infections\nPhase: phase_2_3\nBlinding: QUADRUPLE\nEnrollment: 451\np-value: 0.5603\nEffect size (Mean Difference (Final Values)): 0.01\n95% CI: [-0.09, 0.1]\nInterpretation: safety_stopped", "metadata": {"result_id": 27024, "source_trial_id": "NCT05305040", "intervention_name": "Posoleucel (ALVR105)", "condition_name": "Epstein-Barr Virus Infections", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0271", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Sitaxsentan\nCondition: Pulmonary Hypertension\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 131\nPrimary endpoint met: 1.0\np-value: 0.0049\nSerious adverse events: 91.0\nInterpretation: safety_stopped", "metadata": {"result_id": 3644, "source_trial_id": "NCT00796666", "intervention_name": "Sitaxsentan", "condition_name": "Pulmonary Hypertension", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0272", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: LY2584702\nCondition: Metastases, Neoplasm\nPhase: phase_1\nEnrollment: 29\nTermination reason: \"Primary objective has been met; safety and pharmacokinetics have been characterized.\"\nDetail: Primary objective has been met; safety and pharmacokinetics have been characterized.", "metadata": {"result_id": 15648, "source_trial_id": "NCT01115803", "intervention_name": "LY2584702", "condition_name": "Metastases, Neoplasm", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0273", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38\nCondition: Non-Small Cell Lung Cancer\nPhase: phase_1\nEnrollment: 11\nTermination reason: \"for efficacy and safety reasons\"\nDetail: for efficacy and safety reasons", "metadata": {"result_id": 42670, "source_trial_id": "NCT00787852", "intervention_name": "Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38", "condition_name": "Non-Small Cell Lung Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0274", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Recombinant Granulocyte Colony-Stimulating Factor\nCondition: Recurrent Acute Myeloid Leukemia\nPhase: phase_1\nEnrollment: 13\nTermination reason: \"Terminated due to unfavorable risk-benefit ratio of investigational regimen.\"\nDetail: Terminated due to unfavorable risk-benefit ratio of investigational regimen.", "metadata": {"result_id": 1756, "source_trial_id": "NCT04196010", "intervention_name": "Recombinant Granulocyte Colony-Stimulating Factor", "condition_name": "Recurrent Acute Myeloid Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0275", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Sacubitril / Valsartan Oral Tablet\nCondition: Systemic Right Ventricle\nEnrollment: 15\nTermination reason: \"The trial was prematurely terminated due to safety concerns.\"\nDetail: The trial was prematurely terminated due to safety concerns.", "metadata": {"result_id": 3538, "source_trial_id": "NCT05117736", "intervention_name": "Sacubitril / Valsartan Oral Tablet", "condition_name": "Systemic Right Ventricle", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0276", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Motesanib diphosphate\nCondition: Ovarian Cancer\nPhase: phase_2\nEnrollment: 23\nTermination reason: \"Study was stopped for severe toxicity causing concern for patients\"\nDetail: Study was stopped for severe toxicity causing concern for patients", "metadata": {"result_id": 38387, "source_trial_id": "NCT00574951", "intervention_name": "Motesanib diphosphate", "condition_name": "Ovarian Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0277", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: ACE-031 1.0 mg/kg q2wk\nCondition: Duchenne Muscular Dystrophy\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 24\nPrimary endpoint met: 1.0\np-value: 0.012\nInterpretation: safety_stopped", "metadata": {"result_id": 752, "source_trial_id": "NCT01099761", "intervention_name": "ACE-031 1.0 mg/kg q2wk", "condition_name": "Duchenne Muscular Dystrophy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0278", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Ampion\nCondition: Severe Osteoarthritis of the Knee\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 1043\np-value: 0.3\nSerious adverse events: 63.0\nInterpretation: safety_stopped", "metadata": {"result_id": 41851, "source_trial_id": "NCT03988023", "intervention_name": "Ampion", "condition_name": "Severe Osteoarthritis of the Knee", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0279", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: GSK2248761\nCondition: HIV Infections\nPhase: phase_1\nEnrollment: 13\nTermination reason: \"In a Phase II study in HIV-infected patients there were a number of seizures, although exact causality could not be assessed phase 1 activity was terminated.\"\nDetail: In a Phase II study in HIV-infected patients there were a number of seizures, although exact causality could not be assessed phase 1 activity was terminated.", "metadata": {"result_id": 47065, "source_trial_id": "NCT01195974", "intervention_name": "GSK2248761", "condition_name": "HIV Infections", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-0280", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: TAS0728\nDrug type: unknown\nCondition: Advanced Solid Tumors With HER3 Abnormalities\nPhase: phase_1\nEnrollment: 19\nTermination reason: \"The study was stopped due to unacceptable toxicity during the dose-escalation portion (Phase 1) of the study and did not progress to Phase 2\"\nDetail: The study was stopped due to unacceptable toxicity during the dose-escalation portion (Phase 1) of the study and did not progress to Phase 2", "metadata": {"result_id": 26825, "source_trial_id": "NCT03410927", "intervention_name": "TAS0728", "condition_name": "Advanced Solid Tumors With HER3 Abnormalities", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0281", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Reparixin\nCondition: Ischemia-reperfusion Injury in Liver Transplant\nPhase: phase_2\nBlinding: NONE\nEnrollment: 40\np-value: 0.308\nInterpretation: safety_stopped", "metadata": {"result_id": 48703, "source_trial_id": "NCT03031470", "intervention_name": "Reparixin", "condition_name": "Ischemia-reperfusion Injury in Liver Transplant", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0282", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: 177Lu-3BP-227 (also called 177Lu-IPN01087)\nCondition: Metastatic Tumours\nPhase: phase_1\nEnrollment: 14\nTermination reason: \"Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns\"\nDetail: Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns", "metadata": {"result_id": 4970, "source_trial_id": "NCT03525392", "intervention_name": "177Lu-3BP-227 (also called 177Lu-IPN01087)", "condition_name": "Metastatic Tumours", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0283", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: AV608\nCondition: Irritable Bowel Syndrome (IBS)\nPhase: phase_1\nEnrollment: 24\nTermination reason: \"Animal Safety Data\"\nDetail: Animal Safety Data", "metadata": {"result_id": 12492, "source_trial_id": "NCT00316550", "intervention_name": "AV608", "condition_name": "Irritable Bowel Syndrome (IBS)", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0284", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: CeraLyte 90\nCondition: Fluid Resuscitation\nPhase: phase_1\nEnrollment: 3\nTermination reason: \"Intervention appeared to be associated with increased nausea in some patients.\"\nDetail: Intervention appeared to be associated with increased nausea in some patients.", "metadata": {"result_id": 14072, "source_trial_id": "NCT02124265", "intervention_name": "CeraLyte 90", "condition_name": "Fluid Resuscitation", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0285", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: PF-06952229\nCondition: Breast Neoplasms\nPhase: phase_1\nEnrollment: 49\nTermination reason: \"The decision to stop enrollment was due to strategic considerations and not due to any specific safety reasons or request from a regulatory authority.\"\nDetail: The decision to stop enrollment was due to strategic considerations and not due to any specific safety reasons or request from a regulatory authority.", "metadata": {"result_id": 16369, "source_trial_id": "NCT03685591", "intervention_name": "PF-06952229", "condition_name": "Breast Neoplasms", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0286", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: KHK4323 SC/S\nCondition: Atopic Dermatitis\nPhase: phase_1\nEnrollment: 5\nTermination reason: \"The study terminated for safety reasons.\"\nDetail: The study terminated for safety reasons.", "metadata": {"result_id": 3736, "source_trial_id": "NCT03846466", "intervention_name": "KHK4323 SC/S", "condition_name": "Atopic Dermatitis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0287", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: ATX-559\nCondition: Breast Cancer Recurrent\nPhase: phase_1\nEnrollment: 17\nTermination reason: \"The study was terminated by sponsor based on the adverse event profile.\"\nDetail: The study was terminated by sponsor based on the adverse event profile.", "metadata": {"result_id": 10331, "source_trial_id": "NCT06625515", "intervention_name": "ATX-559", "condition_name": "Breast Cancer Recurrent", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0288", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: DLI\nCondition: Leukemia\nPhase: phase_1_2\nEnrollment: 9\nTermination reason: \"toxicity\"\nDetail: toxicity", "metadata": {"result_id": 14881, "source_trial_id": "NCT00582816", "intervention_name": "DLI", "condition_name": "Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0289", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Anti-thymocyte globulin, rabbit\nDrug type: unknown\nCondition: Leukemia, Acute\nPhase: phase_1_2\nEnrollment: 10\nTermination reason: \"Safety\"\nDetail: Safety", "metadata": {"result_id": 38084, "source_trial_id": "NCT01050764", "intervention_name": "Anti-thymocyte globulin, rabbit", "condition_name": "Leukemia, Acute", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0290", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Sildenafil\nCondition: Sickle Cell Disease\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 74\np-value: 0.7\nEffect size (Mean Difference (Net)): -9.0\n95% CI: [-56.0, 38.0]\nSerious adverse events: 63.0\nInterpretation: safety_stopped", "metadata": {"result_id": 22263, "source_trial_id": "NCT00492531", "intervention_name": "Sildenafil", "condition_name": "Sickle Cell Disease", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0291", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Parathyroid Hormone (teriparatide)\nDrug type: peptide\nCondition: Leukemia, Lymphocytic, Acute\nPhase: phase_2\nEnrollment: 13\nTermination reason: \"Study stopped because of toxicity concerns.\"\nDetail: Study stopped because of toxicity concerns.", "metadata": {"result_id": 39827, "source_trial_id": "NCT00393380", "intervention_name": "Parathyroid Hormone (teriparatide)", "condition_name": "Leukemia, Lymphocytic, Acute", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0292", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: BTH1704\nCondition: Pancreatic Cancer\nPhase: phase_1\nEnrollment: 3\nTermination reason: \"Drug Recall\"\nDetail: Drug Recall", "metadata": {"result_id": 48470, "source_trial_id": "NCT02132403", "intervention_name": "BTH1704", "condition_name": "Pancreatic Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0293", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Anakinra\nDrug type: peptide\nCondition: Rheumatoid Arthritis\nPhase: phase_2\nEnrollment: 22\nTermination reason: \"The safety profile of combination therapy became unacceptable.\"\nDetail: The safety profile of combination therapy became unacceptable.", "metadata": {"result_id": 60675, "source_trial_id": "NCT00537667", "intervention_name": "Anakinra", "condition_name": "Rheumatoid Arthritis", "confidence_tier": "bronze", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL1-0294", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Sitaxsentan\nCondition: Pulmonary Hypertension\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 183\nPrimary endpoint met: 1.0\np-value: 0.0104\nEffect size (Mean Difference (Final Values)): 14.0\n95% CI: [3.0, 26.0]\nSerious adverse events: 56.0\nInterpretation: safety_stopped", "metadata": {"result_id": 56143, "source_trial_id": "NCT00795639", "intervention_name": "Sitaxsentan", "condition_name": "Pulmonary Hypertension", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0295", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Daratumumab\nDrug type: monoclonal_antibody\nCondition: Relapsed T-Cell Lymphoma\nPhase: phase_2\nEnrollment: 8\nTermination reason: \"The enrolment was prematurely terminated after the planned monitoring of the first 5 patients because of an unacceptable level of relevant toxicities, according to statistical stopping rules and the DSMB recommendation.\"\nDetail: The enrolment was prematurely terminated after the planned monitoring of the first 5 patients because of an unacceptable level of relevant toxicities, according to statistical stopping rules and the DSMB recommendation.", "metadata": {"result_id": 20087, "source_trial_id": "NCT04251065", "intervention_name": "Daratumumab", "condition_name": "Relapsed T-Cell Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0296", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: ustekinumab 90 mg\nCondition: Axial Spondyloarthritis\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 347\np-value: 0.669\nEffect size (Percentage difference): 2.586\n95% CI: [-9.138, 14.31]\nSerious adverse events: 32.0\nInterpretation: safety_stopped", "metadata": {"result_id": 35418, "source_trial_id": "NCT02437162", "intervention_name": "ustekinumab 90 mg", "condition_name": "Axial Spondyloarthritis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0297", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Tasisulam\nCondition: Advanced Cancer\nPhase: phase_1\nEnrollment: 4\nTermination reason: \"Terminated based on safety results from another trial\"\nDetail: Terminated based on safety results from another trial", "metadata": {"result_id": 26888, "source_trial_id": "NCT01185548", "intervention_name": "Tasisulam", "condition_name": "Advanced Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0298", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: BEZ235\nCondition: Renal Cancer\nPhase: phase_1_2\nEnrollment: 10\nTermination reason: \"Given the number of toxicities seen and the difficulty with patient retention in the dose escalation portion, the sponsor decided to close the trial.\"\nDetail: Given the number of toxicities seen and the difficulty with patient retention in the dose escalation portion, the sponsor decided to close the trial.", "metadata": {"result_id": 53361, "source_trial_id": "NCT01453595", "intervention_name": "BEZ235", "condition_name": "Renal Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0299", "task": "CT-L1", "gold_answer": "A", "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Tucatinib\nCondition: Locally Advanced HER2 Positive Breast Carcinoma\nPhase: phase_2\nEnrollment: 13\nTermination reason: \"The study was closed early due to safety concerns and an unfavorable benefit-risk balance. Unexpected high neutropenia rates required a costly sub-study, which was not feasible, forcing the sponsor to terminate the trial prematurely.\"\nDetail: The study was closed early due to safety concerns and an unfavorable benefit-risk balance. Unexpected high neutropenia rates required a costly sub-study, which was not feasible, forcing the sponsor to terminate the trial prematurely.", "metadata": {"result_id": 13559, "source_trial_id": "NCT05583110", "intervention_name": "Tucatinib", "condition_name": "Locally Advanced HER2 Positive Breast Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0300", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Ofatumumab 60mg\nDrug type: monoclonal_antibody\nCondition: Multiple Sclerosis\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 232\np-value: 0.075\n95% CI: [0.29, 1.06]\nSerious adverse events: 13.0\nInterpretation: definitive_negative", "metadata": {"result_id": 74964, "source_trial_id": "NCT01457924", "intervention_name": "Ofatumumab 60mg", "condition_name": "Multiple Sclerosis", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "fewshot"}
+{"question_id": "CTL1-0301", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Epirubicine, Oxaliplatin, Capecitabine, Panitumumab\nCondition: KRAS Wild Type\nPhase: phase_2\nEnrollment: 43\nTermination reason: \"REAL trial showed a significant difference in OS for reduced EOX and standard EOX\"\nDetail: REAL trial showed a significant difference in OS for reduced EOX and standard EOX", "metadata": {"result_id": 33166, "source_trial_id": "NCT01351038", "intervention_name": "Epirubicine, Oxaliplatin, Capecitabine, Panitumumab", "condition_name": "KRAS Wild Type", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0302", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Lidocaine HCl\nCondition: Lumbar and Other Intervertebral Disc Disorders With Radiculopathy\nBlinding: QUADRUPLE\nEnrollment: 26\np-value: 0.159\n95% CI: [-0.52, 3.6]\nInterpretation: definitive_negative", "metadata": {"result_id": 97282, "source_trial_id": "NCT00588354", "intervention_name": "Lidocaine HCl", "condition_name": "Lumbar and Other Intervertebral Disc Disorders With Radiculopathy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0303", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Reltecimod 0.5 mg/kg\nCondition: Necrotizing Soft Tissue Infection\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 58\np-value: 0.649\nSerious adverse events: 69.0\nInterpretation: definitive_negative", "metadata": {"result_id": 87290, "source_trial_id": "NCT03403751", "intervention_name": "Reltecimod 0.5 mg/kg", "condition_name": "Necrotizing Soft Tissue Infection", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0304", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: HTL0022562\nCondition: Healthy\nPhase: phase_1\nEnrollment: 33\nTermination reason: \"Early termination of study pending evaluation of emerging preclinical profile.\"\nDetail: Early termination of study pending evaluation of emerging preclinical profile.", "metadata": {"result_id": 42062, "source_trial_id": "NCT04941989", "intervention_name": "HTL0022562", "condition_name": "Healthy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0305", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Olopatadine\nCondition: Seasonal Allergic Conjunctivitis to Ragweed\nPhase: phase_2\nEnrollment: 143\nTermination reason: \"Lack of definitive clinical results.\"\nDetail: Lack of definitive clinical results.", "metadata": {"result_id": 32451, "source_trial_id": "NCT01287338", "intervention_name": "Olopatadine", "condition_name": "Seasonal Allergic Conjunctivitis to Ragweed", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0306", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: LLG783\nCondition: Peripheral Artery Disease (PAD); Intermittent Claudication\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 46\np-value: 0.2612\n95% CI: [-38.03, 2.55]\nSerious adverse events: 6.0\nInterpretation: definitive_negative", "metadata": {"result_id": 104506, "source_trial_id": "NCT03194776", "intervention_name": "LLG783", "condition_name": "Peripheral Artery Disease (PAD); Intermittent Claudication", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0307", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Tirzepatide Dose 2\nCondition: Diabetes Mellitus\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 99\np-value: 0.708\n95% CI: [-0.061, 0.089]\nInterpretation: definitive_negative", "metadata": {"result_id": 108498, "source_trial_id": "NCT05260021", "intervention_name": "Tirzepatide Dose 2", "condition_name": "Diabetes Mellitus", "confidence_tier": "gold", "therapeutic_area": "metabolic"}, "split": "fewshot"}
+{"question_id": "CTL1-0308", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: IM risperidone\nCondition: Schizophrenia\nPhase: phase_3\nBlinding: NONE\nEnrollment: 382\np-value: 0.39\n95% CI: [0.63, 1.2]\nSerious adverse events: 483.0\nInterpretation: definitive_negative", "metadata": {"result_id": 74355, "source_trial_id": "NCT00132314", "intervention_name": "IM risperidone", "condition_name": "Schizophrenia", "confidence_tier": "gold", "therapeutic_area": "psychiatry"}, "split": "fewshot"}
+{"question_id": "CTL1-0309", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: metoprolol, long-acting\nCondition: Hypertension\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 53\np-value: 0.74\nInterpretation: definitive_negative", "metadata": {"result_id": 75192, "source_trial_id": "NCT00605072", "intervention_name": "metoprolol, long-acting", "condition_name": "Hypertension", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "fewshot"}
+{"question_id": "CTL1-0310", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Cemiplimab REGN2810\nCondition: Lymphoma\nPhase: phase_1_2\nEnrollment: 58\nTermination reason: \"Study was stopped after interim analysis for all 4 cohorts with results either not fulfilling the pre-planned interim analysis criteria or fulfilling the criteria but as per sponsor decision. It was not due to any safety concern\"\nDetail: Study was stopped after interim analysis for all 4 cohorts with results either not fulfilling the pre-planned interim analysis criteria or fulfilling the criteria but as per sponsor decision. It was not due to any safety concern", "metadata": {"result_id": 7506, "source_trial_id": "NCT03769181", "intervention_name": "Cemiplimab REGN2810", "condition_name": "Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0311", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: TC-5214\nCondition: Depression\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 813\np-value: 0.697\n95% CI: [0.54, 1.5]\nSerious adverse events: 59.0\nInterpretation: definitive_negative", "metadata": {"result_id": 104023, "source_trial_id": "NCT01152554", "intervention_name": "TC-5214", "condition_name": "Depression", "confidence_tier": "gold", "therapeutic_area": "psychiatry"}, "split": "fewshot"}
+{"question_id": "CTL1-0312", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Platelet transfusion\nCondition: Hematological Malignancies\nPhase: phase_2\nBlinding: NONE\nEnrollment: 29\np-value: 0.5\nSerious adverse events: 45.0\nInterpretation: definitive_negative", "metadata": {"result_id": 78570, "source_trial_id": "NCT02074436", "intervention_name": "Platelet transfusion", "condition_name": "Hematological Malignancies", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0313", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: HGF Plasmid (AMG0001)\nCondition: Critical Limb Ischemia\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 46\np-value: 0.999\nSerious adverse events: 46.0\nInterpretation: definitive_negative", "metadata": {"result_id": 111305, "source_trial_id": "NCT02144610", "intervention_name": "HGF Plasmid (AMG0001)", "condition_name": "Critical Limb Ischemia", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0314", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: GZ/SAR402671\nCondition: Fabry Disease\nPhase: phase_2\nBlinding: NONE\nEnrollment: 11\np-value: 0.3173\nSerious adverse events: 6.0\nInterpretation: definitive_negative", "metadata": {"result_id": 90896, "source_trial_id": "NCT02228460", "intervention_name": "GZ/SAR402671", "condition_name": "Fabry Disease", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0315", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Rituximab (Rituxan®)\nDrug type: monoclonal_antibody\nCondition: Lung Transplant\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 45\np-value: 0.514\n95% CI: [0.248, 1.826]\nSerious adverse events: 122.0\nInterpretation: definitive_negative", "metadata": {"result_id": 110990, "source_trial_id": "NCT02266888", "intervention_name": "Rituximab (Rituxan®)", "condition_name": "Lung Transplant", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0316", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: ReposMBZ\nCondition: Cancer of the Gastrointestinal Tract\nPhase: phase_1_2\nEnrollment: 11\nTermination reason: \"Lack of effect\"\nDetail: Lack of effect", "metadata": {"result_id": 28162, "source_trial_id": "NCT03628079", "intervention_name": "ReposMBZ", "condition_name": "Cancer of the Gastrointestinal Tract", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0317", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: PF-06649751 low dose (1 mg QD)\nCondition: Parkinson Disease\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 108\np-value: 0.5776\n95% CI: [-1.713, 0.304]\nSerious adverse events: 14.0\nInterpretation: definitive_negative", "metadata": {"result_id": 110442, "source_trial_id": "NCT02687542", "intervention_name": "PF-06649751 low dose (1 mg QD)", "condition_name": "Parkinson Disease", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "fewshot"}
+{"question_id": "CTL1-0318", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Tralokinumab\nDrug type: monoclonal_antibody\nCondition: Asthma\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 79\np-value: 0.3862\n95% CI: [0.63, 3.27]\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 79453, "source_trial_id": "NCT02449473", "intervention_name": "Tralokinumab", "condition_name": "Asthma", "confidence_tier": "silver", "therapeutic_area": "respiratory"}, "split": "fewshot"}
+{"question_id": "CTL1-0319", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: AG-013726\nCondition: Colorectal Neoplasms\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 187\np-value: 0.9726\n95% CI: [0.332, 1.031]\nSerious adverse events: 286.0\nInterpretation: definitive_negative", "metadata": {"result_id": 85703, "source_trial_id": "NCT00460603", "intervention_name": "AG-013726", "condition_name": "Colorectal Neoplasms", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0320", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: B/F/TAF\nCondition: HIV-1/HBV Co-Infection\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 244\np-value: 0.2113\nInterpretation: definitive_negative", "metadata": {"result_id": 78726, "source_trial_id": "NCT03547908", "intervention_name": "B/F/TAF", "condition_name": "HIV-1/HBV Co-Infection", "confidence_tier": "gold", "therapeutic_area": "infectious"}, "split": "fewshot"}
+{"question_id": "CTL1-0321", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Apaziquone\nCondition: Bladder Cancer\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 812\np-value: 0.1094\n95% CI: [0.55, 1.06]\nSerious adverse events: 553.0\nInterpretation: definitive_negative", "metadata": {"result_id": 77626, "source_trial_id": "NCT00598806", "intervention_name": "Apaziquone", "condition_name": "Bladder Cancer", "confidence_tier": "gold", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0322", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Autologous Tumor Infiltrating Lymphocytes\nDrug type: cell_therapy\nCondition: Locally Advanced Refractory/Recurrent Melanoma\nPhase: phase_1\nEnrollment: 3\nTermination reason: \"Closed because of feasibility and safety issues, didn't reach our end point\"\nDetail: Closed because of feasibility and safety issues, didn't reach our end point", "metadata": {"result_id": 2425, "source_trial_id": "NCT03991741", "intervention_name": "Autologous Tumor Infiltrating Lymphocytes", "condition_name": "Locally Advanced Refractory/Recurrent Melanoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0323", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Chronic Corticosteroid Therapy\nCondition: Becker Muscular Dystrophy\nPhase: phase_2\nEnrollment: 6\nTermination reason: \"Terminated early because a similar study with Ataluren exhibited lack of efficacy at the high dose (not due to safety concerns).\"\nDetail: Terminated early because a similar study with Ataluren exhibited lack of efficacy at the high dose (not due to safety concerns).", "metadata": {"result_id": 22777, "source_trial_id": "NCT01009294", "intervention_name": "Chronic Corticosteroid Therapy", "condition_name": "Becker Muscular Dystrophy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0324", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: IIV4\nCondition: Quality of Life\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 348\np-value: 0.3851\nInterpretation: definitive_negative", "metadata": {"result_id": 66428, "source_trial_id": "NCT05028361", "intervention_name": "IIV4", "condition_name": "Quality of Life", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0325", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Tigecycline\nCondition: Diverticulitis\nPhase: phase_4\nBlinding: NONE\nEnrollment: 473\np-value: 0.75\nSerious adverse events: 189.0\nInterpretation: definitive_negative", "metadata": {"result_id": 106002, "source_trial_id": "NCT00230971", "intervention_name": "Tigecycline", "condition_name": "Diverticulitis", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0326", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Brincidofovir\nCondition: Cytomegalovirus Disease\nPhase: phase_3\nEnrollment: 5\nTermination reason: \"Study was terminated early due to results from another CMX001 study\"\nDetail: Study was terminated early due to results from another CMX001 study", "metadata": {"result_id": 55525, "source_trial_id": "NCT02439970", "intervention_name": "Brincidofovir", "condition_name": "Cytomegalovirus Disease", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0327", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: VK-2019\nCondition: Nasopharyngeal Cancer\nPhase: phase_1_2\nEnrollment: 14\nTermination reason: \"Lack of efficacy\"\nDetail: Lack of efficacy", "metadata": {"result_id": 33854, "source_trial_id": "NCT03682055", "intervention_name": "VK-2019", "condition_name": "Nasopharyngeal Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0328", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: iHIVARNA-01\nCondition: HIV Infections\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 33\np-value: 0.14\nSerious adverse events: 6.0\nInterpretation: definitive_negative", "metadata": {"result_id": 71068, "source_trial_id": "NCT02888756", "intervention_name": "iHIVARNA-01", "condition_name": "HIV Infections", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "fewshot"}
+{"question_id": "CTL1-0329", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Imatinib Mesylate intravenous solution\nCondition: Endothelial Dysfunction\nPhase: phase_2\nEnrollment: 67\nTermination reason: \"Due to the decline of COVID-19 patients on Dutch ICUs. A sample size reestimation based on blinded study data of 66 patients was furthermore favorable, indicating sufficient power to detect a difference in primary endpoint between groups.\"\nDetail: Due to the decline of COVID-19 patients on Dutch ICUs. A sample size reestimation based on blinded study data of 66 patients was furthermore favorable, indicating sufficient power to detect a difference in primary endpoint between groups.", "metadata": {"result_id": 20049, "source_trial_id": "NCT04794088", "intervention_name": "Imatinib Mesylate intravenous solution", "condition_name": "Endothelial Dysfunction", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0330", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Liraglutide\nDrug type: peptide\nCondition: Type 2 Diabetes\nPhase: phase_3\nBlinding: NONE\nEnrollment: 599\np-value: 0.186\n95% CI: [-0.19, 0.07]\nSerious adverse events: 36.0\nInterpretation: definitive_negative", "metadata": {"result_id": 110425, "source_trial_id": "NCT01624259", "intervention_name": "Liraglutide", "condition_name": "Type 2 Diabetes", "confidence_tier": "gold", "therapeutic_area": "metabolic"}, "split": "fewshot"}
+{"question_id": "CTL1-0331", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Recombinant adenoviral serotype 5 (rAD5) vector vaccine\nCondition: HIV Infections\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 2504\np-value: 0.903\n95% CI: [0.73, 1.42]\nSerious adverse events: 400.0\nInterpretation: definitive_negative", "metadata": {"result_id": 111388, "source_trial_id": "NCT00865566", "intervention_name": "Recombinant adenoviral serotype 5 (rAD5) vector vaccine", "condition_name": "HIV Infections", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "fewshot"}
+{"question_id": "CTL1-0332", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: sodium oxybate\nCondition: Parkinson Disease\nPhase: phase_4\nBlinding: QUADRUPLE\nEnrollment: 24\np-value: 0.11\nInterpretation: definitive_negative", "metadata": {"result_id": 102415, "source_trial_id": "NCT04006925", "intervention_name": "sodium oxybate", "condition_name": "Parkinson Disease", "confidence_tier": "gold", "therapeutic_area": "neurology"}, "split": "fewshot"}
+{"question_id": "CTL1-0333", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: FDC of tiotropium + olodaterol\nCondition: Pulmonary Disease, Chronic Obstructive\nPhase: phase_4\nBlinding: DOUBLE\nEnrollment: 221\np-value: 0.8648\n95% CI: [-0.061, 0.073]\nSerious adverse events: 12.0\nInterpretation: definitive_negative", "metadata": {"result_id": 91669, "source_trial_id": "NCT02683109", "intervention_name": "FDC of tiotropium + olodaterol", "condition_name": "Pulmonary Disease, Chronic Obstructive", "confidence_tier": "gold", "therapeutic_area": "respiratory"}, "split": "fewshot"}
+{"question_id": "CTL1-0334", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Single low dose cyclophosphamide\nCondition: Non-Small Cell Lung Cancer\nPhase: phase_1_2\nBlinding: DOUBLE\nEnrollment: 178\np-value: 0.828\n95% CI: [0.614, 1.479]\nSerious adverse events: 79.0\nInterpretation: definitive_negative", "metadata": {"result_id": 83462, "source_trial_id": "NCT00960115", "intervention_name": "Single low dose cyclophosphamide", "condition_name": "Non-Small Cell Lung Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0335", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: sitagliptin phosphate\nCondition: Type 2 Diabetes\nPhase: phase_3\nBlinding: NONE\nEnrollment: 169\np-value: 0.109\nInterpretation: definitive_negative", "metadata": {"result_id": 80303, "source_trial_id": "NCT00484419", "intervention_name": "sitagliptin phosphate", "condition_name": "Type 2 Diabetes", "confidence_tier": "gold", "therapeutic_area": "metabolic"}, "split": "fewshot"}
+{"question_id": "CTL1-0336", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: CNTX-4975-05\nCondition: Osteoarthritis, Knee\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 332\np-value: 0.0833\n95% CI: [-4.42, 0.27]\nSerious adverse events: 50.0\nInterpretation: definitive_negative", "metadata": {"result_id": 103414, "source_trial_id": "NCT03660943", "intervention_name": "CNTX-4975-05", "condition_name": "Osteoarthritis, Knee", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0337", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: M-M-R®II\nCondition: Pneumococcal Infections\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 1191\np-value: 0.46\n95% CI: [-7.7, 3.5]\nSerious adverse events: 121.0\nInterpretation: definitive_negative", "metadata": {"result_id": 90979, "source_trial_id": "NCT04016714", "intervention_name": "M-M-R®II", "condition_name": "Pneumococcal Infections", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0338", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Canagliflozin 100 mg\nCondition: Heart Failure\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 476\np-value: 0.852\n95% CI: [-284.4, 344.1]\nInterpretation: definitive_negative", "metadata": {"result_id": 110018, "source_trial_id": "NCT04252287", "intervention_name": "Canagliflozin 100 mg", "condition_name": "Heart Failure", "confidence_tier": "gold", "therapeutic_area": "cardiology"}, "split": "fewshot"}
+{"question_id": "CTL1-0339", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: GW642444 Inhalation Powder\nCondition: Pulmonary Disease, Chronic Obstructive\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 1031\np-value: 0.241\n95% CI: [-0.022, 0.088]\nSerious adverse events: 129.0\nInterpretation: definitive_negative", "metadata": {"result_id": 97210, "source_trial_id": "NCT01053988", "intervention_name": "GW642444 Inhalation Powder", "condition_name": "Pulmonary Disease, Chronic Obstructive", "confidence_tier": "gold", "therapeutic_area": "respiratory"}, "split": "fewshot"}
+{"question_id": "CTL1-0340", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Zonisamide\nCondition: Alcohol Abuse\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 40\np-value: 0.94\nInterpretation: definitive_negative", "metadata": {"result_id": 98816, "source_trial_id": "NCT00595556", "intervention_name": "Zonisamide", "condition_name": "Alcohol Abuse", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0341", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Diclofenac Potassium\nCondition: Post Operative Dental Pain\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 328\np-value: 0.211\n95% CI: [-1.8, 8.3]\nInterpretation: definitive_negative", "metadata": {"result_id": 67226, "source_trial_id": "NCT02476422", "intervention_name": "Diclofenac Potassium", "condition_name": "Post Operative Dental Pain", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0342", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: AZD2014\nCondition: Advanced Gastric Adenocarcinoma\nPhase: phase_2\nEnrollment: 27\nTermination reason: \"lack of efficacy\"\nDetail: lack of efficacy", "metadata": {"result_id": 22385, "source_trial_id": "NCT02449655", "intervention_name": "AZD2014", "condition_name": "Advanced Gastric Adenocarcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0343", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: FLOVENT 250mcg\nCondition: Asthma\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 11751\np-value: 0.203\n95% CI: [0.63, 1.103]\nSerious adverse events: 563.0\nInterpretation: definitive_negative", "metadata": {"result_id": 91245, "source_trial_id": "NCT01475721", "intervention_name": "FLOVENT 250mcg", "condition_name": "Asthma", "confidence_tier": "gold", "therapeutic_area": "respiratory"}, "split": "fewshot"}
+{"question_id": "CTL1-0344", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Bimatoprost SR\nCondition: Glaucoma, Open-Angle\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 594\np-value: 0.295\n95% CI: [-1.17, 0.36]\nSerious adverse events: 185.0\nInterpretation: definitive_negative", "metadata": {"result_id": 102312, "source_trial_id": "NCT02247804", "intervention_name": "Bimatoprost SR", "condition_name": "Glaucoma, Open-Angle", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0345", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: RHB-102\nCondition: Gastroenteritis\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 330\np-value: 0.0729\n95% CI: [0.847, 27.2024]\nSerious adverse events: 16.0\nInterpretation: definitive_negative", "metadata": {"result_id": 80378, "source_trial_id": "NCT02246439", "intervention_name": "RHB-102", "condition_name": "Gastroenteritis", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0346", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions\nCondition: Plasma Cell Tumor\nPhase: phase_1\nEnrollment: 11\nTermination reason: \"The study met criteria for stopping due to lack of efficacy per protocol specifications.\"\nDetail: The study met criteria for stopping due to lack of efficacy per protocol specifications.", "metadata": {"result_id": 3410, "source_trial_id": "NCT05350163", "intervention_name": "T-cell Receptor α/β Depleted Donor Lymphocyte Infusions", "condition_name": "Plasma Cell Tumor", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0347", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: magnesium sulfate\nCondition: Atrial Fibrillation New Onset\nPhase: phase_2_3\nEnrollment: 265\nTermination reason: \"Futility after interim analysis\"\nDetail: Futility after interim analysis", "metadata": {"result_id": 58352, "source_trial_id": "NCT05669417", "intervention_name": "magnesium sulfate", "condition_name": "Atrial Fibrillation New Onset", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "fewshot"}
+{"question_id": "CTL1-0348", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: D-methionine\nCondition: Noise-induced Hearing Loss\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 351\np-value: 0.4385\nInterpretation: definitive_negative", "metadata": {"result_id": 67563, "source_trial_id": "NCT02903355", "intervention_name": "D-methionine", "condition_name": "Noise-induced Hearing Loss", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0349", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: SAR3419\nDrug type: antibody_drug_conjugate\nCondition: Acute Lymphocytic Leukaemia\nPhase: phase_2\nEnrollment: 100\nTermination reason: \"The study is stopped due to very modest activity compared to competitors\"\nDetail: The study is stopped due to very modest activity compared to competitors", "metadata": {"result_id": 34064, "source_trial_id": "NCT01440179", "intervention_name": "SAR3419", "condition_name": "Acute Lymphocytic Leukaemia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0350", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: LY3473329\nCondition: Lipoprotein Disorder\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 233\np-value: 0.11\n95% CI: [-18.84, 2.17]\nInterpretation: definitive_negative", "metadata": {"result_id": 82662, "source_trial_id": "NCT05563246", "intervention_name": "LY3473329", "condition_name": "Lipoprotein Disorder", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0351", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: UX007\nCondition: Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 36\np-value: 0.5812\n95% CI: [-38.63, 80.95]\nSerious adverse events: 8.0\nInterpretation: definitive_negative", "metadata": {"result_id": 71886, "source_trial_id": "NCT01993186", "intervention_name": "UX007", "condition_name": "Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0352", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: AIN457\nDrug type: monoclonal_antibody\nCondition: Inflammatory Diseases\nPhase: phase_2\nEnrollment: 16\nTermination reason: \"Data did not show that the two biologic treatments impacted PMR disease activity to the same degree as steroid treatment within a 2-week treatment period.\"\nDetail: Data did not show that the two biologic treatments impacted PMR disease activity to the same degree as steroid treatment within a 2-week treatment period.", "metadata": {"result_id": 64095, "source_trial_id": "NCT01364389", "intervention_name": "AIN457", "condition_name": "Inflammatory Diseases", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0353", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: insulin\nDrug type: peptide\nCondition: Pregnancy in Diabetes\nPhase: phase_4\nBlinding: SINGLE\nEnrollment: 54\np-value: 0.9\nInterpretation: definitive_negative", "metadata": {"result_id": 67477, "source_trial_id": "NCT03029702", "intervention_name": "insulin", "condition_name": "Pregnancy in Diabetes", "confidence_tier": "gold", "therapeutic_area": "metabolic"}, "split": "fewshot"}
+{"question_id": "CTL1-0354", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: 14C-AZD1236\nCondition: Healthy\nPhase: phase_1\nEnrollment: 4\nTermination reason: \"Future development of AZD1236 is currently under review by the project team and no new studies will be started until this review is completed.\"\nDetail: Future development of AZD1236 is currently under review by the project team and no new studies will be started until this review is completed.", "metadata": {"result_id": 58806, "source_trial_id": "NCT01007929", "intervention_name": "14C-AZD1236", "condition_name": "Healthy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0355", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: AMT2003\nDrug type: gene_therapy\nCondition: Genital Neoplasms, Female\nPhase: phase_2_3\nEnrollment: 67\nTermination reason: \"Lack of efficacy. Stopped at first interim evaluation point\"\nDetail: Lack of efficacy. Stopped at first interim evaluation point", "metadata": {"result_id": 23355, "source_trial_id": "NCT00332280", "intervention_name": "AMT2003", "condition_name": "Genital Neoplasms, Female", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0356", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: LAMA/LABA\nCondition: COPD\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 17\np-value: 0.09\nInterpretation: definitive_negative", "metadata": {"result_id": 77365, "source_trial_id": "NCT01491802", "intervention_name": "LAMA/LABA", "condition_name": "COPD", "confidence_tier": "gold", "therapeutic_area": "respiratory"}, "split": "fewshot"}
+{"question_id": "CTL1-0357", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Daunorubicin Hydrochloride\nCondition: Acute Myeloid Leukemia\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 754\np-value: 0.84\nSerious adverse events: 806.0\nInterpretation: definitive_negative", "metadata": {"result_id": 104639, "source_trial_id": "NCT01802333", "intervention_name": "Daunorubicin Hydrochloride", "condition_name": "Acute Myeloid Leukemia", "confidence_tier": "gold", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0358", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Fluorometholone\nCondition: Bullous Keratopathy\nPhase: phase_2\nBlinding: SINGLE\nEnrollment: 264\np-value: 0.17\nInterpretation: definitive_negative", "metadata": {"result_id": 109860, "source_trial_id": "NCT01448213", "intervention_name": "Fluorometholone", "condition_name": "Bullous Keratopathy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0359", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: PegIntron\nDrug type: peptide\nCondition: Hepatitis C/ Human Immunodeficiency Virus Coinfection\nPhase: phase_3\nBlinding: NONE\nEnrollment: 140\np-value: 0.227\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 100076, "source_trial_id": "NCT02103439", "intervention_name": "PegIntron", "condition_name": "Hepatitis C/ Human Immunodeficiency Virus Coinfection", "confidence_tier": "gold", "therapeutic_area": "infectious"}, "split": "fewshot"}
+{"question_id": "CTL1-0360", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Pentosan Polysulfate Na 100Mg Cap\nCondition: Bladder Carcinoma\nPhase: phase_2\nEnrollment: 3\nTermination reason: \"Given the updated precautions on Elmiron as well as the risk benefit profile, we have decided to terminate the study.\"\nDetail: Given the updated precautions on Elmiron as well as the risk benefit profile, we have decided to terminate the study.", "metadata": {"result_id": 53816, "source_trial_id": "NCT03549650", "intervention_name": "Pentosan Polysulfate Na 100Mg Cap", "condition_name": "Bladder Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0361", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Tecovirimat Oral Capsule\nCondition: Mpox\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 719\np-value: 0.89\n95% CI: [0.74, 1.31]\nInterpretation: definitive_negative", "metadata": {"result_id": 71846, "source_trial_id": "NCT05534984", "intervention_name": "Tecovirimat Oral Capsule", "condition_name": "Mpox", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0362", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Melflufen\nCondition: Relapsed Multiple Myeloma\nPhase: phase_3\nBlinding: SINGLE\nEnrollment: 54\np-value: 0.525\n95% CI: [0.026, 6.693]\nInterpretation: definitive_negative", "metadata": {"result_id": 94053, "source_trial_id": "NCT04649060", "intervention_name": "Melflufen", "condition_name": "Relapsed Multiple Myeloma", "confidence_tier": "gold", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0363", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Reldesemtiv 150 mg\nCondition: Spinal Muscular Atrophy\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 70\np-value: 0.9086\n95% CI: [-0.13, 0.11]\nSerious adverse events: 12.0\nInterpretation: definitive_negative", "metadata": {"result_id": 86672, "source_trial_id": "NCT02644668", "intervention_name": "Reldesemtiv 150 mg", "condition_name": "Spinal Muscular Atrophy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0364", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Leuprolide Acetate\nDrug type: peptide\nCondition: High Risk Prostate Cancer\nPhase: phase_2\nBlinding: NONE\nEnrollment: 75\np-value: 0.151\nSerious adverse events: 14.0\nInterpretation: definitive_negative", "metadata": {"result_id": 86991, "source_trial_id": "NCT02268175", "intervention_name": "Leuprolide Acetate", "condition_name": "High Risk Prostate Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0365", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Follitropin Delta (FE 999049)\nDrug type: peptide\nCondition: Infertility\nPhase: phase_3\nBlinding: SINGLE\nEnrollment: 1329\np-value: 0.291\nSerious adverse events: 55.0\nInterpretation: definitive_negative", "metadata": {"result_id": 97557, "source_trial_id": "NCT01956110", "intervention_name": "Follitropin Delta (FE 999049)", "condition_name": "Infertility", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0366", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Interferon β-1a\nDrug type: peptide\nCondition: Multiple Sclerosis\nPhase: phase_3\nBlinding: SINGLE\nEnrollment: 324\np-value: 0.5953\nSerious adverse events: 135.0\nInterpretation: definitive_negative", "metadata": {"result_id": 107391, "source_trial_id": "NCT00883337", "intervention_name": "Interferon β-1a", "condition_name": "Multiple Sclerosis", "confidence_tier": "gold", "therapeutic_area": "neurology"}, "split": "val"}
+{"question_id": "CTL1-0367", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Trimethoprim\nCondition: Staphylococcus Aureus\nEnrollment: 63\nTermination reason: \"Results interim-analysis\"\nDetail: Results interim-analysis", "metadata": {"result_id": 40331, "source_trial_id": "NCT03173053", "intervention_name": "Trimethoprim", "condition_name": "Staphylococcus Aureus", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0368", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Follitropin delta\nDrug type: peptide\nCondition: Infertility\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 579\np-value: 0.22\nInterpretation: definitive_negative", "metadata": {"result_id": 104822, "source_trial_id": "NCT03740737", "intervention_name": "Follitropin delta", "condition_name": "Infertility", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0369", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Saroglitazar Magnesium 4 mg\nCondition: Non-Alcoholic Fatty Liver Disease\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 106\np-value: 0.5681\nInterpretation: definitive_negative", "metadata": {"result_id": 92925, "source_trial_id": "NCT03061721", "intervention_name": "Saroglitazar Magnesium 4 mg", "condition_name": "Non-Alcoholic Fatty Liver Disease", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0370", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Epsilonaminocaproic acid\nCondition: Pathologic Fibrinolysis\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 40\np-value: 0.21\nInterpretation: definitive_negative", "metadata": {"result_id": 92384, "source_trial_id": "NCT01981863", "intervention_name": "Epsilonaminocaproic acid", "condition_name": "Pathologic Fibrinolysis", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0371", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Adenosine Mono Phosphate (AMP)\nCondition: Ischemia\nPhase: phase_1\nBlinding: SINGLE\nEnrollment: 13\np-value: 0.854\nInterpretation: definitive_negative", "metadata": {"result_id": 103462, "source_trial_id": "NCT00179010", "intervention_name": "Adenosine Mono Phosphate (AMP)", "condition_name": "Ischemia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0372", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Tamibarotene\nCondition: Stage IV Non-small Cell Lung Cancer\nPhase: phase_2\nEnrollment: 140\nTermination reason: \"Interim analysis showed that the primary endpoint would not be met.\"\nDetail: Interim analysis showed that the primary endpoint would not be met.", "metadata": {"result_id": 19440, "source_trial_id": "NCT01337154", "intervention_name": "Tamibarotene", "condition_name": "Stage IV Non-small Cell Lung Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0373", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Afamelanotide\nDrug type: peptide\nCondition: Arterial Ischemic Stroke\nPhase: phase_2\nBlinding: NONE\nEnrollment: 6\np-value: 0.0625\nInterpretation: definitive_negative", "metadata": {"result_id": 75054, "source_trial_id": "NCT04962503", "intervention_name": "Afamelanotide", "condition_name": "Arterial Ischemic Stroke", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "val"}
+{"question_id": "CTL1-0374", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Pregabalin capsules\nCondition: Diabetic Peripheral Neuropathy\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 450\np-value: 0.1995\n95% CI: [-0.99, 0.15]\nSerious adverse events: 26.0\nInterpretation: definitive_negative", "metadata": {"result_id": 96580, "source_trial_id": "NCT01504412", "intervention_name": "Pregabalin capsules", "condition_name": "Diabetic Peripheral Neuropathy", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "val"}
+{"question_id": "CTL1-0375", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Definity® with High Mechanical Index Ultrasound\nCondition: ST Elevation Myocardial Infarction\nPhase: phase_2\nEnrollment: 41\nTermination reason: \"Unlikely to demonstrate the intended benefit within the planned study design and statistical framework.\"\nDetail: Unlikely to demonstrate the intended benefit within the planned study design and statistical framework.", "metadata": {"result_id": 47372, "source_trial_id": "NCT04217304", "intervention_name": "Definity® with High Mechanical Index Ultrasound", "condition_name": "ST Elevation Myocardial Infarction", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL1-0376", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg\nCondition: Hypertension\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 1385\np-value: 0.0674\n95% CI: [-0.613, 13.926]\nInterpretation: definitive_negative", "metadata": {"result_id": 91720, "source_trial_id": "NCT04518293", "intervention_name": "Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg", "condition_name": "Hypertension", "confidence_tier": "gold", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL1-0377", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Inactivated influenza vaccine\nCondition: Influenza\nPhase: phase_4\nBlinding: NONE\nEnrollment: 38\np-value: 0.89\nInterpretation: definitive_negative", "metadata": {"result_id": 107093, "source_trial_id": "NCT03101462", "intervention_name": "Inactivated influenza vaccine", "condition_name": "Influenza", "confidence_tier": "gold", "therapeutic_area": "infectious"}, "split": "val"}
+{"question_id": "CTL1-0378", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: vosaroxin + cytarabine\nCondition: Acute Myeloid Leukemia\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 711\np-value: 0.3134\nSerious adverse events: 1381.0\nInterpretation: definitive_negative", "metadata": {"result_id": 91591, "source_trial_id": "NCT01191801", "intervention_name": "vosaroxin + cytarabine", "condition_name": "Acute Myeloid Leukemia", "confidence_tier": "gold", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0379", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Tebotelimab\nDrug type: monoclonal_antibody\nCondition: Head and Neck Squamous Cell Carcinoma\nPhase: phase_2\nEnrollment: 62\nTermination reason: \"Based on internal review of safety data\"\nDetail: Based on internal review of safety data", "metadata": {"result_id": 6874, "source_trial_id": "NCT04634825", "intervention_name": "Tebotelimab", "condition_name": "Head and Neck Squamous Cell Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0380", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Pazopanib and Paclitaxel\nCondition: Stage III Melanoma\nPhase: phase_2\nBlinding: NONE\nEnrollment: 60\np-value: 0.49\n95% CI: [0.41, 1.54]\nSerious adverse events: 43.0\nInterpretation: definitive_negative", "metadata": {"result_id": 95520, "source_trial_id": "NCT01107665", "intervention_name": "Pazopanib and Paclitaxel", "condition_name": "Stage III Melanoma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0381", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: concurrent RAD001 10 mg/day\nCondition: Brain and Central Nervous System Tumors\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 279\np-value: 0.79\n95% CI: [0.82, 1.6]\nSerious adverse events: 291.0\nInterpretation: definitive_negative", "metadata": {"result_id": 70411, "source_trial_id": "NCT01062399", "intervention_name": "concurrent RAD001 10 mg/day", "condition_name": "Brain and Central Nervous System Tumors", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0382", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Aclidinium/Formoterol\nCondition: Pulmonary Disease, Chronic Obstructive\nPhase: phase_4\nBlinding: DOUBLE\nEnrollment: 267\np-value: 0.069\n95% CI: [-0.259, 0.01]\nSerious adverse events: 11.0\nInterpretation: definitive_negative", "metadata": {"result_id": 103858, "source_trial_id": "NCT02424344", "intervention_name": "Aclidinium/Formoterol", "condition_name": "Pulmonary Disease, Chronic Obstructive", "confidence_tier": "gold", "therapeutic_area": "respiratory"}, "split": "val"}
+{"question_id": "CTL1-0383", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Belzutifan\nCondition: Carcinoma, Renal Cell\nPhase: phase_2\nBlinding: NONE\nEnrollment: 154\np-value: 0.5312\n95% CI: [-14.0, 12.9]\nInterpretation: definitive_negative", "metadata": {"result_id": 86470, "source_trial_id": "NCT04489771", "intervention_name": "Belzutifan", "condition_name": "Carcinoma, Renal Cell", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0384", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Therapeutic Immune Globulin\nCondition: Regional Neuroblastoma\nPhase: phase_3\nBlinding: NONE\nEnrollment: 53\np-value: 0.0919\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 77529, "source_trial_id": "NCT00033293", "intervention_name": "Therapeutic Immune Globulin", "condition_name": "Regional Neuroblastoma", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0385", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Sodium zirconium cyclosilicate\nCondition: Heart Failure With Reduced Ejection Fraction\nPhase: phase_4\nBlinding: DOUBLE\nEnrollment: 366\np-value: 0.724\n95% CI: [-6.64, 4.63]\nInterpretation: definitive_negative", "metadata": {"result_id": 71461, "source_trial_id": "NCT04676646", "intervention_name": "Sodium zirconium cyclosilicate", "condition_name": "Heart Failure With Reduced Ejection Fraction", "confidence_tier": "gold", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL1-0386", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Tremelimumab (Regimen 1)\nDrug type: monoclonal_antibody\nCondition: Hepatocellular Carcinoma\nPhase: phase_3\nBlinding: NONE\nEnrollment: 1324\np-value: 0.0674\nInterpretation: definitive_negative", "metadata": {"result_id": 94296, "source_trial_id": "NCT03298451", "intervention_name": "Tremelimumab (Regimen 1)", "condition_name": "Hepatocellular Carcinoma", "confidence_tier": "gold", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0387", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: formoterol fumarate 10 mcg\nCondition: Asthma\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 746\np-value: 0.073\nSerious adverse events: 28.0\nInterpretation: definitive_negative", "metadata": {"result_id": 99440, "source_trial_id": "NCT00383552", "intervention_name": "formoterol fumarate 10 mcg", "condition_name": "Asthma", "confidence_tier": "gold", "therapeutic_area": "respiratory"}, "split": "val"}
+{"question_id": "CTL1-0388", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: PegIntron (peginterferon alfa-2b; SCH 54031)\nDrug type: peptide\nCondition: Hepatitis C, Chronic\nPhase: phase_3\nBlinding: NONE\nEnrollment: 4469\np-value: 0.567\n95% CI: [0.79, 1.14]\nSerious adverse events: 853.0\nInterpretation: definitive_negative", "metadata": {"result_id": 109002, "source_trial_id": "NCT00081770", "intervention_name": "PegIntron (peginterferon alfa-2b; SCH 54031)", "condition_name": "Hepatitis C, Chronic", "confidence_tier": "gold", "therapeutic_area": "infectious"}, "split": "val"}
+{"question_id": "CTL1-0389", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Nerinetide (NA-1), 2.6 mg/kg\nCondition: Stroke, Acute\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 1105\np-value: 0.335\n95% CI: [0.869, 1.511]\nSerious adverse events: 1053.0\nInterpretation: definitive_negative", "metadata": {"result_id": 104675, "source_trial_id": "NCT02930018", "intervention_name": "Nerinetide (NA-1), 2.6 mg/kg", "condition_name": "Stroke, Acute", "confidence_tier": "gold", "therapeutic_area": "neurology"}, "split": "val"}
+{"question_id": "CTL1-0390", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Pazopanib (GW786034)\nCondition: Metastatic Cervical Cancer\nPhase: phase_2\nBlinding: NONE\nEnrollment: 228\np-value: 0.535\n95% CI: [0.65, 1.7]\nSerious adverse events: 230.0\nInterpretation: definitive_negative", "metadata": {"result_id": 70895, "source_trial_id": "NCT00430781", "intervention_name": "Pazopanib (GW786034)", "condition_name": "Metastatic Cervical Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0391", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Ticagrelor 90mg\nCondition: Chronic Kidney Diseases\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 76\np-value: 0.18\nInterpretation: definitive_negative", "metadata": {"result_id": 95903, "source_trial_id": "NCT03649711", "intervention_name": "Ticagrelor 90mg", "condition_name": "Chronic Kidney Diseases", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0392", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: VELCADE 1.3 mg/m^2\nCondition: Mantle Cell Lymphoma\nPhase: phase_3\nBlinding: NONE\nEnrollment: 487\np-value: 0.275\n95% CI: [0.749, 2.722]\nSerious adverse events: 504.0\nInterpretation: definitive_negative", "metadata": {"result_id": 86183, "source_trial_id": "NCT00722137", "intervention_name": "VELCADE 1.3 mg/m^2", "condition_name": "Mantle Cell Lymphoma", "confidence_tier": "gold", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0393", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: AGN-199201 ophthalmic solution\nCondition: Presbyopia\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 151\np-value: 0.1663\n95% CI: [-0.83, 4.74]\nInterpretation: definitive_negative", "metadata": {"result_id": 80418, "source_trial_id": "NCT02780115", "intervention_name": "AGN-199201 ophthalmic solution", "condition_name": "Presbyopia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0394", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: ipratropium bromide\nCondition: Acute Asthma\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 179\np-value: 0.44\nSerious adverse events: 10.0\nInterpretation: definitive_negative", "metadata": {"result_id": 92060, "source_trial_id": "NCT00393367", "intervention_name": "ipratropium bromide", "condition_name": "Acute Asthma", "confidence_tier": "gold", "therapeutic_area": "respiratory"}, "split": "val"}
+{"question_id": "CTL1-0395", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: CE 0.45 mg/MPA 1.5mg\nCondition: Osteoporosis\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 1083\np-value: 0.373\n95% CI: [-0.8, 2.12]\nSerious adverse events: 131.0\nInterpretation: definitive_negative", "metadata": {"result_id": 77664, "source_trial_id": "NCT00242710", "intervention_name": "CE 0.45 mg/MPA 1.5mg", "condition_name": "Osteoporosis", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0396", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Erythromycin\nCondition: Healthy\nPhase: phase_2_3\nBlinding: TRIPLE\nEnrollment: 40\np-value: 0.27\nInterpretation: definitive_negative", "metadata": {"result_id": 97816, "source_trial_id": "NCT01379183", "intervention_name": "Erythromycin", "condition_name": "Healthy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0397", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Ruxolitinib Cream\nCondition: Atopic Dermatitis\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 77\np-value: 0.091\n95% CI: [0.83, 9.47]\nInterpretation: definitive_negative", "metadata": {"result_id": 75009, "source_trial_id": "NCT05127421", "intervention_name": "Ruxolitinib Cream", "condition_name": "Atopic Dermatitis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0398", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: IVIG\nDrug type: other_biologic\nCondition: Epilepsy, Cryptogenic\nPhase: phase_2\nEnrollment: 20\nTermination reason: \"Futility criteria, unable for Phase 2 of study, \\& phase 1 was terminated.\"\nDetail: Futility criteria, unable for Phase 2 of study, \\& phase 1 was terminated.", "metadata": {"result_id": 51607, "source_trial_id": "NCT01545518", "intervention_name": "IVIG", "condition_name": "Epilepsy, Cryptogenic", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "val"}
+{"question_id": "CTL1-0399", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Doxorubicin 30 mg/m2\nCondition: Carcinoma, Hepatocellular\nPhase: phase_3\nBlinding: NONE\nEnrollment: 397\np-value: 0.991\nSerious adverse events: 692.0\nInterpretation: definitive_negative", "metadata": {"result_id": 108379, "source_trial_id": "NCT01655693", "intervention_name": "Doxorubicin 30 mg/m2", "condition_name": "Carcinoma, Hepatocellular", "confidence_tier": "gold", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0400", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: LDK378\nCondition: Cholangiocarcinoma\nPhase: phase_2\nEnrollment: 9\nTermination reason: \"ROS1 in IHC and gene rearrangement result can not match。No tumor response。\"\nDetail: ROS1 in IHC and gene rearrangement result can not match。No tumor response。", "metadata": {"result_id": 45212, "source_trial_id": "NCT02374489", "intervention_name": "LDK378", "condition_name": "Cholangiocarcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0401", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: losartan potassium\nCondition: Hypertension\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 327\np-value: 0.205\n95% CI: [-2.7, 0.6]\nSerious adverse events: 6.0\nInterpretation: definitive_negative", "metadata": {"result_id": 77338, "source_trial_id": "NCT01302691", "intervention_name": "losartan potassium", "condition_name": "Hypertension", "confidence_tier": "gold", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL1-0402", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: dabigatran etexilate\nCondition: Thromboembolism\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 2589\np-value: 0.6932\n95% CI: [-1.1, 1.6]\nSerious adverse events: 786.0\nInterpretation: definitive_negative", "metadata": {"result_id": 79519, "source_trial_id": "NCT00680186", "intervention_name": "dabigatran etexilate", "condition_name": "Thromboembolism", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0403", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: monoclonal antibody SGN-30\nDrug type: antibody_drug_conjugate\nCondition: Adult Nodular Sclerosis Hodgkin Lymphoma\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 30\np-value: 0.06\nSerious adverse events: 142.0\nInterpretation: definitive_negative", "metadata": {"result_id": 86880, "source_trial_id": "NCT00337194", "intervention_name": "monoclonal antibody SGN-30", "condition_name": "Adult Nodular Sclerosis Hodgkin Lymphoma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0404", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: EPI-506\nCondition: Genital Diseases, Male\nPhase: phase_1_2\nEnrollment: 28\nTermination reason: \"At end of Phase 1 excessive high pill burden (18 capsules/day)\"\nDetail: At end of Phase 1 excessive high pill burden (18 capsules/day)", "metadata": {"result_id": 58722, "source_trial_id": "NCT02606123", "intervention_name": "EPI-506", "condition_name": "Genital Diseases, Male", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0405", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: LCZ696\nCondition: Heart Failure With Preserved Ejection Fraction (HFpEF)\nPhase: phase_3\nEnrollment: 52\nTermination reason: \"This study was terminated early because the primary endpoint of PARAGON-HF was not met.\"\nDetail: This study was terminated early because the primary endpoint of PARAGON-HF was not met.", "metadata": {"result_id": 42784, "source_trial_id": "NCT03909295", "intervention_name": "LCZ696", "condition_name": "Heart Failure With Preserved Ejection Fraction (HFpEF)", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL1-0406", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Kenalog\nCondition: Pelvic Pain\nBlinding: DOUBLE\nEnrollment: 21\np-value: 0.072\nInterpretation: definitive_negative", "metadata": {"result_id": 108376, "source_trial_id": "NCT02369068", "intervention_name": "Kenalog", "condition_name": "Pelvic Pain", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0407", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Albuterol 108 mcg Rescue Treatment\nCondition: Allergy\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 345\np-value: 0.066\n95% CI: [-0.88, 0.03]\nSerious adverse events: 8.0\nInterpretation: definitive_negative", "metadata": {"result_id": 102916, "source_trial_id": "NCT00550550", "intervention_name": "Albuterol 108 mcg Rescue Treatment", "condition_name": "Allergy", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0408", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: enzastaurin\nCondition: Non-Small Cell Lung Cancer\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 160\np-value: 0.544\n95% CI: [0.77, 1.65]\nSerious adverse events: 190.0\nInterpretation: definitive_negative", "metadata": {"result_id": 79885, "source_trial_id": "NCT00530621", "intervention_name": "enzastaurin", "condition_name": "Non-Small Cell Lung Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0409", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: 1% Lidocaine with Epinephrine (1:100,000)\nCondition: Pain\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 25\np-value: 0.359\nInterpretation: definitive_negative", "metadata": {"result_id": 83019, "source_trial_id": "NCT01243112", "intervention_name": "1% Lidocaine with Epinephrine (1:100,000)", "condition_name": "Pain", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0410", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Intensive Antihypertensive Therapy\nCondition: Hypertension\nPhase: phase_2\nBlinding: SINGLE\nEnrollment: 51\np-value: 0.7139\nInterpretation: definitive_negative", "metadata": {"result_id": 66047, "source_trial_id": "NCT04401267", "intervention_name": "Intensive Antihypertensive Therapy", "condition_name": "Hypertension", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL1-0411", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: JNJ-38518168\nCondition: Rheumatoid Arthritis\nPhase: phase_2\nEnrollment: 21\nTermination reason: \"The study was stopped due to lack of efficacy in a study conducted in a similar population,38518168ARA2002-NCT01679951.\"\nDetail: The study was stopped due to lack of efficacy in a study conducted in a similar population,38518168ARA2002-NCT01679951.", "metadata": {"result_id": 55702, "source_trial_id": "NCT01862224", "intervention_name": "JNJ-38518168", "condition_name": "Rheumatoid Arthritis", "confidence_tier": "bronze", "therapeutic_area": "autoimmune"}, "split": "val"}
+{"question_id": "CTL1-0412", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: amphetamine extended-release oral suspension, 2.5 mg/mL\nCondition: Attention Deficit Hyperactivity Disorder\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 18\np-value: 0.1128\n95% CI: [-4.94, 42.5]\nInterpretation: definitive_negative", "metadata": {"result_id": 101603, "source_trial_id": "NCT03088267", "intervention_name": "amphetamine extended-release oral suspension, 2.5 mg/mL", "condition_name": "Attention Deficit Hyperactivity Disorder", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0413", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: IBI188\nDrug type: unknown\nCondition: Lung Adenocarcinoma\nPhase: phase_1\nEnrollment: 9\nTermination reason: \"No signs of efficacy in solid tumors\"\nDetail: No signs of efficacy in solid tumors", "metadata": {"result_id": 32494, "source_trial_id": "NCT04861948", "intervention_name": "IBI188", "condition_name": "Lung Adenocarcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0414", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: 18F-PBR06\nCondition: Stroke\nPhase: phase_2\nEnrollment: 3\nTermination reason: \"Negativity of the first results of in vivo binding of 18F-PBR06\"\nDetail: Negativity of the first results of in vivo binding of 18F-PBR06", "metadata": {"result_id": 51614, "source_trial_id": "NCT02513589", "intervention_name": "18F-PBR06", "condition_name": "Stroke", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "val"}
+{"question_id": "CTL1-0415", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Idalopirdine\nCondition: Alzheimer's Disease\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 858\np-value: 1.0\n95% CI: [-1.1, 0.92]\nSerious adverse events: 90.0\nInterpretation: definitive_negative", "metadata": {"result_id": 105384, "source_trial_id": "NCT02006641", "intervention_name": "Idalopirdine", "condition_name": "Alzheimer's Disease", "confidence_tier": "gold", "therapeutic_area": "neurology"}, "split": "val"}
+{"question_id": "CTL1-0416", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Drug: carboplatin\nCondition: Ovarian Cancer\nPhase: phase_2\nBlinding: NONE\nEnrollment: 162\np-value: 0.4379\n95% CI: [0.79, 1.73]\nSerious adverse events: 80.0\nInterpretation: definitive_negative", "metadata": {"result_id": 75810, "source_trial_id": "NCT01081951", "intervention_name": "Drug: carboplatin", "condition_name": "Ovarian Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0417", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: ceftazidime\nCondition: Cirrhosis\nPhase: phase_2_3\nEnrollment: 32\nTermination reason: \"Decision of independent monitoring committee after interim analysis: Risk of failure significantly higher in ceftazidime group.\"\nDetail: Decision of independent monitoring committee after interim analysis: Risk of failure significantly higher in ceftazidime group.", "metadata": {"result_id": 13129, "source_trial_id": "NCT01455246", "intervention_name": "ceftazidime", "condition_name": "Cirrhosis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0418", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: home oral amoxicillin-clavulanate\nCondition: Perforated Appendicitis\nBlinding: NONE\nEnrollment: 82\np-value: 0.7188\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 89050, "source_trial_id": "NCT02724410", "intervention_name": "home oral amoxicillin-clavulanate", "condition_name": "Perforated Appendicitis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0419", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: PF-02545920\nCondition: Schizophrenia\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 259\np-value: 0.2053\n95% CI: [-5.66, 1.24]\nSerious adverse events: 26.0\nInterpretation: definitive_negative", "metadata": {"result_id": 70861, "source_trial_id": "NCT01175135", "intervention_name": "PF-02545920", "condition_name": "Schizophrenia", "confidence_tier": "silver", "therapeutic_area": "psychiatry"}, "split": "val"}
+{"question_id": "CTL1-0420", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Dienogest\nCondition: Contraception\nPhase: phase_4\nBlinding: NONE\nEnrollment: 59\np-value: 0.27\nInterpretation: definitive_negative", "metadata": {"result_id": 76523, "source_trial_id": "NCT02352090", "intervention_name": "Dienogest", "condition_name": "Contraception", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0421", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Tetracycline\nCondition: Skin Rash\nPhase: phase_2\nBlinding: SINGLE\nEnrollment: 107\np-value: 0.41\nInterpretation: definitive_negative", "metadata": {"result_id": 99711, "source_trial_id": "NCT01880515", "intervention_name": "Tetracycline", "condition_name": "Skin Rash", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0422", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: RVT-101 70 mg\nCondition: Dementia With Lewy Bodies\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 484\np-value: 0.158\n95% CI: [-4.8, 0.79]\nSerious adverse events: 88.0\nInterpretation: definitive_negative", "metadata": {"result_id": 94918, "source_trial_id": "NCT02669433", "intervention_name": "RVT-101 70 mg", "condition_name": "Dementia With Lewy Bodies", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0423", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: FMISO\nCondition: Adult Giant Cell Glioblastoma\nPhase: phase_2\nBlinding: NONE\nEnrollment: 50\np-value: 0.5\n95% CI: [0.75, 1.81]\nInterpretation: definitive_negative", "metadata": {"result_id": 90116, "source_trial_id": "NCT00902577", "intervention_name": "FMISO", "condition_name": "Adult Giant Cell Glioblastoma", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0424", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: ZYN002 - Cannabidiol Transdermal Gel\nCondition: Fragile X Syndrome\nPhase: phase_2_3\nBlinding: QUADRUPLE\nEnrollment: 212\np-value: 0.321\nInterpretation: definitive_negative", "metadata": {"result_id": 101477, "source_trial_id": "NCT03614663", "intervention_name": "ZYN002 - Cannabidiol Transdermal Gel", "condition_name": "Fragile X Syndrome", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0425", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: GEM103\nDrug type: peptide\nCondition: Dry Age-Related Macular Degeneration\nPhase: phase_2\nEnrollment: 62\nTermination reason: \"no further benefit\"\nDetail: no further benefit", "metadata": {"result_id": 26997, "source_trial_id": "NCT04643886", "intervention_name": "GEM103", "condition_name": "Dry Age-Related Macular Degeneration", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0426", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Levonorgestrel IUS\nCondition: Uterine Fibroids\nPhase: phase_4\nBlinding: NONE\nEnrollment: 18\np-value: 0.11\nInterpretation: definitive_negative", "metadata": {"result_id": 111856, "source_trial_id": "NCT03317795", "intervention_name": "Levonorgestrel IUS", "condition_name": "Uterine Fibroids", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0427", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: tramadol ER\nCondition: Opioid Addiction\nPhase: phase_1_2\nBlinding: QUADRUPLE\nEnrollment: 106\np-value: 0.275\nInterpretation: definitive_negative", "metadata": {"result_id": 67686, "source_trial_id": "NCT01188421", "intervention_name": "tramadol ER", "condition_name": "Opioid Addiction", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0428", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: aminolevulinic acid HCL (ALA)\nCondition: Acne Vulgaris\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 266\np-value: 0.768\nInterpretation: definitive_negative", "metadata": {"result_id": 108718, "source_trial_id": "NCT00706433", "intervention_name": "aminolevulinic acid HCL (ALA)", "condition_name": "Acne Vulgaris", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0429", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: mRNA-1647\nDrug type: oligonucleotide\nCondition: Cytomegalovirus Infection\nPhase: phase_3\nEnrollment: 7454\nTermination reason: \"The Sponsor decided to terminate the study after it did not meet the primary efficacy endpoint at final analysis. The safety profile was consistent with prior studies, and no safety concerns were raised by the Data and Safety Monitoring Board.\"\nDetail: The Sponsor decided to terminate the study after it did not meet the primary efficacy endpoint at final analysis. The safety profile was consistent with prior studies, and no safety concerns were raised by the Data and Safety Monitoring Board.", "metadata": {"result_id": 11334, "source_trial_id": "NCT05085366", "intervention_name": "mRNA-1647", "condition_name": "Cytomegalovirus Infection", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0430", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Finasteride\nCondition: Muscle Atrophy\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 60\np-value: 0.779\n95% CI: [-5.095, 3.811]\nSerious adverse events: 12.0\nInterpretation: definitive_negative", "metadata": {"result_id": 77056, "source_trial_id": "NCT00475501", "intervention_name": "Finasteride", "condition_name": "Muscle Atrophy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0431", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Combivent (Ipratropium/Albuterol)\nCondition: Pulmonary Disease, Chronic Obstructive\nPhase: phase_4\nBlinding: nan\nEnrollment: 349\np-value: 0.835\n95% CI: [-0.092, 0.114]\nSerious adverse events: 53.0\nInterpretation: definitive_negative", "metadata": {"result_id": 82145, "source_trial_id": "NCT00359788", "intervention_name": "Combivent (Ipratropium/Albuterol)", "condition_name": "Pulmonary Disease, Chronic Obstructive", "confidence_tier": "gold", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-0432", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: PD 0332991 (pre-surgery)\nCondition: Anaplastic Astrocytoma\nPhase: phase_2\nBlinding: NONE\nEnrollment: 23\np-value: 0.1\nSerious adverse events: 26.0\nInterpretation: definitive_negative", "metadata": {"result_id": 68238, "source_trial_id": "NCT01227434", "intervention_name": "PD 0332991 (pre-surgery)", "condition_name": "Anaplastic Astrocytoma", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0433", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: 50,000 IU vitamin D3\nCondition: Polycystic Ovary Syndrome\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 60\np-value: 0.67\nInterpretation: definitive_negative", "metadata": {"result_id": 80736, "source_trial_id": "NCT02328404", "intervention_name": "50,000 IU vitamin D3", "condition_name": "Polycystic Ovary Syndrome", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0434", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Bocidelpar\nCondition: Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction\nPhase: phase_1\nEnrollment: 31\nTermination reason: \"Lack of Pharmacological effect\"\nDetail: Lack of Pharmacological effect", "metadata": {"result_id": 27226, "source_trial_id": "NCT04855201", "intervention_name": "Bocidelpar", "condition_name": "Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0435", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Pembrolizumab Immunotherapy\nCondition: Non-Squamous Non-Small Cell Neoplasm of Lung\nPhase: phase_2\nEnrollment: 40\nTermination reason: \"Lack of Clinical Benefit\"\nDetail: Lack of Clinical Benefit", "metadata": {"result_id": 21480, "source_trial_id": "NCT04265534", "intervention_name": "Pembrolizumab Immunotherapy", "condition_name": "Non-Squamous Non-Small Cell Neoplasm of Lung", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0436", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Calcitriol\nCondition: Type 2 Diabetes\nBlinding: DOUBLE\nEnrollment: 41\np-value: 0.69\nInterpretation: definitive_negative", "metadata": {"result_id": 82076, "source_trial_id": "NCT01635062", "intervention_name": "Calcitriol", "condition_name": "Type 2 Diabetes", "confidence_tier": "silver", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-0437", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Buprenorphine/naloxone\nCondition: Opiate Addiction\nPhase: phase_4\nBlinding: NONE\nEnrollment: 12\nPrimary endpoint met: 1.0\np-value: 0.015\nInterpretation: definitive_negative", "metadata": {"result_id": 44680, "source_trial_id": "NCT00552578", "intervention_name": "Buprenorphine/naloxone", "condition_name": "Opiate Addiction", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0438", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: REL-1017\nCondition: Depressive Disorder, Treatment-Resistant\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 62\np-value: 0.1237\nInterpretation: definitive_negative", "metadata": {"result_id": 81393, "source_trial_id": "NCT03051256", "intervention_name": "REL-1017", "condition_name": "Depressive Disorder, Treatment-Resistant", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0439", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Apremilast 20mg\nCondition: Psoriatic Arthritis\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 529\np-value: 0.7696\n95% CI: [-0.8, 0.6]\nSerious adverse events: 209.0\nInterpretation: definitive_negative", "metadata": {"result_id": 70106, "source_trial_id": "NCT01307423", "intervention_name": "Apremilast 20mg", "condition_name": "Psoriatic Arthritis", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0440", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Acetylsalicylic Acid 75Mg Tablet\nCondition: Insulin Resistance Syndrome\nPhase: phase_4\nBlinding: NONE\nEnrollment: 43\np-value: 0.3\nInterpretation: definitive_negative", "metadata": {"result_id": 76151, "source_trial_id": "NCT03011775", "intervention_name": "Acetylsalicylic Acid 75Mg Tablet", "condition_name": "Insulin Resistance Syndrome", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0441", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Belumosudil Tablet\nCondition: Bioavailability\nPhase: phase_1\nBlinding: NONE\nEnrollment: 23\np-value: 0.23\n95% CI: [80.0, 125.0]\nInterpretation: definitive_negative", "metadata": {"result_id": 111887, "source_trial_id": "NCT02557139", "intervention_name": "Belumosudil Tablet", "condition_name": "Bioavailability", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0442", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: pemetrexed+cisplatin\nCondition: Non-Small Cell Lung Cancer NSCLC\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 401\np-value: 0.074\n95% CI: [0.57, 1.02]\nSerious adverse events: 570.0\nInterpretation: definitive_negative", "metadata": {"result_id": 71617, "source_trial_id": "NCT03775486", "intervention_name": "pemetrexed+cisplatin", "condition_name": "Non-Small Cell Lung Cancer NSCLC", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0443", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: suprachoroidal sham\nCondition: Retinal Vein Occlusion\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 460\np-value: 0.187\nEffect size (Difference in percentages): -6.1\n95% CI: [-15.2, 3.0]\nSerious adverse events: 141.0\nInterpretation: definitive_negative", "metadata": {"result_id": 47031, "source_trial_id": "NCT02980874", "intervention_name": "suprachoroidal sham", "condition_name": "Retinal Vein Occlusion", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0444", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: MEDI3506\nDrug type: monoclonal_antibody\nCondition: Diabetic Kidney Disease\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 609\np-value: 0.8338\n95% CI: [-22.61, 21.94]\nInterpretation: definitive_negative", "metadata": {"result_id": 97970, "source_trial_id": "NCT04170543", "intervention_name": "MEDI3506", "condition_name": "Diabetic Kidney Disease", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0445", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: AGS-003\nDrug type: cell_therapy\nCondition: Renal Cell Carcinoma\nPhase: phase_2\nEnrollment: 2\nTermination reason: \"Lack of efficacy\"\nDetail: Lack of efficacy", "metadata": {"result_id": 27833, "source_trial_id": "NCT01482949", "intervention_name": "AGS-003", "condition_name": "Renal Cell Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0446", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: MK-8150 900 mg\nCondition: Hypertension\nPhase: phase_1\nBlinding: DOUBLE\nEnrollment: 34\np-value: 0.503\n95% CI: [-1.59, 3.15]\nInterpretation: definitive_negative", "metadata": {"result_id": 79248, "source_trial_id": "NCT01590810", "intervention_name": "MK-8150 900 mg", "condition_name": "Hypertension", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0447", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Cetylpyridinium chloride mouthwash\nCondition: Dental Plaque\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 129\np-value: 0.652\nInterpretation: definitive_negative", "metadata": {"result_id": 67126, "source_trial_id": "NCT02360995", "intervention_name": "Cetylpyridinium chloride mouthwash", "condition_name": "Dental Plaque", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0448", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Telmisartan 20 mg/indapamide 1.25 mg\nCondition: Hypertension\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 1385\np-value: 0.0674\n95% CI: [-0.613, 13.926]\nInterpretation: definitive_negative", "metadata": {"result_id": 91724, "source_trial_id": "NCT04518293", "intervention_name": "Telmisartan 20 mg/indapamide 1.25 mg", "condition_name": "Hypertension", "confidence_tier": "gold", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0449", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Vitamin K antagonist\nCondition: Acute Coronary Syndromes\nPhase: phase_4\nBlinding: NONE\nEnrollment: 4614\np-value: 0.2219\n95% CI: [0.96, 1.2]\nSerious adverse events: 614.0\nInterpretation: definitive_negative", "metadata": {"result_id": 100494, "source_trial_id": "NCT02415400", "intervention_name": "Vitamin K antagonist", "condition_name": "Acute Coronary Syndromes", "confidence_tier": "gold", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0450", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: NC410\nDrug type: unknown\nCondition: Ovarian Cancer\nPhase: phase_1_2\nEnrollment: 46\nTermination reason: \"Upon completion of the Phase 1 portion of the NC410 monotherapy trial, NextCure focused efforts on a combination trial of NC410 in solid tumors.\"\nDetail: Upon completion of the Phase 1 portion of the NC410 monotherapy trial, NextCure focused efforts on a combination trial of NC410 in solid tumors.", "metadata": {"result_id": 42198, "source_trial_id": "NCT04408599", "intervention_name": "NC410", "condition_name": "Ovarian Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0451", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: CP 751,871 (Figitumumab)\nDrug type: monoclonal_antibody\nCondition: Carcinoma, Adenosquamous Cell\nPhase: phase_3\nBlinding: NONE\nEnrollment: 583\np-value: 0.35\n95% CI: [0.909, 1.31]\nSerious adverse events: 1128.0\nInterpretation: definitive_negative", "metadata": {"result_id": 98570, "source_trial_id": "NCT00673049", "intervention_name": "CP 751,871 (Figitumumab)", "condition_name": "Carcinoma, Adenosquamous Cell", "confidence_tier": "gold", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0452", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: TAK-935\nCondition: Epilepsy\nPhase: phase_1\nBlinding: QUADRUPLE\nEnrollment: 40\np-value: 0.757\n95% CI: [0.741, 1.374]\nInterpretation: definitive_negative", "metadata": {"result_id": 87665, "source_trial_id": "NCT02539134", "intervention_name": "TAK-935", "condition_name": "Epilepsy", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0453", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: omega-3 fatty acid\nDrug type: unknown\nCondition: Stage IIIC Breast Cancer\nPhase: phase_2\nBlinding: NONE\nEnrollment: 57\np-value: 0.93\nInterpretation: definitive_negative", "metadata": {"result_id": 112150, "source_trial_id": "NCT01869764", "intervention_name": "omega-3 fatty acid", "condition_name": "Stage IIIC Breast Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0454", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: ACT guided heparinization\nCondition: Surgery\nPhase: phase_4\nEnrollment: 294\nTermination reason: \"Futility\"\nDetail: Futility", "metadata": {"result_id": 42659, "source_trial_id": "NCT04061798", "intervention_name": "ACT guided heparinization", "condition_name": "Surgery", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0455", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: corticosteroids\nCondition: Lupus Nephritis\nPhase: phase_3\nEnrollment: 381\nTermination reason: \"Study was terminated due to an imbalance of serious and opportunistic infections in the ocrelizumab treated patients versus the placebo arm.\"\nDetail: Study was terminated due to an imbalance of serious and opportunistic infections in the ocrelizumab treated patients versus the placebo arm.", "metadata": {"result_id": 2767, "source_trial_id": "NCT00626197", "intervention_name": "corticosteroids", "condition_name": "Lupus Nephritis", "confidence_tier": "bronze", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL1-0456", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: AS03-adjuvanted cH8/1N1 IIV\nCondition: Vaccine\nPhase: phase_1\nBlinding: TRIPLE\nEnrollment: 65\np-value: 0.9411\n95% CI: [0.68, 1.66]\nSerious adverse events: 7.0\nInterpretation: definitive_negative", "metadata": {"result_id": 88405, "source_trial_id": "NCT03300050", "intervention_name": "AS03-adjuvanted cH8/1N1 IIV", "condition_name": "Vaccine", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0457", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: N1539\nCondition: Pain, Post-operative\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 201\np-value: 0.1228\nSerious adverse events: 5.0\nInterpretation: definitive_negative", "metadata": {"result_id": 107147, "source_trial_id": "NCT02675907", "intervention_name": "N1539", "condition_name": "Pain, Post-operative", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0458", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: LGG\nCondition: Gastroenteritis\nPhase: phase_2_3\nBlinding: QUADRUPLE\nEnrollment: 971\np-value: 0.83\nSerious adverse events: 42.0\nInterpretation: definitive_negative", "metadata": {"result_id": 91432, "source_trial_id": "NCT01773967", "intervention_name": "LGG", "condition_name": "Gastroenteritis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0459", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Loratadine Syrup 1 mg/mL Rescue Treatment\nCondition: Allergy\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 345\np-value: 0.066\n95% CI: [-0.88, 0.03]\nSerious adverse events: 8.0\nInterpretation: definitive_negative", "metadata": {"result_id": 102908, "source_trial_id": "NCT00550550", "intervention_name": "Loratadine Syrup 1 mg/mL Rescue Treatment", "condition_name": "Allergy", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0460", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Ortho-Cyclen\nCondition: Healthy\nPhase: phase_1\nBlinding: NONE\nEnrollment: 36\np-value: 0.0532\nInterpretation: definitive_negative", "metadata": {"result_id": 112222, "source_trial_id": "NCT01243580", "intervention_name": "Ortho-Cyclen", "condition_name": "Healthy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0461", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: CD5024 1% cream\nCondition: Acne\nPhase: phase_2\nBlinding: SINGLE\nEnrollment: 70\np-value: 0.158\nInterpretation: definitive_negative", "metadata": {"result_id": 110157, "source_trial_id": "NCT03034460", "intervention_name": "CD5024 1% cream", "condition_name": "Acne", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0462", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Tropicamide\nCondition: Transplantation, Cornea\nPhase: phase_4\nBlinding: DOUBLE\nEnrollment: 38\np-value: 0.53\n95% CI: [-326.0, 172.0]\nInterpretation: definitive_negative", "metadata": {"result_id": 88995, "source_trial_id": "NCT02373137", "intervention_name": "Tropicamide", "condition_name": "Transplantation, Cornea", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0463", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Purified pituitary gonadotropin (Fertinorm-P®)\nCondition: Infertility\nPhase: phase_3\nBlinding: SINGLE\nEnrollment: 300\np-value: 0.214\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 74827, "source_trial_id": "NCT01185782", "intervention_name": "Purified pituitary gonadotropin (Fertinorm-P®)", "condition_name": "Infertility", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0464", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Trelegy Ellipta 100/62.5/25Mcg Inh 30D\nCondition: COPD\nPhase: phase_4\nBlinding: NONE\nEnrollment: 30\np-value: 0.33\nInterpretation: definitive_negative", "metadata": {"result_id": 86775, "source_trial_id": "NCT04606394", "intervention_name": "Trelegy Ellipta 100/62.5/25Mcg Inh 30D", "condition_name": "COPD", "confidence_tier": "gold", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-0465", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: degarelix\nDrug type: peptide\nCondition: COVID-19\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 96\np-value: 0.667\n95% CI: [0.46, 3.06]\nSerious adverse events: 91.0\nInterpretation: definitive_negative", "metadata": {"result_id": 74288, "source_trial_id": "NCT04397718", "intervention_name": "degarelix", "condition_name": "COVID-19", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-0466", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: IRX-010\nCondition: Healthy Participants\nPhase: phase_1\nEnrollment: 83\nTermination reason: \"The highest multiple dose planned for this study was not well tolerated by most participants. There is no benefit to continue dosing of healthy participants.\"\nDetail: The highest multiple dose planned for this study was not well tolerated by most participants. There is no benefit to continue dosing of healthy participants.", "metadata": {"result_id": 60429, "source_trial_id": "NCT06356259", "intervention_name": "IRX-010", "condition_name": "Healthy Participants", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0467", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: in utero hematopoietic stem cell transplantation\nCondition: Fetal Anemia\nPhase: phase_1\nEnrollment: 6\nTermination reason: \"Enrollment ended early due to interim data suggesting a lack of efficacy. Interim data did demonstrate that IUHSCT was safe and well tolerated, but the PI and DSMB agreed that enrollment should not continue under the current treatment protocol.\"\nDetail: Enrollment ended early due to interim data suggesting a lack of efficacy. Interim data did demonstrate that IUHSCT was safe and well tolerated, but the PI and DSMB agreed that enrollment should not continue under the current treatment protocol.", "metadata": {"result_id": 44711, "source_trial_id": "NCT02986698", "intervention_name": "in utero hematopoietic stem cell transplantation", "condition_name": "Fetal Anemia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0468", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: citalopram\nCondition: Depressive Disorder, Major\nPhase: phase_1\nBlinding: DOUBLE\nEnrollment: 73\np-value: 0.3495\n95% CI: [-0.08, 0.02]\nInterpretation: definitive_negative", "metadata": {"result_id": 79272, "source_trial_id": "NCT03854578", "intervention_name": "citalopram", "condition_name": "Depressive Disorder, Major", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0469", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: 0.9% sodium chloride for injection\nCondition: Postoperative Complications\nPhase: phase_4\nBlinding: QUADRUPLE\nEnrollment: 285\np-value: 0.341\n95% CI: [0.23, 1.65]\nSerious adverse events: 6.0\nInterpretation: definitive_negative", "metadata": {"result_id": 98766, "source_trial_id": "NCT02267538", "intervention_name": "0.9% sodium chloride for injection", "condition_name": "Postoperative Complications", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0470", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Anti-hyperglycemic Agents\nCondition: Atherosclerosis\nPhase: phase_3\nBlinding: NONE\nEnrollment: 10251\np-value: 0.12\n95% CI: [0.81, 1.03]\nSerious adverse events: 488.0\nInterpretation: definitive_negative", "metadata": {"result_id": 83501, "source_trial_id": "NCT00000620", "intervention_name": "Anti-hyperglycemic Agents", "condition_name": "Atherosclerosis", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0471", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: azithromycin\nCondition: Chlamydial Infection\nPhase: phase_2\nBlinding: NONE\nEnrollment: 100\np-value: 0.656\n95% CI: [0.22, 2.62]\nInterpretation: definitive_negative", "metadata": {"result_id": 94216, "source_trial_id": "NCT03249935", "intervention_name": "azithromycin", "condition_name": "Chlamydial Infection", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0472", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: venglustat GZ402671\nCondition: Congenital Cystic Kidney Disease\nPhase: phase_3\nEnrollment: 24\nTermination reason: \"LTS15823 (long-term extension of the EFC15392 study) was stopped after protocol specified interim analysis for futility of the parent EFC15392 study met the prespecified stopping rule based on the primary outcome measure.\"\nDetail: LTS15823 (long-term extension of the EFC15392 study) was stopped after protocol specified interim analysis for futility of the parent EFC15392 study met the prespecified stopping rule based on the primary outcome measure.", "metadata": {"result_id": 14182, "source_trial_id": "NCT04705051", "intervention_name": "venglustat GZ402671", "condition_name": "Congenital Cystic Kidney Disease", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0473", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Extraneal\nDrug type: unknown\nCondition: ESRD\nPhase: phase_4\nBlinding: NONE\nEnrollment: 137\np-value: 0.312\n95% CI: [-4.7, 14.7]\nSerious adverse events: 272.0\nInterpretation: definitive_negative", "metadata": {"result_id": 78629, "source_trial_id": "NCT00567489", "intervention_name": "Extraneal", "condition_name": "ESRD", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0474", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Nicotine\nCondition: Major Depressive Disorder\nPhase: phase_4\nBlinding: NONE\nEnrollment: 15\np-value: 0.761\nInterpretation: definitive_negative", "metadata": {"result_id": 101332, "source_trial_id": "NCT02816138", "intervention_name": "Nicotine", "condition_name": "Major Depressive Disorder", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0475", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: 2.5x10^6 cells/kg CAR20.19.22 cells\nCondition: B-cell Chronic Lymphocytic Leukemia\nPhase: phase_1\nEnrollment: 4\nTermination reason: \"Treated four patients: 2 at a dose of 1x10\\^6 cells/kg and 2 ad at dose of 2.5x10\\^6 cells/kg. All four patients had no in-vivo expansion and no meaningful response to therapy. At this point per FDA guidance we will not be treating more patients.\"\nDetail: Treated four patients: 2 at a dose of 1x10\\^6 cells/kg and 2 ad at dose of 2.5x10\\^6 cells/kg. All four patients had no in-vivo expansion and no meaningful response to therapy. At this point per FDA guidance we will not be treating more patients.", "metadata": {"result_id": 8886, "source_trial_id": "NCT05094206", "intervention_name": "2.5x10^6 cells/kg CAR20.19.22 cells", "condition_name": "B-cell Chronic Lymphocytic Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0476", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: VRC01\nDrug type: unknown\nCondition: HIV Infections\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 23\np-value: 1.0\nInterpretation: definitive_negative", "metadata": {"result_id": 74434, "source_trial_id": "NCT02664415", "intervention_name": "VRC01", "condition_name": "HIV Infections", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-0477", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Labetalol\nCondition: Hypertension, Pregnancy-Induced\nPhase: phase_4\nBlinding: NONE\nEnrollment: 13\np-value: 0.21\nInterpretation: definitive_negative", "metadata": {"result_id": 64448, "source_trial_id": "NCT04343235", "intervention_name": "Labetalol", "condition_name": "Hypertension, Pregnancy-Induced", "confidence_tier": "gold", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0478", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Artemether-lumefantrine\nCondition: Malaria, Falciparum\nPhase: phase_4\nEnrollment: 245\nTermination reason: \"Interim analysis showed more LCFs in one of the treatment arms\"\nDetail: Interim analysis showed more LCFs in one of the treatment arms", "metadata": {"result_id": 15198, "source_trial_id": "NCT00374205", "intervention_name": "Artemether-lumefantrine", "condition_name": "Malaria, Falciparum", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-0479", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Mepolizumab 100 MG\nCondition: Eosinophilic Esophagitis\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 66\np-value: 0.14\nInterpretation: definitive_negative", "metadata": {"result_id": 93843, "source_trial_id": "NCT03656380", "intervention_name": "Mepolizumab 100 MG", "condition_name": "Eosinophilic Esophagitis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0480", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: DU-176b tablets\nCondition: Atrial Fibrillation\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 536\np-value: 0.429\nSerious adverse events: 30.0\nInterpretation: definitive_negative", "metadata": {"result_id": 66904, "source_trial_id": "NCT00829933", "intervention_name": "DU-176b tablets", "condition_name": "Atrial Fibrillation", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0481", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: ALIS\nCondition: Mycobacterium Infections, Nontuberculous\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 99\np-value: 0.2819\n95% CI: [-8.6, 29.5]\nInterpretation: definitive_negative", "metadata": {"result_id": 91601, "source_trial_id": "NCT04677543", "intervention_name": "ALIS", "condition_name": "Mycobacterium Infections, Nontuberculous", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0482", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Convalescent anti-SARS-CoV-2 plasma\nCondition: Viral Pneumonia\nPhase: phase_3\nEnrollment: 147\nTermination reason: \"DSMB advise due to high probability of futility\"\nDetail: DSMB advise due to high probability of futility", "metadata": {"result_id": 9208, "source_trial_id": "NCT04345289", "intervention_name": "Convalescent anti-SARS-CoV-2 plasma", "condition_name": "Viral Pneumonia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0483", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Dexpramipexole\nCondition: Amyotrophic Lateral Sclerosis\nPhase: phase_3\nEnrollment: 616\nTermination reason: \"The Initial Phase 3 Study (NCTO1281189) did not meet its primary efficacy endpoint.\"\nDetail: The Initial Phase 3 Study (NCTO1281189) did not meet its primary efficacy endpoint.", "metadata": {"result_id": 56732, "source_trial_id": "NCT01622088", "intervention_name": "Dexpramipexole", "condition_name": "Amyotrophic Lateral Sclerosis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0484", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: L-alanyl-L-glutamine dipeptide\nCondition: Coronary Artery Disease\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 60\np-value: 0.993\nInterpretation: definitive_negative", "metadata": {"result_id": 80325, "source_trial_id": "NCT04560309", "intervention_name": "L-alanyl-L-glutamine dipeptide", "condition_name": "Coronary Artery Disease", "confidence_tier": "gold", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0485", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: ABO-102\nDrug type: gene_therapy\nCondition: Sanfilippo A\nPhase: phase_1_2\nEnrollment: 5\nTermination reason: \"Terminated due to lack of efficacy seen in patients with advanced MPS IIIA disease. The patients will be followed up annually for safety until five years post dosing\"\nDetail: Terminated due to lack of efficacy seen in patients with advanced MPS IIIA disease. The patients will be followed up annually for safety until five years post dosing", "metadata": {"result_id": 14501, "source_trial_id": "NCT04088734", "intervention_name": "ABO-102", "condition_name": "Sanfilippo A", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0486", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: targeted therapy\nCondition: Recurrent Non-small Cell Lung Cancer\nEnrollment: 1\nTermination reason: \"Feasibility\"\nDetail: Feasibility", "metadata": {"result_id": 9374, "source_trial_id": "NCT02132884", "intervention_name": "targeted therapy", "condition_name": "Recurrent Non-small Cell Lung Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0487", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Romiplostim\nDrug type: peptide\nCondition: Thrombocytopenia\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 63\np-value: 0.972\nSerious adverse events: 56.0\nInterpretation: definitive_negative", "metadata": {"result_id": 103227, "source_trial_id": "NCT00413283", "intervention_name": "Romiplostim", "condition_name": "Thrombocytopenia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0488", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: LCZ696\nCondition: Heart Failure\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 365\np-value: 0.45\n95% CI: [0.84, 1.08]\nSerious adverse events: 207.0\nInterpretation: definitive_negative", "metadata": {"result_id": 85671, "source_trial_id": "NCT02816736", "intervention_name": "LCZ696", "condition_name": "Heart Failure", "confidence_tier": "gold", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0489", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Pegaspargase\nDrug type: unknown\nCondition: B Acute Lymphoblastic Leukemia\nPhase: phase_3\nBlinding: NONE\nEnrollment: 5949\np-value: 0.893\n95% CI: [0.74, 1.413]\nInterpretation: definitive_negative", "metadata": {"result_id": 73726, "source_trial_id": "NCT02883049", "intervention_name": "Pegaspargase", "condition_name": "B Acute Lymphoblastic Leukemia", "confidence_tier": "gold", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0490", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: ceftriaxone\nCondition: Early Syphilis\nPhase: phase_4\nBlinding: NONE\nEnrollment: 109\np-value: 0.887\n95% CI: [-0.199, 0.172]\nInterpretation: definitive_negative", "metadata": {"result_id": 93226, "source_trial_id": "NCT05980871", "intervention_name": "ceftriaxone", "condition_name": "Early Syphilis", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0491", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: gp100 antigen\nDrug type: unknown\nCondition: Melanoma (Skin)\nPhase: phase_2\nBlinding: NONE\nEnrollment: 40\np-value: 0.13\nSerious adverse events: 16.0\nInterpretation: definitive_negative", "metadata": {"result_id": 101020, "source_trial_id": "NCT00003222", "intervention_name": "gp100 antigen", "condition_name": "Melanoma (Skin)", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0492", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: KHK2866\nDrug type: unknown\nCondition: Fallopian Tube Neoplasms\nPhase: phase_1\nEnrollment: 22\nTermination reason: \"The study was stopped due to the inability to determine an acceptable dose with the potential for further study\"\nDetail: The study was stopped due to the inability to determine an acceptable dose with the potential for further study", "metadata": {"result_id": 54339, "source_trial_id": "NCT01279291", "intervention_name": "KHK2866", "condition_name": "Fallopian Tube Neoplasms", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0493", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Mefenamic acid\nCondition: Healthy Volunteers\nPhase: phase_1\nBlinding: NONE\nEnrollment: 28\np-value: 0.2305\n95% CI: [-0.001, 0.126]\nInterpretation: definitive_negative", "metadata": {"result_id": 77711, "source_trial_id": "NCT05064449", "intervention_name": "Mefenamic acid", "condition_name": "Healthy Volunteers", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0494", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Octagam 10%\nDrug type: unknown\nCondition: Immunologic Deficiency Syndromes\nPhase: phase_3\nEnrollment: 5\nTermination reason: \"Due to limited data available, efficacy, and PK analyses were not performed.\"\nDetail: Due to limited data available, efficacy, and PK analyses were not performed.", "metadata": {"result_id": 1967, "source_trial_id": "NCT00811174", "intervention_name": "Octagam 10%", "condition_name": "Immunologic Deficiency Syndromes", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0495", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Atrovent Respimat (20 mcg)\nCondition: Pulmonary Disease, Chronic Obstructive\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 1480\np-value: 0.7135\n95% CI: [-0.0222, 0.0152]\nSerious adverse events: 157.0\nInterpretation: definitive_negative", "metadata": {"result_id": 66810, "source_trial_id": "NCT00400153", "intervention_name": "Atrovent Respimat (20 mcg)", "condition_name": "Pulmonary Disease, Chronic Obstructive", "confidence_tier": "gold", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-0496", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: FP-025 300 mg\nCondition: Severe to Critical COVID 19 With Associated ARDS\nPhase: phase_2_3\nEnrollment: 90\nTermination reason: \"Study stopped at interim analysis point, due to lack of study subjects to recruit.\"\nDetail: Study stopped at interim analysis point, due to lack of study subjects to recruit.", "metadata": {"result_id": 20311, "source_trial_id": "NCT04750278", "intervention_name": "FP-025 300 mg", "condition_name": "Severe to Critical COVID 19 With Associated ARDS", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-0497", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: TAK-500\nCondition: Hepatocellular Cancer\nPhase: phase_1_2\nEnrollment: 61\nTermination reason: \"Clinical Futility of TAK 500 met. No further development with this compound\"\nDetail: Clinical Futility of TAK 500 met. No further development with this compound", "metadata": {"result_id": 40132, "source_trial_id": "NCT05070247", "intervention_name": "TAK-500", "condition_name": "Hepatocellular Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0498", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose)\nCondition: Asthma\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 1001\np-value: 0.118\n95% CI: [0.445, 1.096]\nSerious adverse events: 28.0\nInterpretation: definitive_negative", "metadata": {"result_id": 111511, "source_trial_id": "NCT03847896", "intervention_name": "Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose)", "condition_name": "Asthma", "confidence_tier": "gold", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-0499", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: BIBW 2948 BS\nCondition: Pulmonary Disease, Chronic Obstructive\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 48\np-value: 0.5305\nSerious adverse events: 33.0\nInterpretation: definitive_negative", "metadata": {"result_id": 79310, "source_trial_id": "NCT00423137", "intervention_name": "BIBW 2948 BS", "condition_name": "Pulmonary Disease, Chronic Obstructive", "confidence_tier": "silver", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-0500", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: cinacalcet capsule\nCondition: Secondary Hyperparathyroidism\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 43\np-value: 0.826\n95% CI: [-22.58, 29.51]\nSerious adverse events: 83.0\nInterpretation: definitive_negative", "metadata": {"result_id": 75571, "source_trial_id": "NCT01277510", "intervention_name": "cinacalcet capsule", "condition_name": "Secondary Hyperparathyroidism", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0501", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: LCZ696\nCondition: Pediatric Heart Failure\nPhase: phase_2_3\nBlinding: DOUBLE\nEnrollment: 393\np-value: 0.7958\n95% CI: [0.6589, 1.7232]\nInterpretation: definitive_negative", "metadata": {"result_id": 74731, "source_trial_id": "NCT02678312", "intervention_name": "LCZ696", "condition_name": "Pediatric Heart Failure", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0502", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin\nCondition: Coronary Artery Disease\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 25682\np-value: 0.704\n95% CI: [0.38, 1.53]\nSerious adverse events: 3703.0\nInterpretation: definitive_negative", "metadata": {"result_id": 93117, "source_trial_id": "NCT00977938", "intervention_name": "Clopidogrel & Aspirin, Prasugrel & Aspirin", "condition_name": "Coronary Artery Disease", "confidence_tier": "gold", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0503", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Optimal drug therapy\nCondition: Parkinson's Disease\nBlinding: SINGLE\nEnrollment: 37\np-value: 0.968\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 89115, "source_trial_id": "NCT00282152", "intervention_name": "Optimal drug therapy", "condition_name": "Parkinson's Disease", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0504", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: sulfadoxine-pyrimethamine\nDrug type: unknown\nCondition: Malaria\nPhase: phase_2\nBlinding: NONE\nEnrollment: 1737\np-value: 0.08\n95% CI: [-2.5, 32.4]\nSerious adverse events: 299.0\nInterpretation: definitive_negative", "metadata": {"result_id": 89242, "source_trial_id": "NCT00323622", "intervention_name": "sulfadoxine-pyrimethamine", "condition_name": "Malaria", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-0505", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Latanoprost Vehicle\nCondition: Ocular Hypertension\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 318\np-value: 0.171\n95% CI: [-0.21, 2.32]\nSerious adverse events: 7.0\nInterpretation: definitive_negative", "metadata": {"result_id": 88912, "source_trial_id": "NCT00572455", "intervention_name": "Latanoprost Vehicle", "condition_name": "Ocular Hypertension", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0506", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Intranasal Ketoralac\nCondition: Urolithiasis\nPhase: phase_4\nEnrollment: 50\nTermination reason: \"Interim analysis showed futility of primary endpoint\"\nDetail: Interim analysis showed futility of primary endpoint", "metadata": {"result_id": 27695, "source_trial_id": "NCT01736358", "intervention_name": "Intranasal Ketoralac", "condition_name": "Urolithiasis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0507", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Gilteritinib\nCondition: Acute Myeloid Leukemia\nPhase: phase_2\nBlinding: NONE\nEnrollment: 181\np-value: 0.366\n95% CI: [-0.205, 0.062]\nInterpretation: definitive_negative", "metadata": {"result_id": 88951, "source_trial_id": "NCT03836209", "intervention_name": "Gilteritinib", "condition_name": "Acute Myeloid Leukemia", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0508", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Mometasone\nCondition: Asthma\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 188\np-value: 0.101\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 104804, "source_trial_id": "NCT00070707", "intervention_name": "Mometasone", "condition_name": "Asthma", "confidence_tier": "gold", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-0509", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: 250 µg AZD7594 once daily\nCondition: Asthma\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 54\np-value: 0.6379\n95% CI: [-0.08626, 0.1401]\nInterpretation: definitive_negative", "metadata": {"result_id": 100208, "source_trial_id": "NCT02479412", "intervention_name": "250 µg AZD7594 once daily", "condition_name": "Asthma", "confidence_tier": "silver", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-0510", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Sativex Medium Dose\nCondition: Cancer\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 360\np-value: 0.33\n95% CI: [0.72, 2.6]\nSerious adverse events: 246.0\nInterpretation: definitive_negative", "metadata": {"result_id": 94909, "source_trial_id": "NCT00530764", "intervention_name": "Sativex Medium Dose", "condition_name": "Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0511", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: 89Zirconium-M7824\nCondition: Non-Small Cell Lung Cancer\nPhase: phase_1_2\nEnrollment: 5\nTermination reason: \"Efficacy finding\"\nDetail: Efficacy finding", "metadata": {"result_id": 58017, "source_trial_id": "NCT04297748", "intervention_name": "89Zirconium-M7824", "condition_name": "Non-Small Cell Lung Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0512", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)\nCondition: Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer\nPhase: phase_3\nBlinding: NONE\nEnrollment: 1221\np-value: 0.2648\n95% CI: [0.887, 1.544]\nSerious adverse events: 1404.0\nInterpretation: definitive_negative", "metadata": {"result_id": 95845, "source_trial_id": "NCT00154102", "intervention_name": "FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)", "condition_name": "Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer", "confidence_tier": "gold", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0513", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Background lipid lowering therapy\nCondition: Elevated Low Density Lipoprotein Cholesterol\nPhase: phase_3\nBlinding: NONE\nEnrollment: 892\np-value: 0.9347\n95% CI: [-0.67, 0.61]\nInterpretation: definitive_negative", "metadata": {"result_id": 84722, "source_trial_id": "NCT04807400", "intervention_name": "Background lipid lowering therapy", "condition_name": "Elevated Low Density Lipoprotein Cholesterol", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0514", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: vandetanib\nCondition: Differentiated Thyroid Cancer\nPhase: phase_2\nEnrollment: 6\nTermination reason: \"Lack of efficacy\"\nDetail: Lack of efficacy", "metadata": {"result_id": 45859, "source_trial_id": "NCT03630120", "intervention_name": "vandetanib", "condition_name": "Differentiated Thyroid Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0515", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Albuterol sulfate 108 mcg\nCondition: Allergy\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 439\np-value: 0.084\n95% CI: [-0.96, 0.06]\nSerious adverse events: 16.0\nInterpretation: definitive_negative", "metadata": {"result_id": 99416, "source_trial_id": "NCT00562159", "intervention_name": "Albuterol sulfate 108 mcg", "condition_name": "Allergy", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0516", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Rilzabrutinib\nCondition: Pemphigus\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 131\np-value: 0.4469\n95% CI: [-9.037, 20.5]\nSerious adverse events: 68.0\nInterpretation: definitive_negative", "metadata": {"result_id": 85299, "source_trial_id": "NCT03762265", "intervention_name": "Rilzabrutinib", "condition_name": "Pemphigus", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0517", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Bromfenac\nCondition: Cataract\nPhase: phase_3\nEnrollment: 628\nTermination reason: \"Results of interim analysis: stop the trial due to one group being significantly different from the other three groups. Furthermore, shortage of study medication.\"\nDetail: Results of interim analysis: stop the trial due to one group being significantly different from the other three groups. Furthermore, shortage of study medication.", "metadata": {"result_id": 46616, "source_trial_id": "NCT05158699", "intervention_name": "Bromfenac", "condition_name": "Cataract", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0518", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: BI1356 high dose\nCondition: Diabetes Mellitus, Type 2\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 40\np-value: 0.3295\n95% CI: [-1.47, 0.51]\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 110691, "source_trial_id": "NCT01342484", "intervention_name": "BI1356 high dose", "condition_name": "Diabetes Mellitus, Type 2", "confidence_tier": "silver", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-0519", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Nutrineal\nCondition: Diabetes\nPhase: phase_4\nBlinding: NONE\nEnrollment: 137\np-value: 0.312\n95% CI: [-4.7, 14.7]\nSerious adverse events: 272.0\nInterpretation: definitive_negative", "metadata": {"result_id": 78640, "source_trial_id": "NCT00567489", "intervention_name": "Nutrineal", "condition_name": "Diabetes", "confidence_tier": "gold", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-0520", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Dietary Supplement containing resistant starch\nCondition: COVID-19\nPhase: phase_2_3\nBlinding: QUADRUPLE\nEnrollment: 226\np-value: 0.99\nInterpretation: definitive_negative", "metadata": {"result_id": 93550, "source_trial_id": "NCT04342689", "intervention_name": "Dietary Supplement containing resistant starch", "condition_name": "COVID-19", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-0521", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Cangrelor (P2Y12 inhibitor)\nCondition: Myocardial Infarction (MI)\nPhase: phase_3\nEnrollment: 8882\nTermination reason: \"Insufficient evidence of the clinical effectiveness of cangrelor\"\nDetail: Insufficient evidence of the clinical effectiveness of cangrelor", "metadata": {"result_id": 26980, "source_trial_id": "NCT00305162", "intervention_name": "Cangrelor (P2Y12 inhibitor)", "condition_name": "Myocardial Infarction (MI)", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0522", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: VP-102 and applicator\nCondition: Sexually Transmitted Diseases, Viral\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 105\np-value: 0.3642\nSerious adverse events: 6.0\nInterpretation: definitive_negative", "metadata": {"result_id": 66874, "source_trial_id": "NCT03981822", "intervention_name": "VP-102 and applicator", "condition_name": "Sexually Transmitted Diseases, Viral", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0523", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: High Dose Suvorexant\nCondition: Opioid Dependence\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 90\np-value: 0.95\nInterpretation: definitive_negative", "metadata": {"result_id": 67279, "source_trial_id": "NCT03789214", "intervention_name": "High Dose Suvorexant", "condition_name": "Opioid Dependence", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0524", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Ceftazidime-avibactam\nCondition: Complicated Intra-abdominal Infection\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 486\np-value: 0.773\nSerious adverse events: 43.0\nInterpretation: definitive_negative", "metadata": {"result_id": 65398, "source_trial_id": "NCT01726023", "intervention_name": "Ceftazidime-avibactam", "condition_name": "Complicated Intra-abdominal Infection", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0525", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Acetylcholine\nCondition: Lymphoma\nPhase: phase_1_2\nEnrollment: 2\nTermination reason: \"Futility in recruitment\"\nDetail: Futility in recruitment", "metadata": {"result_id": 3497, "source_trial_id": "NCT03953326", "intervention_name": "Acetylcholine", "condition_name": "Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0526", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: ingenol disoxate gel 0.018%\nCondition: Actinic Keratosis\nPhase: phase_3\nBlinding: NONE\nEnrollment: 563\np-value: 0.43\n95% CI: [0.61, 3.9]\nSerious adverse events: 5.0\nInterpretation: definitive_negative", "metadata": {"result_id": 86624, "source_trial_id": "NCT03115476", "intervention_name": "ingenol disoxate gel 0.018%", "condition_name": "Actinic Keratosis", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0527", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: First Treatment Period\nCondition: Acetaminophen Toxicity\nPhase: phase_4\nBlinding: DOUBLE\nEnrollment: 21\np-value: 0.59\nInterpretation: definitive_negative", "metadata": {"result_id": 81565, "source_trial_id": "NCT02322879", "intervention_name": "First Treatment Period", "condition_name": "Acetaminophen Toxicity", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0528", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: ISIS 703802 80 mg\nCondition: Fatty Liver, Nonalcoholic\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 105\np-value: 0.256\n95% CI: [-5.55, 20.54]\nSerious adverse events: 10.0\nInterpretation: definitive_negative", "metadata": {"result_id": 69747, "source_trial_id": "NCT03371355", "intervention_name": "ISIS 703802 80 mg", "condition_name": "Fatty Liver, Nonalcoholic", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0529", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: vortioxetine 10 mg tablet\nCondition: Attention Deficit Hyperactivity Disorder\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 227\np-value: 0.9723\n95% CI: [-3.6, 3.5]\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 87617, "source_trial_id": "NCT02327013", "intervention_name": "vortioxetine 10 mg tablet", "condition_name": "Attention Deficit Hyperactivity Disorder", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0530", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Saxagliptin\nCondition: Diabetes Mellitus, Type 2\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 256\np-value: 0.078\n95% CI: [-0.93, 0.05]\nInterpretation: definitive_negative", "metadata": {"result_id": 93090, "source_trial_id": "NCT03199053", "intervention_name": "Saxagliptin", "condition_name": "Diabetes Mellitus, Type 2", "confidence_tier": "gold", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-0531", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: GVAX\nCondition: Chronic Myelomonocytic Leukemia\nPhase: phase_2\nEnrollment: 123\nTermination reason: \"Recommendation by the Data and Safety Monitoring Board due to efficacy concerns\"\nDetail: Recommendation by the Data and Safety Monitoring Board due to efficacy concerns", "metadata": {"result_id": 19062, "source_trial_id": "NCT01773395", "intervention_name": "GVAX", "condition_name": "Chronic Myelomonocytic Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0532", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Lenalidomide and Gemcitabine (Dose level 11)\nCondition: Peripheral T-cell Lymphomas (PTCL)\nPhase: phase_1_2\nEnrollment: 12\nTermination reason: \"The resolution of DSMB\"\nDetail: The resolution of DSMB", "metadata": {"result_id": 45770, "source_trial_id": "NCT05105412", "intervention_name": "Lenalidomide and Gemcitabine (Dose level 11)", "condition_name": "Peripheral T-cell Lymphomas (PTCL)", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0533", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: garlic concentrate\nCondition: Alopecia Areata\nPhase: phase_3\nEnrollment: 8\nTermination reason: \"Lack of efficacy of the study medication\"\nDetail: Lack of efficacy of the study medication", "metadata": {"result_id": 7214, "source_trial_id": "NCT02691117", "intervention_name": "garlic concentrate", "condition_name": "Alopecia Areata", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0534", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Sinemet CR\nCondition: Idiopathic Parkinson's Disease\nBlinding: NONE\nEnrollment: 30\np-value: 0.84\nInterpretation: definitive_negative", "metadata": {"result_id": 67667, "source_trial_id": "NCT01470859", "intervention_name": "Sinemet CR", "condition_name": "Idiopathic Parkinson's Disease", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0535", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Bupivacaine indwelling catheter\nCondition: Rib Trauma\nPhase: phase_4\nBlinding: NONE\nEnrollment: 36\np-value: 0.12\nInterpretation: definitive_negative", "metadata": {"result_id": 105066, "source_trial_id": "NCT03305666", "intervention_name": "Bupivacaine indwelling catheter", "condition_name": "Rib Trauma", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0536", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Pravastatin\nCondition: Hypercholesterolaemia\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 153\np-value: 0.4288\n95% CI: [-21.7, 10.4]\nInterpretation: definitive_negative", "metadata": {"result_id": 94557, "source_trial_id": "NCT03510884", "intervention_name": "Pravastatin", "condition_name": "Hypercholesterolaemia", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0537", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)\nCondition: N. Meningitidis Carriage\nPhase: phase_3\nBlinding: SINGLE\nEnrollment: 2968\np-value: 0.3828\n95% CI: [0.809, 1.737]\nSerious adverse events: 179.0\nInterpretation: definitive_negative", "metadata": {"result_id": 86322, "source_trial_id": "NCT01214850", "intervention_name": "Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)", "condition_name": "N. Meningitidis Carriage", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0538", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: G100\nCondition: Ovarian Cancer\nPhase: phase_1\nEnrollment: 79\nTermination reason: \"This study did not meet the efficacy objective\"\nDetail: This study did not meet the efficacy objective", "metadata": {"result_id": 61330, "source_trial_id": "NCT02387125", "intervention_name": "G100", "condition_name": "Ovarian Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0539", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Experimental: Rivaroxaban\nCondition: Antiphospholipid Syndrome\nPhase: phase_3\nEnrollment: 121\nTermination reason: \"Unbalance in the composite endpoint between arms.\"\nDetail: Unbalance in the composite endpoint between arms.", "metadata": {"result_id": 22545, "source_trial_id": "NCT02157272", "intervention_name": "Experimental: Rivaroxaban", "condition_name": "Antiphospholipid Syndrome", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0540", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Vidaza\nCondition: Pancreatic Cancer\nPhase: phase_1\nEnrollment: 9\nTermination reason: \"The study was terminated as the Prinicipal Investigator left the site- all previous subjects enrolled are deceased\"\nDetail: The study was terminated as the Prinicipal Investigator left the site- all previous subjects enrolled are deceased", "metadata": {"result_id": 56294, "source_trial_id": "NCT01167816", "intervention_name": "Vidaza", "condition_name": "Pancreatic Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0541", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: 3mg AZ-010\nCondition: Cyclic Vomiting Syndrome\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 150\np-value: 0.7024\nInterpretation: definitive_negative", "metadata": {"result_id": 68251, "source_trial_id": "NCT04645953", "intervention_name": "3mg AZ-010", "condition_name": "Cyclic Vomiting Syndrome", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0542", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Ropivacaine\nCondition: Pregnancy Related\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 88\np-value: 0.226\nInterpretation: definitive_negative", "metadata": {"result_id": 89412, "source_trial_id": "NCT05487196", "intervention_name": "Ropivacaine", "condition_name": "Pregnancy Related", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0543", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Growth Hormone\nDrug type: peptide\nCondition: Growth Hormone Deficiency\nPhase: phase_4\nBlinding: NONE\nEnrollment: 9\np-value: 0.644\nInterpretation: definitive_negative", "metadata": {"result_id": 73030, "source_trial_id": "NCT00373386", "intervention_name": "Growth Hormone", "condition_name": "Growth Hormone Deficiency", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0544", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: ACE-I Continuation group\nCondition: Adverse Effects of Angiotensin-converting-enzyme Inhibitors\nBlinding: NONE\nEnrollment: 59\np-value: 0.102\nInterpretation: definitive_negative", "metadata": {"result_id": 32556, "source_trial_id": "NCT01867047", "intervention_name": "ACE-I Continuation group", "condition_name": "Adverse Effects of Angiotensin-converting-enzyme Inhibitors", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0545", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Four naloxone nasal spray doses (2 every 2.5 min)\nCondition: Pharmacokinetics\nPhase: phase_1\nBlinding: NONE\nEnrollment: 21\np-value: 0.1\n95% CI: [0.78, 1.0]\nInterpretation: definitive_negative", "metadata": {"result_id": 82318, "source_trial_id": "NCT04764630", "intervention_name": "Four naloxone nasal spray doses (2 every 2.5 min)", "condition_name": "Pharmacokinetics", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0546", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: BI 201335 NA 240 mg QD / LI\nCondition: Hepatitis C, Chronic\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 719\np-value: 0.0537\nSerious adverse events: 157.0\nInterpretation: definitive_negative", "metadata": {"result_id": 73529, "source_trial_id": "NCT00774397", "intervention_name": "BI 201335 NA 240 mg QD / LI", "condition_name": "Hepatitis C, Chronic", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-0547", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Metreleptin\nDrug type: peptide\nCondition: Obesity\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 636\np-value: 0.251\nSerious adverse events: 20.0\nInterpretation: definitive_negative", "metadata": {"result_id": 83683, "source_trial_id": "NCT00673387", "intervention_name": "Metreleptin", "condition_name": "Obesity", "confidence_tier": "silver", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-0548", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Any approved or standard-of-care therapy\nCondition: RAEB\nPhase: phase_3\nEnrollment: 372\nTermination reason: \"Top line analysis indicated that the study had failed to achieve its primary endpoint.\"\nDetail: Top line analysis indicated that the study had failed to achieve its primary endpoint.", "metadata": {"result_id": 4676, "source_trial_id": "NCT02562443", "intervention_name": "Any approved or standard-of-care therapy", "condition_name": "RAEB", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0549", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: risedronate\nCondition: Metastatic Prostate Cancer\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 63\np-value: 0.3\n95% CI: [0.51, 8.4]\nSerious adverse events: 38.0\nInterpretation: definitive_negative", "metadata": {"result_id": 78651, "source_trial_id": "NCT00216060", "intervention_name": "risedronate", "condition_name": "Metastatic Prostate Cancer", "confidence_tier": "gold", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0550", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Ustekinumab 90 mg SC q12w\nCondition: IBD\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 1282\np-value: 0.189\nSerious adverse events: 968.0\nInterpretation: definitive_negative", "metadata": {"result_id": 85333, "source_trial_id": "NCT01369355", "intervention_name": "Ustekinumab 90 mg SC q12w", "condition_name": "IBD", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0551", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Technosphere® Insulin Inhalation Powder\nCondition: Diabetes, Type 1\nPhase: phase_3\nBlinding: NONE\nEnrollment: 2053\np-value: 0.112\nSerious adverse events: 466.0\nInterpretation: definitive_negative", "metadata": {"result_id": 102405, "source_trial_id": "NCT00308737", "intervention_name": "Technosphere® Insulin Inhalation Powder", "condition_name": "Diabetes, Type 1", "confidence_tier": "gold", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-0552", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: monoclonal antibody SGN-30\nDrug type: antibody_drug_conjugate\nCondition: Adult Mixed Cellularity Hodgkin Lymphoma\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 30\np-value: 0.06\nSerious adverse events: 142.0\nInterpretation: definitive_negative", "metadata": {"result_id": 86879, "source_trial_id": "NCT00337194", "intervention_name": "monoclonal antibody SGN-30", "condition_name": "Adult Mixed Cellularity Hodgkin Lymphoma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0553", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Vortioxetine (Lu AA21004)\nCondition: Major Depressive Disorder\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 639\np-value: 0.0612\n95% CI: [-2.3, 0.05]\nSerious adverse events: 59.0\nInterpretation: definitive_negative", "metadata": {"result_id": 87038, "source_trial_id": "NCT00596817", "intervention_name": "Vortioxetine (Lu AA21004)", "condition_name": "Major Depressive Disorder", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0554", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: BMX-001\nCondition: Glioblastoma\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 177\np-value: 0.135\nInterpretation: definitive_negative", "metadata": {"result_id": 89238, "source_trial_id": "NCT02655601", "intervention_name": "BMX-001", "condition_name": "Glioblastoma", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0555", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Aclidinium bromide\nCondition: COPD\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 1625\np-value: 0.132\n95% CI: [-0.1, 1.0]\nInterpretation: definitive_negative", "metadata": {"result_id": 93241, "source_trial_id": "NCT03022097", "intervention_name": "Aclidinium bromide", "condition_name": "COPD", "confidence_tier": "gold", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-0556", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: dexmedetomidine infusion\nCondition: Retinal Detachment\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 78\np-value: 0.68\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 89782, "source_trial_id": "NCT01001429", "intervention_name": "dexmedetomidine infusion", "condition_name": "Retinal Detachment", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0557", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: BLI800\nCondition: Colonoscopy\nPhase: phase_3\nBlinding: SINGLE\nEnrollment: 136\np-value: 0.644\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 88550, "source_trial_id": "NCT00856843", "intervention_name": "BLI800", "condition_name": "Colonoscopy", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0558", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: CAT-354 150 mg\nCondition: Asthma\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 357\np-value: 0.573\nSerious adverse events: 17.0\nInterpretation: definitive_negative", "metadata": {"result_id": 67005, "source_trial_id": "NCT00873860", "intervention_name": "CAT-354 150 mg", "condition_name": "Asthma", "confidence_tier": "silver", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-0559", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Clobazam High Dose\nCondition: Epilepsy\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 238\np-value: 0.1041\nSerious adverse events: 44.0\nInterpretation: definitive_negative", "metadata": {"result_id": 103950, "source_trial_id": "NCT00518713", "intervention_name": "Clobazam High Dose", "condition_name": "Epilepsy", "confidence_tier": "gold", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0560", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Tadalafil 5 mg\nCondition: Benign Prostatic Hyperplasia (BPH)\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 511\np-value: 0.055\nSerious adverse events: 12.0\nInterpretation: definitive_negative", "metadata": {"result_id": 87082, "source_trial_id": "NCT00970632", "intervention_name": "Tadalafil 5 mg", "condition_name": "Benign Prostatic Hyperplasia (BPH)", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0561", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Flucelvax inactivated influenza vaccine\nCondition: Immune Response\nPhase: phase_4\nBlinding: NONE\nEnrollment: 166\np-value: 0.28\nInterpretation: definitive_negative", "metadata": {"result_id": 67368, "source_trial_id": "NCT03614975", "intervention_name": "Flucelvax inactivated influenza vaccine", "condition_name": "Immune Response", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0562", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: multivitamin\nCondition: Vulvar High Grade Squamous Intraepithelial Lesion\nPhase: phase_2\nEnrollment: 10\nTermination reason: \"Lack of efficacy\"\nDetail: Lack of efficacy", "metadata": {"result_id": 19499, "source_trial_id": "NCT03267680", "intervention_name": "multivitamin", "condition_name": "Vulvar High Grade Squamous Intraepithelial Lesion", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0563", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: fesoterodine 4mg\nCondition: Overactive Bladder\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 2012\np-value: 0.0662\n95% CI: [-0.41, 0.01]\nSerious adverse events: 67.0\nInterpretation: definitive_negative", "metadata": {"result_id": 108422, "source_trial_id": "NCT01302067", "intervention_name": "fesoterodine 4mg", "condition_name": "Overactive Bladder", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0564", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Metformin XR\nCondition: Type 2 Diabetes Mellitus\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 1093\np-value: 0.9144\n95% CI: [-0.22, 0.2]\nSerious adverse events: 27.0\nInterpretation: definitive_negative", "metadata": {"result_id": 71576, "source_trial_id": "NCT00859898", "intervention_name": "Metformin XR", "condition_name": "Type 2 Diabetes Mellitus", "confidence_tier": "gold", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-0565", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Nipocalimab\nDrug type: monoclonal_antibody\nCondition: Arthritis, Rheumatoid\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 53\np-value: 0.224\n95% CI: [-1.17, 0.28]\nInterpretation: definitive_negative", "metadata": {"result_id": 106643, "source_trial_id": "NCT04991753", "intervention_name": "Nipocalimab", "condition_name": "Arthritis, Rheumatoid", "confidence_tier": "silver", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL1-0566", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Prednisone tablet\nCondition: Prostate Neoplasm\nPhase: phase_1\nEnrollment: 50\nTermination reason: \"Closed by PI due to not meeting primary endpoint\"\nDetail: Closed by PI due to not meeting primary endpoint", "metadata": {"result_id": 45041, "source_trial_id": "NCT05276492", "intervention_name": "Prednisone tablet", "condition_name": "Prostate Neoplasm", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0567", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Nicotine Replacement Treatment (NRT)\nCondition: Substance Abuse\nBlinding: NONE\nEnrollment: 340\np-value: 0.606\n95% CI: [0.57, 2.63]\nSerious adverse events: 170.0\nInterpretation: definitive_negative", "metadata": {"result_id": 110628, "source_trial_id": "NCT00807742", "intervention_name": "Nicotine Replacement Treatment (NRT)", "condition_name": "Substance Abuse", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0568", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Brimonidine Tartrate\nCondition: Ocular Graft vs Host Disease\nPhase: phase_3\nEnrollment: 59\nTermination reason: \"Primary endpoint was not met.\"\nDetail: Primary endpoint was not met.", "metadata": {"result_id": 58166, "source_trial_id": "NCT03591874", "intervention_name": "Brimonidine Tartrate", "condition_name": "Ocular Graft vs Host Disease", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0569", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Dual Antiplatelet (DAPT) Therapy\nCondition: Atherosclerosis\nPhase: phase_2\nEnrollment: 50\nTermination reason: \"The DSMC March 16, 2022 reviewed of Interim Analysis and recommendation due to no glaring outcomes found to date.\"\nDetail: The DSMC March 16, 2022 reviewed of Interim Analysis and recommendation due to no glaring outcomes found to date.", "metadata": {"result_id": 42011, "source_trial_id": "NCT03606642", "intervention_name": "Dual Antiplatelet (DAPT) Therapy", "condition_name": "Atherosclerosis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0570", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Peginterferon alfa-2b\nDrug type: peptide\nCondition: Localized Osteosarcoma\nPhase: phase_3\nBlinding: NONE\nEnrollment: 1334\np-value: 0.214\n95% CI: [0.61, 1.12]\nInterpretation: definitive_negative", "metadata": {"result_id": 68161, "source_trial_id": "NCT00134030", "intervention_name": "Peginterferon alfa-2b", "condition_name": "Localized Osteosarcoma", "confidence_tier": "gold", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0571", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Fostamatinib\nCondition: Rheumatoid Arthritis\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 323\np-value: 0.168\n95% CI: [-0.03, 0.18]\nSerious adverse events: 48.0\nInterpretation: definitive_negative", "metadata": {"result_id": 83526, "source_trial_id": "NCT01197755", "intervention_name": "Fostamatinib", "condition_name": "Rheumatoid Arthritis", "confidence_tier": "gold", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL1-0572", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: DKN-01 600mg\nCondition: Gastric Cancer\nPhase: phase_2\nBlinding: NONE\nEnrollment: 247\np-value: 0.2649\nEffect size (Risk Difference (RD)): 8.4\n95% CI: [-18.4, 33.6]\nInterpretation: definitive_negative", "metadata": {"result_id": 6986, "source_trial_id": "NCT04363801", "intervention_name": "DKN-01 600mg", "condition_name": "Gastric Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0573", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Galantamine\nCondition: Cocaine Abuse\nBlinding: DOUBLE\nEnrollment: 34\np-value: 0.5\nInterpretation: definitive_negative", "metadata": {"result_id": 80684, "source_trial_id": "NCT00606801", "intervention_name": "Galantamine", "condition_name": "Cocaine Abuse", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0574", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: AZD1152\nCondition: Solid Tumors\nPhase: phase_1\nEnrollment: 70\nTermination reason: \"Efficacy seen in the solid tumour patient population was not sufficient to continue research with AZD1152 monotherapy in solid tumors at that time.\"\nDetail: Efficacy seen in the solid tumour patient population was not sufficient to continue research with AZD1152 monotherapy in solid tumors at that time.", "metadata": {"result_id": 3164, "source_trial_id": "NCT00497731", "intervention_name": "AZD1152", "condition_name": "Solid Tumors", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0575", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Lipofundin MCT/LCT 20 %\nCondition: Parenteral Nutrition n-3 Fatty Acids\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 48\np-value: 0.3654\nSerious adverse events: 107.0\nInterpretation: definitive_negative", "metadata": {"result_id": 86772, "source_trial_id": "NCT00497289", "intervention_name": "Lipofundin MCT/LCT 20 %", "condition_name": "Parenteral Nutrition n-3 Fatty Acids", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0576", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: EXPAREL\nCondition: Conditions Requiring Colorectal Surgery\nBlinding: NONE\nEnrollment: 209\np-value: 0.102\nSerious adverse events: 16.0\nInterpretation: definitive_negative", "metadata": {"result_id": 104712, "source_trial_id": "NCT02356198", "intervention_name": "EXPAREL", "condition_name": "Conditions Requiring Colorectal Surgery", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0577", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)\nCondition: Pain\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 98\np-value: 0.861\nInterpretation: definitive_negative", "metadata": {"result_id": 73282, "source_trial_id": "NCT02891798", "intervention_name": "Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)", "condition_name": "Pain", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0578", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Epinephrine\nCondition: Shoulder Arthropathy\nPhase: phase_4\nBlinding: SINGLE\nEnrollment: 83\np-value: 0.52\nInterpretation: definitive_negative", "metadata": {"result_id": 71439, "source_trial_id": "NCT05488847", "intervention_name": "Epinephrine", "condition_name": "Shoulder Arthropathy", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0579", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Lopinavir\nCondition: Glioblastoma\nPhase: phase_2\nEnrollment: 19\nTermination reason: \"Study did not meet its primary objective\"\nDetail: Study did not meet its primary objective", "metadata": {"result_id": 12926, "source_trial_id": "NCT01095094", "intervention_name": "Lopinavir", "condition_name": "Glioblastoma", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0580", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: IMMU-107\nDrug type: monoclonal_antibody\nCondition: Metastatic Pancreatic Cancer\nPhase: phase_3\nEnrollment: 334\nTermination reason: \"The DSMB conducted an interim analysis on overall survival, which showed that the treatment arm did not demonstrate a sufficient improvement in OS vs. placebo.\"\nDetail: The DSMB conducted an interim analysis on overall survival, which showed that the treatment arm did not demonstrate a sufficient improvement in OS vs. placebo.", "metadata": {"result_id": 14661, "source_trial_id": "NCT01956812", "intervention_name": "IMMU-107", "condition_name": "Metastatic Pancreatic Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0581", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: 50,000 IU vitamin D3\nCondition: Hypovitaminosis D\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 60\np-value: 0.67\nInterpretation: definitive_negative", "metadata": {"result_id": 80735, "source_trial_id": "NCT02328404", "intervention_name": "50,000 IU vitamin D3", "condition_name": "Hypovitaminosis D", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0582", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Intranasal oxytocin\nDrug type: peptide\nCondition: Oxytocin\nBlinding: TRIPLE\nEnrollment: 270\np-value: 0.89\nInterpretation: definitive_negative", "metadata": {"result_id": 86738, "source_trial_id": "NCT01011465", "intervention_name": "Intranasal oxytocin", "condition_name": "Oxytocin", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0583", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: oral zinc and vitamin C supplements\nCondition: Autism\nPhase: phase_1\nEnrollment: 89\nTermination reason: \"Lack of efficacy to proceed to Phase 2\"\nDetail: Lack of efficacy to proceed to Phase 2", "metadata": {"result_id": 21964, "source_trial_id": "NCT00325572", "intervention_name": "oral zinc and vitamin C supplements", "condition_name": "Autism", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0584", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: 68Gallium DOTATATE\nDrug type: peptide\nCondition: Von Hippel-Lindau Syndrome\nPhase: phase_2\nBlinding: NONE\nEnrollment: 341\np-value: 0.23\nSerious adverse events: 56.0\nInterpretation: definitive_negative", "metadata": {"result_id": 64868, "source_trial_id": "NCT01967537", "intervention_name": "68Gallium DOTATATE", "condition_name": "Von Hippel-Lindau Syndrome", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0585", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Tranexamic acid and Tocilizumab\nCondition: Chronic Subdural Hematoma\nPhase: phase_2_3\nEnrollment: 382\nTermination reason: \"DMC concluded that the results of 382 included patients were clear.\"\nDetail: DMC concluded that the results of 382 included patients were clear.", "metadata": {"result_id": 17289, "source_trial_id": "NCT03353259", "intervention_name": "Tranexamic acid and Tocilizumab", "condition_name": "Chronic Subdural Hematoma", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0586", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: GWP42004\nCondition: Dyslipidemias\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 62\np-value: 0.766\n95% CI: [-0.09, 0.06]\nSerious adverse events: 8.0\nInterpretation: definitive_negative", "metadata": {"result_id": 84888, "source_trial_id": "NCT01217112", "intervention_name": "GWP42004", "condition_name": "Dyslipidemias", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0587", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Gepotidacin HSWG Tablet\nCondition: Infections, Bacterial\nPhase: phase_1\nBlinding: NONE\nEnrollment: 48\np-value: 0.309\nInterpretation: definitive_negative", "metadata": {"result_id": 93404, "source_trial_id": "NCT02853435", "intervention_name": "Gepotidacin HSWG Tablet", "condition_name": "Infections, Bacterial", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0588", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: lapatinib ditosylate\nCondition: Ductal Breast Carcinoma In Situ\nBlinding: TRIPLE\nEnrollment: 22\np-value: 1.0\nSerious adverse events: 3.0\nInterpretation: definitive_negative", "metadata": {"result_id": 83032, "source_trial_id": "NCT00555152", "intervention_name": "lapatinib ditosylate", "condition_name": "Ductal Breast Carcinoma In Situ", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0589", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: RVT-101\nCondition: Alzheimer's Disease\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 1315\np-value: 0.2249\n95% CI: [-0.95, 0.22]\nSerious adverse events: 266.0\nInterpretation: definitive_negative", "metadata": {"result_id": 82998, "source_trial_id": "NCT02585934", "intervention_name": "RVT-101", "condition_name": "Alzheimer's Disease", "confidence_tier": "gold", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0590", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: G-CSF\nDrug type: peptide\nCondition: Retinoblastoma\nPhase: phase_3\nBlinding: NONE\nEnrollment: 107\np-value: 0.452\nSerious adverse events: 36.0\nInterpretation: definitive_negative", "metadata": {"result_id": 107442, "source_trial_id": "NCT00186888", "intervention_name": "G-CSF", "condition_name": "Retinoblastoma", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0591", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: UX007\nCondition: Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 44\nPrimary endpoint met: 1.0\np-value: 0.0001\nSerious adverse events: 10.0\nInterpretation: definitive_negative", "metadata": {"result_id": 4491, "source_trial_id": "NCT02960217", "intervention_name": "UX007", "condition_name": "Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0592", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Seltorexant\nCondition: Alzheimer Disease\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 88\np-value: 0.308\n95% CI: [-3.41, 0.39]\nInterpretation: definitive_negative", "metadata": {"result_id": 112252, "source_trial_id": "NCT05307692", "intervention_name": "Seltorexant", "condition_name": "Alzheimer Disease", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0593", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Peginterferon alfa-2b\nDrug type: peptide\nCondition: Hepatitis C, Chronic\nPhase: phase_2\nEnrollment: 100\nTermination reason: \"Dose levels were determined to be subtherapeutic\"\nDetail: Dose levels were determined to be subtherapeutic", "metadata": {"result_id": 21579, "source_trial_id": "NCT00305383", "intervention_name": "Peginterferon alfa-2b", "condition_name": "Hepatitis C, Chronic", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-0594", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Sugammadex 4 mg/kg\nCondition: Reversal of Neuromuscular Blockade\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 344\np-value: 0.058\n95% CI: [-17.3, 0.2]\nSerious adverse events: 99.0\nInterpretation: definitive_negative", "metadata": {"result_id": 110299, "source_trial_id": "NCT03346057", "intervention_name": "Sugammadex 4 mg/kg", "condition_name": "Reversal of Neuromuscular Blockade", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0595", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: HP802-247\nCondition: Venous Stasis Ulcers\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 228\np-value: 0.0899\nSerious adverse events: 34.0\nInterpretation: definitive_negative", "metadata": {"result_id": 66206, "source_trial_id": "NCT00852995", "intervention_name": "HP802-247", "condition_name": "Venous Stasis Ulcers", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0596", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Formoterol\nCondition: Pulmonary Disease, Chronic Obstructive\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 937\np-value: 0.1999\n95% CI: [-0.213, 1.018]\nSerious adverse events: 411.0\nInterpretation: definitive_negative", "metadata": {"result_id": 70314, "source_trial_id": "NCT00796653", "intervention_name": "Formoterol", "condition_name": "Pulmonary Disease, Chronic Obstructive", "confidence_tier": "gold", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-0597", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Dalteparin\nDrug type: other_biologic\nCondition: Deep Vein Thrombosis\nPhase: phase_3\nBlinding: NONE\nEnrollment: 300\np-value: 0.1316\nSerious adverse events: 432.0\nInterpretation: definitive_negative", "metadata": {"result_id": 89215, "source_trial_id": "NCT02585713", "intervention_name": "Dalteparin", "condition_name": "Deep Vein Thrombosis", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0598", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: testosterone gel\nCondition: Poor Ovarian Response\nPhase: phase_3\nEnrollment: 290\nTermination reason: \"Having reached the sample size described for the interim analysis and having seen the post-interim results, the sponsor has decided to stop the trial due to futility.\"\nDetail: Having reached the sample size described for the interim analysis and having seen the post-interim results, the sponsor has decided to stop the trial due to futility.", "metadata": {"result_id": 5282, "source_trial_id": "NCT02418572", "intervention_name": "testosterone gel", "condition_name": "Poor Ovarian Response", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0599", "task": "CT-L1", "gold_answer": "B", "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Oxytocin\nDrug type: peptide\nCondition: Uterine Atony\nPhase: phase_4\nBlinding: QUADRUPLE\nEnrollment: 1798\np-value: 0.67\n95% CI: [0.63, 1.59]\nInterpretation: definitive_negative", "metadata": {"result_id": 104273, "source_trial_id": "NCT00790062", "intervention_name": "Oxytocin", "condition_name": "Uterine Atony", "confidence_tier": "gold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0600", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Calcitriol, Ketoconazole, Hydrocortisone\nCondition: Castration-resistant Prostate Cancer\nPhase: phase_2\nEnrollment: 1\nTermination reason: \"can not meet enrollment\"\nDetail: can not meet enrollment", "metadata": {"result_id": 4608, "source_trial_id": "NCT03261336", "intervention_name": "Calcitriol, Ketoconazole, Hydrocortisone", "condition_name": "Castration-resistant Prostate Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0601", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: AK112 high dose\nCondition: Ovarian Cancer\nPhase: phase_1_2\nEnrollment: 8\nTermination reason: \"Too low inclusion rate\"\nDetail: Too low inclusion rate", "metadata": {"result_id": 44943, "source_trial_id": "NCT04999605", "intervention_name": "AK112 high dose", "condition_name": "Ovarian Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0602", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Dobutamine\nCondition: Asthma\nPhase: early_phase_1\nEnrollment: 14\nTermination reason: \"Potential participants with COPD/asthma unwilling to participate.\"\nDetail: Potential participants with COPD/asthma unwilling to participate.", "metadata": {"result_id": 6281, "source_trial_id": "NCT00763035", "intervention_name": "Dobutamine", "condition_name": "Asthma", "confidence_tier": "bronze", "therapeutic_area": "respiratory"}, "split": "fewshot"}
+{"question_id": "CTL1-0603", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Brimonidine 0.15%\nCondition: Ocular Graft vs Host Disease\nPhase: phase_1_2\nBlinding: QUADRUPLE\nEnrollment: 15\np-value: 1.0\nInterpretation: definitive_negative", "metadata": {"result_id": 11324, "source_trial_id": "NCT02975557", "intervention_name": "Brimonidine 0.15%", "condition_name": "Ocular Graft vs Host Disease", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0604", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Riluzole\nCondition: Bipolar Disorder\nPhase: phase_2\nEnrollment: 6\nTermination reason: \"Insufficient recruitment of participants\"\nDetail: Insufficient recruitment of participants", "metadata": {"result_id": 18759, "source_trial_id": "NCT00805493", "intervention_name": "Riluzole", "condition_name": "Bipolar Disorder", "confidence_tier": "bronze", "therapeutic_area": "psychiatry"}, "split": "fewshot"}
+{"question_id": "CTL1-0605", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Rivaroxaban 10 MG\nCondition: Central Venous Catheter Thrombosis\nPhase: phase_3\nEnrollment: 4\nTermination reason: \"Study terminated due to slow recruitment.\"\nDetail: Study terminated due to slow recruitment.", "metadata": {"result_id": 43898, "source_trial_id": "NCT05033314", "intervention_name": "Rivaroxaban 10 MG", "condition_name": "Central Venous Catheter Thrombosis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0606", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Carbogen\nDrug type: unknown\nCondition: Acute Ischemic Stroke\nPhase: phase_3\nEnrollment: 3\nTermination reason: \"Slow Patient Enrollment\"\nDetail: Slow Patient Enrollment", "metadata": {"result_id": 49379, "source_trial_id": "NCT04839224", "intervention_name": "Carbogen", "condition_name": "Acute Ischemic Stroke", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "fewshot"}
+{"question_id": "CTL1-0607", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Doxycycline\nCondition: Bladder Pain Syndrome\nPhase: phase_4\nEnrollment: 5\nTermination reason: \"Recruitment problems\"\nDetail: Recruitment problems", "metadata": {"result_id": 41716, "source_trial_id": "NCT01879930", "intervention_name": "Doxycycline", "condition_name": "Bladder Pain Syndrome", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0608", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Labetalol\nCondition: Hypertension, Pregnancy-Induced\nPhase: phase_4\nBlinding: NONE\nEnrollment: 13\np-value: 0.21\nInterpretation: definitive_negative", "metadata": {"result_id": 10891, "source_trial_id": "NCT04343235", "intervention_name": "Labetalol", "condition_name": "Hypertension, Pregnancy-Induced", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "fewshot"}
+{"question_id": "CTL1-0609", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Physician's Choice\nCondition: BRAF Gene Mutation\nPhase: phase_2\nEnrollment: 104\nTermination reason: \"Enrollment challenges\"\nDetail: Enrollment challenges", "metadata": {"result_id": 19676, "source_trial_id": "NCT04488003", "intervention_name": "Physician's Choice", "condition_name": "BRAF Gene Mutation", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0610", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: TEPEZZA\nDrug type: monoclonal_antibody\nCondition: Diffuse Cutaneous Systemic Sclerosis\nPhase: phase_1\nEnrollment: 3\nTermination reason: \"Poor enrollment\"\nDetail: Poor enrollment", "metadata": {"result_id": 9197, "source_trial_id": "NCT04478994", "intervention_name": "TEPEZZA", "condition_name": "Diffuse Cutaneous Systemic Sclerosis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0611", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: RBT-9 (90 mg)\nCondition: COVID-19\nPhase: phase_2\nBlinding: NONE\nEnrollment: 42\nPrimary endpoint met: 1.0\np-value: 0.0352\nInterpretation: definitive_negative", "metadata": {"result_id": 39338, "source_trial_id": "NCT04364763", "intervention_name": "RBT-9 (90 mg)", "condition_name": "COVID-19", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "fewshot"}
+{"question_id": "CTL1-0612", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Tepotinib\nCondition: Advanced Non-Small Cell Lung Cancer With MET Mutations\nPhase: phase_1_2\nEnrollment: 2\nTermination reason: \"Study was terminated due to lack of lack of enrollment and difficult patient population.\"\nDetail: Study was terminated due to lack of lack of enrollment and difficult patient population.", "metadata": {"result_id": 35114, "source_trial_id": "NCT04739358", "intervention_name": "Tepotinib", "condition_name": "Advanced Non-Small Cell Lung Cancer With MET Mutations", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0613", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet\nCondition: Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 6\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Mean Difference (Final Values)): -1.0098\nInterpretation: definitive_negative", "metadata": {"result_id": 35075, "source_trial_id": "NCT02917629", "intervention_name": "Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet", "condition_name": "Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0614", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Cyclophosphamid\nCondition: Metastatic Fallopian Tube Cancer\nPhase: phase_1_2\nEnrollment: 6\nTermination reason: \"Slow recruitment\"\nDetail: Slow recruitment", "metadata": {"result_id": 36136, "source_trial_id": "NCT04611126", "intervention_name": "Cyclophosphamid", "condition_name": "Metastatic Fallopian Tube Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0615", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: S-1\nCondition: Rectum Cancer\nPhase: phase_2\nEnrollment: 20\nTermination reason: \"Slow accrual\"\nDetail: Slow accrual", "metadata": {"result_id": 60984, "source_trial_id": "NCT02216149", "intervention_name": "S-1", "condition_name": "Rectum Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0616", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Tab Premarin (Ethinyl estradiol)\nCondition: Breast Cancer\nPhase: phase_3\nEnrollment: 273\nTermination reason: \"The accrual was very slow and there were many competing studies ongoing/initiated .\"\nDetail: The accrual was very slow and there were many competing studies ongoing/initiated .", "metadata": {"result_id": 1651, "source_trial_id": "NCT00193726", "intervention_name": "Tab Premarin (Ethinyl estradiol)", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0617", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Azacitidine Injection\nCondition: Acute Myeloid Leukemia Refractory\nPhase: phase_1_2\nEnrollment: 1\nTermination reason: \"low recruitment rate\"\nDetail: low recruitment rate", "metadata": {"result_id": 42658, "source_trial_id": "NCT06150040", "intervention_name": "Azacitidine Injection", "condition_name": "Acute Myeloid Leukemia Refractory", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0618", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Align Probiotic Supplement Capsule\nCondition: Cirrhosis, Liver\nPhase: phase_1_2\nEnrollment: 14\nTermination reason: \"lack of enrollment\"\nDetail: lack of enrollment", "metadata": {"result_id": 56846, "source_trial_id": "NCT04175392", "intervention_name": "Align Probiotic Supplement Capsule", "condition_name": "Cirrhosis, Liver", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0619", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: IFN beta-1a\nCondition: Multiple Sclerosis, Relapsing-Remitting\nPhase: phase_2\nEnrollment: 7\nTermination reason: \"Study was terminated early due to slow recruitment rate.\"\nDetail: Study was terminated early due to slow recruitment rate.", "metadata": {"result_id": 40361, "source_trial_id": "NCT03387046", "intervention_name": "IFN beta-1a", "condition_name": "Multiple Sclerosis, Relapsing-Remitting", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "fewshot"}
+{"question_id": "CTL1-0620", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Riluzole\nCondition: Major Depressive Disorder\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 21\nPrimary endpoint met: 1.0\np-value: 0.04\nInterpretation: definitive_negative", "metadata": {"result_id": 23624, "source_trial_id": "NCT01703039", "intervention_name": "Riluzole", "condition_name": "Major Depressive Disorder", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0621", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Methylprednisolone Acetate\nCondition: Lumbar Back Pain\nEnrollment: 8\nTermination reason: \"Low enrollment, too many subjects getting second injection\"\nDetail: Low enrollment, too many subjects getting second injection", "metadata": {"result_id": 26176, "source_trial_id": "NCT01397552", "intervention_name": "Methylprednisolone Acetate", "condition_name": "Lumbar Back Pain", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0622", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: neoadjuvant chemotherapy\nCondition: Breast Cancer\nPhase: phase_3\nEnrollment: 21\nTermination reason: \"Hard to enroll expected number of eligible patients.\"\nDetail: Hard to enroll expected number of eligible patients.", "metadata": {"result_id": 25717, "source_trial_id": "NCT02532400", "intervention_name": "neoadjuvant chemotherapy", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0623", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Febuxostat\nCondition: Gout\nEnrollment: 1\nTermination reason: \"unable to enroll participants\"\nDetail: unable to enroll participants", "metadata": {"result_id": 18208, "source_trial_id": "NCT01701622", "intervention_name": "Febuxostat", "condition_name": "Gout", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0624", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Enteric Coated Mycophenolate Sodium\nCondition: Transplants and Implants\nPhase: phase_4\nBlinding: NONE\nEnrollment: 37\nPrimary endpoint met: 1.0\np-value: 0.012\nSerious adverse events: 100.0\nInterpretation: definitive_negative", "metadata": {"result_id": 24045, "source_trial_id": "NCT00522548", "intervention_name": "Enteric Coated Mycophenolate Sodium", "condition_name": "Transplants and Implants", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0625", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Bupropion\nCondition: Suicidal Behavior\nPhase: phase_4\nBlinding: QUADRUPLE\nEnrollment: 5\np-value: 1.0\nEffect size (Mean Difference (Final Values)): 4.5\nInterpretation: definitive_negative", "metadata": {"result_id": 41184, "source_trial_id": "NCT00449007", "intervention_name": "Bupropion", "condition_name": "Suicidal Behavior", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0626", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Benralizumab\nDrug type: monoclonal_antibody\nCondition: Breast Cancer\nPhase: phase_2\nEnrollment: 1\nTermination reason: \"Limited amount of eligible participants\"\nDetail: Limited amount of eligible participants", "metadata": {"result_id": 58304, "source_trial_id": "NCT05966584", "intervention_name": "Benralizumab", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0627", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Methylprednisolone (40 mg depomedrol, 1ml, injection)\nCondition: Acromioplasty\nPhase: phase_4\nEnrollment: 12\nTermination reason: \"It was difficult to recruit patients to get the appropriate sample size.\"\nDetail: It was difficult to recruit patients to get the appropriate sample size.", "metadata": {"result_id": 18364, "source_trial_id": "NCT02867904", "intervention_name": "Methylprednisolone (40 mg depomedrol, 1ml, injection)", "condition_name": "Acromioplasty", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0628", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Liposome-encapsulated Daunorubicin-Cytarabine\nCondition: Myeloid Neoplasm\nPhase: phase_2\nEnrollment: 1\nTermination reason: \"Terminated due to low accrual\"\nDetail: Terminated due to low accrual", "metadata": {"result_id": 58225, "source_trial_id": "NCT04526288", "intervention_name": "Liposome-encapsulated Daunorubicin-Cytarabine", "condition_name": "Myeloid Neoplasm", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0629", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: PD1 Inhibitor\nCondition: Stage IV Lung Cancer AJCC v8\nPhase: phase_1_2\nEnrollment: 1\nTermination reason: \"Terminated due to slow accrual.\"\nDetail: Terminated due to slow accrual.", "metadata": {"result_id": 5875, "source_trial_id": "NCT04639245", "intervention_name": "PD1 Inhibitor", "condition_name": "Stage IV Lung Cancer AJCC v8", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0630", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Micronized progesterone suppository\nCondition: Premature Birth\nBlinding: QUADRUPLE\nEnrollment: 38\np-value: 0.13\nEffect size (Risk Ratio (RR)): 0.43\n95% CI: [0.14, 1.36]\nInterpretation: definitive_negative", "metadata": {"result_id": 32279, "source_trial_id": "NCT01840228", "intervention_name": "Micronized progesterone suppository", "condition_name": "Premature Birth", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0631", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: ARM B Calcineurin inhibitor and methotrexate\nCondition: Acute Lymphoid Leukemia\nPhase: phase_3\nEnrollment: 3\nTermination reason: \"Lack of accrual\"\nDetail: Lack of accrual", "metadata": {"result_id": 5392, "source_trial_id": "NCT01749111", "intervention_name": "ARM B Calcineurin inhibitor and methotrexate", "condition_name": "Acute Lymphoid Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0632", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: SPD557\nCondition: Gastroesophageal Reflux Disease\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 67\np-value: 0.487\nEffect size (Diference in LS means): 0.264\n95% CI: [-0.495, 1.024]\nInterpretation: definitive_negative", "metadata": {"result_id": 35965, "source_trial_id": "NCT01370863", "intervention_name": "SPD557", "condition_name": "Gastroesophageal Reflux Disease", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0633", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet\nCondition: Oropharyngeal Neoplasm\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 6\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Mean Difference (Final Values)): -1.0098\nInterpretation: definitive_negative", "metadata": {"result_id": 35047, "source_trial_id": "NCT02917629", "intervention_name": "Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet", "condition_name": "Oropharyngeal Neoplasm", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0634", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Naltrexone hydrochloride\nCondition: Anorexia in Adolescence\nPhase: phase_2_3\nEnrollment: 9\nTermination reason: \"Low enrollment numbers, pharmacy not able to acquire sufficient study article component (methylcellulose) due to manufacturer backorder\"\nDetail: Low enrollment numbers, pharmacy not able to acquire sufficient study article component (methylcellulose) due to manufacturer backorder", "metadata": {"result_id": 7926, "source_trial_id": "NCT05073679", "intervention_name": "Naltrexone hydrochloride", "condition_name": "Anorexia in Adolescence", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0635", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: tenofovir/emtricitabine and atazanavir and ritonavir\nCondition: Osteopenia\nPhase: phase_4\nEnrollment: 4\nTermination reason: \"Low enrollment\"\nDetail: Low enrollment", "metadata": {"result_id": 33993, "source_trial_id": "NCT01902186", "intervention_name": "tenofovir/emtricitabine and atazanavir and ritonavir", "condition_name": "Osteopenia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0636", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Melatonin (N-acetyl-5-methoxytryptamine)\nCondition: Breast Cancer\nPhase: phase_2_3\nBlinding: QUADRUPLE\nEnrollment: 54\nPrimary endpoint met: 1.0\np-value: 0.002\nInterpretation: definitive_negative", "metadata": {"result_id": 14043, "source_trial_id": "NCT01355523", "intervention_name": "Melatonin (N-acetyl-5-methoxytryptamine)", "condition_name": "Breast Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0637", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: bortezomib\nCondition: Stage I Multiple Myeloma\nPhase: phase_3\nBlinding: NONE\nEnrollment: 48\nPrimary endpoint met: 1.0\np-value: 0.029\nSerious adverse events: 97.0\nInterpretation: definitive_negative", "metadata": {"result_id": 17094, "source_trial_id": "NCT00522392", "intervention_name": "bortezomib", "condition_name": "Stage I Multiple Myeloma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0638", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: VYVANSE\nCondition: Attention Deficit Disorder\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 22\nPrimary endpoint met: 1.0\np-value: 0.003\nInterpretation: definitive_negative", "metadata": {"result_id": 24444, "source_trial_id": "NCT01000064", "intervention_name": "VYVANSE", "condition_name": "Attention Deficit Disorder", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0639", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Xenograft, Membrane\nCondition: Tooth Injuries\nBlinding: NONE\nEnrollment: 16\np-value: 0.243\nInterpretation: definitive_negative", "metadata": {"result_id": 21567, "source_trial_id": "NCT02532543", "intervention_name": "Xenograft, Membrane", "condition_name": "Tooth Injuries", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0640", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: BUP microdose induction\nCondition: Substance Use Disorders\nPhase: phase_4\nBlinding: NONE\nEnrollment: 23\np-value: 1.0\nEffect size (Odds Ratio (OR)): 0.91\n95% CI: [0.05, 16.54]\nInterpretation: definitive_negative", "metadata": {"result_id": 8345, "source_trial_id": "NCT05118204", "intervention_name": "BUP microdose induction", "condition_name": "Substance Use Disorders", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0641", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Survanta (beractant)\nDrug type: unknown\nCondition: Respiratory Distress Syndrome\nPhase: phase_4\nBlinding: NONE\nEnrollment: 52\nPrimary endpoint met: 1.0\np-value: 0.01\nEffect size (Risk Ratio (RR)): 2.38\n95% CI: [1.29, 4.38]\nSerious adverse events: 66.0\nInterpretation: definitive_negative", "metadata": {"result_id": 15144, "source_trial_id": "NCT00767039", "intervention_name": "Survanta (beractant)", "condition_name": "Respiratory Distress Syndrome", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0642", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Progesterone\nCondition: Polycystic Ovary Syndrome\nEnrollment: 4\nTermination reason: \"Haven't enrolled participants since 2010\"\nDetail: Haven't enrolled participants since 2010", "metadata": {"result_id": 50842, "source_trial_id": "NCT01428193", "intervention_name": "Progesterone", "condition_name": "Polycystic Ovary Syndrome", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0643", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Liposomal Irinotecan\nCondition: Metastatic Digestive System Neuroendocrine Carcinoma\nPhase: phase_2\nBlinding: NONE\nEnrollment: 11\np-value: 0.289\nInterpretation: definitive_negative", "metadata": {"result_id": 46463, "source_trial_id": "NCT03736720", "intervention_name": "Liposomal Irinotecan", "condition_name": "Metastatic Digestive System Neuroendocrine Carcinoma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0644", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Infliximab 7 mg/kg every 8 weeks\nCondition: Crohn's Disease\nPhase: phase_4\nBlinding: NONE\nEnrollment: 100\nPrimary endpoint met: 1.0\np-value: 0.0001\nSerious adverse events: 26.0\nInterpretation: definitive_negative", "metadata": {"result_id": 7515, "source_trial_id": "NCT00752622", "intervention_name": "Infliximab 7 mg/kg every 8 weeks", "condition_name": "Crohn's Disease", "confidence_tier": "silver", "therapeutic_area": "autoimmune"}, "split": "fewshot"}
+{"question_id": "CTL1-0645", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Phenylephrine\nCondition: Pre-Eclampsia\nPhase: phase_4\nBlinding: QUADRUPLE\nEnrollment: 13\np-value: 0.201\nInterpretation: definitive_negative", "metadata": {"result_id": 14369, "source_trial_id": "NCT02025426", "intervention_name": "Phenylephrine", "condition_name": "Pre-Eclampsia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0646", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Niraparib\nCondition: Solid Tumor\nPhase: phase_2\nEnrollment: 22\nTermination reason: \"Recruitment challenges\"\nDetail: Recruitment challenges", "metadata": {"result_id": 23855, "source_trial_id": "NCT05169437", "intervention_name": "Niraparib", "condition_name": "Solid Tumor", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0647", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Methadone hydrochloride\nCondition: Myelodysplastic Syndromes\nEnrollment: 1\nTermination reason: \"Low Accrual.\"\nDetail: Low Accrual.", "metadata": {"result_id": 35352, "source_trial_id": "NCT00726830", "intervention_name": "Methadone hydrochloride", "condition_name": "Myelodysplastic Syndromes", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0648", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Mifamurtide\nCondition: Osteosarcoma\nPhase: phase_2\nEnrollment: 8\nTermination reason: \"Failed to recruit sufficient numbers of patients in the funded period\"\nDetail: Failed to recruit sufficient numbers of patients in the funded period", "metadata": {"result_id": 29087, "source_trial_id": "NCT02441309", "intervention_name": "Mifamurtide", "condition_name": "Osteosarcoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0649", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Glutamine\nCondition: Sepsis\nPhase: phase_2_3\nEnrollment: 20\nTermination reason: \"Unable to meet enrollment numbers\"\nDetail: Unable to meet enrollment numbers", "metadata": {"result_id": 62992, "source_trial_id": "NCT00318331", "intervention_name": "Glutamine", "condition_name": "Sepsis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0650", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Liposomal Bupivacaine Infiltration\nCondition: Shoulder Arthritis\nPhase: phase_4\nEnrollment: 100\nTermination reason: \"Low enrollment\"\nDetail: Low enrollment", "metadata": {"result_id": 18529, "source_trial_id": "NCT02787226", "intervention_name": "Liposomal Bupivacaine Infiltration", "condition_name": "Shoulder Arthritis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0651", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: NaCl 0.9%\nCondition: Anemia\nPhase: phase_4\nEnrollment: 3\nTermination reason: \"Less patients than expected for inclusion, therefore recruitment is too low\"\nDetail: Less patients than expected for inclusion, therefore recruitment is too low", "metadata": {"result_id": 58749, "source_trial_id": "NCT01345968", "intervention_name": "NaCl 0.9%", "condition_name": "Anemia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0652", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: anti-thymocyte globulin\nDrug type: other_biologic\nCondition: Myelodysplastic Syndrome\nEnrollment: 3\nTermination reason: \"Closed due to poor accrual\"\nDetail: Closed due to poor accrual", "metadata": {"result_id": 28990, "source_trial_id": "NCT01598025", "intervention_name": "anti-thymocyte globulin", "condition_name": "Myelodysplastic Syndrome", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0653", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Atropine\nCondition: Amblyopia\nPhase: phase_3\nBlinding: NONE\nEnrollment: 55\np-value: 0.3\nInterpretation: definitive_negative", "metadata": {"result_id": 32277, "source_trial_id": "NCT00506675", "intervention_name": "Atropine", "condition_name": "Amblyopia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0654", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Mild stimulation\nCondition: Ovulation Induction\nPhase: phase_4\nEnrollment: 147\nTermination reason: \"Inclusion of the study didn't go as fast as expected. Expect: 234 patients in 1 year in 2 centers. After 1,5 year only 147 patients were recruited.\"\nDetail: Inclusion of the study didn't go as fast as expected. Expect: 234 patients in 1 year in 2 centers. After 1,5 year only 147 patients were recruited.", "metadata": {"result_id": 41438, "source_trial_id": "NCT00823472", "intervention_name": "Mild stimulation", "condition_name": "Ovulation Induction", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0655", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Poly-ICLC\nDrug type: unknown\nCondition: Breast Cancer\nPhase: phase_2\nEnrollment: 8\nTermination reason: \"PI discretion, low enrollment\"\nDetail: PI discretion, low enrollment", "metadata": {"result_id": 14079, "source_trial_id": "NCT01984892", "intervention_name": "Poly-ICLC", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0656", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Fecal Microbiota Transplantation (FMT)\nCondition: Clostridial Infection\nPhase: phase_1_2\nBlinding: DOUBLE\nEnrollment: 10\np-value: 0.999\nEffect size (Difference in Proportions): 0.05\n95% CI: [-0.58, 0.65]\nSerious adverse events: 21.0\nInterpretation: definitive_negative", "metadata": {"result_id": 13114, "source_trial_id": "NCT03548051", "intervention_name": "Fecal Microbiota Transplantation (FMT)", "condition_name": "Clostridial Infection", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0657", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: saracatinib\nCondition: Stage IV Prostate Cancer\nPhase: phase_2\nBlinding: NONE\nEnrollment: 31\np-value: 0.2\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 17312, "source_trial_id": "NCT01267266", "intervention_name": "saracatinib", "condition_name": "Stage IV Prostate Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0658", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: etoposide\nCondition: Testicular Lymphoma\nEnrollment: 25\nTermination reason: \"Slow Accrual\"\nDetail: Slow Accrual", "metadata": {"result_id": 57785, "source_trial_id": "NCT01408043", "intervention_name": "etoposide", "condition_name": "Testicular Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0659", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Minocycline\nCondition: Head and Neck Cancer\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 30\np-value: 0.98\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 26367, "source_trial_id": "NCT02055963", "intervention_name": "Minocycline", "condition_name": "Head and Neck Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0660", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: blood\nCondition: Thalassemia\nEnrollment: 3\nTermination reason: \"Difficulty recruiting donors and recipients, looking for alternative sites\"\nDetail: Difficulty recruiting donors and recipients, looking for alternative sites", "metadata": {"result_id": 14295, "source_trial_id": "NCT01534676", "intervention_name": "blood", "condition_name": "Thalassemia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0661", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Platelet transfusion\nCondition: Thrombocytopenia\nPhase: phase_2\nBlinding: NONE\nEnrollment: 29\np-value: 0.5\nSerious adverse events: 45.0\nInterpretation: definitive_negative", "metadata": {"result_id": 1861, "source_trial_id": "NCT02074436", "intervention_name": "Platelet transfusion", "condition_name": "Thrombocytopenia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0662", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Alloplast, Membrane\nCondition: Tooth Fractures\nBlinding: NONE\nEnrollment: 16\np-value: 0.243\nInterpretation: definitive_negative", "metadata": {"result_id": 21570, "source_trial_id": "NCT02532543", "intervention_name": "Alloplast, Membrane", "condition_name": "Tooth Fractures", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0663", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Becaplermin\nDrug type: peptide\nCondition: Diabetic Neuropathies\nPhase: phase_3\nEnrollment: 84\nTermination reason: \"Slow recruitment; Study did not address safety concern raised by European Medicines Agency\"\nDetail: Slow recruitment; Study did not address safety concern raised by European Medicines Agency", "metadata": {"result_id": 4881, "source_trial_id": "NCT00034788", "intervention_name": "Becaplermin", "condition_name": "Diabetic Neuropathies", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0664", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Elotuzumab (HuLuc63)\nDrug type: monoclonal_antibody\nCondition: Multiple Myeloma\nPhase: phase_1\nEnrollment: 28\nTermination reason: \"Enrollment has been halted\"\nDetail: Enrollment has been halted", "metadata": {"result_id": 41720, "source_trial_id": "NCT00726869", "intervention_name": "Elotuzumab (HuLuc63)", "condition_name": "Multiple Myeloma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0665", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Eszopiclone\nCondition: Nicotine Dependence\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 4\nPrimary endpoint met: 1.0\np-value: 0.05\nInterpretation: definitive_negative", "metadata": {"result_id": 62238, "source_trial_id": "NCT00511134", "intervention_name": "Eszopiclone", "condition_name": "Nicotine Dependence", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0666", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Mitomycin -C\nCondition: Subglottic Stenosis\nBlinding: QUADRUPLE\nEnrollment: 15\np-value: 0.52\nInterpretation: definitive_negative", "metadata": {"result_id": 10603, "source_trial_id": "NCT01523275", "intervention_name": "Mitomycin -C", "condition_name": "Subglottic Stenosis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0667", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Deoxyspergualin\nCondition: Chronic Rejection\nEnrollment: 35\nTermination reason: \"Insufficient patient enrollment\"\nDetail: Insufficient patient enrollment", "metadata": {"result_id": 43923, "source_trial_id": "NCT01052259", "intervention_name": "Deoxyspergualin", "condition_name": "Chronic Rejection", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0668", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Technetium Tc-99m Sulfur Colloid\nDrug type: unknown\nCondition: Intrahepatic Cholangiocarcinoma\nBlinding: NONE\nEnrollment: 41\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Median Difference (Final Values)): 0.23\nInterpretation: definitive_negative", "metadata": {"result_id": 43106, "source_trial_id": "NCT02881554", "intervention_name": "Technetium Tc-99m Sulfur Colloid", "condition_name": "Intrahepatic Cholangiocarcinoma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0669", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Dasatinib (Sprycel)\nCondition: Chronic Myeloid Leukemia\nPhase: phase_2\nEnrollment: 50\nTermination reason: \"Slow recruitment. No safety concerns during this study.\"\nDetail: Slow recruitment. No safety concerns during this study.", "metadata": {"result_id": 56987, "source_trial_id": "NCT00895297", "intervention_name": "Dasatinib (Sprycel)", "condition_name": "Chronic Myeloid Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0670", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Brimonidine 0.33% gel\nCondition: Capillary Malformations\nPhase: phase_3\nEnrollment: 6\nTermination reason: \"Poor enrollment, lack of feasibility\"\nDetail: Poor enrollment, lack of feasibility", "metadata": {"result_id": 48213, "source_trial_id": "NCT02764411", "intervention_name": "Brimonidine 0.33% gel", "condition_name": "Capillary Malformations", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0671", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: biphasic human insulin 30\nCondition: Diabetes Mellitus, Type 2\nPhase: phase_4\nEnrollment: 40\nTermination reason: \"Low recruitment status\"\nDetail: Low recruitment status", "metadata": {"result_id": 45197, "source_trial_id": "NCT00799448", "intervention_name": "biphasic human insulin 30", "condition_name": "Diabetes Mellitus, Type 2", "confidence_tier": "bronze", "therapeutic_area": "metabolic"}, "split": "val"}
+{"question_id": "CTL1-0672", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: TNX-1300 (Injection)\nDrug type: unknown\nCondition: Cocaine Abuse\nPhase: phase_2\nEnrollment: 3\nTermination reason: \"Tonix has discontinued enrollment and terminated the Phase 2 CATALYST study (TNX-CE-CI202) because enrollment in this emergency department-based study was slower than projected. The study was not discontinued for safety or efficacy reasons.\"\nDetail: Tonix has discontinued enrollment and terminated the Phase 2 CATALYST study (TNX-CE-CI202) because enrollment in this emergency department-based study was slower than projected. The study was not discontinued for safety or efficacy reasons.", "metadata": {"result_id": 60352, "source_trial_id": "NCT06045793", "intervention_name": "TNX-1300 (Injection)", "condition_name": "Cocaine Abuse", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0673", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: GM-CSF\nDrug type: peptide\nCondition: Lymphoma\nPhase: phase_2\nEnrollment: 27\nTermination reason: \"Slow Accrual.\"\nDetail: Slow Accrual.", "metadata": {"result_id": 33423, "source_trial_id": "NCT00505921", "intervention_name": "GM-CSF", "condition_name": "Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0674", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: tazarotene 0.1% cream\nCondition: Hand-foot Skin Reaction\nPhase: phase_2\nEnrollment: 6\nTermination reason: \"Study was halted due to poor subject accrual.\"\nDetail: Study was halted due to poor subject accrual.", "metadata": {"result_id": 44168, "source_trial_id": "NCT00667589", "intervention_name": "tazarotene 0.1% cream", "condition_name": "Hand-foot Skin Reaction", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0675", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Personalized peptide vaccine\nCondition: Glioblastoma Multiforme\nPhase: phase_1\nEnrollment: 1\nTermination reason: \"Low accrual\"\nDetail: Low accrual", "metadata": {"result_id": 38913, "source_trial_id": "NCT02510950", "intervention_name": "Personalized peptide vaccine", "condition_name": "Glioblastoma Multiforme", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0676", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Saline\nCondition: Probiotic Therapy\nPhase: phase_1_2\nBlinding: DOUBLE\nEnrollment: 10\np-value: 0.999\nEffect size (Difference in Proportions): 0.05\n95% CI: [-0.58, 0.65]\nSerious adverse events: 21.0\nInterpretation: definitive_negative", "metadata": {"result_id": 13115, "source_trial_id": "NCT03548051", "intervention_name": "Saline", "condition_name": "Probiotic Therapy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0677", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Belatacept\nDrug type: peptide\nCondition: Simultaneous Kidney and Pancreas Transplantation\nPhase: phase_2\nBlinding: NONE\nEnrollment: 46\np-value: 0.75\nEffect size (Mean Difference (Final Values)): 2.088\n95% CI: [-11.067, 15.242]\nSerious adverse events: 146.0\nInterpretation: definitive_negative", "metadata": {"result_id": 3395, "source_trial_id": "NCT01790594", "intervention_name": "Belatacept", "condition_name": "Simultaneous Kidney and Pancreas Transplantation", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0678", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Survanta (beractant)\nDrug type: unknown\nCondition: Patent Ductus Arteriosus\nPhase: phase_4\nBlinding: NONE\nEnrollment: 52\nPrimary endpoint met: 1.0\np-value: 0.01\nEffect size (Risk Ratio (RR)): 2.38\n95% CI: [1.29, 4.38]\nSerious adverse events: 66.0\nInterpretation: definitive_negative", "metadata": {"result_id": 15142, "source_trial_id": "NCT00767039", "intervention_name": "Survanta (beractant)", "condition_name": "Patent Ductus Arteriosus", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0679", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Standard Chemotherapy\nCondition: Ovarian Cancer\nPhase: phase_2\nEnrollment: 21\nTermination reason: \"due to lack of recruitment\"\nDetail: due to lack of recruitment", "metadata": {"result_id": 42770, "source_trial_id": "NCT03622931", "intervention_name": "Standard Chemotherapy", "condition_name": "Ovarian Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0680", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Gonal -f® [r-hFSH]\nCondition: In Vitro Fertilization\nPhase: phase_4\nEnrollment: 27\nTermination reason: \"Study terminated due to recruitment failure\"\nDetail: Study terminated due to recruitment failure", "metadata": {"result_id": 20448, "source_trial_id": "NCT01210144", "intervention_name": "Gonal -f® [r-hFSH]", "condition_name": "In Vitro Fertilization", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0681", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Lidocaine IV\nCondition: Postoperative Pain\nPhase: phase_4\nEnrollment: 17\nTermination reason: \"Recruitment was unable to be obtained in a timely fashion, so the study was stopped.\"\nDetail: Recruitment was unable to be obtained in a timely fashion, so the study was stopped.", "metadata": {"result_id": 54054, "source_trial_id": "NCT04208516", "intervention_name": "Lidocaine IV", "condition_name": "Postoperative Pain", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0682", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Conivaptan\nCondition: Hyponatremia\nPhase: phase_4\nBlinding: SINGLE\nEnrollment: 6\nPrimary endpoint met: 1.0\np-value: 0.05\nSerious adverse events: 10.0\nInterpretation: definitive_negative", "metadata": {"result_id": 22541, "source_trial_id": "NCT00727090", "intervention_name": "Conivaptan", "condition_name": "Hyponatremia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0683", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Poly ICLC\nDrug type: unknown\nCondition: Cervical Cancer\nPhase: phase_1\nEnrollment: 5\nTermination reason: \"Unable to enroll enough patients to complete targeted enrollment in a reasonable time.\"\nDetail: Unable to enroll enough patients to complete targeted enrollment in a reasonable time.", "metadata": {"result_id": 46368, "source_trial_id": "NCT04116320", "intervention_name": "Poly ICLC", "condition_name": "Cervical Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0684", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Misoprostol 400mcg buccal\nCondition: Second Trimester Abortion\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 7\np-value: 0.695\nInterpretation: definitive_negative", "metadata": {"result_id": 34041, "source_trial_id": "NCT06078501", "intervention_name": "Misoprostol 400mcg buccal", "condition_name": "Second Trimester Abortion", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0685", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Anesthetic Adjuncts\nCondition: Respiratory Infection\nPhase: phase_4\nEnrollment: 3\nTermination reason: \"Study terminated due to lack of enrollment.\"\nDetail: Study terminated due to lack of enrollment.", "metadata": {"result_id": 17754, "source_trial_id": "NCT03962725", "intervention_name": "Anesthetic Adjuncts", "condition_name": "Respiratory Infection", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0686", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: imatinib mesylate\nCondition: Brain and Central Nervous System Tumors\nPhase: phase_1_2\nEnrollment: 85\nTermination reason: \"Poor accrual\"\nDetail: Poor accrual", "metadata": {"result_id": 13368, "source_trial_id": "NCT00021229", "intervention_name": "imatinib mesylate", "condition_name": "Brain and Central Nervous System Tumors", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0687", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Recombinant Human Choriogonadotropin (r-hCG)\nDrug type: unknown\nCondition: Infertility\nPhase: phase_2\nBlinding: NONE\nEnrollment: 93\nPrimary endpoint met: 1.0\np-value: 0.0166\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 56435, "source_trial_id": "NCT01079949", "intervention_name": "Recombinant Human Choriogonadotropin (r-hCG)", "condition_name": "Infertility", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0688", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Parenteral nutrition\nCondition: Malnutrition\nPhase: phase_2\nBlinding: SINGLE\nEnrollment: 18\nPrimary endpoint met: 1.0\np-value: 0.04\nSerious adverse events: 12.0\nInterpretation: definitive_negative", "metadata": {"result_id": 20183, "source_trial_id": "NCT01937884", "intervention_name": "Parenteral nutrition", "condition_name": "Malnutrition", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0689", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Somatropin\nDrug type: peptide\nCondition: Growth Hormone Therapy\nPhase: phase_3\nBlinding: NONE\nEnrollment: 23\nPrimary endpoint met: 1.0\np-value: 0.0161\nEffect size (LS Mean difference): 4.67\n95% CI: [1.13, 8.21]\nInterpretation: definitive_negative", "metadata": {"result_id": 57125, "source_trial_id": "NCT00625872", "intervention_name": "Somatropin", "condition_name": "Growth Hormone Therapy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0690", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: topotecan hydrochloride\nCondition: Ovarian Endometrioid Adenocarcinoma\nPhase: phase_2\nEnrollment: 17\nTermination reason: \"poor accrual\"\nDetail: poor accrual", "metadata": {"result_id": 21200, "source_trial_id": "NCT02364713", "intervention_name": "topotecan hydrochloride", "condition_name": "Ovarian Endometrioid Adenocarcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0691", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Fluorouracil\nCondition: Metastatic Digestive System Neuroendocrine Carcinoma\nPhase: phase_2\nBlinding: NONE\nEnrollment: 11\np-value: 0.289\nInterpretation: definitive_negative", "metadata": {"result_id": 46461, "source_trial_id": "NCT03736720", "intervention_name": "Fluorouracil", "condition_name": "Metastatic Digestive System Neuroendocrine Carcinoma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0692", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: GnRH antagonist\nCondition: Infertility\nPhase: phase_4\nBlinding: NONE\nEnrollment: 15\nPrimary endpoint met: 1.0\np-value: 0.05\nEffect size (Median Difference (Final Values)): 71.1\nInterpretation: definitive_negative", "metadata": {"result_id": 18686, "source_trial_id": "NCT02821819", "intervention_name": "GnRH antagonist", "condition_name": "Infertility", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0693", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Monovalent [B.1.351] CoV2 preS dTM-AS03\nCondition: Juvenile Dermatomyositis (JDM)\nPhase: phase_2\nEnrollment: 258\nTermination reason: \"The study was closed due to continued enrollment hurdles.\"\nDetail: The study was closed due to continued enrollment hurdles.", "metadata": {"result_id": 2838, "source_trial_id": "NCT05000216", "intervention_name": "Monovalent [B.1.351] CoV2 preS dTM-AS03", "condition_name": "Juvenile Dermatomyositis (JDM)", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0694", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Clonidine HCL\nCondition: Neonatal Abstinence Syndrome\nPhase: phase_2_3\nBlinding: QUADRUPLE\nEnrollment: 12\nPrimary endpoint met: 1.0\np-value: 0.05\nEffect size (Mean Difference (Final Values)): 0.05\nInterpretation: definitive_negative", "metadata": {"result_id": 20236, "source_trial_id": "NCT01360450", "intervention_name": "Clonidine HCL", "condition_name": "Neonatal Abstinence Syndrome", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0695", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: TS-161\nCondition: Major Depressive Disorder\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 11\np-value: 0.12\nInterpretation: definitive_negative", "metadata": {"result_id": 56054, "source_trial_id": "NCT04821271", "intervention_name": "TS-161", "condition_name": "Major Depressive Disorder", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0696", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: silicon phthalocyanine 4\nCondition: Lymphoma\nPhase: phase_1\nEnrollment: 3\nTermination reason: \"slow accrual\"\nDetail: slow accrual", "metadata": {"result_id": 23304, "source_trial_id": "NCT00023790", "intervention_name": "silicon phthalocyanine 4", "condition_name": "Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0697", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Azathioprine\nCondition: Crohn's Disease\nPhase: phase_3\nEnrollment: 31\nTermination reason: \"Lack of recruitment\"\nDetail: Lack of recruitment", "metadata": {"result_id": 50042, "source_trial_id": "NCT00098111", "intervention_name": "Azathioprine", "condition_name": "Crohn's Disease", "confidence_tier": "bronze", "therapeutic_area": "autoimmune"}, "split": "val"}
+{"question_id": "CTL1-0698", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: continuous intravenous insulin infusion\nCondition: Abdominal Aortic Aneurysm\nBlinding: SINGLE\nEnrollment: 242\np-value: 0.23\nEffect size (Risk Ratio (RR)): 1.29\n95% CI: [0.85, 1.97]\nSerious adverse events: 30.0\nInterpretation: definitive_negative", "metadata": {"result_id": 14948, "source_trial_id": "NCT00328094", "intervention_name": "continuous intravenous insulin infusion", "condition_name": "Abdominal Aortic Aneurysm", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0699", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Abatacept\nDrug type: peptide\nCondition: COVID-19\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 61\np-value: 0.2724\nEffect size (Odds Ratio (OR)): 2.29\n95% CI: [0.53, 9.82]\nSerious adverse events: 53.0\nInterpretation: definitive_negative", "metadata": {"result_id": 20836, "source_trial_id": "NCT04472494", "intervention_name": "Abatacept", "condition_name": "COVID-19", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "val"}
+{"question_id": "CTL1-0700", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Palbociclib 75mg\nCondition: Breast Cancer Metastatic\nPhase: phase_1_2\nEnrollment: 3\nTermination reason: \"Low accrual\"\nDetail: Low accrual", "metadata": {"result_id": 18140, "source_trial_id": "NCT03709082", "intervention_name": "Palbociclib 75mg", "condition_name": "Breast Cancer Metastatic", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0701", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Ibuprofen\nCondition: Adenotonsillectomy\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 73\np-value: 0.2\nInterpretation: definitive_negative", "metadata": {"result_id": 16275, "source_trial_id": "NCT04791761", "intervention_name": "Ibuprofen", "condition_name": "Adenotonsillectomy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0702", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Ruxolitinib Cream\nCondition: Atopic Dermatitis\nPhase: phase_4\nBlinding: NONE\nEnrollment: 47\nPrimary endpoint met: 1.0\np-value: 0.0001\nInterpretation: definitive_negative", "metadata": {"result_id": 25976, "source_trial_id": "NCT05696392", "intervention_name": "Ruxolitinib Cream", "condition_name": "Atopic Dermatitis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0703", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Protocolized Diuretic Strategy\nCondition: Kidney Failure\nPhase: phase_4\nBlinding: SINGLE\nEnrollment: 19\nPrimary endpoint met: 1.0\np-value: 0.05\nSerious adverse events: 14.0\nInterpretation: definitive_negative", "metadata": {"result_id": 45823, "source_trial_id": "NCT01921829", "intervention_name": "Protocolized Diuretic Strategy", "condition_name": "Kidney Failure", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0704", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: adavosertib\nCondition: Stage I Vaginal Cancer AJCC v6 and v7\nPhase: phase_1\nEnrollment: 10\nTermination reason: \"Inadequate accrual rate\"\nDetail: Inadequate accrual rate", "metadata": {"result_id": 7309, "source_trial_id": "NCT03345784", "intervention_name": "adavosertib", "condition_name": "Stage I Vaginal Cancer AJCC v6 and v7", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0705", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Maintenance with Pemetrexed\nCondition: Carcinoma, Non-Small-Cell Lung\nPhase: phase_2\nEnrollment: 2\nTermination reason: \"low recruitement rate\"\nDetail: low recruitement rate", "metadata": {"result_id": 33957, "source_trial_id": "NCT02919462", "intervention_name": "Maintenance with Pemetrexed", "condition_name": "Carcinoma, Non-Small-Cell Lung", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0706", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Iadademstat\nCondition: Neuroendocrine Carcinoma\nPhase: phase_2\nEnrollment: 20\nTermination reason: \"Closed to accrual due to low probability of successful outcomes\"\nDetail: Closed to accrual due to low probability of successful outcomes", "metadata": {"result_id": 16597, "source_trial_id": "NCT05420636", "intervention_name": "Iadademstat", "condition_name": "Neuroendocrine Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0707", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Intron A, Interferon alpha -2b\nCondition: Cancer\nPhase: phase_2\nBlinding: NONE\nEnrollment: 23\np-value: 0.9179\nSerious adverse events: 22.0\nInterpretation: definitive_negative", "metadata": {"result_id": 50737, "source_trial_id": "NCT00613509", "intervention_name": "Intron A, Interferon alpha -2b", "condition_name": "Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0708", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: oxcarbazepine\nCondition: Cancer\nPhase: phase_1\nEnrollment: 1\nTermination reason: \"Poor Accrual\"\nDetail: Poor Accrual", "metadata": {"result_id": 36420, "source_trial_id": "NCT02078089", "intervention_name": "oxcarbazepine", "condition_name": "Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0709", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Alkalinized lidocaine\nCondition: Local Anesthetics\nBlinding: DOUBLE\nEnrollment: 29\nPrimary endpoint met: 1.0\np-value: 0.0001\nInterpretation: definitive_negative", "metadata": {"result_id": 23696, "source_trial_id": "NCT01304082", "intervention_name": "Alkalinized lidocaine", "condition_name": "Local Anesthetics", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0710", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Bifeprunox\nCondition: Schizophrenia\nPhase: phase_3\nEnrollment: 83\nTermination reason: \"This trial discontinued on 2 May 2008 due to lack of enrolment\"\nDetail: This trial discontinued on 2 May 2008 due to lack of enrolment", "metadata": {"result_id": 62825, "source_trial_id": "NCT00396214", "intervention_name": "Bifeprunox", "condition_name": "Schizophrenia", "confidence_tier": "bronze", "therapeutic_area": "psychiatry"}, "split": "val"}
+{"question_id": "CTL1-0711", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Calcium Chloride\nCondition: Diastolic Dysfunction\nPhase: phase_4\nEnrollment: 8\nTermination reason: \"Inadequate recruitment\"\nDetail: Inadequate recruitment", "metadata": {"result_id": 52462, "source_trial_id": "NCT00955266", "intervention_name": "Calcium Chloride", "condition_name": "Diastolic Dysfunction", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0712", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Metronidazole Oral\nCondition: Vaginal Diseases\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 151\nPrimary endpoint met: 1.0\np-value: 0.025\nEffect size (Farrington-Manning test): -0.5\nInterpretation: definitive_negative", "metadata": {"result_id": 48819, "source_trial_id": "NCT05788991", "intervention_name": "Metronidazole Oral", "condition_name": "Vaginal Diseases", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0713", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Lapatinib, Vinorelbine\nCondition: Metastatic Breast Cancer\nPhase: phase_2\nEnrollment: 9\nTermination reason: \"poor recruitment\"\nDetail: poor recruitment", "metadata": {"result_id": 20648, "source_trial_id": "NCT01161368", "intervention_name": "Lapatinib, Vinorelbine", "condition_name": "Metastatic Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0714", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: therapeutic hydrocortisone\nCondition: Prostate Cancer\nPhase: phase_2\nEnrollment: 2\nTermination reason: \"low accrual\"\nDetail: low accrual", "metadata": {"result_id": 39263, "source_trial_id": "NCT00006371", "intervention_name": "therapeutic hydrocortisone", "condition_name": "Prostate Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0715", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Carduus marianus 12cH\nDrug type: unknown\nCondition: Obesity\nPhase: phase_2\nEnrollment: 62\nTermination reason: \"Difficulties in recruiting process\"\nDetail: Difficulties in recruiting process", "metadata": {"result_id": 62440, "source_trial_id": "NCT02775448", "intervention_name": "Carduus marianus 12cH", "condition_name": "Obesity", "confidence_tier": "bronze", "therapeutic_area": "metabolic"}, "split": "val"}
+{"question_id": "CTL1-0716", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Statins\nCondition: Myocardial Infarction\nEnrollment: 11\nTermination reason: \"The study was prematurely terminated due to low enrollment.\"\nDetail: The study was prematurely terminated due to low enrollment.", "metadata": {"result_id": 20384, "source_trial_id": "NCT00968383", "intervention_name": "Statins", "condition_name": "Myocardial Infarction", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL1-0717", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Inhaled Iloprost (5 μg)\nCondition: Pulmonary Hypertension\nPhase: phase_3\nEnrollment: 67\nTermination reason: \"Terminated due to slow enrollment\"\nDetail: Terminated due to slow enrollment", "metadata": {"result_id": 55318, "source_trial_id": "NCT00302211", "intervention_name": "Inhaled Iloprost (5 μg)", "condition_name": "Pulmonary Hypertension", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL1-0718", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Tofacitinib Citrate\nCondition: Discoid Lupus Erythematosus\nPhase: early_phase_1\nEnrollment: 5\nTermination reason: \"unable to identify additional subjects to qualify for enrollment\"\nDetail: unable to identify additional subjects to qualify for enrollment", "metadata": {"result_id": 25214, "source_trial_id": "NCT03159936", "intervention_name": "Tofacitinib Citrate", "condition_name": "Discoid Lupus Erythematosus", "confidence_tier": "bronze", "therapeutic_area": "autoimmune"}, "split": "val"}
+{"question_id": "CTL1-0719", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Preoperative Chemotherapy\nCondition: Resectable Pancreatic Cancer\nPhase: phase_2\nEnrollment: 30\nTermination reason: \"The study was early closed due to low accrual in August 2022.\"\nDetail: The study was early closed due to low accrual in August 2022.", "metadata": {"result_id": 49478, "source_trial_id": "NCT03822936", "intervention_name": "Preoperative Chemotherapy", "condition_name": "Resectable Pancreatic Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0720", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: HAART regimen\nCondition: HIV Disease\nPhase: phase_4\nBlinding: NONE\nEnrollment: 33\nPrimary endpoint met: 1.0\np-value: 0.03\nInterpretation: definitive_negative", "metadata": {"result_id": 17503, "source_trial_id": "NCT01338025", "intervention_name": "HAART regimen", "condition_name": "HIV Disease", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-0721", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: 6% Hydroxyethylstarch\nDrug type: unknown\nCondition: Peripheral Vascular Disease\nPhase: phase_2\nEnrollment: 16\nTermination reason: \"Very slow enrollment.Study entry criteria not in line w/local standards of care\"\nDetail: Very slow enrollment.Study entry criteria not in line w/local standards of care", "metadata": {"result_id": 39524, "source_trial_id": "NCT00300040", "intervention_name": "6% Hydroxyethylstarch", "condition_name": "Peripheral Vascular Disease", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0722", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: anastrozole\nCondition: Stage IIIA Breast Cancer\nPhase: phase_2\nEnrollment: 2\nTermination reason: \"Slow accrual\"\nDetail: Slow accrual", "metadata": {"result_id": 1591, "source_trial_id": "NCT01394211", "intervention_name": "anastrozole", "condition_name": "Stage IIIA Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0723", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Praziquantel, Ivermectin, Albendazole\nCondition: HIV Infections\nEnrollment: 295\nTermination reason: \"Terminated prematurely due to recruitment difficulties. Expansion to more study sites not planned.\"\nDetail: Terminated prematurely due to recruitment difficulties. Expansion to more study sites not planned.", "metadata": {"result_id": 3044, "source_trial_id": "NCT00817713", "intervention_name": "Praziquantel, Ivermectin, Albendazole", "condition_name": "HIV Infections", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-0724", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Prednisolone\nCondition: Schizophrenia\nPhase: phase_4\nEnrollment: 42\nTermination reason: \"Difficulties with recruitment\"\nDetail: Difficulties with recruitment", "metadata": {"result_id": 62744, "source_trial_id": "NCT02949232", "intervention_name": "Prednisolone", "condition_name": "Schizophrenia", "confidence_tier": "bronze", "therapeutic_area": "psychiatry"}, "split": "test"}
+{"question_id": "CTL1-0725", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Tolvaptan\nCondition: Hyponatremia\nPhase: phase_3\nEnrollment: 3\nTermination reason: \"Issues with recruitment and enrollment made the trial impossible or highly impracticable. Termination of this trial was not due to safety reasons.\"\nDetail: Issues with recruitment and enrollment made the trial impossible or highly impracticable. Termination of this trial was not due to safety reasons.", "metadata": {"result_id": 57403, "source_trial_id": "NCT02020278", "intervention_name": "Tolvaptan", "condition_name": "Hyponatremia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0726", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet\nCondition: Oral Cavity Neoplasm\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 6\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Mean Difference (Final Values)): -1.0098\nInterpretation: definitive_negative", "metadata": {"result_id": 35043, "source_trial_id": "NCT02917629", "intervention_name": "Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet", "condition_name": "Oral Cavity Neoplasm", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0727", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: irinotecan hydrochloride\nCondition: Recurrent Colon Cancer\nPhase: phase_3\nEnrollment: 72\nTermination reason: \"Due to inadequate accrual, study was terminated and limited outcome data was reported.\"\nDetail: Due to inadequate accrual, study was terminated and limited outcome data was reported.", "metadata": {"result_id": 53090, "source_trial_id": "NCT00499369", "intervention_name": "irinotecan hydrochloride", "condition_name": "Recurrent Colon Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0728", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Lead-in Darolutamide followed by Radium-223/Darolutamide\nCondition: Metastatic Castration-resistant Prostate Cancer\nPhase: phase_3\nEnrollment: 23\nTermination reason: \"The study was stopped due to insurmountable enrollment challenges affecting trial accrual, resulting from the rapidly evolving treatment options for advanced prostate cancer.\"\nDetail: The study was stopped due to insurmountable enrollment challenges affecting trial accrual, resulting from the rapidly evolving treatment options for advanced prostate cancer.", "metadata": {"result_id": 48640, "source_trial_id": "NCT04237584", "intervention_name": "Lead-in Darolutamide followed by Radium-223/Darolutamide", "condition_name": "Metastatic Castration-resistant Prostate Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0729", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Mifepristone\nCondition: Fetal Death\nPhase: phase_4\nEnrollment: 9\nTermination reason: \"unable to recruit. Projected completion was 2018 however, enrollment and recruitment were difficult. The study was terminated due to inability to enroll.\"\nDetail: unable to recruit. Projected completion was 2018 however, enrollment and recruitment were difficult. The study was terminated due to inability to enroll.", "metadata": {"result_id": 15547, "source_trial_id": "NCT02620904", "intervention_name": "Mifepristone", "condition_name": "Fetal Death", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0730", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: peginesatide\nDrug type: peptide\nCondition: Chronic Renal Failure\nPhase: phase_2\nEnrollment: 17\nTermination reason: \"Due to slow enrollment\"\nDetail: Due to slow enrollment", "metadata": {"result_id": 53130, "source_trial_id": "NCT00109291", "intervention_name": "peginesatide", "condition_name": "Chronic Renal Failure", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0731", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Mycophenolate mofetil (MMF)\nCondition: Lymphoma\nPhase: phase_2\nEnrollment: 6\nTermination reason: \"Slow accrual\"\nDetail: Slow accrual", "metadata": {"result_id": 15352, "source_trial_id": "NCT00057954", "intervention_name": "Mycophenolate mofetil (MMF)", "condition_name": "Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0732", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: BGJ398\nCondition: Human Papillomavirus Infection\nPhase: phase_2\nEnrollment: 1\nTermination reason: \"Study stopped due to poor enrollment.\"\nDetail: Study stopped due to poor enrollment.", "metadata": {"result_id": 43070, "source_trial_id": "NCT02706691", "intervention_name": "BGJ398", "condition_name": "Human Papillomavirus Infection", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0733", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine\nCondition: Metastases, Neoplasm\nPhase: phase_1_2\nEnrollment: 37\nTermination reason: \"The study was closed to accrual due to very poor enrollment.\"\nDetail: The study was closed to accrual due to very poor enrollment.", "metadata": {"result_id": 18127, "source_trial_id": "NCT00048893", "intervention_name": "Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine", "condition_name": "Metastases, Neoplasm", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0734", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: SF6\nCondition: Lung Infection\nPhase: early_phase_1\nEnrollment: 10\nTermination reason: \"Funding is no longer available due to the failure to enroll the target number of participants within the required timeframe.\"\nDetail: Funding is no longer available due to the failure to enroll the target number of participants within the required timeframe.", "metadata": {"result_id": 48339, "source_trial_id": "NCT02748798", "intervention_name": "SF6", "condition_name": "Lung Infection", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0735", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Nitric Oxide\nCondition: Pressure Ulcer\nPhase: phase_1_2\nEnrollment: 20\nTermination reason: \"limited recruitment\"\nDetail: limited recruitment", "metadata": {"result_id": 27231, "source_trial_id": "NCT00771368", "intervention_name": "Nitric Oxide", "condition_name": "Pressure Ulcer", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0736", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: ATR-101\nCondition: Cushing Syndrome\nPhase: phase_2\nEnrollment: 4\nTermination reason: \"Slow enrollment\"\nDetail: Slow enrollment", "metadata": {"result_id": 20141, "source_trial_id": "NCT03053271", "intervention_name": "ATR-101", "condition_name": "Cushing Syndrome", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0737", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Tolcapone\nCondition: Neuroblastoma\nPhase: phase_1\nEnrollment: 5\nTermination reason: \"Lack of study enrollment\"\nDetail: Lack of study enrollment", "metadata": {"result_id": 13688, "source_trial_id": "NCT02630043", "intervention_name": "Tolcapone", "condition_name": "Neuroblastoma", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0738", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: low-molecular heparine\nCondition: Cancer\nPhase: phase_3\nEnrollment: 246\nTermination reason: \"Recruitment was not as expected.\"\nDetail: Recruitment was not as expected.", "metadata": {"result_id": 36920, "source_trial_id": "NCT02583191", "intervention_name": "low-molecular heparine", "condition_name": "Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0739", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Delgocitinib cream\nCondition: Discoid Lupus Erythematosus\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 27\np-value: 0.4531\nEffect size (Attributable risk): -0.14\n95% CI: [-0.37, 0.09]\nInterpretation: definitive_negative", "metadata": {"result_id": 42511, "source_trial_id": "NCT03958955", "intervention_name": "Delgocitinib cream", "condition_name": "Discoid Lupus Erythematosus", "confidence_tier": "silver", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL1-0740", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Aricept\nCondition: Alzheimer's Disease\nPhase: phase_4\nEnrollment: 4\nTermination reason: \"Reduced access to AchEI medication-naive mild AD patients.\"\nDetail: Reduced access to AchEI medication-naive mild AD patients.", "metadata": {"result_id": 60856, "source_trial_id": "NCT00369603", "intervention_name": "Aricept", "condition_name": "Alzheimer's Disease", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0741", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Amoxicillin 500mg\nCondition: Penicillin Allergy\nPhase: phase_4\nEnrollment: 31\nTermination reason: \"Unable to recruit sufficient number of subjects in the setting\"\nDetail: Unable to recruit sufficient number of subjects in the setting", "metadata": {"result_id": 1439, "source_trial_id": "NCT05563610", "intervention_name": "Amoxicillin 500mg", "condition_name": "Penicillin Allergy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0742", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Apixaban\nCondition: Deep Vein Thrombosis\nPhase: phase_4\nEnrollment: 5\nTermination reason: \"Lack of participant enrollment\"\nDetail: Lack of participant enrollment", "metadata": {"result_id": 33389, "source_trial_id": "NCT03590743", "intervention_name": "Apixaban", "condition_name": "Deep Vein Thrombosis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0743", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Quizartinib\nCondition: Leukemia, Myeloid, Acute\nPhase: phase_2\nEnrollment: 1\nTermination reason: \"Closed due to slow enrollment\"\nDetail: Closed due to slow enrollment", "metadata": {"result_id": 13910, "source_trial_id": "NCT04209725", "intervention_name": "Quizartinib", "condition_name": "Leukemia, Myeloid, Acute", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0744", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: ZD6474 (vandetanib)\nCondition: Non-small Cell Lung Cancer (NSCLC)\nPhase: phase_1\nEnrollment: 5\nTermination reason: \"Very slow recruitment\"\nDetail: Very slow recruitment", "metadata": {"result_id": 23608, "source_trial_id": "NCT00807170", "intervention_name": "ZD6474 (vandetanib)", "condition_name": "Non-small Cell Lung Cancer (NSCLC)", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0745", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Neratinib\nCondition: Stage IV Breast Cancer AJCC v6 and v7\nPhase: phase_1_2\nEnrollment: 34\nTermination reason: \"\\<75% accrued\"\nDetail: \\<75% accrued", "metadata": {"result_id": 51799, "source_trial_id": "NCT03101748", "intervention_name": "Neratinib", "condition_name": "Stage IV Breast Cancer AJCC v6 and v7", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0746", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: metoprolol\nCondition: Ventricular Fibrillation\nPhase: phase_2\nEnrollment: 7\nTermination reason: \"Difficult accrual\"\nDetail: Difficult accrual", "metadata": {"result_id": 18755, "source_trial_id": "NCT00401882", "intervention_name": "metoprolol", "condition_name": "Ventricular Fibrillation", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0747", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Tyrosine kinase inhibitor\nCondition: EGFR Activating Mutation\nPhase: phase_2\nBlinding: NONE\nEnrollment: 19\np-value: 0.6\nInterpretation: definitive_negative", "metadata": {"result_id": 11181, "source_trial_id": "NCT02949843", "intervention_name": "Tyrosine kinase inhibitor", "condition_name": "EGFR Activating Mutation", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0748", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Paclitaxel+Gemcitabine\nCondition: Advanced Breast Cancer\nPhase: phase_3\nBlinding: NONE\nEnrollment: 1004\np-value: 0.1\nEffect size (Hazard Ratio (HR)): 11.3\n95% CI: [8.7, 14.4]\nSerious adverse events: 1891.0\nInterpretation: definitive_negative", "metadata": {"result_id": 53431, "source_trial_id": "NCT02054338", "intervention_name": "Paclitaxel+Gemcitabine", "condition_name": "Advanced Breast Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0749", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: ibuprofen marketed formulation\nCondition: Headache, Tension-Type\nPhase: phase_2_3\nBlinding: DOUBLE\nEnrollment: 66\np-value: 0.2008\nEffect size (Hazard Ratio (HR)): 1.32\n95% CI: [0.86, 2.01]\nInterpretation: definitive_negative", "metadata": {"result_id": 15454, "source_trial_id": "NCT01755702", "intervention_name": "ibuprofen marketed formulation", "condition_name": "Headache, Tension-Type", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0750", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Different timing of influenza vaccination\nCondition: Cancer\nEnrollment: 97\nTermination reason: \"Insufficient enrollment\"\nDetail: Insufficient enrollment", "metadata": {"result_id": 8496, "source_trial_id": "NCT02213432", "intervention_name": "Different timing of influenza vaccination", "condition_name": "Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0751", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Auriculotherapy\nCondition: Auriculotherapy\nEnrollment: 10\nTermination reason: \"difficulty of recruitment\"\nDetail: difficulty of recruitment", "metadata": {"result_id": 23001, "source_trial_id": "NCT05126615", "intervention_name": "Auriculotherapy", "condition_name": "Auriculotherapy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0752", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: obatoclax mesylate\nCondition: Refractory Multiple Myeloma\nPhase: phase_1_2\nEnrollment: 11\nTermination reason: \"This trial was terminated due to slow accrual and the drug supply of Obatoclax during the phase I; therefore, the phase II portion will never open.\"\nDetail: This trial was terminated due to slow accrual and the drug supply of Obatoclax during the phase I; therefore, the phase II portion will never open.", "metadata": {"result_id": 26503, "source_trial_id": "NCT00719901", "intervention_name": "obatoclax mesylate", "condition_name": "Refractory Multiple Myeloma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0753", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Tirofiban\nCondition: Ischemic Stroke\nPhase: phase_2_3\nEnrollment: 30\nTermination reason: \"The number and speed of enrollment were significantly less than expected.\"\nDetail: The number and speed of enrollment were significantly less than expected.", "metadata": {"result_id": 19409, "source_trial_id": "NCT03357133", "intervention_name": "Tirofiban", "condition_name": "Ischemic Stroke", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0754", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: INKmune\nCondition: Myelodysplastic Syndromes\nPhase: phase_1\nEnrollment: 2\nTermination reason: \"Slow/low Enrollment\"\nDetail: Slow/low Enrollment", "metadata": {"result_id": 13136, "source_trial_id": "NCT05933070", "intervention_name": "INKmune", "condition_name": "Myelodysplastic Syndromes", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0755", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Cabazitaxel XRP6258\nCondition: Prostate Cancer Metastatic\nPhase: phase_2\nEnrollment: 8\nTermination reason: \"Unsatisfactory patient accrual\"\nDetail: Unsatisfactory patient accrual", "metadata": {"result_id": 32850, "source_trial_id": "NCT02379390", "intervention_name": "Cabazitaxel XRP6258", "condition_name": "Prostate Cancer Metastatic", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0756", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: CAR-20/19-T cells\nCondition: Acute Lymphoblastic Leukemia With Failed Remission\nPhase: phase_1\nEnrollment: 5\nTermination reason: \"Low accrual\"\nDetail: Low accrual", "metadata": {"result_id": 45704, "source_trial_id": "NCT04049383", "intervention_name": "CAR-20/19-T cells", "condition_name": "Acute Lymphoblastic Leukemia With Failed Remission", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0757", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: 3 million MSCs/kg\nCondition: Abdominal Aortic Aneurysm\nPhase: phase_1\nBlinding: TRIPLE\nEnrollment: 28\nPrimary endpoint met: 1.0\np-value: 0.05\nEffect size (Mean Difference (Final Values)): 81.0\nInterpretation: definitive_negative", "metadata": {"result_id": 37162, "source_trial_id": "NCT02846883", "intervention_name": "3 million MSCs/kg", "condition_name": "Abdominal Aortic Aneurysm", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0758", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Granulocyte Colony Stimulating Factor\nCondition: Hematologic Malignancies\nEnrollment: 8\nTermination reason: \"lack of enrollment\"\nDetail: lack of enrollment", "metadata": {"result_id": 56199, "source_trial_id": "NCT00228813", "intervention_name": "Granulocyte Colony Stimulating Factor", "condition_name": "Hematologic Malignancies", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0759", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: MTX 25\nCondition: Ulcerative Colitis\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 22\np-value: 0.758\nSerious adverse events: 6.0\nInterpretation: definitive_negative", "metadata": {"result_id": 49291, "source_trial_id": "NCT01716039", "intervention_name": "MTX 25", "condition_name": "Ulcerative Colitis", "confidence_tier": "silver", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL1-0760", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Sucraid (sacrosidase) Oral Solution 8500 IU/mL\nCondition: Sucrase Isomaltase Deficiency\nPhase: phase_4\nEnrollment: 312\nTermination reason: \"Lack of subject enrollment\"\nDetail: Lack of subject enrollment", "metadata": {"result_id": 44207, "source_trial_id": "NCT05480761", "intervention_name": "Sucraid (sacrosidase) Oral Solution 8500 IU/mL", "condition_name": "Sucrase Isomaltase Deficiency", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0761", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Lyso-Thermosensitive Liposomal Doxorubicin\nCondition: Pediatric Cancer\nPhase: phase_1\nEnrollment: 2\nTermination reason: \"low accrual\"\nDetail: low accrual", "metadata": {"result_id": 13481, "source_trial_id": "NCT02536183", "intervention_name": "Lyso-Thermosensitive Liposomal Doxorubicin", "condition_name": "Pediatric Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0762", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Rabeprazole\nCondition: Peptic Ulcer Hemorrhage\nPhase: phase_4\nBlinding: NONE\nEnrollment: 106\nPrimary endpoint met: 1.0\np-value: 0.05\nInterpretation: definitive_negative", "metadata": {"result_id": 12224, "source_trial_id": "NCT00838682", "intervention_name": "Rabeprazole", "condition_name": "Peptic Ulcer Hemorrhage", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0763", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Valsartan\nCondition: Hyperkalemia\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 1112\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Hazard Ratio (HR)): 0.34\n95% CI: [0.25, 0.47]\nInterpretation: definitive_negative", "metadata": {"result_id": 19327, "source_trial_id": "NCT05056727", "intervention_name": "Valsartan", "condition_name": "Hyperkalemia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0764", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Dexamethasone sodium phosphate\nCondition: Apophysitis; Juvenile\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 45\nPrimary endpoint met: 1.0\np-value: 0.0232\nEffect size (Hazard Ratio (HR)): 4.16\n95% CI: [1.215, 14.273]\nInterpretation: definitive_negative", "metadata": {"result_id": 8753, "source_trial_id": "NCT03606980", "intervention_name": "Dexamethasone sodium phosphate", "condition_name": "Apophysitis; Juvenile", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0765", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Matched control\nCondition: Optic Nerve Diseases\nPhase: phase_3\nEnrollment: 34\nTermination reason: \"Study was stopped due to poor enrollment on 28 Feb 2012. Reason for termination was not due to safety concerns.\"\nDetail: Study was stopped due to poor enrollment on 28 Feb 2012. Reason for termination was not due to safety concerns.", "metadata": {"result_id": 43603, "source_trial_id": "NCT00359632", "intervention_name": "Matched control", "condition_name": "Optic Nerve Diseases", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0766", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Posaconazole Pill\nCondition: Glioblastoma Multiforme of Brain\nPhase: early_phase_1\nEnrollment: 7\nTermination reason: \"The study was stopped due to slow accrual.\"\nDetail: The study was stopped due to slow accrual.", "metadata": {"result_id": 12534, "source_trial_id": "NCT04825275", "intervention_name": "Posaconazole Pill", "condition_name": "Glioblastoma Multiforme of Brain", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0767", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: E7050\nCondition: Previously Untreated Gastric Cancer\nPhase: phase_1_2\nEnrollment: 7\nTermination reason: \"Sites not recruiting\"\nDetail: Sites not recruiting", "metadata": {"result_id": 39332, "source_trial_id": "NCT01355302", "intervention_name": "E7050", "condition_name": "Previously Untreated Gastric Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0768", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: OGX-427\nDrug type: oligonucleotide\nCondition: PSA\nPhase: phase_2\nEnrollment: 72\nTermination reason: \"lack of accrual\"\nDetail: lack of accrual", "metadata": {"result_id": 13993, "source_trial_id": "NCT01681433", "intervention_name": "OGX-427", "condition_name": "PSA", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0769", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Aspirin\nCondition: Fontan Procedure\nPhase: phase_4\nBlinding: NONE\nEnrollment: 9\np-value: 0.18\nInterpretation: definitive_negative", "metadata": {"result_id": 18934, "source_trial_id": "NCT02966002", "intervention_name": "Aspirin", "condition_name": "Fontan Procedure", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0770", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Deferiprone (L1)\nCondition: Cardiovascular Diseases\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 20\np-value: 0.89\nSerious adverse events: 28.0\nInterpretation: definitive_negative", "metadata": {"result_id": 26259, "source_trial_id": "NCT00115349", "intervention_name": "Deferiprone (L1)", "condition_name": "Cardiovascular Diseases", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0771", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Standard concentration unfractionated heparin\nCondition: Heart Failure\nPhase: phase_4\nEnrollment: 12\nTermination reason: \"lack of recruitment\"\nDetail: lack of recruitment", "metadata": {"result_id": 29101, "source_trial_id": "NCT01318811", "intervention_name": "Standard concentration unfractionated heparin", "condition_name": "Heart Failure", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0772", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: PFP\nCondition: Asbestosis\nPhase: early_phase_1\nEnrollment: 10\nTermination reason: \"Funding is no longer available due to the failure to enroll the target number of participants within the required timeframe.\"\nDetail: Funding is no longer available due to the failure to enroll the target number of participants within the required timeframe.", "metadata": {"result_id": 48357, "source_trial_id": "NCT02748798", "intervention_name": "PFP", "condition_name": "Asbestosis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0773", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Iron sucrose\nCondition: Unexplained Anemia (UAE)\nPhase: phase_2\nBlinding: NONE\nEnrollment: 19\nPrimary endpoint met: 1.0\np-value: 0.001\nSerious adverse events: 6.0\nInterpretation: definitive_negative", "metadata": {"result_id": 10680, "source_trial_id": "NCT01309659", "intervention_name": "Iron sucrose", "condition_name": "Unexplained Anemia (UAE)", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0774", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Fucidin® cream\nCondition: Impetigo\nPhase: phase_4\nBlinding: DOUBLE\nEnrollment: 58\nPrimary endpoint met: 1.0\np-value: 0.007\nEffect size (Odds Ratio (OR)): 12.8\n95% CI: [1.5, 109.6]\nInterpretation: definitive_negative", "metadata": {"result_id": 48621, "source_trial_id": "NCT00986856", "intervention_name": "Fucidin® cream", "condition_name": "Impetigo", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0775", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: cellular immunotherapy\nCondition: Burkitts Lymphoma\nPhase: phase_2\nEnrollment: 6\nTermination reason: \"Lack of accrual and low efficacy\"\nDetail: Lack of accrual and low efficacy", "metadata": {"result_id": 40101, "source_trial_id": "NCT01685606", "intervention_name": "cellular immunotherapy", "condition_name": "Burkitts Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0776", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter\nCondition: Fallopian Tube Serous Adenocarcinoma\nPhase: phase_2\nEnrollment: 17\nTermination reason: \"poor accrual\"\nDetail: poor accrual", "metadata": {"result_id": 21266, "source_trial_id": "NCT02364713", "intervention_name": "Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter", "condition_name": "Fallopian Tube Serous Adenocarcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0777", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Clindamycin\nCondition: Abscess\nBlinding: NONE\nEnrollment: 25\np-value: 1.0\nInterpretation: definitive_negative", "metadata": {"result_id": 41742, "source_trial_id": "NCT01619410", "intervention_name": "Clindamycin", "condition_name": "Abscess", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0778", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Omacor\nCondition: Hyper-Triglyceridemia\nPhase: phase_4\nEnrollment: 51\nTermination reason: \"The study was discontinued prematurely on December 18 2008 due to slow recruitment\"\nDetail: The study was discontinued prematurely on December 18 2008 due to slow recruitment", "metadata": {"result_id": 8290, "source_trial_id": "NCT00598910", "intervention_name": "Omacor", "condition_name": "Hyper-Triglyceridemia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0779", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Lorlatinib\nCondition: Recurrent Myeloproliferative Neoplasm\nPhase: phase_1\nEnrollment: 2\nTermination reason: \"Low accrual\"\nDetail: Low accrual", "metadata": {"result_id": 31800, "source_trial_id": "NCT03878524", "intervention_name": "Lorlatinib", "condition_name": "Recurrent Myeloproliferative Neoplasm", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0780", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: ReCell\nCondition: Carbon Dioxide Laser\nPhase: phase_4\nEnrollment: 1\nTermination reason: \"Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention. PI decided to terminate due to slow enrollment.\"\nDetail: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention. PI decided to terminate due to slow enrollment.", "metadata": {"result_id": 1733, "source_trial_id": "NCT05386368", "intervention_name": "ReCell", "condition_name": "Carbon Dioxide Laser", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0781", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Micronized progesterone suppository\nCondition: Obstetric Labor, Premature\nBlinding: QUADRUPLE\nEnrollment: 38\np-value: 0.13\nEffect size (Risk Ratio (RR)): 0.43\n95% CI: [0.14, 1.36]\nInterpretation: definitive_negative", "metadata": {"result_id": 32280, "source_trial_id": "NCT01840228", "intervention_name": "Micronized progesterone suppository", "condition_name": "Obstetric Labor, Premature", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0782", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Mesalamine\nCondition: Ulcerative Colitis\nPhase: phase_1\nEnrollment: 34\nTermination reason: \"Slow enrollment.\"\nDetail: Slow enrollment.", "metadata": {"result_id": 5635, "source_trial_id": "NCT00254618", "intervention_name": "Mesalamine", "condition_name": "Ulcerative Colitis", "confidence_tier": "bronze", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL1-0783", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Epacadostat\nCondition: Genitourinary (GU) Tumors\nPhase: phase_2\nEnrollment: 83\nTermination reason: \"Study was terminated by the sponsor for lack of evidence of superiority and slow study accrual.\"\nDetail: Study was terminated by the sponsor for lack of evidence of superiority and slow study accrual.", "metadata": {"result_id": 36542, "source_trial_id": "NCT01685255", "intervention_name": "Epacadostat", "condition_name": "Genitourinary (GU) Tumors", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0784", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Canagliflozin\nCondition: Gout\nPhase: phase_4\nBlinding: NONE\nEnrollment: 30\nPrimary endpoint met: 1.0\np-value: 0.01\nInterpretation: definitive_negative", "metadata": {"result_id": 18370, "source_trial_id": "NCT02462421", "intervention_name": "Canagliflozin", "condition_name": "Gout", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0785", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Mifepristone and misoprostol\nCondition: Miscarriage\nEnrollment: 16\nTermination reason: \"poor enrollment\"\nDetail: poor enrollment", "metadata": {"result_id": 4152, "source_trial_id": "NCT00468299", "intervention_name": "Mifepristone and misoprostol", "condition_name": "Miscarriage", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0786", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: W_ova1 Vaccine\nCondition: Ovarian Cancer\nPhase: phase_1\nEnrollment: 8\nTermination reason: \"Despite the extension of the original recruitment period, the target number of evaluable patients defined in the study protocol could not be reached and recruitment for the trial was stopped at that point of time.\"\nDetail: Despite the extension of the original recruitment period, the target number of evaluable patients defined in the study protocol could not be reached and recruitment for the trial was stopped at that point of time.", "metadata": {"result_id": 37213, "source_trial_id": "NCT04163094", "intervention_name": "W_ova1 Vaccine", "condition_name": "Ovarian Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0787", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Entrectinib\nCondition: Stage IV Prostate Cancer AJCC v8\nPhase: phase_1\nEnrollment: 2\nTermination reason: \"Low accrual\"\nDetail: Low accrual", "metadata": {"result_id": 30067, "source_trial_id": "NCT03878524", "intervention_name": "Entrectinib", "condition_name": "Stage IV Prostate Cancer AJCC v8", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0788", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: RSV 6120/ΔNS2/1030s Vaccine\nCondition: Respiratory Syncytial Virus (RSV)\nPhase: phase_1_2\nBlinding: QUADRUPLE\nEnrollment: 67\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Difference in proportions): 61.0\n95% CI: [27.0, 83.0]\nInterpretation: definitive_negative", "metadata": {"result_id": 50025, "source_trial_id": "NCT03916185", "intervention_name": "RSV 6120/ΔNS2/1030s Vaccine", "condition_name": "Respiratory Syncytial Virus (RSV)", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0789", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Lidocaine HCl\nCondition: Lumbar and Other Intervertebral Disc Disorders With Radiculopathy\nBlinding: QUADRUPLE\nEnrollment: 26\nPrimary endpoint met: 1.0\np-value: 0.022\nEffect size (Mean Difference (Net)): 5.67\n95% CI: [1.22, 10.12]\nInterpretation: definitive_negative", "metadata": {"result_id": 884, "source_trial_id": "NCT00588354", "intervention_name": "Lidocaine HCl", "condition_name": "Lumbar and Other Intervertebral Disc Disorders With Radiculopathy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0790", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: florbetapir F 18\nCondition: Alzheimer's Disease\nPhase: phase_2\nBlinding: NONE\nEnrollment: 44\np-value: 0.2837\nInterpretation: definitive_negative", "metadata": {"result_id": 4390, "source_trial_id": "NCT02051764", "intervention_name": "florbetapir F 18", "condition_name": "Alzheimer's Disease", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0791", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Processed Amniotic Fluid\nCondition: Wounds and Injuries\nPhase: phase_1_2\nEnrollment: 1\nTermination reason: \"Enrollment was halted prematurely after enrolling one participant due to difficulty finding eligible participants.\"\nDetail: Enrollment was halted prematurely after enrolling one participant due to difficulty finding eligible participants.", "metadata": {"result_id": 14688, "source_trial_id": "NCT04438174", "intervention_name": "Processed Amniotic Fluid", "condition_name": "Wounds and Injuries", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0792", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination\nCondition: Sarcoma\nPhase: phase_1_2\nEnrollment: 5\nTermination reason: \"Lack of accrual\"\nDetail: Lack of accrual", "metadata": {"result_id": 14753, "source_trial_id": "NCT01418001", "intervention_name": "Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination", "condition_name": "Sarcoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0793", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Haloperidol 2Mg encapsulated Tab\nCondition: Behavioural Emergency\nPhase: phase_4\nEnrollment: 12\nTermination reason: \"The study was terminated prematurely due to difficulties in patient recruitment and associated potential for selection bias.\"\nDetail: The study was terminated prematurely due to difficulties in patient recruitment and associated potential for selection bias.", "metadata": {"result_id": 16977, "source_trial_id": "NCT03246620", "intervention_name": "Haloperidol 2Mg encapsulated Tab", "condition_name": "Behavioural Emergency", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0794", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: oral docetaxel (ModraDoc/r)\nCondition: Prostatic Neoplasms\nPhase: phase_1\nEnrollment: 24\nTermination reason: \"low inclusion of patients and availability of the IP\"\nDetail: low inclusion of patients and availability of the IP", "metadata": {"result_id": 17460, "source_trial_id": "NCT03066154", "intervention_name": "oral docetaxel (ModraDoc/r)", "condition_name": "Prostatic Neoplasms", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0795", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Radioactive iodine\nCondition: Thyroid\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 13\np-value: 0.404\nEffect size (Mean Difference (Net)): 0.52\n95% CI: [-1.26, 2.29]\nInterpretation: definitive_negative", "metadata": {"result_id": 20841, "source_trial_id": "NCT03109847", "intervention_name": "Radioactive iodine", "condition_name": "Thyroid", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0796", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Tocilizumab\nDrug type: monoclonal_antibody\nCondition: Behcet Syndrome\nPhase: phase_2\nEnrollment: 1\nTermination reason: \"low enrollment\"\nDetail: low enrollment", "metadata": {"result_id": 40005, "source_trial_id": "NCT01693653", "intervention_name": "Tocilizumab", "condition_name": "Behcet Syndrome", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0797", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Pancrelipase\nDrug type: unknown\nCondition: Pancreatic Insufficiency\nPhase: phase_1_2\nEnrollment: 16\nTermination reason: \"Study was terminated due to difficulty in recruiting subjects.\"\nDetail: Study was terminated due to difficulty in recruiting subjects.", "metadata": {"result_id": 19318, "source_trial_id": "NCT02985801", "intervention_name": "Pancrelipase", "condition_name": "Pancreatic Insufficiency", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0798", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Gonadotrophins\nDrug type: unknown\nCondition: Infertility\nPhase: phase_4\nBlinding: NONE\nEnrollment: 15\nPrimary endpoint met: 1.0\np-value: 0.05\nEffect size (Median Difference (Final Values)): 71.1\nInterpretation: definitive_negative", "metadata": {"result_id": 18689, "source_trial_id": "NCT02821819", "intervention_name": "Gonadotrophins", "condition_name": "Infertility", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0799", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: CTX130\nCondition: T Cell Lymphoma\nPhase: phase_1\nEnrollment: 49\nTermination reason: \"Patients to be followed up in the CRSP-ONC-LTF study\"\nDetail: Patients to be followed up in the CRSP-ONC-LTF study", "metadata": {"result_id": 41986, "source_trial_id": "NCT04502446", "intervention_name": "CTX130", "condition_name": "T Cell Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0800", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Velcade\nCondition: Multiple Myeloma\nPhase: phase_2\nBlinding: NONE\nEnrollment: 8\np-value: 0.066\nInterpretation: definitive_negative", "metadata": {"result_id": 32144, "source_trial_id": "NCT01720043", "intervention_name": "Velcade", "condition_name": "Multiple Myeloma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0801", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: ARC1779 Injection\nCondition: Cerebral Thromboembolism\nPhase: phase_2\nEnrollment: 100\nTermination reason: \"Enrollment slower than expected\"\nDetail: Enrollment slower than expected", "metadata": {"result_id": 5382, "source_trial_id": "NCT00742612", "intervention_name": "ARC1779 Injection", "condition_name": "Cerebral Thromboembolism", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0802", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Brimonidine 0.15%\nCondition: Meibomian Gland Dysfunction\nPhase: phase_1_2\nBlinding: QUADRUPLE\nEnrollment: 15\np-value: 1.0\nInterpretation: definitive_negative", "metadata": {"result_id": 11327, "source_trial_id": "NCT02975557", "intervention_name": "Brimonidine 0.15%", "condition_name": "Meibomian Gland Dysfunction", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0803", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: CMTX-101\nDrug type: monoclonal_antibody\nCondition: Bacterial Pneumonia\nPhase: phase_1\nEnrollment: 28\nTermination reason: \"Study was stopped due to slow enrollment. No safety issues were identified. Part 1 (healthy volunteers) fully enrolled; Part 2 (CABP patients) enrolled the first 2 cohorts. Data currently under review. Results will be posted when final.\"\nDetail: Study was stopped due to slow enrollment. No safety issues were identified. Part 1 (healthy volunteers) fully enrolled; Part 2 (CABP patients) enrolled the first 2 cohorts. Data currently under review. Results will be posted when final.", "metadata": {"result_id": 10251, "source_trial_id": "NCT05629741", "intervention_name": "CMTX-101", "condition_name": "Bacterial Pneumonia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0804", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Baseline 18F-thymidine (FLT) PET/CT\nCondition: Starting Pemetrexed Based Therapy\nEnrollment: 3\nTermination reason: \"Poor Accrual\"\nDetail: Poor Accrual", "metadata": {"result_id": 14219, "source_trial_id": "NCT02274038", "intervention_name": "Baseline 18F-thymidine (FLT) PET/CT", "condition_name": "Starting Pemetrexed Based Therapy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0805", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: BXQ-350\nDrug type: unknown\nCondition: Neoplasms\nPhase: phase_1\nEnrollment: 5\nTermination reason: \"Bexion Pharmaceuticals no longer has open studies in which subjects would be eligible to rollover and continue treatment under the BXQ-350.AE protocol. Therefore, no additional subjects will be enrolled in this trial.\"\nDetail: Bexion Pharmaceuticals no longer has open studies in which subjects would be eligible to rollover and continue treatment under the BXQ-350.AE protocol. Therefore, no additional subjects will be enrolled in this trial.", "metadata": {"result_id": 41105, "source_trial_id": "NCT04404569", "intervention_name": "BXQ-350", "condition_name": "Neoplasms", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0806", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Capecitabine\nCondition: Gastric Cancer\nPhase: phase_2\nEnrollment: 5\nTermination reason: \"Poor accrual\"\nDetail: Poor accrual", "metadata": {"result_id": 42489, "source_trial_id": "NCT02485834", "intervention_name": "Capecitabine", "condition_name": "Gastric Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0807", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Pantoprazole\nCondition: Upper Gastrointestinal Bleed\nEnrollment: 3\nTermination reason: \"Difficulty recruiting and consenting participants\"\nDetail: Difficulty recruiting and consenting participants", "metadata": {"result_id": 4887, "source_trial_id": "NCT02235311", "intervention_name": "Pantoprazole", "condition_name": "Upper Gastrointestinal Bleed", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0808", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: dalteparin injection\nCondition: Venous Thromboembolism\nPhase: phase_3\nBlinding: NONE\nEnrollment: 218\nPrimary endpoint met: 1.0\np-value: 0.0252\nEffect size (Hazard Ratio (HR)): 7.019\n95% CI: [1.236, 131.632]\nSerious adverse events: 185.0\nInterpretation: definitive_negative", "metadata": {"result_id": 54068, "source_trial_id": "NCT00876915", "intervention_name": "dalteparin injection", "condition_name": "Venous Thromboembolism", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0809", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Doxorubicin\nCondition: Multiple Myleoma\nPhase: phase_2\nEnrollment: 442\nTermination reason: \"Premature closure due to inability to accrue to ARM IVD, cohorts 1 and 2\"\nDetail: Premature closure due to inability to accrue to ARM IVD, cohorts 1 and 2", "metadata": {"result_id": 9720, "source_trial_id": "NCT00074490", "intervention_name": "Doxorubicin", "condition_name": "Multiple Myleoma", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0810", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Ivosidenib\nCondition: Advanced Cholangiocarcinoma\nPhase: phase_1\nEnrollment: 8\nTermination reason: \"Low accrual\"\nDetail: Low accrual", "metadata": {"result_id": 32175, "source_trial_id": "NCT04088188", "intervention_name": "Ivosidenib", "condition_name": "Advanced Cholangiocarcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0811", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: arsenic trioxide\nCondition: Leukemia\nPhase: phase_2\nEnrollment: 2\nTermination reason: \"low accrual\"\nDetail: low accrual", "metadata": {"result_id": 11082, "source_trial_id": "NCT00006092", "intervention_name": "arsenic trioxide", "condition_name": "Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0812", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Brimonidine 0.075%\nCondition: Ocular Graft vs Host Disease\nPhase: phase_1_2\nBlinding: QUADRUPLE\nEnrollment: 15\np-value: 1.0\nInterpretation: definitive_negative", "metadata": {"result_id": 11325, "source_trial_id": "NCT02975557", "intervention_name": "Brimonidine 0.075%", "condition_name": "Ocular Graft vs Host Disease", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0813", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Acetaminophen/Ibuprofen\nCondition: Trigger Finger\nPhase: phase_4\nBlinding: DOUBLE\nEnrollment: 72\np-value: 0.06\nInterpretation: definitive_negative", "metadata": {"result_id": 54756, "source_trial_id": "NCT02029235", "intervention_name": "Acetaminophen/Ibuprofen", "condition_name": "Trigger Finger", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0814", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: IMRT + oral chemotherapy\nCondition: Radiotherapy\nEnrollment: 9\nTermination reason: \"the study was stopped for lack of inclusion\"\nDetail: the study was stopped for lack of inclusion", "metadata": {"result_id": 25090, "source_trial_id": "NCT03634202", "intervention_name": "IMRT + oral chemotherapy", "condition_name": "Radiotherapy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0815", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: EMLA\nCondition: Pain\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 168\np-value: 0.5\nInterpretation: definitive_negative", "metadata": {"result_id": 60471, "source_trial_id": "NCT00187135", "intervention_name": "EMLA", "condition_name": "Pain", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0816", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: 0.9% sodium chloride (normal saline)\nCondition: COVID-19\nPhase: phase_2\nBlinding: NONE\nEnrollment: 42\nPrimary endpoint met: 1.0\np-value: 0.0352\nInterpretation: definitive_negative", "metadata": {"result_id": 39337, "source_trial_id": "NCT04364763", "intervention_name": "0.9% sodium chloride (normal saline)", "condition_name": "COVID-19", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-0817", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Campath -1H\nDrug type: monoclonal_antibody\nCondition: Sickle Cell Anemia\nPhase: phase_2\nEnrollment: 15\nTermination reason: \"accrual was slow and sporadic so the study was closed\"\nDetail: accrual was slow and sporadic so the study was closed", "metadata": {"result_id": 34008, "source_trial_id": "NCT00040469", "intervention_name": "Campath -1H", "condition_name": "Sickle Cell Anemia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0818", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: FK506\nCondition: Hemoglobinopathy\nPhase: phase_2\nEnrollment: 15\nTermination reason: \"unable to accrue patients\"\nDetail: unable to accrue patients", "metadata": {"result_id": 2925, "source_trial_id": "NCT00040417", "intervention_name": "FK506", "condition_name": "Hemoglobinopathy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0819", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Inclacumab\nDrug type: monoclonal_antibody\nCondition: Vaso-occlusive Pain Episode in Sickle Cell Disease\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 72\np-value: 0.1143\nEffect size (Difference in percentage): -16.8\n95% CI: [-34.4, 0.8]\nInterpretation: definitive_negative", "metadata": {"result_id": 2946, "source_trial_id": "NCT04927247", "intervention_name": "Inclacumab", "condition_name": "Vaso-occlusive Pain Episode in Sickle Cell Disease", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0820", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Simvastatin 40mg\nCondition: Ache\nPhase: phase_4\nEnrollment: 3\nTermination reason: \"No grant obtained. Enrolled participants were not assigned to the intervention and was study terminated\"\nDetail: No grant obtained. Enrolled participants were not assigned to the intervention and was study terminated", "metadata": {"result_id": 11150, "source_trial_id": "NCT04507373", "intervention_name": "Simvastatin 40mg", "condition_name": "Ache", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0821", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: mRNA COVD19 vaccine\nCondition: Inflammatory Myositis\nPhase: early_phase_1\nEnrollment: 58\nTermination reason: \"Difficulty with enrollment\"\nDetail: Difficulty with enrollment", "metadata": {"result_id": 17936, "source_trial_id": "NCT04839315", "intervention_name": "mRNA COVD19 vaccine", "condition_name": "Inflammatory Myositis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0822", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Necitumumab\nDrug type: monoclonal_antibody\nCondition: Non-small Cell Lung Carcinoma\nPhase: phase_1\nEnrollment: 22\nTermination reason: \"Low accrual\"\nDetail: Low accrual", "metadata": {"result_id": 21074, "source_trial_id": "NCT03054038", "intervention_name": "Necitumumab", "condition_name": "Non-small Cell Lung Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0823", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Durvalumab in combination with carboplatin and etoposide\nCondition: Small Cell Lung Carcinoma\nPhase: phase_1\nEnrollment: 1\nTermination reason: \"low accrual\"\nDetail: low accrual", "metadata": {"result_id": 9268, "source_trial_id": "NCT03963414", "intervention_name": "Durvalumab in combination with carboplatin and etoposide", "condition_name": "Small Cell Lung Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0824", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: benzathine penicillin G\nCondition: Early Syphilis\nPhase: phase_4\nBlinding: NONE\nEnrollment: 109\nPrimary endpoint met: 1.0\np-value: 0.05\nEffect size (Risk Difference (RD)): -0.148\n95% CI: [-0.32, 0.025]\nInterpretation: definitive_negative", "metadata": {"result_id": 60713, "source_trial_id": "NCT05980871", "intervention_name": "benzathine penicillin G", "condition_name": "Early Syphilis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0825", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Brachyury-TRICOM\nCondition: HER2+ Breast Cancer\nPhase: phase_1\nEnrollment: 1\nTermination reason: \"One participant was accrued, and the study was stopped due to new safety data from the company for M7824 and slow accrual.\"\nDetail: One participant was accrued, and the study was stopped due to new safety data from the company for M7824 and slow accrual.", "metadata": {"result_id": 29081, "source_trial_id": "NCT04296942", "intervention_name": "Brachyury-TRICOM", "condition_name": "HER2+ Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0826", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Treprostinil\nCondition: Congenital Heart Disease\nPhase: phase_2\nEnrollment: 15\nTermination reason: \"Study was stopped early due to inability to recruit additional participants\"\nDetail: Study was stopped early due to inability to recruit additional participants", "metadata": {"result_id": 15106, "source_trial_id": "NCT02769624", "intervention_name": "Treprostinil", "condition_name": "Congenital Heart Disease", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0827", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: New Formulation Phenylephrine HCl\nCondition: Common Cold\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 193\np-value: 0.085\nEffect size (Mean Difference (Final Values)): 0.4\n95% CI: [-0.06, 0.86]\nInterpretation: definitive_negative", "metadata": {"result_id": 12823, "source_trial_id": "NCT03339726", "intervention_name": "New Formulation Phenylephrine HCl", "condition_name": "Common Cold", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0828", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Leflunomide 20 mg\nCondition: MEN1 Gene Mutation\nEnrollment: 3\nTermination reason: \"The study was prematurely terminated due to significant difficulties in recruiting participants, arising from the extremely rare nature of the targeted gene mutation.\"\nDetail: The study was prematurely terminated due to significant difficulties in recruiting participants, arising from the extremely rare nature of the targeted gene mutation.", "metadata": {"result_id": 34291, "source_trial_id": "NCT05605587", "intervention_name": "Leflunomide 20 mg", "condition_name": "MEN1 Gene Mutation", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0829", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Rituximab and Hyaluronidase Human\nCondition: Refractory Marginal Zone Lymphoma\nPhase: phase_2\nEnrollment: 3\nTermination reason: \"Trial closed due to low accrual rate\"\nDetail: Trial closed due to low accrual rate", "metadata": {"result_id": 5448, "source_trial_id": "NCT04659044", "intervention_name": "Rituximab and Hyaluronidase Human", "condition_name": "Refractory Marginal Zone Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0830", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Famotidine\nCondition: Laryngomalacia\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 65\nPrimary endpoint met: 1.0\np-value: 0.01\nInterpretation: definitive_negative", "metadata": {"result_id": 8833, "source_trial_id": "NCT04614974", "intervention_name": "Famotidine", "condition_name": "Laryngomalacia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0831", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: CDX1127\nDrug type: monoclonal_antibody\nCondition: Prostatic Neoplasms\nPhase: phase_1\nEnrollment: 2\nTermination reason: \"Low accruals\"\nDetail: Low accruals", "metadata": {"result_id": 13864, "source_trial_id": "NCT02284971", "intervention_name": "CDX1127", "condition_name": "Prostatic Neoplasms", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0832", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: ceritinib\nCondition: Pancreatic Adenocarcinoma\nPhase: phase_2\nEnrollment: 4\nTermination reason: \"Lack of Enrollment\"\nDetail: Lack of Enrollment", "metadata": {"result_id": 48681, "source_trial_id": "NCT02638909", "intervention_name": "ceritinib", "condition_name": "Pancreatic Adenocarcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0833", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Bendamustine\nCondition: Non Hodgkin Lymphoma\nPhase: phase_2\nEnrollment: 6\nTermination reason: \"Low accruals\"\nDetail: Low accruals", "metadata": {"result_id": 20843, "source_trial_id": "NCT04217317", "intervention_name": "Bendamustine", "condition_name": "Non Hodgkin Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0834", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Precedex\nCondition: Heart Diseases\nPhase: phase_4\nEnrollment: 3\nTermination reason: \"Unable to find participants who met inclusion/exclusion criteria\"\nDetail: Unable to find participants who met inclusion/exclusion criteria", "metadata": {"result_id": 23203, "source_trial_id": "NCT02734940", "intervention_name": "Precedex", "condition_name": "Heart Diseases", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0835", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: EXPAREL\nCondition: Bowel Obstruction\nPhase: phase_4\nBlinding: NONE\nEnrollment: 122\nPrimary endpoint met: 1.0\np-value: 0.0001\nSerious adverse events: 47.0\nInterpretation: definitive_negative", "metadata": {"result_id": 23839, "source_trial_id": "NCT02058290", "intervention_name": "EXPAREL", "condition_name": "Bowel Obstruction", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0836", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Gardasil\nDrug type: other_biologic\nCondition: Papillomavirus Vaccines\nPhase: phase_1\nBlinding: NONE\nEnrollment: 26\nPrimary endpoint met: 1.0\np-value: 0.0001\nInterpretation: definitive_negative", "metadata": {"result_id": 37097, "source_trial_id": "NCT00798265", "intervention_name": "Gardasil", "condition_name": "Papillomavirus Vaccines", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0837", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Misoprostol 400mcg buccal\nCondition: Blood Loss, Surgical\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 7\np-value: 0.695\nInterpretation: definitive_negative", "metadata": {"result_id": 34039, "source_trial_id": "NCT06078501", "intervention_name": "Misoprostol 400mcg buccal", "condition_name": "Blood Loss, Surgical", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0838", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Zileuton (Zyflo®) Dasatinib (Sprycel®)\nCondition: Chronic Myelogenous Leukemia\nPhase: phase_1\nEnrollment: 2\nTermination reason: \"Low accrual\"\nDetail: Low accrual", "metadata": {"result_id": 18731, "source_trial_id": "NCT02047149", "intervention_name": "Zileuton (Zyflo®) Dasatinib (Sprycel®)", "condition_name": "Chronic Myelogenous Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0839", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: MAb-3F8\nDrug type: unknown\nCondition: Primary Refractory Neuroblastoma\nPhase: phase_2\nEnrollment: 1\nTermination reason: \"Lack of enrollment.\"\nDetail: Lack of enrollment.", "metadata": {"result_id": 20927, "source_trial_id": "NCT00969722", "intervention_name": "MAb-3F8", "condition_name": "Primary Refractory Neuroblastoma", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0840", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Sirolimus\nCondition: Severe Aplastic Anemia\nPhase: phase_2\nEnrollment: 14\nTermination reason: \"Low accrual\"\nDetail: Low accrual", "metadata": {"result_id": 15382, "source_trial_id": "NCT00358657", "intervention_name": "Sirolimus", "condition_name": "Severe Aplastic Anemia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0841", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: ISA101b\nDrug type: peptide\nCondition: Oropharyngeal Cancer\nPhase: phase_2\nEnrollment: 3\nTermination reason: \"Closed the trial for infeasibility due to slow accrual\"\nDetail: Closed the trial for infeasibility due to slow accrual", "metadata": {"result_id": 14201, "source_trial_id": "NCT03258008", "intervention_name": "ISA101b", "condition_name": "Oropharyngeal Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0842", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: isotretinoin\nCondition: Adult Giant Cell Glioblastoma\nPhase: phase_1\nEnrollment: 5\nTermination reason: \"Slow accrual\"\nDetail: Slow accrual", "metadata": {"result_id": 12426, "source_trial_id": "NCT01103375", "intervention_name": "isotretinoin", "condition_name": "Adult Giant Cell Glioblastoma", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0843", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: PRO-067\nCondition: Primary Open Angle Glaucoma\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 116\nPrimary endpoint met: 1.0\nInterpretation: definitive_negative", "metadata": {"result_id": 58343, "source_trial_id": "NCT02801617", "intervention_name": "PRO-067", "condition_name": "Primary Open Angle Glaucoma", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0844", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Pasireotide LAR\nDrug type: peptide\nCondition: Pancreatic Neoplasm\nPhase: phase_2\nEnrollment: 118\nTermination reason: \"Slow recruitment rate into this study with rare tumors of neuroendocrine origin (enrollment issues)\"\nDetail: Slow recruitment rate into this study with rare tumors of neuroendocrine origin (enrollment issues)", "metadata": {"result_id": 5540, "source_trial_id": "NCT00958841", "intervention_name": "Pasireotide LAR", "condition_name": "Pancreatic Neoplasm", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0845", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: foradil\nCondition: Chronic Obstructive Pulmonary Disease\nPhase: phase_4\nEnrollment: 48\nTermination reason: \"Delays in the opening and activation of participating sites, and a low recruitment rate, with only 48 participants enrolled over the course of one year\"\nDetail: Delays in the opening and activation of participating sites, and a low recruitment rate, with only 48 participants enrolled over the course of one year", "metadata": {"result_id": 37892, "source_trial_id": "NCT06282861", "intervention_name": "foradil", "condition_name": "Chronic Obstructive Pulmonary Disease", "confidence_tier": "bronze", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-0846", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: RAD001, everolimus\nCondition: Neurofibromatosis Type 2\nPhase: phase_2\nEnrollment: 4\nTermination reason: \"slow accrual\"\nDetail: slow accrual", "metadata": {"result_id": 9012, "source_trial_id": "NCT01345136", "intervention_name": "RAD001, everolimus", "condition_name": "Neurofibromatosis Type 2", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0847", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Peanut Immunotherapy\nCondition: Peanut Allergy\nPhase: phase_1_2\nEnrollment: 12\nTermination reason: \"early termination due to insufficient recruitment\"\nDetail: early termination due to insufficient recruitment", "metadata": {"result_id": 50570, "source_trial_id": "NCT04974970", "intervention_name": "Peanut Immunotherapy", "condition_name": "Peanut Allergy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0848", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Axicabtagene Ciloleucel\nDrug type: gene_therapy\nCondition: Recurrent High Grade B-Cell Lymphoma\nPhase: phase_2\nEnrollment: 23\nTermination reason: \"slow accrual\"\nDetail: slow accrual", "metadata": {"result_id": 3551, "source_trial_id": "NCT04205838", "intervention_name": "Axicabtagene Ciloleucel", "condition_name": "Recurrent High Grade B-Cell Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0849", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Ephedrine\nCondition: Pre-Eclampsia\nPhase: phase_4\nBlinding: QUADRUPLE\nEnrollment: 13\np-value: 0.201\nInterpretation: definitive_negative", "metadata": {"result_id": 14370, "source_trial_id": "NCT02025426", "intervention_name": "Ephedrine", "condition_name": "Pre-Eclampsia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0850", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Bupivicaine (Injectable local anesthetic)\nCondition: Toothache\nPhase: phase_2\nEnrollment: 2\nTermination reason: \"Difficulty recruiting patients\"\nDetail: Difficulty recruiting patients", "metadata": {"result_id": 15873, "source_trial_id": "NCT02862691", "intervention_name": "Bupivicaine (Injectable local anesthetic)", "condition_name": "Toothache", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0851", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Anti-Epileptic Drug (AED)\nCondition: Epilepsy\nPhase: phase_4\nBlinding: NONE\nEnrollment: 134\nPrimary endpoint met: 1.0\np-value: 0.025\nSerious adverse events: 41.0\nInterpretation: definitive_negative", "metadata": {"result_id": 20368, "source_trial_id": "NCT01118455", "intervention_name": "Anti-Epileptic Drug (AED)", "condition_name": "Epilepsy", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0852", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Monovalent [B.1.351] CoV2 preS dTM-AS03\nCondition: Pemphigus Vulgaris\nPhase: phase_2\nEnrollment: 258\nTermination reason: \"The study was closed due to continued enrollment hurdles.\"\nDetail: The study was closed due to continued enrollment hurdles.", "metadata": {"result_id": 2862, "source_trial_id": "NCT05000216", "intervention_name": "Monovalent [B.1.351] CoV2 preS dTM-AS03", "condition_name": "Pemphigus Vulgaris", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0853", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Fosfomycin tromethamine\nCondition: Urinary Tract Infection\nPhase: phase_4\nBlinding: NONE\nEnrollment: 62\np-value: 0.264\nEffect size (Risk Difference (RD)): -18.0\n95% CI: [-43.4, 8.7]\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 62338, "source_trial_id": "NCT03697993", "intervention_name": "Fosfomycin tromethamine", "condition_name": "Urinary Tract Infection", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0854", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Paliperidone palmitate\nCondition: Schizophrenia\nPhase: phase_4\nEnrollment: 163\nTermination reason: \"The recruitment rate for the study was inadequate to achieve its enrollment goals.\"\nDetail: The recruitment rate for the study was inadequate to achieve its enrollment goals.", "metadata": {"result_id": 11388, "source_trial_id": "NCT00946985", "intervention_name": "Paliperidone palmitate", "condition_name": "Schizophrenia", "confidence_tier": "bronze", "therapeutic_area": "psychiatry"}, "split": "test"}
+{"question_id": "CTL1-0855", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension\nCondition: Open-Angle Glaucoma\nPhase: phase_4\nBlinding: DOUBLE\nEnrollment: 173\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Mean Difference (Final Values)): -2.15\n95% CI: [-2.8, -1.5]\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 41876, "source_trial_id": "NCT02730871", "intervention_name": "Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension", "condition_name": "Open-Angle Glaucoma", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0856", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Protocolized Diuretic Strategy\nCondition: Cardiac Failure\nPhase: phase_4\nBlinding: SINGLE\nEnrollment: 19\nPrimary endpoint met: 1.0\np-value: 0.05\nSerious adverse events: 14.0\nInterpretation: definitive_negative", "metadata": {"result_id": 45825, "source_trial_id": "NCT01921829", "intervention_name": "Protocolized Diuretic Strategy", "condition_name": "Cardiac Failure", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0857", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Experimental paracetamol + caffeine formulation\nCondition: Headache, Tension-Type\nPhase: phase_2_3\nBlinding: DOUBLE\nEnrollment: 66\np-value: 0.2008\nEffect size (Hazard Ratio (HR)): 1.32\n95% CI: [0.86, 2.01]\nInterpretation: definitive_negative", "metadata": {"result_id": 15453, "source_trial_id": "NCT01755702", "intervention_name": "Experimental paracetamol + caffeine formulation", "condition_name": "Headache, Tension-Type", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0858", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Feraheme\nDrug type: unknown\nCondition: Anemia\nPhase: phase_1_2\nEnrollment: 5\nTermination reason: \"Initial patients were seen at St Paul Hospital. Enrollment changes occurred with the move to Clements Hospital. We were unable to identify an infusion room at CUH despite an exhaustive search for alternatives and forced to terminate early.\"\nDetail: Initial patients were seen at St Paul Hospital. Enrollment changes occurred with the move to Clements Hospital. We were unable to identify an infusion room at CUH despite an exhaustive search for alternatives and forced to terminate early.", "metadata": {"result_id": 49096, "source_trial_id": "NCT02189889", "intervention_name": "Feraheme", "condition_name": "Anemia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0859", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: glatiramer acetate\nCondition: Relapsing Remitting Multiple Sclerosis\nPhase: phase_4\nBlinding: DOUBLE\nEnrollment: 414\np-value: 0.8023\nEffect size (Mean Difference (Final Values)): -0.03\n95% CI: [-0.26, 0.2]\nSerious adverse events: 82.0\nInterpretation: definitive_negative", "metadata": {"result_id": 389, "source_trial_id": "NCT00203047", "intervention_name": "glatiramer acetate", "condition_name": "Relapsing Remitting Multiple Sclerosis", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-0860", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Acetaminophen/hydrocodone\nCondition: De Quervain Disease\nPhase: phase_4\nBlinding: DOUBLE\nEnrollment: 72\np-value: 0.06\nInterpretation: definitive_negative", "metadata": {"result_id": 54753, "source_trial_id": "NCT02029235", "intervention_name": "Acetaminophen/hydrocodone", "condition_name": "De Quervain Disease", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0861", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension\nCondition: Ocular Hypertension\nPhase: phase_4\nBlinding: DOUBLE\nEnrollment: 173\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Mean Difference (Final Values)): -2.15\n95% CI: [-2.8, -1.5]\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 41873, "source_trial_id": "NCT02730871", "intervention_name": "Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension", "condition_name": "Ocular Hypertension", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0862", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: RAD001 (in addition to standard radiation and chemotherapy)\nCondition: Non-Small Cell Lung Cancer\nPhase: phase_1\nEnrollment: 3\nTermination reason: \"Poor accrual\"\nDetail: Poor accrual", "metadata": {"result_id": 17085, "source_trial_id": "NCT01063478", "intervention_name": "RAD001 (in addition to standard radiation and chemotherapy)", "condition_name": "Non-Small Cell Lung Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0863", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Treprostinil\nCondition: Pulmonary Arterial Hypertension\nPhase: phase_4\nBlinding: NONE\nEnrollment: 8\nPrimary endpoint met: 1.0\np-value: 0.01\nSerious adverse events: 7.0\nInterpretation: definitive_negative", "metadata": {"result_id": 12525, "source_trial_id": "NCT00439946", "intervention_name": "Treprostinil", "condition_name": "Pulmonary Arterial Hypertension", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-0864", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: ALVAC(2) Melanoma multi-antigen therapeutic vaccine\nCondition: Cancer\nPhase: phase_2\nBlinding: NONE\nEnrollment: 23\np-value: 0.9179\nSerious adverse events: 22.0\nInterpretation: definitive_negative", "metadata": {"result_id": 50736, "source_trial_id": "NCT00613509", "intervention_name": "ALVAC(2) Melanoma multi-antigen therapeutic vaccine", "condition_name": "Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0865", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Estradiol/norethindrone acetate\nCondition: Menopause\nPhase: phase_4\nEnrollment: 4\nTermination reason: \"Enrollment goals not being met\"\nDetail: Enrollment goals not being met", "metadata": {"result_id": 58388, "source_trial_id": "NCT02693002", "intervention_name": "Estradiol/norethindrone acetate", "condition_name": "Menopause", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0866", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Withhold IS (MMF or MPA)\nCondition: Rheumatoid Arthritis (RA)\nPhase: phase_2\nEnrollment: 258\nTermination reason: \"The study was closed due to continued enrollment hurdles.\"\nDetail: The study was closed due to continued enrollment hurdles.", "metadata": {"result_id": 2815, "source_trial_id": "NCT05000216", "intervention_name": "Withhold IS (MMF or MPA)", "condition_name": "Rheumatoid Arthritis (RA)", "confidence_tier": "bronze", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL1-0867", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: PEG-liposomal prednisolone sodium phosphate\nCondition: Neointima\nPhase: phase_2\nEnrollment: 30\nTermination reason: \"Slow inclusion\"\nDetail: Slow inclusion", "metadata": {"result_id": 54140, "source_trial_id": "NCT02495662", "intervention_name": "PEG-liposomal prednisolone sodium phosphate", "condition_name": "Neointima", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0868", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: CV301\nCondition: Pancreatic Adenocarcinoma\nPhase: phase_1_2\nEnrollment: 8\nTermination reason: \"Study closed due to lack of enrollment.\"\nDetail: Study closed due to lack of enrollment.", "metadata": {"result_id": 55024, "source_trial_id": "NCT03376659", "intervention_name": "CV301", "condition_name": "Pancreatic Adenocarcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0869", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Standard concentration unfractionated heparin\nCondition: Acute Renal Failure\nPhase: phase_4\nEnrollment: 12\nTermination reason: \"lack of recruitment\"\nDetail: lack of recruitment", "metadata": {"result_id": 29105, "source_trial_id": "NCT01318811", "intervention_name": "Standard concentration unfractionated heparin", "condition_name": "Acute Renal Failure", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0870", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Mometasone\nCondition: Seasonal Allergic Rhinitis\nPhase: phase_4\nBlinding: DOUBLE\nEnrollment: 17\nPrimary endpoint met: 1.0\np-value: 0.002\nInterpretation: definitive_negative", "metadata": {"result_id": 18638, "source_trial_id": "NCT00361439", "intervention_name": "Mometasone", "condition_name": "Seasonal Allergic Rhinitis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0871", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Inclacumab\nDrug type: monoclonal_antibody\nCondition: Vaso-occlusive Crisis\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 72\np-value: 0.1143\nEffect size (Difference in percentage): -16.8\n95% CI: [-34.4, 0.8]\nInterpretation: definitive_negative", "metadata": {"result_id": 2944, "source_trial_id": "NCT04927247", "intervention_name": "Inclacumab", "condition_name": "Vaso-occlusive Crisis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0872", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Dabrafenib\nCondition: Stage III Cutaneous Melanoma AJCC v7\nPhase: phase_1\nEnrollment: 15\nTermination reason: \"Inadequate accrual rate\"\nDetail: Inadequate accrual rate", "metadata": {"result_id": 45926, "source_trial_id": "NCT01940809", "intervention_name": "Dabrafenib", "condition_name": "Stage III Cutaneous Melanoma AJCC v7", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0873", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: standardized cannabis extract\nDrug type: unknown\nCondition: Muscle Spasticity\nPhase: phase_3\nEnrollment: 279\nTermination reason: \"due to recruitment problems / based on recommendation of Independent Review Board\"\nDetail: due to recruitment problems / based on recommendation of Independent Review Board", "metadata": {"result_id": 63107, "source_trial_id": "NCT00552604", "intervention_name": "standardized cannabis extract", "condition_name": "Muscle Spasticity", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0874", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Modified FOLFOX6\nCondition: Esophageal Cancer\nEnrollment: 13\nTermination reason: \"Issues with recruitment.\"\nDetail: Issues with recruitment.", "metadata": {"result_id": 34924, "source_trial_id": "NCT02358863", "intervention_name": "Modified FOLFOX6", "condition_name": "Esophageal Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0875", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Asmanex twisthaler\nCondition: Asthma\nPhase: phase_4\nEnrollment: 26\nTermination reason: \"Slow Enrollment\"\nDetail: Slow Enrollment", "metadata": {"result_id": 36911, "source_trial_id": "NCT00442351", "intervention_name": "Asmanex twisthaler", "condition_name": "Asthma", "confidence_tier": "bronze", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-0876", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: FOLFOX\nCondition: Gastric Carcinoma Stage IV\nPhase: phase_3\nEnrollment: 42\nTermination reason: \"Poor enrollment of patients\"\nDetail: Poor enrollment of patients", "metadata": {"result_id": 60783, "source_trial_id": "NCT01748851", "intervention_name": "FOLFOX", "condition_name": "Gastric Carcinoma Stage IV", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0877", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Acetaminophen\nCondition: Surgery\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 222\nPrimary endpoint met: 1.0\np-value: 0.03\nInterpretation: definitive_negative", "metadata": {"result_id": 57187, "source_trial_id": "NCT04879823", "intervention_name": "Acetaminophen", "condition_name": "Surgery", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0878", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Cyanocobalamin\nCondition: Cerebral Edema\nPhase: phase_2\nBlinding: NONE\nEnrollment: 12\np-value: 0.12\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 255, "source_trial_id": "NCT00243022", "intervention_name": "Cyanocobalamin", "condition_name": "Cerebral Edema", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0879", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Ipilimumab\nDrug type: monoclonal_antibody\nCondition: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative\nPhase: phase_1\nEnrollment: 2\nTermination reason: \"Low accrual\"\nDetail: Low accrual", "metadata": {"result_id": 30757, "source_trial_id": "NCT03878524", "intervention_name": "Ipilimumab", "condition_name": "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0880", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: KLH\nCondition: Prostate Cancer\nPhase: phase_1\nEnrollment: 14\nTermination reason: \"lack of accrual\"\nDetail: lack of accrual", "metadata": {"result_id": 43264, "source_trial_id": "NCT00023634", "intervention_name": "KLH", "condition_name": "Prostate Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0881", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Buccal Misoprostol\nCondition: Pregnancy\nPhase: phase_4\nBlinding: QUADRUPLE\nEnrollment: 73\nPrimary endpoint met: 1.0\np-value: 0.018\nInterpretation: definitive_negative", "metadata": {"result_id": 12068, "source_trial_id": "NCT01519765", "intervention_name": "Buccal Misoprostol", "condition_name": "Pregnancy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0882", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Desmopressin\nDrug type: peptide\nCondition: Nocturia\nPhase: phase_2_3\nEnrollment: 4\nTermination reason: \"Poor recruitment\"\nDetail: Poor recruitment", "metadata": {"result_id": 4583, "source_trial_id": "NCT02262936", "intervention_name": "Desmopressin", "condition_name": "Nocturia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0883", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Alendronate\nCondition: Osteoporosis\nPhase: phase_3\nEnrollment: 436\nTermination reason: \"low recruitment rate\"\nDetail: low recruitment rate", "metadata": {"result_id": 11261, "source_trial_id": "NCT01512446", "intervention_name": "Alendronate", "condition_name": "Osteoporosis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0884", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: PM00104\nCondition: Lymphoma\nPhase: phase_1\nEnrollment: 12\nTermination reason: \"Low recruitment\"\nDetail: Low recruitment", "metadata": {"result_id": 21794, "source_trial_id": "NCT00359294", "intervention_name": "PM00104", "condition_name": "Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0885", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Intravaginal prostaglandin E2\nCondition: Induction of Labor Affected Fetus / Newborn\nEnrollment: 88\nTermination reason: \"Poor recruitment\"\nDetail: Poor recruitment", "metadata": {"result_id": 49608, "source_trial_id": "NCT05622968", "intervention_name": "Intravaginal prostaglandin E2", "condition_name": "Induction of Labor Affected Fetus / Newborn", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0886", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Vorinostat and Tamoxifen\nCondition: Invasive Breast Cancer\nPhase: phase_2\nEnrollment: 2\nTermination reason: \"Difficulty meeting patient accrual goals\"\nDetail: Difficulty meeting patient accrual goals", "metadata": {"result_id": 15515, "source_trial_id": "NCT01194427", "intervention_name": "Vorinostat and Tamoxifen", "condition_name": "Invasive Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0887", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Tivozanib + capecitabine\nCondition: Solid Tumors\nEnrollment: 225\nTermination reason: \"Lack of new studies contributing subjects to this study\"\nDetail: Lack of new studies contributing subjects to this study", "metadata": {"result_id": 33434, "source_trial_id": "NCT01369433", "intervention_name": "Tivozanib + capecitabine", "condition_name": "Solid Tumors", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0888", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Control\nCondition: Anorexia Nervosa, Binge Eating/Purging Type\nPhase: phase_2_3\nEnrollment: 9\nTermination reason: \"Low enrollment numbers, pharmacy not able to acquire sufficient study article component (methylcellulose) due to manufacturer backorder\"\nDetail: Low enrollment numbers, pharmacy not able to acquire sufficient study article component (methylcellulose) due to manufacturer backorder", "metadata": {"result_id": 7929, "source_trial_id": "NCT05073679", "intervention_name": "Control", "condition_name": "Anorexia Nervosa, Binge Eating/Purging Type", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0889", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Levonorgestrel and Ethinyl Estradiol\nCondition: Contraception\nPhase: phase_4\nBlinding: NONE\nEnrollment: 17\nPrimary endpoint met: 1.0\np-value: 0.05\nInterpretation: definitive_negative", "metadata": {"result_id": 48588, "source_trial_id": "NCT02531321", "intervention_name": "Levonorgestrel and Ethinyl Estradiol", "condition_name": "Contraception", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0890", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: ALVAC(2) Melanoma multi-antigen therapeutic vaccine\nCondition: Melanoma\nPhase: phase_2\nBlinding: NONE\nEnrollment: 23\np-value: 0.9179\nSerious adverse events: 22.0\nInterpretation: definitive_negative", "metadata": {"result_id": 50734, "source_trial_id": "NCT00613509", "intervention_name": "ALVAC(2) Melanoma multi-antigen therapeutic vaccine", "condition_name": "Melanoma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0891", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Afatinib Dimaleate\nCondition: Stage III Bladder Cancer\nPhase: phase_2\nEnrollment: 32\nTermination reason: \"Unable to meet accrual goal after several years\"\nDetail: Unable to meet accrual goal after several years", "metadata": {"result_id": 62650, "source_trial_id": "NCT02122172", "intervention_name": "Afatinib Dimaleate", "condition_name": "Stage III Bladder Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0892", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Irinotecan Hydrochloride (HCI) Treatment\nCondition: Astrocytoma\nPhase: phase_2\nEnrollment: 10\nTermination reason: \"Principal Investigator left Moffitt and study had low accrual.\"\nDetail: Principal Investigator left Moffitt and study had low accrual.", "metadata": {"result_id": 44691, "source_trial_id": "NCT00360828", "intervention_name": "Irinotecan Hydrochloride (HCI) Treatment", "condition_name": "Astrocytoma", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0893", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: 20% Human albumin solution\nCondition: Systemic Inflammatory Response Syndrome\nPhase: phase_2\nEnrollment: 232\nTermination reason: \"Recruitment under target, Finding\"\nDetail: Recruitment under target, Finding", "metadata": {"result_id": 42674, "source_trial_id": "NCT00773110", "intervention_name": "20% Human albumin solution", "condition_name": "Systemic Inflammatory Response Syndrome", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0894", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Boswellia serrata extract\nCondition: Brain and Central Nervous System Tumors\nPhase: phase_2\nBlinding: NONE\nEnrollment: 12\np-value: 0.12\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 254, "source_trial_id": "NCT00243022", "intervention_name": "Boswellia serrata extract", "condition_name": "Brain and Central Nervous System Tumors", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0895", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Fluticasone/Salmeterol\nCondition: Asthma\nPhase: phase_4\nEnrollment: 15\nTermination reason: \"Difficulty of patients enrollments\"\nDetail: Difficulty of patients enrollments", "metadata": {"result_id": 22510, "source_trial_id": "NCT02491970", "intervention_name": "Fluticasone/Salmeterol", "condition_name": "Asthma", "confidence_tier": "bronze", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-0896", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Dequalinium Chloride\nCondition: Vaginal Infection\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 151\nPrimary endpoint met: 1.0\np-value: 0.025\nEffect size (Farrington-Manning test): -0.5\nInterpretation: definitive_negative", "metadata": {"result_id": 48818, "source_trial_id": "NCT05788991", "intervention_name": "Dequalinium Chloride", "condition_name": "Vaginal Infection", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0897", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: 90Y-AHN-12\nDrug type: monoclonal_antibody\nCondition: Acute Myelogenous Leukemia\nPhase: phase_1\nEnrollment: 8\nTermination reason: \"Slow accrual\"\nDetail: Slow accrual", "metadata": {"result_id": 58776, "source_trial_id": "NCT01207076", "intervention_name": "90Y-AHN-12", "condition_name": "Acute Myelogenous Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-0898", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Propanolol\nCondition: Post-Traumatic Stress Disorder\nPhase: phase_4\nEnrollment: 12\nTermination reason: \"inadequate recruitment\"\nDetail: inadequate recruitment", "metadata": {"result_id": 12820, "source_trial_id": "NCT00648375", "intervention_name": "Propanolol", "condition_name": "Post-Traumatic Stress Disorder", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0899", "task": "CT-L1", "gold_answer": "C", "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Ceftolozane / Tazobactam Injection\nCondition: Pseudomonas Aeruginosa Infection\nPhase: phase_4\nBlinding: NONE\nEnrollment: 17\np-value: 0.4\nInterpretation: definitive_negative", "metadata": {"result_id": 53281, "source_trial_id": "NCT04673175", "intervention_name": "Ceftolozane / Tazobactam Injection", "condition_name": "Pseudomonas Aeruginosa Infection", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-0900", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: CTX-009 (ABL001)\nDrug type: gene_therapy\nCondition: P1b: Advanced Solid Tumors\nPhase: phase_1_2\nEnrollment: 41\nTermination reason: \"Change of Development Plan\"\nDetail: Change of Development Plan", "metadata": {"result_id": 37122, "source_trial_id": "NCT04492033", "intervention_name": "CTX-009 (ABL001)", "condition_name": "P1b: Advanced Solid Tumors", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0901", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: pegylated liposomal doxorubicin hydrochloride\nCondition: Lymphoma\nPhase: phase_2\nEnrollment: 9\nTermination reason: \"Lack of sponsor support\"\nDetail: Lack of sponsor support", "metadata": {"result_id": 51544, "source_trial_id": "NCT00851552", "intervention_name": "pegylated liposomal doxorubicin hydrochloride", "condition_name": "Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0902", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Oraxol\nCondition: Solid Tumor, Adult\nPhase: phase_1\nEnrollment: 29\nTermination reason: \"STUDY HALTED DUE TO FINANCIAL CONTRAINTS\"\nDetail: STUDY HALTED DUE TO FINANCIAL CONTRAINTS", "metadata": {"result_id": 55563, "source_trial_id": "NCT03892018", "intervention_name": "Oraxol", "condition_name": "Solid Tumor, Adult", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0903", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: phenylephrine and clonidine\nCondition: Complex Regional Pain Syndrome (CRPS)\nBlinding: NONE\nEnrollment: 128\nPrimary endpoint met: 1.0\np-value: 0.009\nInterpretation: definitive_negative", "metadata": {"result_id": 3713, "source_trial_id": "NCT01813149", "intervention_name": "phenylephrine and clonidine", "condition_name": "Complex Regional Pain Syndrome (CRPS)", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0904", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Aminolevulinic Acid\nCondition: Actinic Keratoses\nPhase: phase_2\nEnrollment: 6\nTermination reason: \"Orphan Drug Designation for this indication not granted\"\nDetail: Orphan Drug Designation for this indication not granted", "metadata": {"result_id": 58455, "source_trial_id": "NCT00865878", "intervention_name": "Aminolevulinic Acid", "condition_name": "Actinic Keratoses", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0905", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Ciprofloxacin/Dexamethasone\nCondition: Otitis Externa\nPhase: phase_3\nEnrollment: 455\nTermination reason: \"FDA's draft guidance (March 2015) provided option of in-vitro or in-vivo studies for bioequivalence. Small study size resulted in negative culture rates.\"\nDetail: FDA's draft guidance (March 2015) provided option of in-vitro or in-vivo studies for bioequivalence. Small study size resulted in negative culture rates.", "metadata": {"result_id": 46727, "source_trial_id": "NCT01910155", "intervention_name": "Ciprofloxacin/Dexamethasone", "condition_name": "Otitis Externa", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0906", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: AZD1402\nDrug type: peptide\nCondition: Asthma\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 72\nPrimary endpoint met: 1.0\np-value: 0.035\nEffect size (Least Square Mean Difference): 0.196\n95% CI: [0.0143, 0.3778]\nInterpretation: definitive_negative", "metadata": {"result_id": 9589, "source_trial_id": "NCT04643158", "intervention_name": "AZD1402", "condition_name": "Asthma", "confidence_tier": "silver", "therapeutic_area": "respiratory"}, "split": "fewshot"}
+{"question_id": "CTL1-0907", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Drisapersen\nDrug type: oligonucleotide\nCondition: Muscular Dystrophies\nPhase: phase_2\nEnrollment: 12\nTermination reason: \"Regulatory approval was not obtained for drisapersen, hence BioMarin is stopping the development of all exon skipping oligonucleotides in DMD.\"\nDetail: Regulatory approval was not obtained for drisapersen, hence BioMarin is stopping the development of all exon skipping oligonucleotides in DMD.", "metadata": {"result_id": 1845, "source_trial_id": "NCT01910649", "intervention_name": "Drisapersen", "condition_name": "Muscular Dystrophies", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0908", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Riociguat Oral Tablet\nCondition: Primary Pulmonary Hypertension\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 35\nPrimary endpoint met: 1.0\np-value: 0.043\nInterpretation: definitive_negative", "metadata": {"result_id": 51273, "source_trial_id": "NCT05339087", "intervention_name": "Riociguat Oral Tablet", "condition_name": "Primary Pulmonary Hypertension", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "fewshot"}
+{"question_id": "CTL1-0909", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Epacadostat\nCondition: Lung Cancer\nPhase: phase_3\nEnrollment: 2\nTermination reason: \"Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.\"\nDetail: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.", "metadata": {"result_id": 51095, "source_trial_id": "NCT03348904", "intervention_name": "Epacadostat", "condition_name": "Lung Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0910", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: ABP-671\nDrug type: monoclonal_antibody\nCondition: Gout\nPhase: phase_2_3\nEnrollment: 43\nTermination reason: \"For business consideration, a new long-term safety study will be conducted in the next new pivotal studies.\"\nDetail: For business consideration, a new long-term safety study will be conducted in the next new pivotal studies.", "metadata": {"result_id": 33778, "source_trial_id": "NCT06276556", "intervention_name": "ABP-671", "condition_name": "Gout", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0911", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Rybelsus\nDrug type: peptide\nCondition: Obesity\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 902\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (LS Mean Difference): -0.95\n95% CI: [-1.2, -0.7]\nInterpretation: definitive_negative", "metadata": {"result_id": 3847, "source_trial_id": "NCT05579977", "intervention_name": "Rybelsus", "condition_name": "Obesity", "confidence_tier": "silver", "therapeutic_area": "metabolic"}, "split": "fewshot"}
+{"question_id": "CTL1-0912", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Elagolix\nCondition: Endometriosis\nPhase: phase_3\nEnrollment: 11\nTermination reason: \"The study was terminated early for business reasons, not for safety concerns.\"\nDetail: The study was terminated early for business reasons, not for safety concerns.", "metadata": {"result_id": 15628, "source_trial_id": "NCT03343067", "intervention_name": "Elagolix", "condition_name": "Endometriosis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0913", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Durvalumab - 1500 mg\nCondition: Advanced Cancer\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 83\nPrimary endpoint met: 1.0\np-value: 0.025\nSerious adverse events: 143.0\nInterpretation: definitive_negative", "metadata": {"result_id": 13091, "source_trial_id": "NCT02805660", "intervention_name": "Durvalumab - 1500 mg", "condition_name": "Advanced Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0914", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Treatment with WST09 Vascular Photodynamic therapy\nCondition: Prostate Cancer\nPhase: phase_2_3\nEnrollment: 16\nTermination reason: \"STEBA decided to develop WST11 that is soluble in aqueous solutions. The property of WST 11 make it safer and better candidate for therapeutic applications.\"\nDetail: STEBA decided to develop WST11 that is soluble in aqueous solutions. The property of WST 11 make it safer and better candidate for therapeutic applications.", "metadata": {"result_id": 33989, "source_trial_id": "NCT00312442", "intervention_name": "Treatment with WST09 Vascular Photodynamic therapy", "condition_name": "Prostate Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0915", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Patients treated by antibiotherapy\nCondition: Infection, Bacterial\nEnrollment: 12\nTermination reason: \"the study had to be stopped because the period of the Financial contract was over\"\nDetail: the study had to be stopped because the period of the Financial contract was over", "metadata": {"result_id": 16272, "source_trial_id": "NCT03633188", "intervention_name": "Patients treated by antibiotherapy", "condition_name": "Infection, Bacterial", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0916", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Tacrolimus (Tac)\nCondition: Kidney Transplantation\nPhase: phase_2\nEnrollment: 33\nTermination reason: \"After enrolment was complete, and sufficient data was collected to fully characterize the highest dose cohort, study follow up was terminated by the sponsor for non-safety related reasons.\"\nDetail: After enrolment was complete, and sufficient data was collected to fully characterize the highest dose cohort, study follow up was terminated by the sponsor for non-safety related reasons.", "metadata": {"result_id": 24407, "source_trial_id": "NCT06365437", "intervention_name": "Tacrolimus (Tac)", "condition_name": "Kidney Transplantation", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0917", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: USL311\nCondition: Relapsed/Recurrent GBM (Phase 2)\nPhase: phase_1_2\nEnrollment: 26\nTermination reason: \"Business reasons not related to safety\"\nDetail: Business reasons not related to safety", "metadata": {"result_id": 32376, "source_trial_id": "NCT02765165", "intervention_name": "USL311", "condition_name": "Relapsed/Recurrent GBM (Phase 2)", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0918", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Piperacillin/tazobactam\nCondition: Febrile Neutropenia\nPhase: phase_2\nEnrollment: 2\nTermination reason: \"No longer aligned with the revised clinical development plan and commercial strategy\"\nDetail: No longer aligned with the revised clinical development plan and commercial strategy", "metadata": {"result_id": 21893, "source_trial_id": "NCT02732327", "intervention_name": "Piperacillin/tazobactam", "condition_name": "Febrile Neutropenia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0919", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Tenofovir disoproxil fumarate (TDF)\nCondition: Healthy\nPhase: phase_1\nEnrollment: 60\nTermination reason: \"Strategic business decision, not due to safety concerns\"\nDetail: Strategic business decision, not due to safety concerns", "metadata": {"result_id": 41773, "source_trial_id": "NCT05423106", "intervention_name": "Tenofovir disoproxil fumarate (TDF)", "condition_name": "Healthy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0920", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Acetazolamide\nCondition: PMM2-CDG\nPhase: phase_2_3\nBlinding: QUADRUPLE\nEnrollment: 25\np-value: 0.09\nInterpretation: definitive_negative", "metadata": {"result_id": 53916, "source_trial_id": "NCT04679389", "intervention_name": "Acetazolamide", "condition_name": "PMM2-CDG", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0921", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: [225Ac]-FPI-1434 Injection single-dose\nCondition: Adrenocortical Carcinoma\nPhase: phase_1\nEnrollment: 78\nTermination reason: \"A strategic decision was made to discontinue the study and prioritize other programs within the portfolio. The study was not discontinued due to safety issues or adverse events related to FPI-1434, FPE-1547, or FPI-1175.\"\nDetail: A strategic decision was made to discontinue the study and prioritize other programs within the portfolio. The study was not discontinued due to safety issues or adverse events related to FPI-1434, FPE-1547, or FPI-1175.", "metadata": {"result_id": 63361, "source_trial_id": "NCT03746431", "intervention_name": "[225Ac]-FPI-1434 Injection single-dose", "condition_name": "Adrenocortical Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0922", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Otelixizumab - low dose\nCondition: Graves Ophthalmopathy\nPhase: phase_2\nEnrollment: 2\nTermination reason: \"Clinical study in Graves' ophthalmopathy terminated until there is a better understanding of an efficacious dose with Otelixizumab from other clinical studies.\"\nDetail: Clinical study in Graves' ophthalmopathy terminated until there is a better understanding of an efficacious dose with Otelixizumab from other clinical studies.", "metadata": {"result_id": 9313, "source_trial_id": "NCT01114503", "intervention_name": "Otelixizumab - low dose", "condition_name": "Graves Ophthalmopathy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0923", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: toripalimab (anti-PD-1)\nDrug type: monoclonal_antibody\nCondition: Hepatocellular Carcinoma\nPhase: phase_1\nEnrollment: 22\nTermination reason: \"The study was terminated for strategic reasons (not for safety concerns)\"\nDetail: The study was terminated for strategic reasons (not for safety concerns)", "metadata": {"result_id": 52575, "source_trial_id": "NCT05757492", "intervention_name": "toripalimab (anti-PD-1)", "condition_name": "Hepatocellular Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0924", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: PH94B Nasal Spray\nCondition: Social Anxiety Disorder\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 228\nPrimary endpoint met: 1.0\np-value: 0.0153\nEffect size (Mean Difference (Net)): -5.8\n95% CI: [-10.5, -1.1]\nInterpretation: definitive_negative", "metadata": {"result_id": 38801, "source_trial_id": "NCT05011396", "intervention_name": "PH94B Nasal Spray", "condition_name": "Social Anxiety Disorder", "confidence_tier": "silver", "therapeutic_area": "psychiatry"}, "split": "fewshot"}
+{"question_id": "CTL1-0925", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: 0.12% Chlorohexidine Gluconate\nCondition: Coronavirus Infection\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 128\np-value: 0.6\nInterpretation: definitive_negative", "metadata": {"result_id": 56798, "source_trial_id": "NCT04584684", "intervention_name": "0.12% Chlorohexidine Gluconate", "condition_name": "Coronavirus Infection", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0926", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Poziotinib Hydrochloride\nCondition: Glioblastome Multiforme\nPhase: phase_2\nEnrollment: 1\nTermination reason: \"Strategic business decision (unrelated to safety)\"\nDetail: Strategic business decision (unrelated to safety)", "metadata": {"result_id": 54469, "source_trial_id": "NCT04172597", "intervention_name": "Poziotinib Hydrochloride", "condition_name": "Glioblastome Multiforme", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0927", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Acetaminophen and Ibuprofen\nCondition: Thoracic Surgery, Video-Assisted\nPhase: phase_4\nEnrollment: 25\nTermination reason: \"The study was terminated early owing to challenges in completing the research registration process.\"\nDetail: The study was terminated early owing to challenges in completing the research registration process.", "metadata": {"result_id": 10282, "source_trial_id": "NCT05834569", "intervention_name": "Acetaminophen and Ibuprofen", "condition_name": "Thoracic Surgery, Video-Assisted", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0928", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Tyrosine kinase inhibitor\nCondition: Chronic Myeloid Leukemia, Chronic Phase\nPhase: phase_1_2\nEnrollment: 1\nTermination reason: \"Product complaint\"\nDetail: Product complaint", "metadata": {"result_id": 15342, "source_trial_id": "NCT04006847", "intervention_name": "Tyrosine kinase inhibitor", "condition_name": "Chronic Myeloid Leukemia, Chronic Phase", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0929", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Indocyanine green\nCondition: Thyroid Disease\nPhase: phase_1\nEnrollment: 20\nTermination reason: \"The NIH-funded project period has come to an end.\"\nDetail: The NIH-funded project period has come to an end.", "metadata": {"result_id": 27335, "source_trial_id": "NCT06939946", "intervention_name": "Indocyanine green", "condition_name": "Thyroid Disease", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0930", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: 1.5% w/v Hydrogen Peroxide\nCondition: Covid19\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 128\np-value: 0.6\nInterpretation: definitive_negative", "metadata": {"result_id": 56785, "source_trial_id": "NCT04584684", "intervention_name": "1.5% w/v Hydrogen Peroxide", "condition_name": "Covid19", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "fewshot"}
+{"question_id": "CTL1-0931", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: GI-6207\nCondition: Triple Negative Breast Cancer\nPhase: phase_1_2\nEnrollment: 9\nTermination reason: \"Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention\"\nDetail: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention", "metadata": {"result_id": 10306, "source_trial_id": "NCT03387085", "intervention_name": "GI-6207", "condition_name": "Triple Negative Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0932", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: BKM120\nCondition: Metastatic Breast Cancer\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 432\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Hazard Ratio (HR)): 0.67\nSerious adverse events: 928.0\nInterpretation: definitive_negative", "metadata": {"result_id": 22774, "source_trial_id": "NCT01633060", "intervention_name": "BKM120", "condition_name": "Metastatic Breast Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0933", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Pralsetinib\nCondition: Lung Neoplasm\nPhase: phase_3\nBlinding: NONE\nEnrollment: 223\nPrimary endpoint met: 1.0\np-value: 0.0002\nEffect size (Difference in Overall Response Rates): 23.86\n95% CI: [10.25, 37.47]\nInterpretation: definitive_negative", "metadata": {"result_id": 39004, "source_trial_id": "NCT04222972", "intervention_name": "Pralsetinib", "condition_name": "Lung Neoplasm", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0934", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Pravastatin\nCondition: Obstetric Labor Complications\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 102\np-value: 0.08\nInterpretation: definitive_negative", "metadata": {"result_id": 37119, "source_trial_id": "NCT03944512", "intervention_name": "Pravastatin", "condition_name": "Obstetric Labor Complications", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0935", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Pitolisant\nCondition: Hypoglycemia\nPhase: phase_1\nEnrollment: 5\nTermination reason: \"Based on scientific data collected during the trial and high screen fail rate.\"\nDetail: Based on scientific data collected during the trial and high screen fail rate.", "metadata": {"result_id": 21970, "source_trial_id": "NCT04026750", "intervention_name": "Pitolisant", "condition_name": "Hypoglycemia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0936", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: AZD4831\nCondition: Heart Failure\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 41\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Least Square Means Ratio): 0.25\n95% CI: [0.12, 0.52]\nSerious adverse events: 9.0\nInterpretation: definitive_negative", "metadata": {"result_id": 1269, "source_trial_id": "NCT03756285", "intervention_name": "AZD4831", "condition_name": "Heart Failure", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "fewshot"}
+{"question_id": "CTL1-0937", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Efpeglenatide\nDrug type: peptide\nCondition: Type 2 Diabetes Mellitus\nPhase: phase_3\nBlinding: NONE\nEnrollment: 908\np-value: 0.3427\nSerious adverse events: 144.0\nInterpretation: definitive_negative", "metadata": {"result_id": 8247, "source_trial_id": "NCT03684642", "intervention_name": "Efpeglenatide", "condition_name": "Type 2 Diabetes Mellitus", "confidence_tier": "silver", "therapeutic_area": "metabolic"}, "split": "fewshot"}
+{"question_id": "CTL1-0938", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: CRD-740\nCondition: Heart Failure With Reduced Ejection Fraction\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 60\nPrimary endpoint met: 1.0\np-value: 0.0032\nEffect size (LS Mean of Treatment Difference): 26.473\n95% CI: [7.847, 45.099]\nInterpretation: definitive_negative", "metadata": {"result_id": 43316, "source_trial_id": "NCT05409183", "intervention_name": "CRD-740", "condition_name": "Heart Failure With Reduced Ejection Fraction", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "fewshot"}
+{"question_id": "CTL1-0939", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Mocetinostat - Recommended Phase 2 Dose (70 mg)\nCondition: Advanced Cancer\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 83\nPrimary endpoint met: 1.0\np-value: 0.025\nSerious adverse events: 143.0\nInterpretation: definitive_negative", "metadata": {"result_id": 13090, "source_trial_id": "NCT02805660", "intervention_name": "Mocetinostat - Recommended Phase 2 Dose (70 mg)", "condition_name": "Advanced Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0940", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: GNKG168\nDrug type: unknown\nCondition: Relapsed Acute Myelogenous Leukemia\nPhase: phase_1\nBlinding: NONE\nEnrollment: 4\nPrimary endpoint met: 1.0\np-value: 0.05\nInterpretation: definitive_negative", "metadata": {"result_id": 46813, "source_trial_id": "NCT01743807", "intervention_name": "GNKG168", "condition_name": "Relapsed Acute Myelogenous Leukemia", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0941", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Tamoxifen\nCondition: Breast Cancer Metastatic\nPhase: phase_2\nBlinding: SINGLE\nEnrollment: 367\np-value: 0.6437\nEffect size (Hazard Ratio (HR)): 1.051\n95% CI: [0.789, 1.4]\nInterpretation: definitive_negative", "metadata": {"result_id": 9919, "source_trial_id": "NCT04059484", "intervention_name": "Tamoxifen", "condition_name": "Breast Cancer Metastatic", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0942", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: PF-07263689\nDrug type: unknown\nCondition: Colorectal Cancer\nPhase: phase_1\nEnrollment: 13\nTermination reason: \"The study was terminated by the Sponsor due to business decision and not due to any safety concerns with PF-07263689. There are no changes to the risk-benefit for participants who have received PF-07263689 in the study.\"\nDetail: The study was terminated by the Sponsor due to business decision and not due to any safety concerns with PF-07263689. There are no changes to the risk-benefit for participants who have received PF-07263689 in the study.", "metadata": {"result_id": 18965, "source_trial_id": "NCT05061537", "intervention_name": "PF-07263689", "condition_name": "Colorectal Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0943", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: CP-751,871\nDrug type: monoclonal_antibody\nCondition: Breast Neoplasms\nPhase: phase_2\nBlinding: NONE\nEnrollment: 219\np-value: 0.331\nEffect size (Hazard Ratio (HR)): 0.764\n95% CI: [0.572, 1.02]\nSerious adverse events: 265.0\nInterpretation: definitive_negative", "metadata": {"result_id": 38240, "source_trial_id": "NCT00372996", "intervention_name": "CP-751,871", "condition_name": "Breast Neoplasms", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0944", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: BIIB093\nDrug type: monoclonal_antibody\nCondition: Stroke, Acute\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 535\np-value: 0.1242\nEffect size (Mean Difference (Final Values)): 0.82\n95% CI: [-0.23, 1.87]\nInterpretation: definitive_negative", "metadata": {"result_id": 11752, "source_trial_id": "NCT02864953", "intervention_name": "BIIB093", "condition_name": "Stroke, Acute", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "fewshot"}
+{"question_id": "CTL1-0945", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Veliparib\nCondition: Ovarian Neoplasm\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 1140\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Hazard Ratio (HR)): 0.435\n95% CI: [0.277, 0.683]\nSerious adverse events: 1486.0\nInterpretation: definitive_negative", "metadata": {"result_id": 58846, "source_trial_id": "NCT02470585", "intervention_name": "Veliparib", "condition_name": "Ovarian Neoplasm", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0946", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: haNK for infusion\nCondition: Pancreatic Cancer\nPhase: phase_1_2\nEnrollment: 4\nTermination reason: \"Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention\"\nDetail: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention", "metadata": {"result_id": 20831, "source_trial_id": "NCT03387098", "intervention_name": "haNK for infusion", "condition_name": "Pancreatic Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0947", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: RG1507\nDrug type: monoclonal_antibody\nCondition: Breast Cancer\nPhase: phase_2\nEnrollment: 6\nTermination reason: \"Due to the discontinuation of compound development, this study has been terminated.\"\nDetail: Due to the discontinuation of compound development, this study has been terminated.", "metadata": {"result_id": 55146, "source_trial_id": "NCT00796107", "intervention_name": "RG1507", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0948", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: AMG 986 IV\nCondition: Heart Failure\nPhase: phase_1\nEnrollment: 182\nTermination reason: \"Terminated (Decision by the Sponsor. The study was not terminated due to a safety reason.)\"\nDetail: Terminated (Decision by the Sponsor. The study was not terminated due to a safety reason.)", "metadata": {"result_id": 49765, "source_trial_id": "NCT03276728", "intervention_name": "AMG 986 IV", "condition_name": "Heart Failure", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "fewshot"}
+{"question_id": "CTL1-0949", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: CDX-301\nDrug type: unknown\nCondition: Cancer of the Pancreas\nPhase: phase_2\nEnrollment: 16\nTermination reason: \"Celldex decision\"\nDetail: Celldex decision", "metadata": {"result_id": 36552, "source_trial_id": "NCT04536077", "intervention_name": "CDX-301", "condition_name": "Cancer of the Pancreas", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0950", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: DSP-0337\nDrug type: unknown\nCondition: Neoplasms\nPhase: phase_1\nEnrollment: 23\nTermination reason: \"Alternate development strategy\"\nDetail: Alternate development strategy", "metadata": {"result_id": 45003, "source_trial_id": "NCT03416816", "intervention_name": "DSP-0337", "condition_name": "Neoplasms", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0951", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: XmAb18968 - Dose level -1\nCondition: T Cell Acute Lymphoblastic Leukemia\nPhase: phase_1\nEnrollment: 22\nTermination reason: \"Drug expired May 31, 2024.\"\nDetail: Drug expired May 31, 2024.", "metadata": {"result_id": 52849, "source_trial_id": "NCT05038644", "intervention_name": "XmAb18968 - Dose level -1", "condition_name": "T Cell Acute Lymphoblastic Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0952", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG)\nCondition: Kidney Transplantation\nPhase: phase_4\nEnrollment: 20\nTermination reason: \"Research contract expired\"\nDetail: Research contract expired", "metadata": {"result_id": 44027, "source_trial_id": "NCT04773392", "intervention_name": "Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG)", "condition_name": "Kidney Transplantation", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0953", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Trichuris suis ova (TSO)\nCondition: Colitis, Ulcerative\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 16\np-value: 0.242\nInterpretation: definitive_negative", "metadata": {"result_id": 44222, "source_trial_id": "NCT01953354", "intervention_name": "Trichuris suis ova (TSO)", "condition_name": "Colitis, Ulcerative", "confidence_tier": "silver", "therapeutic_area": "autoimmune"}, "split": "fewshot"}
+{"question_id": "CTL1-0954", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: MDK-703\nCondition: Advanced or Metastatic Solid Tumors\nPhase: phase_1_2\nEnrollment: 26\nTermination reason: \"Corporate decision\"\nDetail: Corporate decision", "metadata": {"result_id": 5120, "source_trial_id": "NCT05716295", "intervention_name": "MDK-703", "condition_name": "Advanced or Metastatic Solid Tumors", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-0955", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: ITI-214 Dose E\nCondition: Schizophrenia\nPhase: phase_1\nEnrollment: 76\nTermination reason: \"Business Decision; No Safety or Efficacy Concerns\"\nDetail: Business Decision; No Safety or Efficacy Concerns", "metadata": {"result_id": 58857, "source_trial_id": "NCT01900522", "intervention_name": "ITI-214 Dose E", "condition_name": "Schizophrenia", "confidence_tier": "bronze", "therapeutic_area": "psychiatry"}, "split": "fewshot"}
+{"question_id": "CTL1-0956", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: CVL-871 1.0 mg\nCondition: Apathy in Dementia\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 41\nPrimary endpoint met: 1.0\np-value: 0.019\nEffect size (LS Mean of Difference): 2.9\n95% CI: [1.4, 4.4]\nInterpretation: definitive_negative", "metadata": {"result_id": 28862, "source_trial_id": "NCT04958031", "intervention_name": "CVL-871 1.0 mg", "condition_name": "Apathy in Dementia", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "fewshot"}
+{"question_id": "CTL1-0957", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: CRD-740\nCondition: Cardiovascular Diseases\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 60\nPrimary endpoint met: 1.0\np-value: 0.0032\nEffect size (LS Mean of Treatment Difference): 26.473\n95% CI: [7.847, 45.099]\nInterpretation: definitive_negative", "metadata": {"result_id": 43310, "source_trial_id": "NCT05409183", "intervention_name": "CRD-740", "condition_name": "Cardiovascular Diseases", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0958", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3\nCondition: Gram-negative Bacterial Infection\nPhase: phase_2\nEnrollment: 48\nTermination reason: \"Following regulatory consultation, the Sponsor has decided to terminate the study and analyze the current dataset. The decision to terminate was solely based on a business decision, not due to safety concerns.\"\nDetail: Following regulatory consultation, the Sponsor has decided to terminate the study and analyze the current dataset. The decision to terminate was solely based on a business decision, not due to safety concerns.", "metadata": {"result_id": 35856, "source_trial_id": "NCT04126031", "intervention_name": "Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3", "condition_name": "Gram-negative Bacterial Infection", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0959", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: BIIB093\nDrug type: monoclonal_antibody\nCondition: Brain Edema\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 535\np-value: 0.1242\nEffect size (Mean Difference (Final Values)): 0.82\n95% CI: [-0.23, 1.87]\nInterpretation: definitive_negative", "metadata": {"result_id": 11754, "source_trial_id": "NCT02864953", "intervention_name": "BIIB093", "condition_name": "Brain Edema", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-0960", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Oxycodone Immediate-Release\nCondition: Osteoarthritis\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 418\nPrimary endpoint met: 1.0\np-value: 0.007\nEffect size (Mean Difference (Final Values)): -0.8\n95% CI: [-1.47, -0.2]\nSerious adverse events: 64.0\nInterpretation: definitive_negative", "metadata": {"result_id": 8173, "source_trial_id": "NCT00312221", "intervention_name": "Oxycodone Immediate-Release", "condition_name": "Osteoarthritis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0961", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Pralsetinib\nCondition: Respiratory Tract Disease\nPhase: phase_3\nBlinding: NONE\nEnrollment: 223\nPrimary endpoint met: 1.0\np-value: 0.0002\nEffect size (Difference in Overall Response Rates): 23.86\n95% CI: [10.25, 37.47]\nInterpretation: definitive_negative", "metadata": {"result_id": 39020, "source_trial_id": "NCT04222972", "intervention_name": "Pralsetinib", "condition_name": "Respiratory Tract Disease", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0962", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: 0.12% Chlorohexidine Gluconate\nCondition: Covid19\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 128\np-value: 0.6\nInterpretation: definitive_negative", "metadata": {"result_id": 56786, "source_trial_id": "NCT04584684", "intervention_name": "0.12% Chlorohexidine Gluconate", "condition_name": "Covid19", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "val"}
+{"question_id": "CTL1-0963", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: intrathecal chemotherapy\nCondition: Acute Lymphoblastic Leukemia (ALL)\nPhase: phase_1_2\nEnrollment: 38\nTermination reason: \"Study was terminated by the sponsor based on insufficient tolerability and efficacy to proceed beyond Part 1b.\"\nDetail: Study was terminated by the sponsor based on insufficient tolerability and efficacy to proceed beyond Part 1b.", "metadata": {"result_id": 43416, "source_trial_id": "NCT04029688", "intervention_name": "intrathecal chemotherapy", "condition_name": "Acute Lymphoblastic Leukemia (ALL)", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0964", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: NM21-1480\nDrug type: unknown\nCondition: Ovarian Carcinoma\nPhase: phase_1_2\nEnrollment: 52\nTermination reason: \"A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.\"\nDetail: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.", "metadata": {"result_id": 42470, "source_trial_id": "NCT04442126", "intervention_name": "NM21-1480", "condition_name": "Ovarian Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0965", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: JNJ-26113100 (50 mg) once daily\nCondition: Atopic Dermatitis\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 84\np-value: 0.077\nInterpretation: definitive_negative", "metadata": {"result_id": 46045, "source_trial_id": "NCT00455429", "intervention_name": "JNJ-26113100 (50 mg) once daily", "condition_name": "Atopic Dermatitis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0966", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Dextromethorphan\nCondition: Rett Syndrome\nPhase: phase_2\nBlinding: NONE\nEnrollment: 38\nPrimary endpoint met: 1.0\np-value: 0.05\nEffect size (Mean Difference (Final Values)): 5.947\nInterpretation: definitive_negative", "metadata": {"result_id": 7676, "source_trial_id": "NCT00593957", "intervention_name": "Dextromethorphan", "condition_name": "Rett Syndrome", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0967", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: ilixadencel\nCondition: Gastric Adenocarcinoma\nPhase: phase_1\nEnrollment: 21\nTermination reason: \"Decision made not to move to Phase 2\"\nDetail: Decision made not to move to Phase 2", "metadata": {"result_id": 25710, "source_trial_id": "NCT03735290", "intervention_name": "ilixadencel", "condition_name": "Gastric Adenocarcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0968", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Azilsartan medoxomil\nCondition: Diabetes\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 105\nPrimary endpoint met: 1.0\np-value: 0.007\nSerious adverse events: 3.0\nInterpretation: definitive_negative", "metadata": {"result_id": 27861, "source_trial_id": "NCT01496430", "intervention_name": "Azilsartan medoxomil", "condition_name": "Diabetes", "confidence_tier": "silver", "therapeutic_area": "metabolic"}, "split": "val"}
+{"question_id": "CTL1-0969", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: floxuridine\nCondition: Liver Metastases\nPhase: phase_3\nEnrollment: 92\nTermination reason: \"Production halt of FUDR in China\"\nDetail: Production halt of FUDR in China", "metadata": {"result_id": 1799, "source_trial_id": "NCT03678428", "intervention_name": "floxuridine", "condition_name": "Liver Metastases", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0970", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Sitravatinib\nCondition: Breast Cancer Metastatic\nPhase: phase_2\nEnrollment: 3\nTermination reason: \"Terminated by sponsor due to lack of interest\"\nDetail: Terminated by sponsor due to lack of interest", "metadata": {"result_id": 46688, "source_trial_id": "NCT04123704", "intervention_name": "Sitravatinib", "condition_name": "Breast Cancer Metastatic", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0971", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Exemestane\nCondition: Estrogen Receptor Positive\nPhase: phase_1\nEnrollment: 15\nTermination reason: \"Manufacturer discontinued drug development.\"\nDetail: Manufacturer discontinued drug development.", "metadata": {"result_id": 6495, "source_trial_id": "NCT01149356", "intervention_name": "Exemestane", "condition_name": "Estrogen Receptor Positive", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0972", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Precedex (Dexmedetomidine)\nCondition: POCD\nPhase: phase_4\nEnrollment: 27\nTermination reason: \"Pilot study initiated to provide support data for main grant GCO 06-0217 funded. only baseline characteristic data collected. no results for this study.\"\nDetail: Pilot study initiated to provide support data for main grant GCO 06-0217 funded. only baseline characteristic data collected. no results for this study.", "metadata": {"result_id": 63451, "source_trial_id": "NCT00455143", "intervention_name": "Precedex (Dexmedetomidine)", "condition_name": "POCD", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0973", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Cyclophosphamide\nCondition: Aspartylglucosaminuria\nPhase: phase_2\nEnrollment: 18\nTermination reason: \"Replaced by another study\"\nDetail: Replaced by another study", "metadata": {"result_id": 39464, "source_trial_id": "NCT00668564", "intervention_name": "Cyclophosphamide", "condition_name": "Aspartylglucosaminuria", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0974", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes\nCondition: Platinum-Resistant Fallopian Tube Carcinoma\nPhase: phase_1\nEnrollment: 4\nTermination reason: \"Lack of funding\"\nDetail: Lack of funding", "metadata": {"result_id": 6112, "source_trial_id": "NCT03691376", "intervention_name": "Autologous NY-ESO-1-specific CD8-positive T Lymphocytes", "condition_name": "Platinum-Resistant Fallopian Tube Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0975", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Cholecalciferol\nCondition: Stage IV Colon Cancer\nPhase: phase_2\nEnrollment: 10\nTermination reason: \"Lack of funding\"\nDetail: Lack of funding", "metadata": {"result_id": 43133, "source_trial_id": "NCT01198548", "intervention_name": "Cholecalciferol", "condition_name": "Stage IV Colon Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0976", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Cocaine HCl 4% Topical Solution\nCondition: Diagnostic\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 159\nPrimary endpoint met: 1.0\np-value: 0.0005\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 27972, "source_trial_id": "NCT01746940", "intervention_name": "Cocaine HCl 4% Topical Solution", "condition_name": "Diagnostic", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0977", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Orvepitant\nCondition: Depressive Disorder, Major\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 328\nPrimary endpoint met: 1.0\np-value: 0.0004\nEffect size (Mean Difference (Net)): -0.37\n95% CI: [-0.58, -0.17]\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 10390, "source_trial_id": "NCT00880399", "intervention_name": "Orvepitant", "condition_name": "Depressive Disorder, Major", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0978", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: ingenol disoxate gel 0.018%\nCondition: Squamous Cell Carcinoma\nPhase: phase_3\nBlinding: NONE\nEnrollment: 563\nPrimary endpoint met: 1.0\np-value: 0.01\nEffect size (Hazard Ratio (HR)): 1.99\n95% CI: [1.17, 3.62]\nSerious adverse events: 5.0\nInterpretation: definitive_negative", "metadata": {"result_id": 46847, "source_trial_id": "NCT03115476", "intervention_name": "ingenol disoxate gel 0.018%", "condition_name": "Squamous Cell Carcinoma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0979", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: PF-07921585\nCondition: Non Small Cell Lung Cancer\nPhase: phase_1\nEnrollment: 4\nTermination reason: \"The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns\"\nDetail: The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns", "metadata": {"result_id": 7610, "source_trial_id": "NCT06580938", "intervention_name": "PF-07921585", "condition_name": "Non Small Cell Lung Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0980", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: [11C]DPA-713\nCondition: Schizophrenia\nPhase: phase_1\nEnrollment: 35\nTermination reason: \"Lack of funding\"\nDetail: Lack of funding", "metadata": {"result_id": 19166, "source_trial_id": "NCT03257592", "intervention_name": "[11C]DPA-713", "condition_name": "Schizophrenia", "confidence_tier": "bronze", "therapeutic_area": "psychiatry"}, "split": "val"}
+{"question_id": "CTL1-0981", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: JNJ-47910382\nCondition: Chronic Hepatitis C Infection\nPhase: phase_1\nEnrollment: 11\nTermination reason: \"Because of many competing trials using the same mechanism of action, but being further advanced in development\"\nDetail: Because of many competing trials using the same mechanism of action, but being further advanced in development", "metadata": {"result_id": 41746, "source_trial_id": "NCT01651767", "intervention_name": "JNJ-47910382", "condition_name": "Chronic Hepatitis C Infection", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "val"}
+{"question_id": "CTL1-0982", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Riociguat Oral Tablet\nCondition: Pulmonary Vascular Disorder\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 35\nPrimary endpoint met: 1.0\np-value: 0.043\nInterpretation: definitive_negative", "metadata": {"result_id": 51275, "source_trial_id": "NCT05339087", "intervention_name": "Riociguat Oral Tablet", "condition_name": "Pulmonary Vascular Disorder", "confidence_tier": "silver", "therapeutic_area": "respiratory"}, "split": "val"}
+{"question_id": "CTL1-0983", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Akt/ERK Inhibitor ONC201\nCondition: Refractory Mantle Cell Lymphoma\nPhase: phase_1_2\nEnrollment: 16\nTermination reason: \"Per PI Request\"\nDetail: Per PI Request", "metadata": {"result_id": 28578, "source_trial_id": "NCT02420795", "intervention_name": "Akt/ERK Inhibitor ONC201", "condition_name": "Refractory Mantle Cell Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0984", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Sabatolimab\nDrug type: monoclonal_antibody\nCondition: Leukemia, Myelomonocytic, Chronic\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 530\np-value: 0.0825\nEffect size (Hazard Ratio (HR)): 0.847\n95% CI: [0.671, 1.07]\nInterpretation: definitive_negative", "metadata": {"result_id": 7616, "source_trial_id": "NCT04266301", "intervention_name": "Sabatolimab", "condition_name": "Leukemia, Myelomonocytic, Chronic", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0985", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: GEN3009\nCondition: Primary Mediastinal Large B-Cell Lymphoma\nPhase: phase_1_2\nEnrollment: 46\nTermination reason: \"Due to strategic evaluation of GEN3009 within context of Genmab's portfolio, decision not based on any safety or regulatory concerns.\"\nDetail: Due to strategic evaluation of GEN3009 within context of Genmab's portfolio, decision not based on any safety or regulatory concerns.", "metadata": {"result_id": 21743, "source_trial_id": "NCT04358458", "intervention_name": "GEN3009", "condition_name": "Primary Mediastinal Large B-Cell Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0986", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: PVP-I 0.6%\nCondition: Adenoviral Conjunctivitis\nPhase: phase_3\nEnrollment: 219\nTermination reason: \"Sponsor decision, unrelated to safety\"\nDetail: Sponsor decision, unrelated to safety", "metadata": {"result_id": 34887, "source_trial_id": "NCT02998541", "intervention_name": "PVP-I 0.6%", "condition_name": "Adenoviral Conjunctivitis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0987", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Oxycodone Immediate-Release\nCondition: Back Pain Lower Back Chronic\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 660\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Mean Difference (Final Values)): -0.67\n95% CI: [-0.99, -0.35]\nSerious adverse events: 82.0\nInterpretation: definitive_negative", "metadata": {"result_id": 4557, "source_trial_id": "NCT00313014", "intervention_name": "Oxycodone Immediate-Release", "condition_name": "Back Pain Lower Back Chronic", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0988", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Etripamil Test Dose\nCondition: Paroxysmal Supraventricular Tachycardia\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 1097\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Hazard Ratio (HR)): 2.857\n95% CI: [1.868, 4.371]\nInterpretation: definitive_negative", "metadata": {"result_id": 63008, "source_trial_id": "NCT03464019", "intervention_name": "Etripamil Test Dose", "condition_name": "Paroxysmal Supraventricular Tachycardia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0989", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Norethindrone acetate\nCondition: Endometriosis\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 9\np-value: 0.06\nEffect size (Mean Difference (Final Values)): 28.9\n95% CI: [-1.9, 59.6]\nInterpretation: definitive_negative", "metadata": {"result_id": 3961, "source_trial_id": "NCT03970330", "intervention_name": "Norethindrone acetate", "condition_name": "Endometriosis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0990", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Belladonna and Opium Suppository\nCondition: Overactive Bladder\nPhase: phase_4\nEnrollment: 23\nTermination reason: \"Another study published with similar results\"\nDetail: Another study published with similar results", "metadata": {"result_id": 39394, "source_trial_id": "NCT02865395", "intervention_name": "Belladonna and Opium Suppository", "condition_name": "Overactive Bladder", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0991", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: ingenol disoxate gel 0.037%\nCondition: Squamous Cell Carcinoma\nPhase: phase_3\nBlinding: NONE\nEnrollment: 563\nPrimary endpoint met: 1.0\np-value: 0.01\nEffect size (Hazard Ratio (HR)): 1.99\n95% CI: [1.17, 3.62]\nSerious adverse events: 5.0\nInterpretation: definitive_negative", "metadata": {"result_id": 46848, "source_trial_id": "NCT03115476", "intervention_name": "ingenol disoxate gel 0.037%", "condition_name": "Squamous Cell Carcinoma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0992", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: PQ912\nCondition: Alzheimer Disease\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 112\np-value: 0.1398\nEffect size (Difference LS Mean): -0.02857\n95% CI: [-0.06746, 0.01032]\nInterpretation: definitive_negative", "metadata": {"result_id": 40748, "source_trial_id": "NCT03919162", "intervention_name": "PQ912", "condition_name": "Alzheimer Disease", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "val"}
+{"question_id": "CTL1-0993", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: AIN457\nDrug type: monoclonal_antibody\nCondition: Multiple Sclerosis\nPhase: phase_2\nEnrollment: 28\nTermination reason: \"Study terminated early based upon development of another anti-IL17 fully human monoclonal antibody with better potential for treating MS patients\"\nDetail: Study terminated early based upon development of another anti-IL17 fully human monoclonal antibody with better potential for treating MS patients", "metadata": {"result_id": 10428, "source_trial_id": "NCT01874340", "intervention_name": "AIN457", "condition_name": "Multiple Sclerosis", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "val"}
+{"question_id": "CTL1-0994", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Ruxolitinib\nCondition: Breast Cancer\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 149\np-value: 0.762\nEffect size (Hazard Ratio (HR)): 0.932\n95% CI: [0.694, 1.252]\nSerious adverse events: 204.0\nInterpretation: definitive_negative", "metadata": {"result_id": 18199, "source_trial_id": "NCT02120417", "intervention_name": "Ruxolitinib", "condition_name": "Breast Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0995", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: PF-07081532\nCondition: Diabetes Mellitus\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 902\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (LS Mean Difference): -0.95\n95% CI: [-1.2, -0.7]\nInterpretation: definitive_negative", "metadata": {"result_id": 3843, "source_trial_id": "NCT05579977", "intervention_name": "PF-07081532", "condition_name": "Diabetes Mellitus", "confidence_tier": "silver", "therapeutic_area": "metabolic"}, "split": "val"}
+{"question_id": "CTL1-0996", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Luveltamab tazevibulin\nDrug type: antibody_drug_conjugate\nCondition: Fallopian Tube Cancer\nPhase: phase_2_3\nEnrollment: 600\nTermination reason: \"Due to strategic business considerations, Sutro has deprioritized the development of luveltamab tazevibulin, leading to termination of the REFRaME program. This decision is not related to any safety or efficacy concerns associated with luvelta\"\nDetail: Due to strategic business considerations, Sutro has deprioritized the development of luveltamab tazevibulin, leading to termination of the REFRaME program. This decision is not related to any safety or efficacy concerns associated with luvelta", "metadata": {"result_id": 7688, "source_trial_id": "NCT05870748", "intervention_name": "Luveltamab tazevibulin", "condition_name": "Fallopian Tube Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0997", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: GI-4000\nCondition: Pancreatic Cancer\nPhase: phase_1_2\nEnrollment: 3\nTermination reason: \"Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention\"\nDetail: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention", "metadata": {"result_id": 34982, "source_trial_id": "NCT03136406", "intervention_name": "GI-4000", "condition_name": "Pancreatic Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-0998", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Canasa®\nCondition: Proctitis, Ulcerative\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 119\nPrimary endpoint met: 1.0\np-value: 0.0047\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 2782, "source_trial_id": "NCT01016262", "intervention_name": "Canasa®", "condition_name": "Proctitis, Ulcerative", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-0999", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: 1.5% w/v Hydrogen Peroxide\nCondition: SARS-CoV-2 Infection\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 128\np-value: 0.6\nInterpretation: definitive_negative", "metadata": {"result_id": 56791, "source_trial_id": "NCT04584684", "intervention_name": "1.5% w/v Hydrogen Peroxide", "condition_name": "SARS-CoV-2 Infection", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1000", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: WJ01075\nCondition: Advanced Solid Tumors\nPhase: phase_1\nEnrollment: 7\nTermination reason: \"Terminate the study and close the research center based on strategic changes in product development, unrelated to drug safety.\"\nDetail: Terminate the study and close the research center based on strategic changes in product development, unrelated to drug safety.", "metadata": {"result_id": 40482, "source_trial_id": "NCT05470933", "intervention_name": "WJ01075", "condition_name": "Advanced Solid Tumors", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1001", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Cixutumumab\nDrug type: monoclonal_antibody\nCondition: Stage IV Non-small Cell Lung Cancer\nPhase: phase_2\nBlinding: NONE\nEnrollment: 175\np-value: 0.15\nSerious adverse events: 524.0\nInterpretation: definitive_negative", "metadata": {"result_id": 10723, "source_trial_id": "NCT00955305", "intervention_name": "Cixutumumab", "condition_name": "Stage IV Non-small Cell Lung Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1002", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: 1.5% w/v Hydrogen Peroxide\nCondition: Coronavirus Infection\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 128\np-value: 0.6\nInterpretation: definitive_negative", "metadata": {"result_id": 56797, "source_trial_id": "NCT04584684", "intervention_name": "1.5% w/v Hydrogen Peroxide", "condition_name": "Coronavirus Infection", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1003", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Sacituzumab Govitecan\nDrug type: antibody_drug_conjugate\nCondition: Triple-negative Breast Cancer\nPhase: phase_1_2\nEnrollment: 25\nTermination reason: \"Due to a change in development priorities, no further clinical development of the lucitanib plus rucaparib or lucitanib plus sacituzumab govitecan combinations is planned at this time.\"\nDetail: Due to a change in development priorities, no further clinical development of the lucitanib plus rucaparib or lucitanib plus sacituzumab govitecan combinations is planned at this time.", "metadata": {"result_id": 5554, "source_trial_id": "NCT03992131", "intervention_name": "Sacituzumab Govitecan", "condition_name": "Triple-negative Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1004", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Enecadin\nCondition: Stroke\nPhase: phase_2\nEnrollment: 24\nTermination reason: \"Scientific data called into question the viability of the substance class\"\nDetail: Scientific data called into question the viability of the substance class", "metadata": {"result_id": 47288, "source_trial_id": "NCT00331721", "intervention_name": "Enecadin", "condition_name": "Stroke", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "val"}
+{"question_id": "CTL1-1005", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Physician's Choice of Salvage Therapy - carboplatin\nCondition: Brain Cancer\nPhase: phase_3\nEnrollment: 2\nTermination reason: \"Change in clinical development plan\"\nDetail: Change in clinical development plan", "metadata": {"result_id": 4573, "source_trial_id": "NCT03149575", "intervention_name": "Physician's Choice of Salvage Therapy - carboplatin", "condition_name": "Brain Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1006", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Descartes-25\nDrug type: unknown\nCondition: Multiple Myeloma\nPhase: phase_1\nEnrollment: 9\nTermination reason: \"Phase 1 enrollment completed. Further clinical development terminated.\"\nDetail: Phase 1 enrollment completed. Further clinical development terminated.", "metadata": {"result_id": 14171, "source_trial_id": "NCT05113342", "intervention_name": "Descartes-25", "condition_name": "Multiple Myeloma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1007", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Optimized Medical Treatment\nCondition: Acute Decompensated Heart Failure\nBlinding: NONE\nEnrollment: 126\np-value: 0.916\nSerious adverse events: 11.0\nInterpretation: definitive_negative", "metadata": {"result_id": 4547, "source_trial_id": "NCT01953874", "intervention_name": "Optimized Medical Treatment", "condition_name": "Acute Decompensated Heart Failure", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL1-1008", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Bardoxolone methyl\nCondition: Chronic Kidney Diseases\nPhase: phase_3\nEnrollment: 270\nTermination reason: \"Discontinuation of all bardoxolone chronic kidney disease programs\"\nDetail: Discontinuation of all bardoxolone chronic kidney disease programs", "metadata": {"result_id": 23631, "source_trial_id": "NCT03749447", "intervention_name": "Bardoxolone methyl", "condition_name": "Chronic Kidney Diseases", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1009", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Evacetrapib\nCondition: Hyperlipidemia\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 366\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Median Difference (Final Values)): -33.48\n95% CI: [-44.4, -23.3]\nSerious adverse events: 52.0\nInterpretation: definitive_negative", "metadata": {"result_id": 25931, "source_trial_id": "NCT02227784", "intervention_name": "Evacetrapib", "condition_name": "Hyperlipidemia", "confidence_tier": "silver", "therapeutic_area": "metabolic"}, "split": "val"}
+{"question_id": "CTL1-1010", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: GDC-0152\nDrug type: peptide\nCondition: Solid Cancers\nPhase: phase_1\nEnrollment: 40\nTermination reason: \"The study was terminated early by the Sponsor for reasons unrelated to patient safety or anti-tumor activity.\"\nDetail: The study was terminated early by the Sponsor for reasons unrelated to patient safety or anti-tumor activity.", "metadata": {"result_id": 48406, "source_trial_id": "NCT00977067", "intervention_name": "GDC-0152", "condition_name": "Solid Cancers", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1011", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: TMZ\nCondition: Breast Cancer\nPhase: phase_1_2\nEnrollment: 12\nTermination reason: \"The phase II portion was never started as we could no longer get the drug from the manufacturer.\"\nDetail: The phase II portion was never started as we could no longer get the drug from the manufacturer.", "metadata": {"result_id": 37033, "source_trial_id": "NCT03190967", "intervention_name": "TMZ", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1012", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Cebranopadol\nCondition: Pain\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 200\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (point-estimate): -7.48\n95% CI: [-12.05, -2.918]\nSerious adverse events: 67.0\nInterpretation: definitive_negative", "metadata": {"result_id": 49597, "source_trial_id": "NCT01964378", "intervention_name": "Cebranopadol", "condition_name": "Pain", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1013", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Capecitabine, Oxaliplatin, Docetaxel\nCondition: Gastric Adenocarcinoma\nPhase: phase_2\nEnrollment: 51\nTermination reason: \"The budget issues.\"\nDetail: The budget issues.", "metadata": {"result_id": 7452, "source_trial_id": "NCT01558011", "intervention_name": "Capecitabine, Oxaliplatin, Docetaxel", "condition_name": "Gastric Adenocarcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1014", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: NM21-1480\nDrug type: unknown\nCondition: Head and Neck Squamous Cell Carcinoma\nPhase: phase_1_2\nEnrollment: 52\nTermination reason: \"A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.\"\nDetail: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.", "metadata": {"result_id": 42472, "source_trial_id": "NCT04442126", "intervention_name": "NM21-1480", "condition_name": "Head and Neck Squamous Cell Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1015", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Therapeutic Liquid Paracetamol (TLP)\nCondition: Meningococcal Vaccine\nPhase: phase_2\nEnrollment: 326\nTermination reason: \"The Sponsor decided to discontinue the study based on Sponsor's careful review of available safety data in concert with the recommendation of an independent Data Monitoring Committee.\"\nDetail: The Sponsor decided to discontinue the study based on Sponsor's careful review of available safety data in concert with the recommendation of an independent Data Monitoring Committee.", "metadata": {"result_id": 44670, "source_trial_id": "NCT04645966", "intervention_name": "Therapeutic Liquid Paracetamol (TLP)", "condition_name": "Meningococcal Vaccine", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1016", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Cyclophosphamide + Fludarabine Lymphodepletive Conditioning\nCondition: Brain Stem Glioma\nPhase: phase_1\nEnrollment: 11\nTermination reason: \"Not feasible to accrue due to competing studies\"\nDetail: Not feasible to accrue due to competing studies", "metadata": {"result_id": 42998, "source_trial_id": "NCT03396575", "intervention_name": "Cyclophosphamide + Fludarabine Lymphodepletive Conditioning", "condition_name": "Brain Stem Glioma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1017", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Follitropin delta\nDrug type: peptide\nCondition: Fertility\nPhase: phase_1\nEnrollment: 310\nTermination reason: \"This is a company decision made not related to safety concerns. Rather, it reflects a broader portfolio assessment and the desire to focus on programs that can bring timely and meaningful benefit to patients.\"\nDetail: This is a company decision made not related to safety concerns. Rather, it reflects a broader portfolio assessment and the desire to focus on programs that can bring timely and meaningful benefit to patients.", "metadata": {"result_id": 56576, "source_trial_id": "NCT06466486", "intervention_name": "Follitropin delta", "condition_name": "Fertility", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1018", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: HAI with FOLFOX\nCondition: Metastatic Breast Cancer\nPhase: phase_2\nEnrollment: 2\nTermination reason: \"PI Decision\"\nDetail: PI Decision", "metadata": {"result_id": 39439, "source_trial_id": "NCT01937507", "intervention_name": "HAI with FOLFOX", "condition_name": "Metastatic Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1019", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: PF-06940434\nCondition: Urothelial Cancer\nPhase: phase_1\nEnrollment: 85\nTermination reason: \"Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority.\"\nDetail: Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority.", "metadata": {"result_id": 7420, "source_trial_id": "NCT04152018", "intervention_name": "PF-06940434", "condition_name": "Urothelial Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1020", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: REGN5069\nDrug type: monoclonal_antibody\nCondition: Pain\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 259\np-value: 0.0604\nSerious adverse events: 14.0\nInterpretation: definitive_negative", "metadata": {"result_id": 3732, "source_trial_id": "NCT03956550", "intervention_name": "REGN5069", "condition_name": "Pain", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1021", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: [225Ac]-FPI-1434 Injection single-dose\nCondition: Ovarian Cancer\nPhase: phase_1\nEnrollment: 78\nTermination reason: \"A strategic decision was made to discontinue the study and prioritize other programs within the portfolio. The study was not discontinued due to safety issues or adverse events related to FPI-1434, FPE-1547, or FPI-1175.\"\nDetail: A strategic decision was made to discontinue the study and prioritize other programs within the portfolio. The study was not discontinued due to safety issues or adverse events related to FPI-1434, FPE-1547, or FPI-1175.", "metadata": {"result_id": 63337, "source_trial_id": "NCT03746431", "intervention_name": "[225Ac]-FPI-1434 Injection single-dose", "condition_name": "Ovarian Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1022", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: haNK for infusion\nCondition: Squamous Cell Carcinoma\nPhase: phase_1_2\nEnrollment: 4\nTermination reason: \"Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention\"\nDetail: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention", "metadata": {"result_id": 10572, "source_trial_id": "NCT03387111", "intervention_name": "haNK for infusion", "condition_name": "Squamous Cell Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1023", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: GALIDA\nCondition: Diabetes Mellitus, Type 2\nPhase: phase_3\nEnrollment: 1450\nTermination reason: \"The development program has been terminated\"\nDetail: The development program has been terminated", "metadata": {"result_id": 43207, "source_trial_id": "NCT00214565", "intervention_name": "GALIDA", "condition_name": "Diabetes Mellitus, Type 2", "confidence_tier": "bronze", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-1024", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Fluorescein\nCondition: Colonic Dysplasia\nEnrollment: 72\nTermination reason: \"Study terminated due to equipment breakage and lack of funding.\"\nDetail: Study terminated due to equipment breakage and lack of funding.", "metadata": {"result_id": 33242, "source_trial_id": "NCT03220711", "intervention_name": "Fluorescein", "condition_name": "Colonic Dysplasia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1025", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: CG-806\nCondition: Small Lymphocytic Lymphoma\nPhase: phase_1\nEnrollment: 36\nTermination reason: \"Change in corporate strategy\"\nDetail: Change in corporate strategy", "metadata": {"result_id": 50494, "source_trial_id": "NCT03893682", "intervention_name": "CG-806", "condition_name": "Small Lymphocytic Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1026", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: 0.075% Cetylpyridinium Chloride\nCondition: Coronavirus Infection\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 128\np-value: 0.6\nInterpretation: definitive_negative", "metadata": {"result_id": 56801, "source_trial_id": "NCT04584684", "intervention_name": "0.075% Cetylpyridinium Chloride", "condition_name": "Coronavirus Infection", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1027", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Docetaxel + Sorafenib\nCondition: Non Squamous Cell Lung Cancer\nPhase: phase_2\nEnrollment: 5\nTermination reason: \"Sponsors withdrew funding; preliminary efficacy data was not encouraging.\"\nDetail: Sponsors withdrew funding; preliminary efficacy data was not encouraging.", "metadata": {"result_id": 16325, "source_trial_id": "NCT00801801", "intervention_name": "Docetaxel + Sorafenib", "condition_name": "Non Squamous Cell Lung Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1028", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: goserelin acetate\nDrug type: peptide\nCondition: HER2/Neu Negative\nPhase: phase_1\nEnrollment: 15\nTermination reason: \"Manufacturer discontinued drug development.\"\nDetail: Manufacturer discontinued drug development.", "metadata": {"result_id": 6488, "source_trial_id": "NCT01149356", "intervention_name": "goserelin acetate", "condition_name": "HER2/Neu Negative", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1029", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Ceftolozane/Tazobactam\nCondition: Ventilator-Associated Pneumonia (VAP)\nPhase: phase_3\nEnrollment: 4\nTermination reason: \"Terminated to focus on a larger study within the clinical development program.\"\nDetail: Terminated to focus on a larger study within the clinical development program.", "metadata": {"result_id": 7862, "source_trial_id": "NCT01853982", "intervention_name": "Ceftolozane/Tazobactam", "condition_name": "Ventilator-Associated Pneumonia (VAP)", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1030", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: PF-06753512\nCondition: Prostatic Neoplasms\nPhase: phase_1\nEnrollment: 91\nTermination reason: \"Due to strategic evaluation of PF-06753512 (VBIR-1) within context of Pfizer's oncology portfolio, decision not based on any safety or regulatory concerns.\"\nDetail: Due to strategic evaluation of PF-06753512 (VBIR-1) within context of Pfizer's oncology portfolio, decision not based on any safety or regulatory concerns.", "metadata": {"result_id": 26621, "source_trial_id": "NCT02616185", "intervention_name": "PF-06753512", "condition_name": "Prostatic Neoplasms", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1031", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Nivolumab and Ipilimumab\nCondition: Metastatic Melanoma\nPhase: early_phase_1\nEnrollment: 6\nTermination reason: \"lack of funds\"\nDetail: lack of funds", "metadata": {"result_id": 16955, "source_trial_id": "NCT03526185", "intervention_name": "Nivolumab and Ipilimumab", "condition_name": "Metastatic Melanoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1032", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: BMF-219\nCondition: Stage III Non-small Cell Lung Cancer\nPhase: phase_1\nEnrollment: 13\nTermination reason: \"Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure.\"\nDetail: Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure.", "metadata": {"result_id": 41465, "source_trial_id": "NCT05631574", "intervention_name": "BMF-219", "condition_name": "Stage III Non-small Cell Lung Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1033", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: PBF-999 / 160 mg\nCondition: Huntington Disease\nPhase: phase_1\nEnrollment: 8\nTermination reason: \"change in the therapeutic indication\"\nDetail: change in the therapeutic indication", "metadata": {"result_id": 11212, "source_trial_id": "NCT02907294", "intervention_name": "PBF-999 / 160 mg", "condition_name": "Huntington Disease", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1034", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Amivantamab\nDrug type: monoclonal_antibody\nCondition: Esophageal Neoplasms\nPhase: phase_2\nEnrollment: 62\nTermination reason: \"Due to reconsideration of development strategy\"\nDetail: Due to reconsideration of development strategy", "metadata": {"result_id": 4858, "source_trial_id": "NCT04945733", "intervention_name": "Amivantamab", "condition_name": "Esophageal Neoplasms", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1035", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: [S,S]-Reboxetine\nCondition: Pain\nPhase: phase_2\nEnrollment: 112\nTermination reason: \"This study has been terminated early as the esreboxetine development program is being discontinued. There are no safety or efficacy concerns.\"\nDetail: This study has been terminated early as the esreboxetine development program is being discontinued. There are no safety or efficacy concerns.", "metadata": {"result_id": 58848, "source_trial_id": "NCT00353808", "intervention_name": "[S,S]-Reboxetine", "condition_name": "Pain", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1036", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Batiraxcept\nDrug type: peptide\nCondition: Platinum-Resistant Fallopian Tube Carcinoma\nPhase: phase_1_2\nEnrollment: 12\nTermination reason: \"PI Request\"\nDetail: PI Request", "metadata": {"result_id": 22841, "source_trial_id": "NCT04019288", "intervention_name": "Batiraxcept", "condition_name": "Platinum-Resistant Fallopian Tube Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1037", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Aldoxorubicin HCl\nCondition: Squamous Cell Carcinoma\nPhase: phase_1_2\nEnrollment: 4\nTermination reason: \"Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention\"\nDetail: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention", "metadata": {"result_id": 10578, "source_trial_id": "NCT03387111", "intervention_name": "Aldoxorubicin HCl", "condition_name": "Squamous Cell Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1038", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: injection of 68Ga-DOTATATE\nCondition: Coronary Arteriosclerosis\nPhase: phase_3\nEnrollment: 12\nTermination reason: \"Financial issues\"\nDetail: Financial issues", "metadata": {"result_id": 27238, "source_trial_id": "NCT04043377", "intervention_name": "injection of 68Ga-DOTATATE", "condition_name": "Coronary Arteriosclerosis", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-1039", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: CAP-1002 Allogeneic Cardiosphere-Derived Cells\nCondition: Myocardial Infarction\nPhase: phase_1_2\nBlinding: TRIPLE\nEnrollment: 135\np-value: 0.6453\nInterpretation: definitive_negative", "metadata": {"result_id": 23988, "source_trial_id": "NCT01458405", "intervention_name": "CAP-1002 Allogeneic Cardiosphere-Derived Cells", "condition_name": "Myocardial Infarction", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-1040", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: AFM24\nCondition: Refractory Tumor\nPhase: phase_1_2\nEnrollment: 11\nTermination reason: \"Affimed and NKGen have mutually decided to discontinue the study. Affimed will evaluate the best options to advance this project with an allogeneic off-the-shelf NK cell product while NKGen will focus on CNS with SNK01.\"\nDetail: Affimed and NKGen have mutually decided to discontinue the study. Affimed will evaluate the best options to advance this project with an allogeneic off-the-shelf NK cell product while NKGen will focus on CNS with SNK01.", "metadata": {"result_id": 40203, "source_trial_id": "NCT05099549", "intervention_name": "AFM24", "condition_name": "Refractory Tumor", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1041", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: AMG 330\nDrug type: monoclonal_antibody\nCondition: Relapsed or Refractory Acute Myeloid Leukemia\nPhase: phase_1\nEnrollment: 1\nTermination reason: \"Amgen Decision\"\nDetail: Amgen Decision", "metadata": {"result_id": 58473, "source_trial_id": "NCT04478695", "intervention_name": "AMG 330", "condition_name": "Relapsed or Refractory Acute Myeloid Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1042", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Insuline glargine\nDrug type: peptide\nCondition: Diabetes Mellitus, Type 2\nPhase: phase_4\nEnrollment: 4\nTermination reason: \"prematurely terminated due to loss of interest\"\nDetail: prematurely terminated due to loss of interest", "metadata": {"result_id": 47106, "source_trial_id": "NCT00349986", "intervention_name": "Insuline glargine", "condition_name": "Diabetes Mellitus, Type 2", "confidence_tier": "bronze", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-1043", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: ENS-002\nCondition: Atopic Dermatitis Eczema\nPhase: phase_1\nEnrollment: 9\nTermination reason: \"Planned safety, efficacy and proof of mechanism obtained\"\nDetail: Planned safety, efficacy and proof of mechanism obtained", "metadata": {"result_id": 36362, "source_trial_id": "NCT06469385", "intervention_name": "ENS-002", "condition_name": "Atopic Dermatitis Eczema", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1044", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Extended-release Epidural Morphine (EREM) 120\nCondition: Spastic Cerebral Palsy\nEnrollment: 13\nTermination reason: \"The manufacturer decided to stop drug production.\"\nDetail: The manufacturer decided to stop drug production.", "metadata": {"result_id": 53942, "source_trial_id": "NCT00955877", "intervention_name": "Extended-release Epidural Morphine (EREM) 120", "condition_name": "Spastic Cerebral Palsy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1045", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: 18F-fluoro-dihydroxyphenylalanine\nCondition: Untreated Childhood Cerebral Astrocytoma\nEnrollment: 2\nTermination reason: \"Re-evaluate indication with the referring physicians\"\nDetail: Re-evaluate indication with the referring physicians", "metadata": {"result_id": 62021, "source_trial_id": "NCT02175745", "intervention_name": "18F-fluoro-dihydroxyphenylalanine", "condition_name": "Untreated Childhood Cerebral Astrocytoma", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1046", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: BLU-451\nCondition: Bronchial Neoplasms\nPhase: phase_1\nEnrollment: 103\nTermination reason: \"Sponsor decision, not related to safety concerns\"\nDetail: Sponsor decision, not related to safety concerns", "metadata": {"result_id": 56482, "source_trial_id": "NCT05241873", "intervention_name": "BLU-451", "condition_name": "Bronchial Neoplasms", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1047", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Run-in medications (ICS-LABA combination)\nCondition: Asthma\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 72\nPrimary endpoint met: 1.0\np-value: 0.035\nEffect size (Least Square Mean Difference): 0.196\n95% CI: [0.0143, 0.3778]\nInterpretation: definitive_negative", "metadata": {"result_id": 9591, "source_trial_id": "NCT04643158", "intervention_name": "Run-in medications (ICS-LABA combination)", "condition_name": "Asthma", "confidence_tier": "silver", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-1048", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: 0.075% Cetylpyridinium Chloride\nCondition: SARS-CoV-2 Infection\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 128\np-value: 0.6\nInterpretation: definitive_negative", "metadata": {"result_id": 56795, "source_trial_id": "NCT04584684", "intervention_name": "0.075% Cetylpyridinium Chloride", "condition_name": "SARS-CoV-2 Infection", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1049", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Erbitux\nDrug type: monoclonal_antibody\nCondition: Undifferentiated Carcinoma\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 29\nPrimary endpoint met: 1.0\np-value: 0.01\nSerious adverse events: 93.0\nInterpretation: definitive_negative", "metadata": {"result_id": 53215, "source_trial_id": "NCT00570674", "intervention_name": "Erbitux", "condition_name": "Undifferentiated Carcinoma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1050", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: BGB-A3055\nCondition: Advanced Solid Tumor\nPhase: phase_1\nEnrollment: 99\nTermination reason: \"This decision was conducted by the sponsor and not driven by safety concerns as no new safety signals have been observed in the CCR8 program.\"\nDetail: This decision was conducted by the sponsor and not driven by safety concerns as no new safety signals have been observed in the CCR8 program.", "metadata": {"result_id": 24741, "source_trial_id": "NCT05935098", "intervention_name": "BGB-A3055", "condition_name": "Advanced Solid Tumor", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1051", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Coagulation Factor VIIa variant\nDrug type: peptide\nCondition: Glanzmann Thrombasthenia\nPhase: phase_1_2\nEnrollment: 19\nTermination reason: \"Company decision (not a safety issue)\"\nDetail: Company decision (not a safety issue)", "metadata": {"result_id": 56192, "source_trial_id": "NCT04548791", "intervention_name": "Coagulation Factor VIIa variant", "condition_name": "Glanzmann Thrombasthenia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1052", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Osanetant\nCondition: Prostate Adenocarcinoma\nPhase: early_phase_1\nEnrollment: 1\nTermination reason: \"Development of the drug program has been discontinued\"\nDetail: Development of the drug program has been discontinued", "metadata": {"result_id": 1626, "source_trial_id": "NCT05607342", "intervention_name": "Osanetant", "condition_name": "Prostate Adenocarcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1053", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Bupivacaine high combined with epinephrine (C2)\nCondition: Analgesia\nPhase: phase_1\nEnrollment: 242\nTermination reason: \"The sponsor decided to stop further dosing of healthy volunteers after reviewing the obtained efficacy data. The decision is not related to any safety concern.\"\nDetail: The sponsor decided to stop further dosing of healthy volunteers after reviewing the obtained efficacy data. The decision is not related to any safety concern.", "metadata": {"result_id": 18998, "source_trial_id": "NCT03399435", "intervention_name": "Bupivacaine high combined with epinephrine (C2)", "condition_name": "Analgesia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1054", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: rhPTH(1-84)\nCondition: Hypoparathyroidism\nPhase: phase_3\nEnrollment: 22\nTermination reason: \"The study was terminated due to Takeda commercial Natpara recall.\"\nDetail: The study was terminated due to Takeda commercial Natpara recall.", "metadata": {"result_id": 2111, "source_trial_id": "NCT03364738", "intervention_name": "rhPTH(1-84)", "condition_name": "Hypoparathyroidism", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1055", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Buprenorphine transdermal patch\nCondition: Postoperative Pain\nPhase: phase_2\nEnrollment: 10\nTermination reason: \"due to administrative reasons not related to efficacy or safety.\"\nDetail: due to administrative reasons not related to efficacy or safety.", "metadata": {"result_id": 22379, "source_trial_id": "NCT00403234", "intervention_name": "Buprenorphine transdermal patch", "condition_name": "Postoperative Pain", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1056", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: MPC-7869\nCondition: Dementia\nPhase: phase_3\nEnrollment: 800\nTermination reason: \"Myriad has discontinued the development of Flurizan.\"\nDetail: Myriad has discontinued the development of Flurizan.", "metadata": {"result_id": 33429, "source_trial_id": "NCT00322036", "intervention_name": "MPC-7869", "condition_name": "Dementia", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-1057", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Eltrombopag\nCondition: Human Immunodeficiency Virus\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 292\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (Absolute difference in proportions): 52.8\n95% CI: [43.2, 62.4]\nSerious adverse events: 102.0\nInterpretation: definitive_negative", "metadata": {"result_id": 27266, "source_trial_id": "NCT00678587", "intervention_name": "Eltrombopag", "condition_name": "Human Immunodeficiency Virus", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1058", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Sevelamer\nCondition: Hemodialysis\nPhase: phase_3\nEnrollment: 176\nTermination reason: \"Financial problem\"\nDetail: Financial problem", "metadata": {"result_id": 61077, "source_trial_id": "NCT01011699", "intervention_name": "Sevelamer", "condition_name": "Hemodialysis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1059", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Exendin-4 SC\nDrug type: peptide\nCondition: Alzheimer's Disease\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 57\nPrimary endpoint met: 1.0\np-value: 0.009\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 26688, "source_trial_id": "NCT01255163", "intervention_name": "Exendin-4 SC", "condition_name": "Alzheimer's Disease", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-1060", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: XmAb18968 - Dose level 1\nCondition: T Cell Lymphoblastic Lymphoma\nPhase: phase_1\nEnrollment: 22\nTermination reason: \"Drug expired May 31, 2024.\"\nDetail: Drug expired May 31, 2024.", "metadata": {"result_id": 52856, "source_trial_id": "NCT05038644", "intervention_name": "XmAb18968 - Dose level 1", "condition_name": "T Cell Lymphoblastic Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1061", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Pembrolizumab [KEYTRUDA®]\nCondition: Melanoma\nPhase: phase_1_2\nEnrollment: 31\nTermination reason: \"Sponsor decision following completion of Phase I part not driven by safety reason\"\nDetail: Sponsor decision following completion of Phase I part not driven by safety reason", "metadata": {"result_id": 14900, "source_trial_id": "NCT04725331", "intervention_name": "Pembrolizumab [KEYTRUDA®]", "condition_name": "Melanoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1062", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Ozanimod\nCondition: Crohn Disease\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 550\nPrimary endpoint met: 1.0\np-value: 0.0308\nEffect size (Odds Ratio (OR)): 1.88\n95% CI: [1.06, 3.33]\nInterpretation: definitive_negative", "metadata": {"result_id": 6967, "source_trial_id": "NCT03464097", "intervention_name": "Ozanimod", "condition_name": "Crohn Disease", "confidence_tier": "silver", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL1-1063", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Morphine prolonged release\nCondition: Pain\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 200\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (point-estimate): -7.48\n95% CI: [-12.05, -2.918]\nSerious adverse events: 67.0\nInterpretation: definitive_negative", "metadata": {"result_id": 49596, "source_trial_id": "NCT01964378", "intervention_name": "Morphine prolonged release", "condition_name": "Pain", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1064", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: 0.5% w/v Povidone-iodide\nCondition: Covid19\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 128\np-value: 0.6\nInterpretation: definitive_negative", "metadata": {"result_id": 56788, "source_trial_id": "NCT04584684", "intervention_name": "0.5% w/v Povidone-iodide", "condition_name": "Covid19", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-1065", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: PF-07284890\nCondition: Brain Neoplasms, Primary\nPhase: phase_1\nEnrollment: 65\nTermination reason: \"Pfizer has made an internal business decision to not continue further development of PF-07284890. This decision was not due to major safety concerns or requests from any regulatory authorities.\"\nDetail: Pfizer has made an internal business decision to not continue further development of PF-07284890. This decision was not due to major safety concerns or requests from any regulatory authorities.", "metadata": {"result_id": 18426, "source_trial_id": "NCT04543188", "intervention_name": "PF-07284890", "condition_name": "Brain Neoplasms, Primary", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1066", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: FSD201\nCondition: Mast Cell Activation Syndrome\nPhase: phase_2\nEnrollment: 2\nTermination reason: \"For business reasons and not for reasons related to safety or efficacy\"\nDetail: For business reasons and not for reasons related to safety or efficacy", "metadata": {"result_id": 55482, "source_trial_id": "NCT05652907", "intervention_name": "FSD201", "condition_name": "Mast Cell Activation Syndrome", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1067", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: PF-06940434\nCondition: Ovarian Cancer\nPhase: phase_1\nEnrollment: 85\nTermination reason: \"Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority.\"\nDetail: Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority.", "metadata": {"result_id": 7416, "source_trial_id": "NCT04152018", "intervention_name": "PF-06940434", "condition_name": "Ovarian Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1068", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Nelotanserin\nCondition: Dementia With Lewy Bodies\nPhase: phase_2\nEnrollment: 80\nTermination reason: \"Changes to the overall development program for the study medication\"\nDetail: Changes to the overall development program for the study medication", "metadata": {"result_id": 34030, "source_trial_id": "NCT02871427", "intervention_name": "Nelotanserin", "condition_name": "Dementia With Lewy Bodies", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-1069", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Filgotinib\nCondition: Noninfectious Uveitis\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 74\nPrimary endpoint met: 1.0\np-value: 0.0014\nEffect size (Stratified Hazard Ratio): 0.309\n95% CI: [0.144, 0.663]\nSerious adverse events: 16.0\nInterpretation: definitive_negative", "metadata": {"result_id": 57471, "source_trial_id": "NCT03207815", "intervention_name": "Filgotinib", "condition_name": "Noninfectious Uveitis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1070", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Lidocaine w/ epi\nCondition: Symptomatic Irreversible Pulpitis\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 40\np-value: 0.09\nInterpretation: definitive_negative", "metadata": {"result_id": 58276, "source_trial_id": "NCT06047366", "intervention_name": "Lidocaine w/ epi", "condition_name": "Symptomatic Irreversible Pulpitis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1071", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Batiraxcept\nDrug type: peptide\nCondition: Recurrent Ovarian Carcinoma\nPhase: phase_1_2\nEnrollment: 12\nTermination reason: \"PI Request\"\nDetail: PI Request", "metadata": {"result_id": 22833, "source_trial_id": "NCT04019288", "intervention_name": "Batiraxcept", "condition_name": "Recurrent Ovarian Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1072", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: autologous ET1402L1-CART cells\nCondition: Hepatocellular Carcinoma\nPhase: phase_1\nEnrollment: 3\nTermination reason: \"Will study new T-cell construct for the same indication\"\nDetail: Will study new T-cell construct for the same indication", "metadata": {"result_id": 49708, "source_trial_id": "NCT03349255", "intervention_name": "autologous ET1402L1-CART cells", "condition_name": "Hepatocellular Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1073", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: prucalopride\nCondition: Opioid Induced Constipation\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 174\np-value: 0.305\nSerious adverse events: 8.0\nInterpretation: definitive_negative", "metadata": {"result_id": 15573, "source_trial_id": "NCT01117051", "intervention_name": "prucalopride", "condition_name": "Opioid Induced Constipation", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1074", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: GNKG168\nDrug type: unknown\nCondition: Relapsed Acute Lymphoblastic Leukemia\nPhase: phase_1\nBlinding: NONE\nEnrollment: 4\nPrimary endpoint met: 1.0\np-value: 0.05\nInterpretation: definitive_negative", "metadata": {"result_id": 46812, "source_trial_id": "NCT01743807", "intervention_name": "GNKG168", "condition_name": "Relapsed Acute Lymphoblastic Leukemia", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1075", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Cannabidiol (CBD) Extract\nCondition: Pelvic Pain\nPhase: phase_3\nEnrollment: 12\nTermination reason: \"Recruitment has been challenging due to the BMI cutoff, need to take oral progesterone and abstain from cannabis products prior to the study.\"\nDetail: Recruitment has been challenging due to the BMI cutoff, need to take oral progesterone and abstain from cannabis products prior to the study.", "metadata": {"result_id": 15126, "source_trial_id": "NCT04527003", "intervention_name": "Cannabidiol (CBD) Extract", "condition_name": "Pelvic Pain", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1076", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: AMG 706\nCondition: Solid Tumors\nPhase: phase_2\nEnrollment: 94\nTermination reason: \"Amgen decision\"\nDetail: Amgen decision", "metadata": {"result_id": 20041, "source_trial_id": "NCT00360867", "intervention_name": "AMG 706", "condition_name": "Solid Tumors", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1077", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Bardoxolone methyl oral capsule\nCondition: ADPKD\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 667\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (Least Square Means Difference): 7.94\n95% CI: [6.41, 9.47]\nInterpretation: definitive_negative", "metadata": {"result_id": 44310, "source_trial_id": "NCT03918447", "intervention_name": "Bardoxolone methyl oral capsule", "condition_name": "ADPKD", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1078", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: NKTR-262\nDrug type: unknown\nCondition: Sarcoma\nPhase: phase_1_2\nEnrollment: 64\nTermination reason: \"Based on the overall results from the Phase 1 part of the study the sponsor decided to end the study. The decision was not due to safety reasons.\"\nDetail: Based on the overall results from the Phase 1 part of the study the sponsor decided to end the study. The decision was not due to safety reasons.", "metadata": {"result_id": 14793, "source_trial_id": "NCT03435640", "intervention_name": "NKTR-262", "condition_name": "Sarcoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1079", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Convalescent Plasma\nCondition: SARS-CoV 2\nPhase: phase_2\nEnrollment: 1\nTermination reason: \"Study was stopped because the Promoter was changed and a new study on convalescent plasma promoted by AIFA was started in Italy.\"\nDetail: Study was stopped because the Promoter was changed and a new study on convalescent plasma promoted by AIFA was started in Italy.", "metadata": {"result_id": 27569, "source_trial_id": "NCT04393727", "intervention_name": "Convalescent Plasma", "condition_name": "SARS-CoV 2", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1080", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: PF-07062119\nCondition: Colorectal Adenocarcinomas\nPhase: phase_1\nEnrollment: 79\nTermination reason: \"Study was terminated due to strategic considerations and not due to safety.\"\nDetail: Study was terminated due to strategic considerations and not due to safety.", "metadata": {"result_id": 48720, "source_trial_id": "NCT04171141", "intervention_name": "PF-07062119", "condition_name": "Colorectal Adenocarcinomas", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1081", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Pralsetinib\nCondition: Carcinoma\nPhase: phase_3\nBlinding: NONE\nEnrollment: 223\nPrimary endpoint met: 1.0\np-value: 0.0002\nEffect size (Difference in Overall Response Rates): 23.86\n95% CI: [10.25, 37.47]\nInterpretation: definitive_negative", "metadata": {"result_id": 38988, "source_trial_id": "NCT04222972", "intervention_name": "Pralsetinib", "condition_name": "Carcinoma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1082", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Low volume bolus\nCondition: Anesthesia\nPhase: phase_4\nEnrollment: 146\nTermination reason: \"Lack of continued funding\"\nDetail: Lack of continued funding", "metadata": {"result_id": 48416, "source_trial_id": "NCT03553576", "intervention_name": "Low volume bolus", "condition_name": "Anesthesia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1083", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Carboplatin Injection\nCondition: Sarcoma of Uterus\nPhase: phase_2\nEnrollment: 71\nTermination reason: \"Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.\"\nDetail: Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.", "metadata": {"result_id": 49159, "source_trial_id": "NCT05481645", "intervention_name": "Carboplatin Injection", "condition_name": "Sarcoma of Uterus", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1084", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Izokibep\nDrug type: peptide\nCondition: Hidradenitis Suppurativa\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 258\nPrimary endpoint met: 1.0\np-value: 0.0007\nEffect size (Risk Difference (RD)): 15.8\n95% CI: [6.7, 25.0]\nInterpretation: definitive_negative", "metadata": {"result_id": 24771, "source_trial_id": "NCT05905783", "intervention_name": "Izokibep", "condition_name": "Hidradenitis Suppurativa", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1085", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: CDX-301\nDrug type: unknown\nCondition: Pancreas Cancer\nPhase: phase_2\nEnrollment: 16\nTermination reason: \"Celldex decision\"\nDetail: Celldex decision", "metadata": {"result_id": 36549, "source_trial_id": "NCT04536077", "intervention_name": "CDX-301", "condition_name": "Pancreas Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1086", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: KO-947\nCondition: Advanced Malignant Neoplasm\nPhase: phase_1\nEnrollment: 61\nTermination reason: \"Due to a strategic business decision Kura has stopped development of KO-947. Neither safety nor efficacy reasons were the cause of study termination.\"\nDetail: Due to a strategic business decision Kura has stopped development of KO-947. Neither safety nor efficacy reasons were the cause of study termination.", "metadata": {"result_id": 44065, "source_trial_id": "NCT03051035", "intervention_name": "KO-947", "condition_name": "Advanced Malignant Neoplasm", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1087", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Coagulation Factor VIIa variant\nDrug type: peptide\nCondition: Factor VII Deficiency\nPhase: phase_1_2\nEnrollment: 19\nTermination reason: \"Company decision (not a safety issue)\"\nDetail: Company decision (not a safety issue)", "metadata": {"result_id": 56191, "source_trial_id": "NCT04548791", "intervention_name": "Coagulation Factor VIIa variant", "condition_name": "Factor VII Deficiency", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1088", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: REGN5069\nDrug type: monoclonal_antibody\nCondition: Osteoarthritis of the Knee\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 259\np-value: 0.0604\nSerious adverse events: 14.0\nInterpretation: definitive_negative", "metadata": {"result_id": 3734, "source_trial_id": "NCT03956550", "intervention_name": "REGN5069", "condition_name": "Osteoarthritis of the Knee", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1089", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Mocetinostat - 90 mg\nCondition: Advanced Cancer\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 83\nPrimary endpoint met: 1.0\np-value: 0.025\nSerious adverse events: 143.0\nInterpretation: definitive_negative", "metadata": {"result_id": 13089, "source_trial_id": "NCT02805660", "intervention_name": "Mocetinostat - 90 mg", "condition_name": "Advanced Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1090", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Erbitux\nDrug type: monoclonal_antibody\nCondition: Basaloid Squamous Cell Carcinoma\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 29\nPrimary endpoint met: 1.0\np-value: 0.01\nSerious adverse events: 93.0\nInterpretation: definitive_negative", "metadata": {"result_id": 53211, "source_trial_id": "NCT00570674", "intervention_name": "Erbitux", "condition_name": "Basaloid Squamous Cell Carcinoma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1091", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: GTB-3550 TriKE® Phase II\nCondition: Acute Myelogenous Leukemia\nPhase: phase_1_2\nEnrollment: 12\nTermination reason: \"Development of GTB-3550 halted due to development of the second generation camelid nanobody TriKE drug product, GTB-3650.\"\nDetail: Development of GTB-3550 halted due to development of the second generation camelid nanobody TriKE drug product, GTB-3650.", "metadata": {"result_id": 9242, "source_trial_id": "NCT03214666", "intervention_name": "GTB-3550 TriKE® Phase II", "condition_name": "Acute Myelogenous Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1092", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: CD4+/CD25+ cells\nCondition: Leukemia, Lymphocytic, Acute\nEnrollment: 330\nTermination reason: \"replaced by another study ; Trial re-written as MT2015-29\"\nDetail: replaced by another study ; Trial re-written as MT2015-29", "metadata": {"result_id": 38837, "source_trial_id": "NCT00176930", "intervention_name": "CD4+/CD25+ cells", "condition_name": "Leukemia, Lymphocytic, Acute", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1093", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: IMSA101\nDrug type: peptide\nCondition: Oligoprogressive\nPhase: phase_2\nEnrollment: 16\nTermination reason: \"Change in ImmuneSensor corporate strategy\"\nDetail: Change in ImmuneSensor corporate strategy", "metadata": {"result_id": 1430, "source_trial_id": "NCT05846659", "intervention_name": "IMSA101", "condition_name": "Oligoprogressive", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1094", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Propranolol\nCondition: Unresectable Malignant Melanoma\nPhase: phase_2\nEnrollment: 2\nTermination reason: \"Lack of financing of the study drug. Not sufficient financial support.\"\nDetail: Lack of financing of the study drug. Not sufficient financial support.", "metadata": {"result_id": 46025, "source_trial_id": "NCT01705392", "intervention_name": "Propranolol", "condition_name": "Unresectable Malignant Melanoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1095", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: EDP-305 1.5 mg\nCondition: Non-alcoholic Steatohepatitis\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 98\nPrimary endpoint met: 1.0\np-value: 0.003\nEffect size (LS mean difference): 1.05\n95% CI: [0.365, 1.736]\nInterpretation: definitive_negative", "metadata": {"result_id": 15711, "source_trial_id": "NCT04378010", "intervention_name": "EDP-305 1.5 mg", "condition_name": "Non-alcoholic Steatohepatitis", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-1096", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: ChAdOx1 MERS\nCondition: MERS (Middle East Respiratory Syndrome)\nPhase: phase_1\nEnrollment: 29\nTermination reason: \"The scientific questions proposed remain relevant, but will now be addressed in a larger phase II immunogenicity trial of the ChAdOx1 MERS vaccine given at 2 doses.\"\nDetail: The scientific questions proposed remain relevant, but will now be addressed in a larger phase II immunogenicity trial of the ChAdOx1 MERS vaccine given at 2 doses.", "metadata": {"result_id": 40973, "source_trial_id": "NCT03399578", "intervention_name": "ChAdOx1 MERS", "condition_name": "MERS (Middle East Respiratory Syndrome)", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1097", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: nikkomycin Z\nCondition: Coccidioidomycosis\nPhase: phase_1_2\nEnrollment: 6\nTermination reason: \"Recruitment challenges and lack of funding caused an early end to this study\"\nDetail: Recruitment challenges and lack of funding caused an early end to this study", "metadata": {"result_id": 24380, "source_trial_id": "NCT00614666", "intervention_name": "nikkomycin Z", "condition_name": "Coccidioidomycosis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1098", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Etripamil\nCondition: Paroxysmal Supraventricular Tachycardia\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 1097\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Hazard Ratio (HR)): 2.857\n95% CI: [1.868, 4.371]\nInterpretation: definitive_negative", "metadata": {"result_id": 63007, "source_trial_id": "NCT03464019", "intervention_name": "Etripamil", "condition_name": "Paroxysmal Supraventricular Tachycardia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1099", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Tocilizumab\nDrug type: monoclonal_antibody\nCondition: Colorectal Cancer\nPhase: phase_1\nEnrollment: 3\nTermination reason: \"Sponsor decision (not related to safety, efficacy or quality).\"\nDetail: Sponsor decision (not related to safety, efficacy or quality).", "metadata": {"result_id": 50722, "source_trial_id": "NCT05769959", "intervention_name": "Tocilizumab", "condition_name": "Colorectal Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1100", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Dulaglutide\nDrug type: peptide\nCondition: Type 2 Diabetes Mellitus\nPhase: phase_3\nBlinding: NONE\nEnrollment: 908\np-value: 0.3427\nSerious adverse events: 144.0\nInterpretation: definitive_negative", "metadata": {"result_id": 8246, "source_trial_id": "NCT03684642", "intervention_name": "Dulaglutide", "condition_name": "Type 2 Diabetes Mellitus", "confidence_tier": "silver", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-1101", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: ICX-RHY-013\nCondition: Burn Scar Contractures\nPhase: phase_1_2\nEnrollment: 15\nTermination reason: \"Study Terminated due to lack of Funding\"\nDetail: Study Terminated due to lack of Funding", "metadata": {"result_id": 35992, "source_trial_id": "NCT01564407", "intervention_name": "ICX-RHY-013", "condition_name": "Burn Scar Contractures", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1102", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Vilaprisan (BAY1002670)\nCondition: Uterine Fibroids\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 103\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (Risk Difference (RD)): 0.82\n95% CI: [0.72, 0.93]\nSerious adverse events: 55.0\nInterpretation: definitive_negative", "metadata": {"result_id": 12996, "source_trial_id": "NCT03400956", "intervention_name": "Vilaprisan (BAY1002670)", "condition_name": "Uterine Fibroids", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1103", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Arm C: RPTR-147:2\nCondition: Solid Tumor\nPhase: phase_1\nEnrollment: 23\nTermination reason: \"Development program terminated\"\nDetail: Development program terminated", "metadata": {"result_id": 6240, "source_trial_id": "NCT03815682", "intervention_name": "Arm C: RPTR-147:2", "condition_name": "Solid Tumor", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1104", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: EZN-2208\nDrug type: unknown\nCondition: Metastatic Breast Cancer\nPhase: phase_2\nEnrollment: 160\nTermination reason: \"Program suspended and divested\"\nDetail: Program suspended and divested", "metadata": {"result_id": 34302, "source_trial_id": "NCT01036113", "intervention_name": "EZN-2208", "condition_name": "Metastatic Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1105", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: No drug name provided by Sponsor; drug referenced as PD 0332334\nCondition: Anxiety Disorders\nPhase: phase_3\nEnrollment: 5\nTermination reason: \"Pfizer has terminated the execution of this protocol\"\nDetail: Pfizer has terminated the execution of this protocol", "metadata": {"result_id": 37668, "source_trial_id": "NCT00836069", "intervention_name": "No drug name provided by Sponsor; drug referenced as PD 0332334", "condition_name": "Anxiety Disorders", "confidence_tier": "bronze", "therapeutic_area": "psychiatry"}, "split": "test"}
+{"question_id": "CTL1-1106", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: EN3285\nCondition: Head and Neck Cancer\nPhase: phase_3\nEnrollment: 240\nTermination reason: \"Additional research\"\nDetail: Additional research", "metadata": {"result_id": 50855, "source_trial_id": "NCT00574860", "intervention_name": "EN3285", "condition_name": "Head and Neck Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1107", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Experimental: CHF6001 3200 μg\nCondition: Uncontrolled Asthma\nPhase: phase_2\nEnrollment: 517\nTermination reason: \"Strategic decision by Sponsor; not due to safety reasons\"\nDetail: Strategic decision by Sponsor; not due to safety reasons", "metadata": {"result_id": 38794, "source_trial_id": "NCT06029595", "intervention_name": "Experimental: CHF6001 3200 μg", "condition_name": "Uncontrolled Asthma", "confidence_tier": "bronze", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-1108", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Sabatolimab\nDrug type: monoclonal_antibody\nCondition: Myelodysplastic Syndromes\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 530\np-value: 0.0825\nEffect size (Hazard Ratio (HR)): 0.847\n95% CI: [0.671, 1.07]\nInterpretation: definitive_negative", "metadata": {"result_id": 7613, "source_trial_id": "NCT04266301", "intervention_name": "Sabatolimab", "condition_name": "Myelodysplastic Syndromes", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1109", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Bupivacaine high combined with epinephrine (C2)\nCondition: Anesthesia\nPhase: phase_1\nEnrollment: 242\nTermination reason: \"The sponsor decided to stop further dosing of healthy volunteers after reviewing the obtained efficacy data. The decision is not related to any safety concern.\"\nDetail: The sponsor decided to stop further dosing of healthy volunteers after reviewing the obtained efficacy data. The decision is not related to any safety concern.", "metadata": {"result_id": 19008, "source_trial_id": "NCT03399435", "intervention_name": "Bupivacaine high combined with epinephrine (C2)", "condition_name": "Anesthesia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1110", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: PF-0791800 (TTI-621)\nDrug type: peptide\nCondition: Solid Tumor\nPhase: phase_1\nEnrollment: 249\nTermination reason: \"Pfizer decided terminating study for administrative reasons on 22Mar2022 (stopping enrollment as of 15Apr2022). The decision wasn't due to safety concerns or requests from regulatory authorities.\"\nDetail: Pfizer decided terminating study for administrative reasons on 22Mar2022 (stopping enrollment as of 15Apr2022). The decision wasn't due to safety concerns or requests from regulatory authorities.", "metadata": {"result_id": 5625, "source_trial_id": "NCT02663518", "intervention_name": "PF-0791800 (TTI-621)", "condition_name": "Solid Tumor", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1111", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: neostigmine/glycopyrrolate\nCondition: Surgery\nPhase: phase_4\nEnrollment: 22\nTermination reason: \"Study was terminated due to lack of funding.\"\nDetail: Study was terminated due to lack of funding.", "metadata": {"result_id": 4050, "source_trial_id": "NCT05256901", "intervention_name": "neostigmine/glycopyrrolate", "condition_name": "Surgery", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1112", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Exendin-4 SC\nDrug type: peptide\nCondition: Mild Cognitive Impairment\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 57\nPrimary endpoint met: 1.0\np-value: 0.009\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 26690, "source_trial_id": "NCT01255163", "intervention_name": "Exendin-4 SC", "condition_name": "Mild Cognitive Impairment", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1113", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Triamcinolone Acetonide\nCondition: Gout Attack\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 5\nPrimary endpoint met: 1.0\np-value: 0.05\nInterpretation: definitive_negative", "metadata": {"result_id": 328, "source_trial_id": "NCT03636373", "intervention_name": "Triamcinolone Acetonide", "condition_name": "Gout Attack", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1114", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Misoprostol 200mcg\nCondition: Fetal Death\nPhase: phase_3\nEnrollment: 200\nTermination reason: \"Lack of funding\"\nDetail: Lack of funding", "metadata": {"result_id": 16964, "source_trial_id": "NCT02633761", "intervention_name": "Misoprostol 200mcg", "condition_name": "Fetal Death", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1115", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Mocetinostat - 70 mg\nCondition: Advanced Cancer\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 83\nPrimary endpoint met: 1.0\np-value: 0.025\nSerious adverse events: 143.0\nInterpretation: definitive_negative", "metadata": {"result_id": 13088, "source_trial_id": "NCT02805660", "intervention_name": "Mocetinostat - 70 mg", "condition_name": "Advanced Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1116", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: SOM230\nDrug type: peptide\nCondition: Cluster Headache - Episodic and Chronic\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 28\np-value: 0.385\nEffect size (Odds Ratio (OR)): 2.033\n95% CI: [0.53, 7.79]\nInterpretation: definitive_negative", "metadata": {"result_id": 24773, "source_trial_id": "NCT02619617", "intervention_name": "SOM230", "condition_name": "Cluster Headache - Episodic and Chronic", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1117", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Tacrolimus granules\nCondition: Heart Transplantation\nPhase: phase_4\nEnrollment: 47\nTermination reason: \"Trial will not complete until at least 2025 and evolution of immunosuppressant therapy has made it unlikely that patients will convert from Modigraf to Prograf.\"\nDetail: Trial will not complete until at least 2025 and evolution of immunosuppressant therapy has made it unlikely that patients will convert from Modigraf to Prograf.", "metadata": {"result_id": 53660, "source_trial_id": "NCT01371344", "intervention_name": "Tacrolimus granules", "condition_name": "Heart Transplantation", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-1118", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: meningococcal B rLP2086 vaccine\nCondition: Meningitis, Meningococcal\nPhase: phase_2\nEnrollment: 46\nTermination reason: \"Following program review within Pfizer, decision was made not to go ahead with this study. This study is cancelled\"\nDetail: Following program review within Pfizer, decision was made not to go ahead with this study. This study is cancelled", "metadata": {"result_id": 36667, "source_trial_id": "NCT00798304", "intervention_name": "meningococcal B rLP2086 vaccine", "condition_name": "Meningitis, Meningococcal", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1119", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: 27% Ethanol plus essential oils\nCondition: SARS-CoV-2 Infection\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 128\np-value: 0.6\nInterpretation: definitive_negative", "metadata": {"result_id": 56793, "source_trial_id": "NCT04584684", "intervention_name": "27% Ethanol plus essential oils", "condition_name": "SARS-CoV-2 Infection", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1120", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: PF-06342674 0.25 mg/kg\nCondition: Multiple Sclerosis\nPhase: phase_1\nEnrollment: 4\nTermination reason: \"This study terminated on April 8, 2015 due to a corporate decision and not related to the safety or efficacy of the protocol.\"\nDetail: This study terminated on April 8, 2015 due to a corporate decision and not related to the safety or efficacy of the protocol.", "metadata": {"result_id": 12252, "source_trial_id": "NCT02045732", "intervention_name": "PF-06342674 0.25 mg/kg", "condition_name": "Multiple Sclerosis", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-1121", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Octreotide pamoate\nDrug type: peptide\nCondition: Stage IIA Prostate Cancer\nPhase: phase_2\nEnrollment: 9\nTermination reason: \"lack of funding\"\nDetail: lack of funding", "metadata": {"result_id": 10131, "source_trial_id": "NCT01469338", "intervention_name": "Octreotide pamoate", "condition_name": "Stage IIA Prostate Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1122", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: SHR-1210\nDrug type: monoclonal_antibody\nCondition: Lung Neoplasms\nPhase: phase_2\nEnrollment: 5\nTermination reason: \"changes in the R\\&D strategy\"\nDetail: changes in the R\\&D strategy", "metadata": {"result_id": 27075, "source_trial_id": "NCT03666728", "intervention_name": "SHR-1210", "condition_name": "Lung Neoplasms", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1123", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: MEK-1/MEKK-1 Inhibitor E6201\nCondition: Metastatic Malignant Neoplasm in the Central Nervous System\nPhase: phase_1\nEnrollment: 13\nTermination reason: \"Financial issues\"\nDetail: Financial issues", "metadata": {"result_id": 7846, "source_trial_id": "NCT05388877", "intervention_name": "MEK-1/MEKK-1 Inhibitor E6201", "condition_name": "Metastatic Malignant Neoplasm in the Central Nervous System", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1124", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Vilaprisan (BAY1002670)\nCondition: Uterine Fibroids\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 93\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (Risk Difference (RD)): 0.56\n95% CI: [0.33, 0.78]\nSerious adverse events: 21.0\nInterpretation: definitive_negative", "metadata": {"result_id": 46094, "source_trial_id": "NCT03400943", "intervention_name": "Vilaprisan (BAY1002670)", "condition_name": "Uterine Fibroids", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1125", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: [225Ac]-FPI-1434 Injection multi-dose\nCondition: Endometrial Cancer\nPhase: phase_1\nEnrollment: 78\nTermination reason: \"A strategic decision was made to discontinue the study and prioritize other programs within the portfolio. The study was not discontinued due to safety issues or adverse events related to FPI-1434, FPE-1547, or FPI-1175.\"\nDetail: A strategic decision was made to discontinue the study and prioritize other programs within the portfolio. The study was not discontinued due to safety issues or adverse events related to FPI-1434, FPE-1547, or FPI-1175.", "metadata": {"result_id": 63339, "source_trial_id": "NCT03746431", "intervention_name": "[225Ac]-FPI-1434 Injection multi-dose", "condition_name": "Endometrial Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1126", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: H1 Blocker\nCondition: Glycogen Storage Disease Type III\nPhase: phase_1_2\nEnrollment: 9\nTermination reason: \"Sponsor decision not related to safety concerns\"\nDetail: Sponsor decision not related to safety concerns", "metadata": {"result_id": 57000, "source_trial_id": "NCT04990388", "intervention_name": "H1 Blocker", "condition_name": "Glycogen Storage Disease Type III", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1127", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Acetazolamide\nCondition: CDG1A\nPhase: phase_2_3\nBlinding: QUADRUPLE\nEnrollment: 25\np-value: 0.09\nInterpretation: definitive_negative", "metadata": {"result_id": 53918, "source_trial_id": "NCT04679389", "intervention_name": "Acetazolamide", "condition_name": "CDG1A", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1128", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Lucitanib\nCondition: Urothelial Carcinoma\nPhase: phase_1_2\nEnrollment: 25\nTermination reason: \"Due to a change in development priorities, no further clinical development of the lucitanib plus rucaparib or lucitanib plus sacituzumab govitecan combinations is planned at this time.\"\nDetail: Due to a change in development priorities, no further clinical development of the lucitanib plus rucaparib or lucitanib plus sacituzumab govitecan combinations is planned at this time.", "metadata": {"result_id": 5552, "source_trial_id": "NCT03992131", "intervention_name": "Lucitanib", "condition_name": "Urothelial Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1129", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Sasanlimab Prefilled syringe\nCondition: Carcinoma, Non-Small-Cell Lung\nPhase: phase_1_2\nEnrollment: 34\nTermination reason: \"Study was terminated due to portfolio re-prioritization and strategic considerations. The decision was not based on any safety concerns and/or regulatory interactions\"\nDetail: Study was terminated due to portfolio re-prioritization and strategic considerations. The decision was not based on any safety concerns and/or regulatory interactions", "metadata": {"result_id": 49298, "source_trial_id": "NCT04585815", "intervention_name": "Sasanlimab Prefilled syringe", "condition_name": "Carcinoma, Non-Small-Cell Lung", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1130", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Etanercept\nDrug type: peptide\nCondition: Gout Attack\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 5\nPrimary endpoint met: 1.0\np-value: 0.05\nInterpretation: definitive_negative", "metadata": {"result_id": 327, "source_trial_id": "NCT03636373", "intervention_name": "Etanercept", "condition_name": "Gout Attack", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1131", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Hydromorphone 100mcg\nCondition: Pain\nPhase: phase_4\nEnrollment: 29\nTermination reason: \"Research question answered by another group of researchers (Sviggum et al)\"\nDetail: Research question answered by another group of researchers (Sviggum et al)", "metadata": {"result_id": 15994, "source_trial_id": "NCT01943565", "intervention_name": "Hydromorphone 100mcg", "condition_name": "Pain", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1132", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Pepcid\nCondition: Opioid Use\nPhase: phase_4\nEnrollment: 57\nTermination reason: \"Loss of surgery team member deemed the study procedures impossible to achieve, and no replacement could be found in a timely manner to complete trial as initially planned.\"\nDetail: Loss of surgery team member deemed the study procedures impossible to achieve, and no replacement could be found in a timely manner to complete trial as initially planned.", "metadata": {"result_id": 55762, "source_trial_id": "NCT04766996", "intervention_name": "Pepcid", "condition_name": "Opioid Use", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1133", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: BIIB074\nCondition: Small Fiber Neuropathy\nPhase: phase_2\nEnrollment: 265\nTermination reason: \"Sponsor decision to close study early; not due to safety concerns\"\nDetail: Sponsor decision to close study early; not due to safety concerns", "metadata": {"result_id": 23336, "source_trial_id": "NCT03339336", "intervention_name": "BIIB074", "condition_name": "Small Fiber Neuropathy", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-1134", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: RG1507\nDrug type: monoclonal_antibody\nCondition: Non-Squamous Non-Small Cell Lung Cancer\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 171\nPrimary endpoint met: 1.0\np-value: 0.0342\nEffect size (Hazard Ratio (HR)): 0.61\n95% CI: [0.42, 0.9]\nSerious adverse events: 223.0\nInterpretation: definitive_negative", "metadata": {"result_id": 52927, "source_trial_id": "NCT00760929", "intervention_name": "RG1507", "condition_name": "Non-Squamous Non-Small Cell Lung Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1135", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Veliparib\nCondition: Ovarian Cancer\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 1140\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Hazard Ratio (HR)): 0.435\n95% CI: [0.277, 0.683]\nSerious adverse events: 1486.0\nInterpretation: definitive_negative", "metadata": {"result_id": 58842, "source_trial_id": "NCT02470585", "intervention_name": "Veliparib", "condition_name": "Ovarian Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1136", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: buprenorphine\nCondition: Osteoarthritis\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 418\nPrimary endpoint met: 1.0\np-value: 0.007\nEffect size (Mean Difference (Final Values)): -0.8\n95% CI: [-1.47, -0.2]\nSerious adverse events: 64.0\nInterpretation: definitive_negative", "metadata": {"result_id": 8172, "source_trial_id": "NCT00312221", "intervention_name": "buprenorphine", "condition_name": "Osteoarthritis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1137", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Parsaclisib\nCondition: MPN (Myeloproliferative Neoplasms)\nPhase: phase_2\nBlinding: NONE\nEnrollment: 74\np-value: 0.0756\nInterpretation: definitive_negative", "metadata": {"result_id": 21392, "source_trial_id": "NCT02718300", "intervention_name": "Parsaclisib", "condition_name": "MPN (Myeloproliferative Neoplasms)", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1138", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: doxazosin\nCondition: Hypertension\nEnrollment: 10\nTermination reason: \"Due to recent findings relating MRI contrast to nephrogenic systemic fibrosis\"\nDetail: Due to recent findings relating MRI contrast to nephrogenic systemic fibrosis", "metadata": {"result_id": 21116, "source_trial_id": "NCT00424801", "intervention_name": "doxazosin", "condition_name": "Hypertension", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-1139", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: PF-07284890\nCondition: Malignant Neoplasms\nPhase: phase_1\nEnrollment: 65\nTermination reason: \"Pfizer has made an internal business decision to not continue further development of PF-07284890. This decision was not due to major safety concerns or requests from any regulatory authorities.\"\nDetail: Pfizer has made an internal business decision to not continue further development of PF-07284890. This decision was not due to major safety concerns or requests from any regulatory authorities.", "metadata": {"result_id": 18420, "source_trial_id": "NCT04543188", "intervention_name": "PF-07284890", "condition_name": "Malignant Neoplasms", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1140", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: EZN-2208\nDrug type: unknown\nCondition: Solid Tumors\nPhase: phase_1_2\nEnrollment: 32\nTermination reason: \"Program suspended and divested\"\nDetail: Program suspended and divested", "metadata": {"result_id": 39358, "source_trial_id": "NCT01295697", "intervention_name": "EZN-2208", "condition_name": "Solid Tumors", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1141", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: AK119\nDrug type: monoclonal_antibody\nCondition: Solid Tumor, Adult\nPhase: phase_1_2\nEnrollment: 33\nTermination reason: \"Development strategy adjustment\"\nDetail: Development strategy adjustment", "metadata": {"result_id": 42065, "source_trial_id": "NCT05559541", "intervention_name": "AK119", "condition_name": "Solid Tumor, Adult", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1142", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: FT538\nCondition: Fallopian Tube Cancer\nPhase: phase_1\nEnrollment: 1\nTermination reason: \"Product withdrawn from clinical development\"\nDetail: Product withdrawn from clinical development", "metadata": {"result_id": 36984, "source_trial_id": "NCT05708924", "intervention_name": "FT538", "condition_name": "Fallopian Tube Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1143", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Sibutramine\nCondition: Obesity\nPhase: phase_4\nBlinding: DOUBLE\nEnrollment: 14\nPrimary endpoint met: 1.0\np-value: 0.004\nInterpretation: definitive_negative", "metadata": {"result_id": 16889, "source_trial_id": "NCT01170364", "intervention_name": "Sibutramine", "condition_name": "Obesity", "confidence_tier": "silver", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-1144", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: HPN424 2 Prime Step IV 450 ng/kg Target\nCondition: Advanced Prostate Cancer\nPhase: phase_1_2\nEnrollment: 104\nTermination reason: \"Decision not to continue to the expansion portion of the study\"\nDetail: Decision not to continue to the expansion portion of the study", "metadata": {"result_id": 820, "source_trial_id": "NCT03577028", "intervention_name": "HPN424 2 Prime Step IV 450 ng/kg Target", "condition_name": "Advanced Prostate Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1145", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Rosiglitazone XR\nCondition: Alzheimer's Disease\nPhase: phase_3\nEnrollment: 1461\nTermination reason: \"Based on preliminary parent study results\"\nDetail: Based on preliminary parent study results", "metadata": {"result_id": 11868, "source_trial_id": "NCT00490568", "intervention_name": "Rosiglitazone XR", "condition_name": "Alzheimer's Disease", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-1146", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: ETBX-011\nCondition: Pancreatic Cancer\nPhase: phase_1_2\nEnrollment: 6\nTermination reason: \"Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention\"\nDetail: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention", "metadata": {"result_id": 15212, "source_trial_id": "NCT03329248", "intervention_name": "ETBX-011", "condition_name": "Pancreatic Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1147", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Myeloablative Preparative Regimen\nCondition: Glanzmann Thrombasthenia\nEnrollment: 38\nTermination reason: \"Replaced by another study\"\nDetail: Replaced by another study", "metadata": {"result_id": 49730, "source_trial_id": "NCT02179359", "intervention_name": "Myeloablative Preparative Regimen", "condition_name": "Glanzmann Thrombasthenia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1148", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Mogamulizumab\nDrug type: monoclonal_antibody\nCondition: Mycosis Fungoides\nPhase: phase_1_2\nEnrollment: 5\nTermination reason: \"Lack of funding\"\nDetail: Lack of funding", "metadata": {"result_id": 49779, "source_trial_id": "NCT04676087", "intervention_name": "Mogamulizumab", "condition_name": "Mycosis Fungoides", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1149", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: 0.12% Chlorohexidine Gluconate\nCondition: SARS-CoV-2 Infection\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 128\np-value: 0.6\nInterpretation: definitive_negative", "metadata": {"result_id": 56792, "source_trial_id": "NCT04584684", "intervention_name": "0.12% Chlorohexidine Gluconate", "condition_name": "SARS-CoV-2 Infection", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1150", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Once-daily envarsus XR\nCondition: Kidney Transplantation\nPhase: phase_4\nEnrollment: 20\nTermination reason: \"Research contract expired\"\nDetail: Research contract expired", "metadata": {"result_id": 44026, "source_trial_id": "NCT04773392", "intervention_name": "Once-daily envarsus XR", "condition_name": "Kidney Transplantation", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1151", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Filgotinib\nCondition: Psoriatic Arthritis\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 106\nPrimary endpoint met: 1.0\np-value: 0.002\nEffect size (Difference in response rates): 40.7\n95% CI: [19.5, 62.0]\nSerious adverse events: 12.0\nInterpretation: definitive_negative", "metadata": {"result_id": 23881, "source_trial_id": "NCT04115839", "intervention_name": "Filgotinib", "condition_name": "Psoriatic Arthritis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1152", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Extended Release Epidural Morphine (EREM)\nCondition: Hip Arthroplasty\nPhase: phase_4\nEnrollment: 40\nTermination reason: \"Drug was discontinued by manufacturer\"\nDetail: Drug was discontinued by manufacturer", "metadata": {"result_id": 4027, "source_trial_id": "NCT00934661", "intervention_name": "Extended Release Epidural Morphine (EREM)", "condition_name": "Hip Arthroplasty", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1153", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Analgesics\nCondition: Pain, Postoperative\nPhase: phase_4\nBlinding: NONE\nEnrollment: 24\np-value: 0.16\nEffect size (Mean Difference (Final Values)): 6.9\n95% CI: [-2.9, 16.7]\nInterpretation: definitive_negative", "metadata": {"result_id": 44511, "source_trial_id": "NCT04541147", "intervention_name": "Analgesics", "condition_name": "Pain, Postoperative", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1154", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Gamma-Secretase Inhibitor RO4929097\nCondition: HER2/Neu Negative\nPhase: phase_1\nEnrollment: 15\nTermination reason: \"Manufacturer discontinued drug development.\"\nDetail: Manufacturer discontinued drug development.", "metadata": {"result_id": 6490, "source_trial_id": "NCT01149356", "intervention_name": "Gamma-Secretase Inhibitor RO4929097", "condition_name": "HER2/Neu Negative", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1155", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: 0.5% w/v Povidone-iodide\nCondition: SARS-CoV-2 Infection\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 128\np-value: 0.6\nInterpretation: definitive_negative", "metadata": {"result_id": 56794, "source_trial_id": "NCT04584684", "intervention_name": "0.5% w/v Povidone-iodide", "condition_name": "SARS-CoV-2 Infection", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1156", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Short acting beta agonist (SABA) (rescue medication)\nCondition: Asthma\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 72\nPrimary endpoint met: 1.0\np-value: 0.035\nEffect size (Least Square Mean Difference): 0.196\n95% CI: [0.0143, 0.3778]\nInterpretation: definitive_negative", "metadata": {"result_id": 9590, "source_trial_id": "NCT04643158", "intervention_name": "Short acting beta agonist (SABA) (rescue medication)", "condition_name": "Asthma", "confidence_tier": "silver", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-1157", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Volanesorsen\nDrug type: oligonucleotide\nCondition: Familial Partial Lipodystrophy\nPhase: phase_2_3\nBlinding: TRIPLE\nEnrollment: 40\nPrimary endpoint met: 1.0\np-value: 0.0009\nEffect size (Difference in Least Square Mean): -66.83\n95% CI: [-104.17, -29.48]\nSerious adverse events: 43.0\nInterpretation: definitive_negative", "metadata": {"result_id": 6618, "source_trial_id": "NCT02527343", "intervention_name": "Volanesorsen", "condition_name": "Familial Partial Lipodystrophy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1158", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: ISMN\nCondition: Renal Insufficiency, Chronic\nPhase: phase_2\nEnrollment: 8\nTermination reason: \"lack of funding\"\nDetail: lack of funding", "metadata": {"result_id": 6548, "source_trial_id": "NCT02791906", "intervention_name": "ISMN", "condition_name": "Renal Insufficiency, Chronic", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1159", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Sibutramine\nCondition: Obesity\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 343\nPrimary endpoint met: 1.0\np-value: 0.001\nSerious adverse events: 17.0\nInterpretation: definitive_negative", "metadata": {"result_id": 55772, "source_trial_id": "NCT00993421", "intervention_name": "Sibutramine", "condition_name": "Obesity", "confidence_tier": "silver", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-1160", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: MEDI528 50 mg\nCondition: Asthma\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 11\nPrimary endpoint met: 1.0\np-value: 0.01\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 23260, "source_trial_id": "NCT00590720", "intervention_name": "MEDI528 50 mg", "condition_name": "Asthma", "confidence_tier": "silver", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-1161", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: ELAD\nDrug type: peptide\nCondition: Severe Acute Alcoholic Hepatitis\nPhase: phase_3\nBlinding: NONE\nEnrollment: 18\np-value: 0.076\nEffect size (Hazard Ratio (HR)): 0.31\n95% CI: [0.085, 1.133]\nSerious adverse events: 39.0\nInterpretation: definitive_negative", "metadata": {"result_id": 27793, "source_trial_id": "NCT01829347", "intervention_name": "ELAD", "condition_name": "Severe Acute Alcoholic Hepatitis", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-1162", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: autologous dendritic cells\nCondition: Liver Cancer\nPhase: phase_1\nEnrollment: 22\nTermination reason: \"Study closed due to lack of funding\"\nDetail: Study closed due to lack of funding", "metadata": {"result_id": 62969, "source_trial_id": "NCT00185874", "intervention_name": "autologous dendritic cells", "condition_name": "Liver Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1163", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: JNJ-26113100 (250 mg) twice daily\nCondition: Atopic Dermatitis\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 84\np-value: 0.077\nInterpretation: definitive_negative", "metadata": {"result_id": 46048, "source_trial_id": "NCT00455429", "intervention_name": "JNJ-26113100 (250 mg) twice daily", "condition_name": "Atopic Dermatitis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1164", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Gabapentin\nCondition: Total Knee Replacement\nPhase: phase_4\nBlinding: QUADRUPLE\nEnrollment: 350\nPrimary endpoint met: 1.0\np-value: 0.0001\nInterpretation: definitive_negative", "metadata": {"result_id": 35255, "source_trial_id": "NCT02685735", "intervention_name": "Gabapentin", "condition_name": "Total Knee Replacement", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1165", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Osimertinib\nCondition: Carcinoma, Non-Small-Cell Lung\nPhase: phase_1\nEnrollment: 177\nTermination reason: \"Sponsor decision, not related to safety concerns\"\nDetail: Sponsor decision, not related to safety concerns", "metadata": {"result_id": 43143, "source_trial_id": "NCT04862780", "intervention_name": "Osimertinib", "condition_name": "Carcinoma, Non-Small-Cell Lung", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1166", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Fluorescein\nCondition: Irritable Bowel Disease\nEnrollment: 72\nTermination reason: \"Study terminated due to equipment breakage and lack of funding.\"\nDetail: Study terminated due to equipment breakage and lack of funding.", "metadata": {"result_id": 33246, "source_trial_id": "NCT03220711", "intervention_name": "Fluorescein", "condition_name": "Irritable Bowel Disease", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1167", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Timoptic\nCondition: Burns\nPhase: phase_2\nEnrollment: 40\nTermination reason: \"Lack of funding.\"\nDetail: Lack of funding.", "metadata": {"result_id": 55676, "source_trial_id": "NCT00368602", "intervention_name": "Timoptic", "condition_name": "Burns", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1168", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: omega 3 fats\nCondition: Infertility\nPhase: phase_2\nEnrollment: 6\nTermination reason: \"reports indicating that increased folic acid intake may increase colin cancer\"\nDetail: reports indicating that increased folic acid intake may increase colin cancer", "metadata": {"result_id": 60640, "source_trial_id": "NCT00406874", "intervention_name": "omega 3 fats", "condition_name": "Infertility", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1169", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Erythropoietin\nDrug type: peptide\nCondition: Drug Resistance\nPhase: phase_3\nEnrollment: 6\nTermination reason: \"New evidence and trouble recruiting\"\nDetail: New evidence and trouble recruiting", "metadata": {"result_id": 9078, "source_trial_id": "NCT00319150", "intervention_name": "Erythropoietin", "condition_name": "Drug Resistance", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1170", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: MBG453\nDrug type: monoclonal_antibody\nCondition: Myelodysplastic Syndromes\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 127\np-value: 0.1022\nEffect size (Cox Proportional Hazard): 0.749\n95% CI: [0.479, 1.173]\nInterpretation: definitive_negative", "metadata": {"result_id": 7654, "source_trial_id": "NCT03946670", "intervention_name": "MBG453", "condition_name": "Myelodysplastic Syndromes", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1171", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: 27% Ethanol plus essential oils\nCondition: Covid19\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 128\np-value: 0.6\nInterpretation: definitive_negative", "metadata": {"result_id": 56787, "source_trial_id": "NCT04584684", "intervention_name": "27% Ethanol plus essential oils", "condition_name": "Covid19", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-1172", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Ribociclib\nCondition: Diffuse Intrinsic Pontine Glioma\nPhase: phase_1_2\nEnrollment: 11\nTermination reason: \"A competing trial was opened for patient population with combination of ribociclib and everolimus.\"\nDetail: A competing trial was opened for patient population with combination of ribociclib and everolimus.", "metadata": {"result_id": 49165, "source_trial_id": "NCT02607124", "intervention_name": "Ribociclib", "condition_name": "Diffuse Intrinsic Pontine Glioma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1173", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: amcenestrant\nCondition: Breast Cancer\nPhase: phase_3\nEnrollment: 3\nTermination reason: \"Sponsor decision to prematurely stop the study, not linked to any safety concern\"\nDetail: Sponsor decision to prematurely stop the study, not linked to any safety concern", "metadata": {"result_id": 12116, "source_trial_id": "NCT05128773", "intervention_name": "amcenestrant", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1174", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: dirucotide\nDrug type: peptide\nCondition: Secondary Progressive Multiple Sclerosis\nPhase: phase_2_3\nEnrollment: 546\nTermination reason: \"Negative efficacy results of the MAESTRO-01 trial\"\nDetail: Negative efficacy results of the MAESTRO-01 trial", "metadata": {"result_id": 44849, "source_trial_id": "NCT00870155", "intervention_name": "dirucotide", "condition_name": "Secondary Progressive Multiple Sclerosis", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-1175", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1\nCondition: Metastatic Mucosal Melanoma\nPhase: phase_1\nEnrollment: 12\nTermination reason: \"Lack of funding; lack of objective response\"\nDetail: Lack of funding; lack of objective response", "metadata": {"result_id": 55372, "source_trial_id": "NCT03865212", "intervention_name": "Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1", "condition_name": "Metastatic Mucosal Melanoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1176", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: RhGAA\nDrug type: unknown\nCondition: Pompe Disease\nPhase: phase_1_2\nEnrollment: 12\nTermination reason: \"Company closure due to lack of funding\"\nDetail: Company closure due to lack of funding", "metadata": {"result_id": 46992, "source_trial_id": "NCT02898753", "intervention_name": "RhGAA", "condition_name": "Pompe Disease", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1177", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: JNJ-64281802\nCondition: Dengue\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 1595\nPrimary endpoint met: 1.0\np-value: 0.0192\nEffect size (Odds Ratio (OR)): 87.8\nInterpretation: definitive_negative", "metadata": {"result_id": 57478, "source_trial_id": "NCT05201794", "intervention_name": "JNJ-64281802", "condition_name": "Dengue", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1178", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Cebranopadol\nCondition: Chronic Pain\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 200\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (point-estimate): -7.48\n95% CI: [-12.05, -2.918]\nSerious adverse events: 67.0\nInterpretation: definitive_negative", "metadata": {"result_id": 49599, "source_trial_id": "NCT01964378", "intervention_name": "Cebranopadol", "condition_name": "Chronic Pain", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1179", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: PF-07209960\nCondition: Colorectal Carcinoma\nPhase: phase_1\nEnrollment: 37\nTermination reason: \"Pfizer has made an internal business decision to not continue further development of PF-07209960. This decision was not based on safety or regulatory considerations\"\nDetail: Pfizer has made an internal business decision to not continue further development of PF-07209960. This decision was not based on safety or regulatory considerations", "metadata": {"result_id": 3266, "source_trial_id": "NCT04628780", "intervention_name": "PF-07209960", "condition_name": "Colorectal Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1180", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Soliramfetol\nCondition: Glioma\nPhase: phase_2\nEnrollment: 2\nTermination reason: \"Axsome has conducted a review of the ongoing IST program and are unable to continue supporting this study\"\nDetail: Axsome has conducted a review of the ongoing IST program and are unable to continue supporting this study", "metadata": {"result_id": 2765, "source_trial_id": "NCT03868943", "intervention_name": "Soliramfetol", "condition_name": "Glioma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1181", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: catridecacog\nDrug type: peptide\nCondition: Ulcerative Colitis\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 20\np-value: 0.3056\nEffect size (Odds Ratio (OR)): 0.16\n95% CI: [0.01, 3.05]\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 55037, "source_trial_id": "NCT01706159", "intervention_name": "catridecacog", "condition_name": "Ulcerative Colitis", "confidence_tier": "silver", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL1-1182", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: COVID-19 convalescent plasma treatment\nCondition: COVID-19 Convalescent Plasma Treatment\nEnrollment: 396\nTermination reason: \"The main reasons for the premature termination of the study are the inability to reliably assess the effectiveness of therapy due to the emergence of new variants of SARS-CoV-2 and reports of the lack of benefits of using plasma in previous studies.\"\nDetail: The main reasons for the premature termination of the study are the inability to reliably assess the effectiveness of therapy due to the emergence of new variants of SARS-CoV-2 and reports of the lack of benefits of using plasma in previous studies.", "metadata": {"result_id": 15069, "source_trial_id": "NCT04642014", "intervention_name": "COVID-19 convalescent plasma treatment", "condition_name": "COVID-19 Convalescent Plasma Treatment", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-1183", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Part 1 (Dose Escalation): Duvortuxizumab\nCondition: Lymphoma, Follicular\nPhase: phase_1\nEnrollment: 59\nTermination reason: \"Recent advances in the treatment of B cell malignancies resulting in new treatments being approved for marketing and many others in late stage development\"\nDetail: Recent advances in the treatment of B cell malignancies resulting in new treatments being approved for marketing and many others in late stage development", "metadata": {"result_id": 20791, "source_trial_id": "NCT02454270", "intervention_name": "Part 1 (Dose Escalation): Duvortuxizumab", "condition_name": "Lymphoma, Follicular", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1184", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: VEGFR1 and VEGFR2\nCondition: Colon Cancer\nPhase: phase_1_2\nEnrollment: 14\nTermination reason: \"Lack of financial support\"\nDetail: Lack of financial support", "metadata": {"result_id": 43249, "source_trial_id": "NCT00677612", "intervention_name": "VEGFR1 and VEGFR2", "condition_name": "Colon Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1185", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: BAT6026\nCondition: Advanced Solid Tumour\nPhase: phase_1\nEnrollment: 13\nTermination reason: \"Considering that the high budget will affect the subsequent development, it is decided to terminate the test voluntarily\"\nDetail: Considering that the high budget will affect the subsequent development, it is decided to terminate the test voluntarily", "metadata": {"result_id": 33366, "source_trial_id": "NCT05109650", "intervention_name": "BAT6026", "condition_name": "Advanced Solid Tumour", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1186", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Dantrolene\nCondition: Hyperthermia\nPhase: phase_2_3\nEnrollment: 34\nTermination reason: \"organizationally not possible\"\nDetail: organizationally not possible", "metadata": {"result_id": 23338, "source_trial_id": "NCT00796900", "intervention_name": "Dantrolene", "condition_name": "Hyperthermia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1187", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: lidocaine infusion\nCondition: Rib Fractures\nPhase: phase_4\nEnrollment: 1\nTermination reason: \"Lack of personnel and lack of funding for the study drug\"\nDetail: Lack of personnel and lack of funding for the study drug", "metadata": {"result_id": 3188, "source_trial_id": "NCT04140396", "intervention_name": "lidocaine infusion", "condition_name": "Rib Fractures", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1188", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Gamma-Secretase Inhibitor RO4929097\nCondition: Stage IIIB Breast Cancer\nPhase: phase_1\nEnrollment: 15\nTermination reason: \"Manufacturer discontinued drug development.\"\nDetail: Manufacturer discontinued drug development.", "metadata": {"result_id": 6481, "source_trial_id": "NCT01149356", "intervention_name": "Gamma-Secretase Inhibitor RO4929097", "condition_name": "Stage IIIB Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1189", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: 0.5% w/v Povidone-iodide\nCondition: Coronavirus Infection\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 128\np-value: 0.6\nInterpretation: definitive_negative", "metadata": {"result_id": 56800, "source_trial_id": "NCT04584684", "intervention_name": "0.5% w/v Povidone-iodide", "condition_name": "Coronavirus Infection", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1190", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Vehicle gel\nCondition: Actinic Keratosis\nPhase: phase_3\nBlinding: NONE\nEnrollment: 563\nPrimary endpoint met: 1.0\np-value: 0.01\nEffect size (Hazard Ratio (HR)): 1.99\n95% CI: [1.17, 3.62]\nSerious adverse events: 5.0\nInterpretation: definitive_negative", "metadata": {"result_id": 46843, "source_trial_id": "NCT03115476", "intervention_name": "Vehicle gel", "condition_name": "Actinic Keratosis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1191", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: AV-101\nCondition: Pulmonary Arterial Hypertension\nPhase: phase_3\nEnrollment: 186\nTermination reason: \"Results from the parent study (IMPAHCT) demonstrated that while inhaled imatinib was well tolerated, it did not prove to be efficacious at any of the doses of AV-101 evaluated in the study.\"\nDetail: Results from the parent study (IMPAHCT) demonstrated that while inhaled imatinib was well tolerated, it did not prove to be efficacious at any of the doses of AV-101 evaluated in the study.", "metadata": {"result_id": 53878, "source_trial_id": "NCT05557942", "intervention_name": "AV-101", "condition_name": "Pulmonary Arterial Hypertension", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-1192", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: NMS-1116354\nDrug type: unknown\nCondition: Advanced Solid Tumors\nPhase: phase_1\nEnrollment: 15\nTermination reason: \"Discontinuation of clinical investigation with NMS-1116354\"\nDetail: Discontinuation of clinical investigation with NMS-1116354", "metadata": {"result_id": 45010, "source_trial_id": "NCT01016327", "intervention_name": "NMS-1116354", "condition_name": "Advanced Solid Tumors", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1193", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Sitravatinib\nCondition: Urothelial Carcinoma of the Renal Pelvis and Ureter\nPhase: phase_2\nEnrollment: 260\nTermination reason: \"The study was terminated due to sponsor decision / portfolio prioritization, and not due to safety reasons.\"\nDetail: The study was terminated due to sponsor decision / portfolio prioritization, and not due to safety reasons.", "metadata": {"result_id": 33027, "source_trial_id": "NCT03606174", "intervention_name": "Sitravatinib", "condition_name": "Urothelial Carcinoma of the Renal Pelvis and Ureter", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1194", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: sodium oxybate\nCondition: Chronic Fatigue Syndrome\nPhase: phase_4\nBlinding: DOUBLE\nEnrollment: 17\nPrimary endpoint met: 1.0\np-value: 0.04\nInterpretation: definitive_negative", "metadata": {"result_id": 44038, "source_trial_id": "NCT00498485", "intervention_name": "sodium oxybate", "condition_name": "Chronic Fatigue Syndrome", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1195", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: OTO-104\nCondition: Meniere's Disease\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 176\nPrimary endpoint met: 1.0\np-value: 0.014\nEffect size (Risk Ratio (RR)): 0.59\n95% CI: [0.388, 0.896]\nInterpretation: definitive_negative", "metadata": {"result_id": 21917, "source_trial_id": "NCT02717442", "intervention_name": "OTO-104", "condition_name": "Meniere's Disease", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1196", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Abraxane\nCondition: Squamous Cell Carcinoma of the Head and Neck\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 29\nPrimary endpoint met: 1.0\np-value: 0.01\nSerious adverse events: 93.0\nInterpretation: definitive_negative", "metadata": {"result_id": 53205, "source_trial_id": "NCT00570674", "intervention_name": "Abraxane", "condition_name": "Squamous Cell Carcinoma of the Head and Neck", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1197", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: GSK3901961\nCondition: Neoplasms\nPhase: phase_1\nEnrollment: 12\nTermination reason: \"The study was terminated due to a change in GSK's R\\&D priorities.\"\nDetail: The study was terminated due to a change in GSK's R\\&D priorities.", "metadata": {"result_id": 20904, "source_trial_id": "NCT04526509", "intervention_name": "GSK3901961", "condition_name": "Neoplasms", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1198", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Valsartan\nCondition: Sleep Apnea\nPhase: phase_4\nEnrollment: 12\nTermination reason: \"budget constraints\"\nDetail: budget constraints", "metadata": {"result_id": 12405, "source_trial_id": "NCT02058823", "intervention_name": "Valsartan", "condition_name": "Sleep Apnea", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1199", "task": "CT-L1", "gold_answer": "D", "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: amcenestrant\nCondition: Breast Cancer Metastatic\nPhase: phase_2\nBlinding: SINGLE\nEnrollment: 367\np-value: 0.6437\nEffect size (Hazard Ratio (HR)): 1.051\n95% CI: [0.789, 1.4]\nInterpretation: definitive_negative", "metadata": {"result_id": 9921, "source_trial_id": "NCT04059484", "intervention_name": "amcenestrant", "condition_name": "Breast Cancer Metastatic", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1200", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Niacin/Laropiprant combination\nCondition: Peripheral Arterial Disease\nEnrollment: 7\nTermination reason: \"Tredaptive has been suspended worldwide\"\nDetail: Tredaptive has been suspended worldwide", "metadata": {"result_id": 52601, "source_trial_id": "NCT01391377", "intervention_name": "Niacin/Laropiprant combination", "condition_name": "Peripheral Arterial Disease", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1201", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Belinostat\nCondition: Recurrent Acute Myeloid Leukemia\nPhase: phase_1\nEnrollment: 18\nTermination reason: \"Drug supply issues\"\nDetail: Drug supply issues", "metadata": {"result_id": 22045, "source_trial_id": "NCT03772925", "intervention_name": "Belinostat", "condition_name": "Recurrent Acute Myeloid Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1202", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Pregabalin\nCondition: Postherpetic Neuralgia\nPhase: phase_4\nEnrollment: 9\nTermination reason: \"See termination reason in detailed description.\"\nDetail: See termination reason in detailed description.", "metadata": {"result_id": 20435, "source_trial_id": "NCT01603394", "intervention_name": "Pregabalin", "condition_name": "Postherpetic Neuralgia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1203", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Depodur\nCondition: Arthroplasty, Replacement, Knee\nPhase: phase_4\nBlinding: SINGLE\nEnrollment: 75\np-value: 0.95\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 41117, "source_trial_id": "NCT00895531", "intervention_name": "Depodur", "condition_name": "Arthroplasty, Replacement, Knee", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1204", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Botox Instillation\nCondition: Urinary Incontinence\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 25\nPrimary endpoint met: 1.0\np-value: 0.024\nSerious adverse events: 5.0\nInterpretation: definitive_negative", "metadata": {"result_id": 26382, "source_trial_id": "NCT00667095", "intervention_name": "Botox Instillation", "condition_name": "Urinary Incontinence", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1205", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Acalabrutinib\nCondition: Chronic Lymphocytic Leukemia\nPhase: phase_2\nEnrollment: 2\nTermination reason: \"Investigator Decision\"\nDetail: Investigator Decision", "metadata": {"result_id": 7026, "source_trial_id": "NCT04189952", "intervention_name": "Acalabrutinib", "condition_name": "Chronic Lymphocytic Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1206", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: PH-10 (rose bengal disodium 0.001%)\nCondition: Plaque Psoriasis\nPhase: phase_2\nEnrollment: 6\nTermination reason: \"Change of dose regimen (new protocol)\"\nDetail: Change of dose regimen (new protocol)", "metadata": {"result_id": 60860, "source_trial_id": "NCT00555646", "intervention_name": "PH-10 (rose bengal disodium 0.001%)", "condition_name": "Plaque Psoriasis", "confidence_tier": "bronze", "therapeutic_area": "autoimmune"}, "split": "fewshot"}
+{"question_id": "CTL1-1207", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: G-CSF\nDrug type: peptide\nCondition: Untreated Adult Acute Myeloid Leukemia\nEnrollment: 6\nTermination reason: \"No patients were eligible to receive the experimental component of the protocol therapy.\"\nDetail: No patients were eligible to receive the experimental component of the protocol therapy.", "metadata": {"result_id": 51706, "source_trial_id": "NCT02105116", "intervention_name": "G-CSF", "condition_name": "Untreated Adult Acute Myeloid Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1208", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: epoetin alpha\nCondition: Anemia\nPhase: phase_4\nBlinding: QUADRUPLE\nEnrollment: 22\nPrimary endpoint met: 1.0\np-value: 0.02\nEffect size (Mean Difference (Net)): 1.7\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 7017, "source_trial_id": "NCT00511901", "intervention_name": "epoetin alpha", "condition_name": "Anemia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1209", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Metformin, 1000 mg extended release tablet\nCondition: Diabetes Mellitus, Type 2\nPhase: phase_1\nEnrollment: 20\nTermination reason: \"Due to changes in EMA guidelines on modified release dosage forms (Feb 2013; EMA/CHMP/EWP/280/96). The Part B formulation would not meet the new guidelines.\"\nDetail: Due to changes in EMA guidelines on modified release dosage forms (Feb 2013; EMA/CHMP/EWP/280/96). The Part B formulation would not meet the new guidelines.", "metadata": {"result_id": 33516, "source_trial_id": "NCT01725672", "intervention_name": "Metformin, 1000 mg extended release tablet", "condition_name": "Diabetes Mellitus, Type 2", "confidence_tier": "bronze", "therapeutic_area": "metabolic"}, "split": "fewshot"}
+{"question_id": "CTL1-1210", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Gabapentin + dexamethasone + ketamine\nCondition: Pain, Postoperative\nPhase: phase_4\nEnrollment: 48\nTermination reason: \"Structural changes that stopped the type of operations used in the study\"\nDetail: Structural changes that stopped the type of operations used in the study", "metadata": {"result_id": 5926, "source_trial_id": "NCT00236223", "intervention_name": "Gabapentin + dexamethasone + ketamine", "condition_name": "Pain, Postoperative", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1211", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Liraglutide Pen Injector\nDrug type: peptide\nCondition: Irritable Pouch Syndrome\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 8\nPrimary endpoint met: 1.0\np-value: 0.01\nInterpretation: definitive_negative", "metadata": {"result_id": 44448, "source_trial_id": "NCT04763564", "intervention_name": "Liraglutide Pen Injector", "condition_name": "Irritable Pouch Syndrome", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1212", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "hard", "context_text": "Drug: Ibuprofen 800 mg oral\nCondition: Infertility, Female\nPhase: phase_4\nEnrollment: 12\nTermination reason: \"IRB voted to terminate the protocol for noncompliance\"\nDetail: IRB voted to terminate the protocol for noncompliance", "metadata": {"result_id": 54306, "source_trial_id": "NCT05190341", "intervention_name": "Ibuprofen 800 mg oral", "condition_name": "Infertility, Female", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1213", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: CP-751,871 (Figitumumab)\nDrug type: monoclonal_antibody\nCondition: Carcinoma, Non-Small-Cell Lung\nPhase: phase_3\nBlinding: NONE\nEnrollment: 681\np-value: 0.064\nEffect size (Hazard Ratio (HR)): 1.179\n95% CI: [0.99, 1.404]\nSerious adverse events: 1081.0\nInterpretation: definitive_negative", "metadata": {"result_id": 13698, "source_trial_id": "NCT00596830", "intervention_name": "CP-751,871 (Figitumumab)", "condition_name": "Carcinoma, Non-Small-Cell Lung", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1214", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: PXD101with cisplatin+doxorubicin+cyclophosphamide\nCondition: Thymoma\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 26\nPrimary endpoint met: 1.0\np-value: 0.0001\nSerious adverse events: 66.0\nInterpretation: definitive_negative", "metadata": {"result_id": 13574, "source_trial_id": "NCT01100944", "intervention_name": "PXD101with cisplatin+doxorubicin+cyclophosphamide", "condition_name": "Thymoma", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1215", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "medium", "context_text": "Drug: S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)\nCondition: Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction\nPhase: phase_3\nBlinding: NONE\nEnrollment: 361\np-value: 0.1683\nEffect size (Hazard Ratio (HR)): 0.84\n95% CI: [0.66, 1.08]\nSerious adverse events: 542.0\nInterpretation: definitive_negative", "metadata": {"result_id": 8569, "source_trial_id": "NCT01285557", "intervention_name": "S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)", "condition_name": "Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1216", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Chlorogenic acid\nCondition: Advanced Cancer\nPhase: phase_1\nTermination reason: \"Study site change\"\nDetail: Study site change", "metadata": {"result_id": 60866, "source_trial_id": "NCT02136342", "intervention_name": "Chlorogenic acid", "condition_name": "Advanced Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1217", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "hard", "context_text": "Drug: mannitol\nCondition: Brain and Central Nervous System Tumors\nPhase: phase_1\nEnrollment: 2\nTermination reason: \"OHSU IRB closed study to further enrollment 2/17/2006\"\nDetail: OHSU IRB closed study to further enrollment 2/17/2006", "metadata": {"result_id": 7987, "source_trial_id": "NCT00238173", "intervention_name": "mannitol", "condition_name": "Brain and Central Nervous System Tumors", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1218", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: CTAP101\nCondition: Chronic Kidney Disease stage4\nPhase: phase_3\nEnrollment: 2\nTermination reason: \"FDA changed the post-marketing requirement necessitating a new study design and protocol.\"\nDetail: FDA changed the post-marketing requirement necessitating a new study design and protocol.", "metadata": {"result_id": 49493, "source_trial_id": "NCT05543928", "intervention_name": "CTAP101", "condition_name": "Chronic Kidney Disease stage4", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1219", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Caffeine and Sodium Benzoate 20 mg/kg IV\nCondition: Enlargement of Tonsil or Adenoid\nEnrollment: 42\nTermination reason: \"The study medication was no longer available in the market\"\nDetail: The study medication was no longer available in the market", "metadata": {"result_id": 48585, "source_trial_id": "NCT01349205", "intervention_name": "Caffeine and Sodium Benzoate 20 mg/kg IV", "condition_name": "Enlargement of Tonsil or Adenoid", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1220", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Erythromycin\nCondition: Gastroparesis\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 26\nPrimary endpoint met: 1.0\np-value: 0.0083\nEffect size (Median Difference (Net)): -6.4\n95% CI: [-10.97, -1.83]\nInterpretation: definitive_negative", "metadata": {"result_id": 4678, "source_trial_id": "NCT01323582", "intervention_name": "Erythromycin", "condition_name": "Gastroparesis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1221", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: NBE-002\nCondition: Triple Negative Breast Cancer\nPhase: phase_1_2\nEnrollment: 12\nTermination reason: \"End of Program\"\nDetail: End of Program", "metadata": {"result_id": 39326, "source_trial_id": "NCT04441099", "intervention_name": "NBE-002", "condition_name": "Triple Negative Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1222", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Clobetasol 0.05% Topical Ointment\nCondition: Bullous Pemphigoid\nPhase: phase_2\nEnrollment: 10\nTermination reason: \"Terminated with partial enrollment completed\"\nDetail: Terminated with partial enrollment completed", "metadata": {"result_id": 19955, "source_trial_id": "NCT03286582", "intervention_name": "Clobetasol 0.05% Topical Ointment", "condition_name": "Bullous Pemphigoid", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1223", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Venetoclax, daunorubicin, cytarabine\nCondition: Measurable Disease\nPhase: phase_2\nEnrollment: 20\nTermination reason: \"The research center has conducted a more comprehensive study.\"\nDetail: The research center has conducted a more comprehensive study.", "metadata": {"result_id": 371, "source_trial_id": "NCT05361057", "intervention_name": "Venetoclax, daunorubicin, cytarabine", "condition_name": "Measurable Disease", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1224", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: MTA\nCondition: Primary Teeth\nBlinding: TRIPLE\nEnrollment: 57\np-value: 0.808\nInterpretation: definitive_negative", "metadata": {"result_id": 27229, "source_trial_id": "NCT02783911", "intervention_name": "MTA", "condition_name": "Primary Teeth", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1225", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: casirivimab+imdevimab combination therapy\nCondition: COVID-19\nPhase: phase_3\nBlinding: NONE\nEnrollment: 10078\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (LS Mean): -0.37\n95% CI: [-0.56, -0.19]\nInterpretation: definitive_negative", "metadata": {"result_id": 40219, "source_trial_id": "NCT04425629", "intervention_name": "casirivimab+imdevimab combination therapy", "condition_name": "COVID-19", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "fewshot"}
+{"question_id": "CTL1-1226", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Scopolamine\nCondition: Depression\nPhase: phase_2\nEnrollment: 7\nTermination reason: \"This was an inpatient study, but PI left inpatient service at MGH\"\nDetail: This was an inpatient study, but PI left inpatient service at MGH", "metadata": {"result_id": 28143, "source_trial_id": "NCT01312844", "intervention_name": "Scopolamine", "condition_name": "Depression", "confidence_tier": "bronze", "therapeutic_area": "psychiatry"}, "split": "fewshot"}
+{"question_id": "CTL1-1227", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Avelumab Phase 1b\nCondition: Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors\nPhase: phase_1_2\nEnrollment: 223\nTermination reason: \"The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522).\"\nDetail: The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522).", "metadata": {"result_id": 4679, "source_trial_id": "NCT03330405", "intervention_name": "Avelumab Phase 1b", "condition_name": "Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1228", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: E6201\nCondition: Malignant Melanoma\nPhase: phase_1\nEnrollment: 4\nTermination reason: \"Single center study: Principal Investigator left institution.\"\nDetail: Single center study: Principal Investigator left institution.", "metadata": {"result_id": 55210, "source_trial_id": "NCT03332589", "intervention_name": "E6201", "condition_name": "Malignant Melanoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1229", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: RVM-V001 30 µg\nCondition: COVID-19\nPhase: phase_1\nEnrollment: 13\nTermination reason: \"The landscape of the study area changed, making it impossible to continue the study.\"\nDetail: The landscape of the study area changed, making it impossible to continue the study.", "metadata": {"result_id": 23807, "source_trial_id": "NCT05420077", "intervention_name": "RVM-V001 30 µg", "condition_name": "COVID-19", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "fewshot"}
+{"question_id": "CTL1-1230", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: ketorolac tromethamine opthalmic solution\nCondition: Hip Arthroplasty\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 62\np-value: 0.66\nInterpretation: definitive_negative", "metadata": {"result_id": 33253, "source_trial_id": "NCT00621530", "intervention_name": "ketorolac tromethamine opthalmic solution", "condition_name": "Hip Arthroplasty", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1231", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: P-PSMA-101 CAR-T cells\nCondition: Salivary Gland Tumor\nPhase: phase_1\nEnrollment: 40\nTermination reason: \"Study closed\"\nDetail: Study closed", "metadata": {"result_id": 42384, "source_trial_id": "NCT04249947", "intervention_name": "P-PSMA-101 CAR-T cells", "condition_name": "Salivary Gland Tumor", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1232", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: azithromycin\nCondition: Gastroparesis\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 26\nPrimary endpoint met: 1.0\np-value: 0.0083\nEffect size (Median Difference (Net)): -6.4\n95% CI: [-10.97, -1.83]\nInterpretation: definitive_negative", "metadata": {"result_id": 4677, "source_trial_id": "NCT01323582", "intervention_name": "azithromycin", "condition_name": "Gastroparesis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1233", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: defined green tea catechin extract\nCondition: Adenocarcinoma of the Colon\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 39\np-value: 0.1439\nInterpretation: definitive_negative", "metadata": {"result_id": 32811, "source_trial_id": "NCT01606124", "intervention_name": "defined green tea catechin extract", "condition_name": "Adenocarcinoma of the Colon", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1234", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "hard", "context_text": "Drug: Early Glargine\nCondition: Type 2 Diabetes\nPhase: phase_4\nEnrollment: 39\nTermination reason: \"Stopped after internal review\"\nDetail: Stopped after internal review", "metadata": {"result_id": 43257, "source_trial_id": "NCT04567225", "intervention_name": "Early Glargine", "condition_name": "Type 2 Diabetes", "confidence_tier": "bronze", "therapeutic_area": "metabolic"}, "split": "fewshot"}
+{"question_id": "CTL1-1235", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: GSK2485852 210 mg +Ritonavir 100mg\nCondition: Hepatitis C\nPhase: phase_1\nEnrollment: 27\nTermination reason: \"Terminated due to unfavorable human pharmacokinetic properties\"\nDetail: Terminated due to unfavorable human pharmacokinetic properties", "metadata": {"result_id": 55031, "source_trial_id": "NCT01332552", "intervention_name": "GSK2485852 210 mg +Ritonavir 100mg", "condition_name": "Hepatitis C", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "fewshot"}
+{"question_id": "CTL1-1236", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Dalteparin (Fragmin)\nDrug type: other_biologic\nCondition: Venous Thromboembolism\nPhase: phase_4\nBlinding: NONE\nEnrollment: 84\np-value: 0.1355\nSerious adverse events: 14.0\nInterpretation: definitive_negative", "metadata": {"result_id": 51000, "source_trial_id": "NCT00445328", "intervention_name": "Dalteparin (Fragmin)", "condition_name": "Venous Thromboembolism", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1237", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: H1299 Cell Lysates\nCondition: Thorasic Cancers\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 21\np-value: 0.36\nInterpretation: definitive_negative", "metadata": {"result_id": 6271, "source_trial_id": "NCT02054104", "intervention_name": "H1299 Cell Lysates", "condition_name": "Thorasic Cancers", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1238", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Fenofibrate\nCondition: Healthy\nBlinding: QUADRUPLE\nEnrollment: 11\nPrimary endpoint met: 1.0\np-value: 0.015\nEffect size (Ratio of mean effects): 1.27\n95% CI: [1.06, 1.52]\nInterpretation: definitive_negative", "metadata": {"result_id": 18994, "source_trial_id": "NCT00644592", "intervention_name": "Fenofibrate", "condition_name": "Healthy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1239", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: MEDI7352\nDrug type: monoclonal_antibody\nCondition: Painful Diabetic Neuropathy\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 112\nPrimary endpoint met: 1.0\np-value: 0.0009\nEffect size (LS mean estimate): -1.39\n95% CI: [-2.19, -0.58]\nInterpretation: definitive_negative", "metadata": {"result_id": 7354, "source_trial_id": "NCT03755934", "intervention_name": "MEDI7352", "condition_name": "Painful Diabetic Neuropathy", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "fewshot"}
+{"question_id": "CTL1-1240", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Botox Instillation\nCondition: Overactive Bladder\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 25\nPrimary endpoint met: 1.0\np-value: 0.024\nSerious adverse events: 5.0\nInterpretation: definitive_negative", "metadata": {"result_id": 26380, "source_trial_id": "NCT00667095", "intervention_name": "Botox Instillation", "condition_name": "Overactive Bladder", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1241", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Botox Instillation\nCondition: Urinary Urge Incontinence\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 25\nPrimary endpoint met: 1.0\np-value: 0.024\nSerious adverse events: 5.0\nInterpretation: definitive_negative", "metadata": {"result_id": 26388, "source_trial_id": "NCT00667095", "intervention_name": "Botox Instillation", "condition_name": "Urinary Urge Incontinence", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1242", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: re-activated T cells\nCondition: Colorectal Carcinoma\nPhase: phase_1\nEnrollment: 1\nTermination reason: \"not feasible\"\nDetail: not feasible", "metadata": {"result_id": 63904, "source_trial_id": "NCT02577588", "intervention_name": "re-activated T cells", "condition_name": "Colorectal Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1243", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Bevacizumab\nDrug type: monoclonal_antibody\nCondition: Neoplasm Metastasis\nPhase: phase_2\nBlinding: NONE\nEnrollment: 208\np-value: 0.4476\nSerious adverse events: 171.0\nInterpretation: definitive_negative", "metadata": {"result_id": 863, "source_trial_id": "NCT00281528", "intervention_name": "Bevacizumab", "condition_name": "Neoplasm Metastasis", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1244", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Vitamin D3 50,000 IU\nCondition: Covid19\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 90\np-value: 0.09\nInterpretation: definitive_negative", "metadata": {"result_id": 6893, "source_trial_id": "NCT04780061", "intervention_name": "Vitamin D3 50,000 IU", "condition_name": "Covid19", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "fewshot"}
+{"question_id": "CTL1-1245", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Iscomatrix adjuvant\nCondition: Thoracic Sarcomas\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 21\np-value: 0.36\nInterpretation: definitive_negative", "metadata": {"result_id": 6264, "source_trial_id": "NCT02054104", "intervention_name": "Iscomatrix adjuvant", "condition_name": "Thoracic Sarcomas", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1246", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Relugolix Pill\nCondition: Prostate Adenocarcinoma\nPhase: phase_1\nEnrollment: 60\nTermination reason: \"Terminated by the PI\"\nDetail: Terminated by the PI", "metadata": {"result_id": 6330, "source_trial_id": "NCT05679388", "intervention_name": "Relugolix Pill", "condition_name": "Prostate Adenocarcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1247", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: oxaliplatin+capecitabine\nCondition: Liver Metastases\nPhase: phase_3\nEnrollment: 79\nTermination reason: \"Data from the C08 study and Avant study\"\nDetail: Data from the C08 study and Avant study", "metadata": {"result_id": 12945, "source_trial_id": "NCT00394992", "intervention_name": "oxaliplatin+capecitabine", "condition_name": "Liver Metastases", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1248", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "hard", "context_text": "Drug: Tegaserod\nCondition: Opioid-induced Constipation\nPhase: phase_3\nEnrollment: 360\nTermination reason: \"This study was terminated early as a result of regulatory action suspending tegaserod use in 2007\"\nDetail: This study was terminated early as a result of regulatory action suspending tegaserod use in 2007", "metadata": {"result_id": 58824, "source_trial_id": "NCT00399659", "intervention_name": "Tegaserod", "condition_name": "Opioid-induced Constipation", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1249", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "hard", "context_text": "Drug: Tauroursodeoxycholic Acid\nCondition: Asthma\nPhase: phase_1\nEnrollment: 11\nTermination reason: \"IRB protocol violations\"\nDetail: IRB protocol violations", "metadata": {"result_id": 28836, "source_trial_id": "NCT03878654", "intervention_name": "Tauroursodeoxycholic Acid", "condition_name": "Asthma", "confidence_tier": "bronze", "therapeutic_area": "respiratory"}, "split": "fewshot"}
+{"question_id": "CTL1-1250", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Droxidopa\nCondition: Autonomic Nervous System Diseases\nPhase: phase_1_2\nEnrollment: 14\nTermination reason: \"Study terminated due to contamination droxidopa\"\nDetail: Study terminated due to contamination droxidopa", "metadata": {"result_id": 25857, "source_trial_id": "NCT00547911", "intervention_name": "Droxidopa", "condition_name": "Autonomic Nervous System Diseases", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1251", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Ethinylestradiol/drospirenone 0.02 mg/3 mg\nCondition: Healthy\nPhase: phase_1\nEnrollment: 18\nTermination reason: \"Study stopping rules were met.\"\nDetail: Study stopping rules were met.", "metadata": {"result_id": 50145, "source_trial_id": "NCT03126097", "intervention_name": "Ethinylestradiol/drospirenone 0.02 mg/3 mg", "condition_name": "Healthy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1252", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457\nCondition: Human Papillomavirus-16 Positive\nPhase: phase_2\nEnrollment: 41\nTermination reason: \"Project delays\"\nDetail: Project delays", "metadata": {"result_id": 38602, "source_trial_id": "NCT03439085", "intervention_name": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457", "condition_name": "Human Papillomavirus-16 Positive", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1253", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: DMSO Instillation\nCondition: Urge Incontinence\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 25\nPrimary endpoint met: 1.0\np-value: 0.024\nSerious adverse events: 5.0\nInterpretation: definitive_negative", "metadata": {"result_id": 26385, "source_trial_id": "NCT00667095", "intervention_name": "DMSO Instillation", "condition_name": "Urge Incontinence", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1254", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: tanezumab 10 mg\nCondition: Low Back Pain\nPhase: phase_2\nEnrollment: 849\nTermination reason: \"See termination reason in detailed description.\"\nDetail: See termination reason in detailed description.", "metadata": {"result_id": 26638, "source_trial_id": "NCT00924664", "intervention_name": "tanezumab 10 mg", "condition_name": "Low Back Pain", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1255", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: CAT-8015 10 mcg/kg\nCondition: Leukemia, Lymphoma, Chronic Lymphocytic\nPhase: phase_1\nEnrollment: 11\nTermination reason: \"The study is terminated early due to unavailability of investigational product.\"\nDetail: The study is terminated early due to unavailability of investigational product.", "metadata": {"result_id": 38127, "source_trial_id": "NCT00587457", "intervention_name": "CAT-8015 10 mcg/kg", "condition_name": "Leukemia, Lymphoma, Chronic Lymphocytic", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1256", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Fluorouracil/cisplatin (control arm)\nCondition: Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction\nPhase: phase_3\nBlinding: NONE\nEnrollment: 361\np-value: 0.1683\nEffect size (Hazard Ratio (HR)): 0.84\n95% CI: [0.66, 1.08]\nSerious adverse events: 542.0\nInterpretation: definitive_negative", "metadata": {"result_id": 8570, "source_trial_id": "NCT01285557", "intervention_name": "Fluorouracil/cisplatin (control arm)", "condition_name": "Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL1-1257", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Botox Instillation\nCondition: Detrusor Hyperreflexia\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 25\nPrimary endpoint met: 1.0\np-value: 0.024\nSerious adverse events: 5.0\nInterpretation: definitive_negative", "metadata": {"result_id": 26386, "source_trial_id": "NCT00667095", "intervention_name": "Botox Instillation", "condition_name": "Detrusor Hyperreflexia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1258", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Opioid Analgesic\nCondition: Surgery\nPhase: phase_4\nEnrollment: 8\nTermination reason: \"Limitations of the prospective study design revealed that a retrospective study design would be better suited.\"\nDetail: Limitations of the prospective study design revealed that a retrospective study design would be better suited.", "metadata": {"result_id": 9408, "source_trial_id": "NCT04990804", "intervention_name": "Opioid Analgesic", "condition_name": "Surgery", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL1-1259", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: Asundexian (BAY2433334)\nDrug type: unknown\nCondition: Prevention of Stroke or Systemic Embolism\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 14830\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (Cox Proportional Hazard): 3.785\n95% CI: [2.457, 5.833]\nInterpretation: definitive_negative", "metadata": {"result_id": 10835, "source_trial_id": "NCT05643573", "intervention_name": "Asundexian (BAY2433334)", "condition_name": "Prevention of Stroke or Systemic Embolism", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "fewshot"}
+{"question_id": "CTL1-1260", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab\nCondition: Melanoma\nPhase: phase_1\nEnrollment: 11\nTermination reason: \"recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated\"\nDetail: recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated", "metadata": {"result_id": 52701, "source_trial_id": "NCT03565406", "intervention_name": "Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab", "condition_name": "Melanoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1261", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: TBC3711\nCondition: Resistant Hypertension\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 60\nPrimary endpoint met: 1.0\np-value: 0.016\nEffect size (LS Mean Difference): 6.37\n95% CI: [1.28, 11.45]\nSerious adverse events: 5.0\nInterpretation: definitive_negative", "metadata": {"result_id": 17248, "source_trial_id": "NCT00272961", "intervention_name": "TBC3711", "condition_name": "Resistant Hypertension", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL1-1262", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Omegaven\nDrug type: unknown\nCondition: Hepatic Injury\nPhase: phase_2\nBlinding: NONE\nEnrollment: 12\np-value: 0.07\nSerious adverse events: 1.0\nInterpretation: definitive_negative", "metadata": {"result_id": 44445, "source_trial_id": "NCT01325584", "intervention_name": "Omegaven", "condition_name": "Hepatic Injury", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1263", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: ISF35\nCondition: Small Lymphocytic Lymphoma\nPhase: phase_2\nEnrollment: 5\nTermination reason: \"drug supply was no longer available\"\nDetail: drug supply was no longer available", "metadata": {"result_id": 18175, "source_trial_id": "NCT00942409", "intervention_name": "ISF35", "condition_name": "Small Lymphocytic Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1264", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Triamcinolone Acetonide 40 mg/ml Inj, Susp\nCondition: Knee Osteoarthritis\nPhase: phase_1_2\nEnrollment: 23\nTermination reason: \"Principal Investigator is Retiring.\"\nDetail: Principal Investigator is Retiring.", "metadata": {"result_id": 22473, "source_trial_id": "NCT05657496", "intervention_name": "Triamcinolone Acetonide 40 mg/ml Inj, Susp", "condition_name": "Knee Osteoarthritis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1265", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Azathioprine (Aza)\nCondition: Ulcerative Colitis\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 242\nPrimary endpoint met: 1.0\np-value: 0.032\nSerious adverse events: 56.0\nInterpretation: definitive_negative", "metadata": {"result_id": 11090, "source_trial_id": "NCT00537316", "intervention_name": "Azathioprine (Aza)", "condition_name": "Ulcerative Colitis", "confidence_tier": "silver", "therapeutic_area": "autoimmune"}, "split": "val"}
+{"question_id": "CTL1-1266", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: CP-751,871 (Figitumumab)\nDrug type: monoclonal_antibody\nCondition: Carcinoma, Large Cell\nPhase: phase_3\nBlinding: NONE\nEnrollment: 681\np-value: 0.064\nEffect size (Hazard Ratio (HR)): 1.179\n95% CI: [0.99, 1.404]\nSerious adverse events: 1081.0\nInterpretation: definitive_negative", "metadata": {"result_id": 13704, "source_trial_id": "NCT00596830", "intervention_name": "CP-751,871 (Figitumumab)", "condition_name": "Carcinoma, Large Cell", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1267", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: DNR\nCondition: Adult Lymphoblastic Lymphoma\nPhase: phase_2\nEnrollment: 31\nTermination reason: \"Original investigator for the trial has left\"\nDetail: Original investigator for the trial has left", "metadata": {"result_id": 44653, "source_trial_id": "NCT02043587", "intervention_name": "DNR", "condition_name": "Adult Lymphoblastic Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1268", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Intraspinal Gabapentin\nCondition: Chronic Intractable Pain\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 254\np-value: 0.083\nSerious adverse events: 22.0\nInterpretation: definitive_negative", "metadata": {"result_id": 22724, "source_trial_id": "NCT00414466", "intervention_name": "Intraspinal Gabapentin", "condition_name": "Chronic Intractable Pain", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1269", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: methotrexate\nCondition: Juvenile Myelomonocytic Leukemia\nPhase: phase_1\nEnrollment: 12\nTermination reason: \"PI left institution\"\nDetail: PI left institution", "metadata": {"result_id": 2687, "source_trial_id": "NCT00669890", "intervention_name": "methotrexate", "condition_name": "Juvenile Myelomonocytic Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1270", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Talazoparib Phase 1b\nCondition: Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors\nPhase: phase_1_2\nEnrollment: 223\nTermination reason: \"The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522).\"\nDetail: The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522).", "metadata": {"result_id": 4680, "source_trial_id": "NCT03330405", "intervention_name": "Talazoparib Phase 1b", "condition_name": "Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1271", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "hard", "context_text": "Drug: COVID-19 convalescent plasma\nCondition: Coronavirus Infections\nPhase: phase_2\nEnrollment: 71\nTermination reason: \"The EUA for CCP was updated by FDA, stipulating that only high titer units be used. This study required untitered units. The study became infeasible\"\nDetail: The EUA for CCP was updated by FDA, stipulating that only high titer units be used. This study required untitered units. The study became infeasible", "metadata": {"result_id": 22042, "source_trial_id": "NCT04432272", "intervention_name": "COVID-19 convalescent plasma", "condition_name": "Coronavirus Infections", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1272", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "hard", "context_text": "Drug: GSK2202083A vaccine\nCondition: Neisseria Meningitidis\nPhase: phase_2\nEnrollment: 16\nTermination reason: \"Study stopped due to non-approval of IEC to proposed change in locations. Study discontinuation not due to safety/efficacy reasons related to the vaccine.\"\nDetail: Study stopped due to non-approval of IEC to proposed change in locations. Study discontinuation not due to safety/efficacy reasons related to the vaccine.", "metadata": {"result_id": 48125, "source_trial_id": "NCT00871741", "intervention_name": "GSK2202083A vaccine", "condition_name": "Neisseria Meningitidis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1273", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: BMS-833923\nCondition: Leukemia\nPhase: phase_2\nEnrollment: 70\nTermination reason: \"No participants enrolled in this trial could receive the SMO antagonist as a recommended phase 2 dose was not determined by a different, concurrently-run trial.\"\nDetail: No participants enrolled in this trial could receive the SMO antagonist as a recommended phase 2 dose was not determined by a different, concurrently-run trial.", "metadata": {"result_id": 12176, "source_trial_id": "NCT01357655", "intervention_name": "BMS-833923", "condition_name": "Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1274", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Systemic antifungal therapy\nCondition: Invasive Aspergillosis\nPhase: phase_2\nEnrollment: 17\nTermination reason: \"Study was stopped due to difficulties in recruitment and changes in standard care for invasive aspergillosis\"\nDetail: Study was stopped due to difficulties in recruitment and changes in standard care for invasive aspergillosis", "metadata": {"result_id": 9541, "source_trial_id": "NCT00376337", "intervention_name": "Systemic antifungal therapy", "condition_name": "Invasive Aspergillosis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1275", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Ad4-mgag\nCondition: Healthy Volunteer\nPhase: phase_1\nEnrollment: 20\nTermination reason: \"Study endpoints not met.\"\nDetail: Study endpoints not met.", "metadata": {"result_id": 19473, "source_trial_id": "NCT02771730", "intervention_name": "Ad4-mgag", "condition_name": "Healthy Volunteer", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1276", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: Guanfacine extended-release tablets\nCondition: Sleep Disorders\nPhase: phase_4\nBlinding: QUADRUPLE\nEnrollment: 29\nPrimary endpoint met: 1.0\np-value: 0.001\nInterpretation: definitive_negative", "metadata": {"result_id": 21160, "source_trial_id": "NCT01156051", "intervention_name": "Guanfacine extended-release tablets", "condition_name": "Sleep Disorders", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1277", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Maraviroc\nCondition: Arthritis, Rheumatoid\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 128\np-value: 0.063\nEffect size (Mean Difference (Final Values)): -0.22\n95% CI: [-0.41, -0.03]\nInterpretation: definitive_negative", "metadata": {"result_id": 26934, "source_trial_id": "NCT00427934", "intervention_name": "Maraviroc", "condition_name": "Arthritis, Rheumatoid", "confidence_tier": "silver", "therapeutic_area": "autoimmune"}, "split": "val"}
+{"question_id": "CTL1-1278", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: emtricitabine/tenofovir\nCondition: HIV-1\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 813\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (Mean Difference (Final Values)): -2.3\n95% CI: [-3.1, -1.5]\nSerious adverse events: 188.0\nInterpretation: definitive_negative", "metadata": {"result_id": 12179, "source_trial_id": "NCT01345630", "intervention_name": "emtricitabine/tenofovir", "condition_name": "HIV-1", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "val"}
+{"question_id": "CTL1-1279", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: pegylated interferon alpha2b\nDrug type: peptide\nCondition: Liver Disease\nPhase: phase_2\nEnrollment: 10\nTermination reason: \"Schering-Plough discontinued supplying study drug.\"\nDetail: Schering-Plough discontinued supplying study drug.", "metadata": {"result_id": 22563, "source_trial_id": "NCT00588146", "intervention_name": "pegylated interferon alpha2b", "condition_name": "Liver Disease", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1280", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Viscous Lidocaine\nCondition: Anesthetics, Local\nPhase: phase_4\nEnrollment: 119\nTermination reason: \"Lack of ressources\"\nDetail: Lack of ressources", "metadata": {"result_id": 45008, "source_trial_id": "NCT04725695", "intervention_name": "Viscous Lidocaine", "condition_name": "Anesthetics, Local", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1281", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Subcutan implantation of autologus skin graft after ex-vivo treatment\nCondition: End Stage Renal Disease\nPhase: phase_1_2\nEnrollment: 4\nTermination reason: \"New protocol to start with improved product\"\nDetail: New protocol to start with improved product", "metadata": {"result_id": 62879, "source_trial_id": "NCT01555515", "intervention_name": "Subcutan implantation of autologus skin graft after ex-vivo treatment", "condition_name": "End Stage Renal Disease", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1282", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: PF-04191834\nCondition: Osteoarthritis, Knee\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 190\np-value: 0.067\nEffect size (Mean Difference (Net)): 0.56\n95% CI: [0.08, 1.04]\nSerious adverse events: 6.0\nInterpretation: definitive_negative", "metadata": {"result_id": 36371, "source_trial_id": "NCT01147458", "intervention_name": "PF-04191834", "condition_name": "Osteoarthritis, Knee", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1283", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Viagra (Sildenafil citrate)\nCondition: Prostatitis\nPhase: phase_4\nEnrollment: 30\nTermination reason: \"Illness of PI forced termination.\"\nDetail: Illness of PI forced termination.", "metadata": {"result_id": 22856, "source_trial_id": "NCT00194597", "intervention_name": "Viagra (Sildenafil citrate)", "condition_name": "Prostatitis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1284", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Insulin, intranasal\nDrug type: peptide\nCondition: HIV-Associated Cognitive Motor Complex\nPhase: phase_1_2\nBlinding: QUADRUPLE\nEnrollment: 21\nPrimary endpoint met: 1.0\np-value: 0.0103\nEffect size (Mean Difference (Net)): -0.5146\nSerious adverse events: 9.0\nInterpretation: definitive_negative", "metadata": {"result_id": 5790, "source_trial_id": "NCT03081117", "intervention_name": "Insulin, intranasal", "condition_name": "HIV-Associated Cognitive Motor Complex", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "val"}
+{"question_id": "CTL1-1285", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Cabazitaxel chemotherapy\nCondition: High-Risk Cancer\nPhase: phase_2\nEnrollment: 11\nTermination reason: \"Investigator left the site. Site closed.\"\nDetail: Investigator left the site. Site closed.", "metadata": {"result_id": 23261, "source_trial_id": "NCT01941550", "intervention_name": "Cabazitaxel chemotherapy", "condition_name": "High-Risk Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1286", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Promacta\nCondition: Wiskott-Aldrich Syndrome\nPhase: phase_2\nEnrollment: 24\nTermination reason: \"retirement of PI\"\nDetail: retirement of PI", "metadata": {"result_id": 38673, "source_trial_id": "NCT00909363", "intervention_name": "Promacta", "condition_name": "Wiskott-Aldrich Syndrome", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1287", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition\nCondition: Marijuana Abuse\nPhase: phase_1\nBlinding: NONE\nEnrollment: 22\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (ratio of geometric means): 1.786\n95% CI: [1.47, 2.17]\nInterpretation: definitive_negative", "metadata": {"result_id": 40041, "source_trial_id": "NCT05451017", "intervention_name": "3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition", "condition_name": "Marijuana Abuse", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1288", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: PA21 (Velphoro®)\nCondition: Hyperphosphatemia\nPhase: phase_3\nBlinding: NONE\nEnrollment: 85\nPrimary endpoint met: 1.0\np-value: 0.0058\nSerious adverse events: 69.0\nInterpretation: definitive_negative", "metadata": {"result_id": 22167, "source_trial_id": "NCT02688764", "intervention_name": "PA21 (Velphoro®)", "condition_name": "Hyperphosphatemia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1289", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Liraglutide Pen Injector\nDrug type: peptide\nCondition: Pouchitis\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 8\nPrimary endpoint met: 1.0\np-value: 0.01\nInterpretation: definitive_negative", "metadata": {"result_id": 44446, "source_trial_id": "NCT04763564", "intervention_name": "Liraglutide Pen Injector", "condition_name": "Pouchitis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1290", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Ibuprofen\nCondition: Post-surgical Dental Pain\nPhase: phase_2\nEnrollment: 90\nTermination reason: \"See termination reason in detailed description.\"\nDetail: See termination reason in detailed description.", "metadata": {"result_id": 57083, "source_trial_id": "NCT01512160", "intervention_name": "Ibuprofen", "condition_name": "Post-surgical Dental Pain", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1291", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: PF-00489791\nCondition: Hypertension, Pulmonary\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 48\nPrimary endpoint met: 1.0\np-value: 0.02\nEffect size (Adjusted Mean Difference): -9.01\n95% CI: [-16.52, -1.5]\nSerious adverse events: 8.0\nInterpretation: definitive_negative", "metadata": {"result_id": 37801, "source_trial_id": "NCT00853112", "intervention_name": "PF-00489791", "condition_name": "Hypertension, Pulmonary", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL1-1292", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: Asundexian (BAY2433334)\nDrug type: unknown\nCondition: Atrial Fibrillation\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 14830\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (Cox Proportional Hazard): 3.785\n95% CI: [2.457, 5.833]\nInterpretation: definitive_negative", "metadata": {"result_id": 10831, "source_trial_id": "NCT05643573", "intervention_name": "Asundexian (BAY2433334)", "condition_name": "Atrial Fibrillation", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL1-1293", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: PMX-60056\nCondition: Coronary Artery Disease (CAD)\nPhase: phase_2\nEnrollment: 17\nTermination reason: \"PolyMedix decided to stop enrollment in both clinical trials due to observations of reductions in blood pressure.\"\nDetail: PolyMedix decided to stop enrollment in both clinical trials due to observations of reductions in blood pressure.", "metadata": {"result_id": 13678, "source_trial_id": "NCT01312935", "intervention_name": "PMX-60056", "condition_name": "Coronary Artery Disease (CAD)", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL1-1294", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: CP-195,543\nCondition: Arthritis, Rheumatoid\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 70\nPrimary endpoint met: 1.0\np-value: 0.018\nSerious adverse events: 9.0\nInterpretation: definitive_negative", "metadata": {"result_id": 26819, "source_trial_id": "NCT00424294", "intervention_name": "CP-195,543", "condition_name": "Arthritis, Rheumatoid", "confidence_tier": "silver", "therapeutic_area": "autoimmune"}, "split": "val"}
+{"question_id": "CTL1-1295", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Investigational Agent\nCondition: Multiple Myeloma\nPhase: phase_2\nBlinding: NONE\nEnrollment: 45\np-value: 0.966\nInterpretation: definitive_negative", "metadata": {"result_id": 32582, "source_trial_id": "NCT04111107", "intervention_name": "Investigational Agent", "condition_name": "Multiple Myeloma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1296", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: KIO-101\nCondition: Dry Eye Disease\nPhase: phase_2\nEnrollment: 4\nTermination reason: \"Study halted prematurely but potentially will resume\"\nDetail: Study halted prematurely but potentially will resume", "metadata": {"result_id": 28748, "source_trial_id": "NCT05629364", "intervention_name": "KIO-101", "condition_name": "Dry Eye Disease", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1297", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Paclitaxel, Cisplatin IP\nCondition: Fallopian Tube Cancer\nPhase: phase_2\nEnrollment: 21\nTermination reason: \"Study completed per investigator.\"\nDetail: Study completed per investigator.", "metadata": {"result_id": 36658, "source_trial_id": "NCT00582205", "intervention_name": "Paclitaxel, Cisplatin IP", "condition_name": "Fallopian Tube Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1298", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: MGCD265+erlotinib\nCondition: Advanced Malignancies, Non-small Cell Lung Cancer\nPhase: phase_1\nEnrollment: 126\nTermination reason: \"The study was terminated due to a need for a reformulation of the study drug. Phase 1 completed, no patients enrolled in Phase 2.\"\nDetail: The study was terminated due to a need for a reformulation of the study drug. Phase 1 completed, no patients enrolled in Phase 2.", "metadata": {"result_id": 5117, "source_trial_id": "NCT00975767", "intervention_name": "MGCD265+erlotinib", "condition_name": "Advanced Malignancies, Non-small Cell Lung Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1299", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Obeticholic Acid (OCA)\nCondition: Liver Cirrhosis, Biliary\nPhase: phase_4\nBlinding: QUADRUPLE\nEnrollment: 334\np-value: 0.178\nEffect size (Hazard Ratio (HR)): 0.43\n95% CI: [0.13, 1.41]\nInterpretation: definitive_negative", "metadata": {"result_id": 21093, "source_trial_id": "NCT02308111", "intervention_name": "Obeticholic Acid (OCA)", "condition_name": "Liver Cirrhosis, Biliary", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1300", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Oraxol\nCondition: Breastcancer\nPhase: phase_1\nEnrollment: 11\nTermination reason: \"No need to complete the overall survival (OS) follow-up as the sample size was too small to interpret OS.\"\nDetail: No need to complete the overall survival (OS) follow-up as the sample size was too small to interpret OS.", "metadata": {"result_id": 27151, "source_trial_id": "NCT04168957", "intervention_name": "Oraxol", "condition_name": "Breastcancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1301", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Botox Instillation\nCondition: Urge Incontinence\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 25\nPrimary endpoint met: 1.0\np-value: 0.024\nSerious adverse events: 5.0\nInterpretation: definitive_negative", "metadata": {"result_id": 26384, "source_trial_id": "NCT00667095", "intervention_name": "Botox Instillation", "condition_name": "Urge Incontinence", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1302", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Dose-Establishing Study 1 Niacin 500mg\nCondition: Growth Hormone Deficiency\nPhase: phase_1_2\nBlinding: QUADRUPLE\nEnrollment: 37\nPrimary endpoint met: 1.0\np-value: 0.016\nInterpretation: definitive_negative", "metadata": {"result_id": 58060, "source_trial_id": "NCT01237041", "intervention_name": "Dose-Establishing Study 1 Niacin 500mg", "condition_name": "Growth Hormone Deficiency", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1303", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Ropivacaine injection Location 1\nCondition: Opioid Use\nPhase: phase_3\nEnrollment: 9\nTermination reason: \"PI left the institution. Decision made to close the study.\"\nDetail: PI left the institution. Decision made to close the study.", "metadata": {"result_id": 63414, "source_trial_id": "NCT04588389", "intervention_name": "Ropivacaine injection Location 1", "condition_name": "Opioid Use", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1304", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: PF-03758309\nCondition: Advanced Solid Tumors\nPhase: phase_1\nEnrollment: 35\nTermination reason: \"See termination reason in detailed description.\"\nDetail: See termination reason in detailed description.", "metadata": {"result_id": 23342, "source_trial_id": "NCT00932126", "intervention_name": "PF-03758309", "condition_name": "Advanced Solid Tumors", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1305", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Lactated Ringers\nCondition: Diabetic Ketoacidosis\nPhase: phase_4\nEnrollment: 53\nTermination reason: \"Shortage of potassium acetate for study intravenous fluids\"\nDetail: Shortage of potassium acetate for study intravenous fluids", "metadata": {"result_id": 16946, "source_trial_id": "NCT03066440", "intervention_name": "Lactated Ringers", "condition_name": "Diabetic Ketoacidosis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1306", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Standard dosing of methadone\nCondition: Pain, Postoperative\nPhase: phase_2\nEnrollment: 36\nTermination reason: \"PI left institution.\"\nDetail: PI left institution.", "metadata": {"result_id": 54897, "source_trial_id": "NCT03605901", "intervention_name": "Standard dosing of methadone", "condition_name": "Pain, Postoperative", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1307", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Baminercept\nDrug type: peptide\nCondition: Primary Sjögren's Syndrome\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 52\np-value: 0.33\nSerious adverse events: 12.0\nInterpretation: definitive_negative", "metadata": {"result_id": 14942, "source_trial_id": "NCT01552681", "intervention_name": "Baminercept", "condition_name": "Primary Sjögren's Syndrome", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1308", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: folic acid 5mg/day\nCondition: Heart Failure\nPhase: phase_4\nTermination reason: \"recruitment is finished\"\nDetail: recruitment is finished", "metadata": {"result_id": 38043, "source_trial_id": "NCT00491907", "intervention_name": "folic acid 5mg/day", "condition_name": "Heart Failure", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL1-1309", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: darunavir/ritonavir 800/100 mg\nCondition: HIV-1\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 813\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (Mean Difference (Final Values)): -2.3\n95% CI: [-3.1, -1.5]\nSerious adverse events: 188.0\nInterpretation: definitive_negative", "metadata": {"result_id": 12180, "source_trial_id": "NCT01345630", "intervention_name": "darunavir/ritonavir 800/100 mg", "condition_name": "HIV-1", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "val"}
+{"question_id": "CTL1-1310", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Fidaxomicin 200 mg\nCondition: Clostridium Difficile\nPhase: phase_2\nEnrollment: 4\nTermination reason: \"Difficulty enrolling participants/COVID pandemic/lack of continued in-kind support from product manufacturer.\"\nDetail: Difficulty enrolling participants/COVID pandemic/lack of continued in-kind support from product manufacturer.", "metadata": {"result_id": 15092, "source_trial_id": "NCT03760484", "intervention_name": "Fidaxomicin 200 mg", "condition_name": "Clostridium Difficile", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1311", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "hard", "context_text": "Drug: Enfortumab vedotin\nDrug type: antibody_drug_conjugate\nCondition: Non-muscle Invasive Bladder Cancer\nPhase: phase_1\nEnrollment: 37\nTermination reason: \"Trial was discontinued for strategic reasons. Decision was not based on safety concerns, futility, or request from regulatory authority, ethics committee, or institutional review board or EC/IRB.\"\nDetail: Trial was discontinued for strategic reasons. Decision was not based on safety concerns, futility, or request from regulatory authority, ethics committee, or institutional review board or EC/IRB.", "metadata": {"result_id": 12915, "source_trial_id": "NCT05014139", "intervention_name": "Enfortumab vedotin", "condition_name": "Non-muscle Invasive Bladder Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1312", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Amitriptyline\nCondition: Migraine Disorders\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 488\np-value: 0.0754\nEffect size (Odds Ratio (OR)): 2.31\n95% CI: [0.95, 5.62]\nSerious adverse events: 24.0\nInterpretation: definitive_negative", "metadata": {"result_id": 53473, "source_trial_id": "NCT01581281", "intervention_name": "Amitriptyline", "condition_name": "Migraine Disorders", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "val"}
+{"question_id": "CTL1-1313", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: CPI-613\nCondition: Pancreatic Carcinoma\nPhase: phase_1_2\nEnrollment: 6\nTermination reason: \"Suspended trial was not restarted.\"\nDetail: Suspended trial was not restarted.", "metadata": {"result_id": 63502, "source_trial_id": "NCT00907166", "intervention_name": "CPI-613", "condition_name": "Pancreatic Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1314", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: ABT-869\nCondition: Hepatocellular Carcinoma Non-resectable\nPhase: phase_3\nEnrollment: 1035\nTermination reason: \"See termination reason in detailed description\"\nDetail: See termination reason in detailed description", "metadata": {"result_id": 25564, "source_trial_id": "NCT01009593", "intervention_name": "ABT-869", "condition_name": "Hepatocellular Carcinoma Non-resectable", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1315", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Dronabinol\nCondition: Trauma Injury\nPhase: phase_4\nEnrollment: 484\nTermination reason: \"Study concluded because of drug shortage\"\nDetail: Study concluded because of drug shortage", "metadata": {"result_id": 42443, "source_trial_id": "NCT05820685", "intervention_name": "Dronabinol", "condition_name": "Trauma Injury", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1316", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: RPM CD19-mbIL15-CAR-T cells\nCondition: Mantle Cell Lymphoma\nPhase: phase_1\nEnrollment: 2\nTermination reason: \"CAR-T manufacturing technology can not meet the dose requirement for clinical patients.\"\nDetail: CAR-T manufacturing technology can not meet the dose requirement for clinical patients.", "metadata": {"result_id": 62867, "source_trial_id": "NCT04844086", "intervention_name": "RPM CD19-mbIL15-CAR-T cells", "condition_name": "Mantle Cell Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1317", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Irinotecan + capecitabine\nCondition: Colorectal Carcinoma\nPhase: phase_1_2\nEnrollment: 33\nTermination reason: \"Investigator no longer at site to enroll patients or write up data\"\nDetail: Investigator no longer at site to enroll patients or write up data", "metadata": {"result_id": 45410, "source_trial_id": "NCT02423954", "intervention_name": "Irinotecan + capecitabine", "condition_name": "Colorectal Carcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1318", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Riluzole (100 mg)\nCondition: Amyotrophic Lateral Sclerosis\nPhase: phase_1_2\nEnrollment: 23\nTermination reason: \"Terminated as it is considered that necessary data have been collected\"\nDetail: Terminated as it is considered that necessary data have been collected", "metadata": {"result_id": 8592, "source_trial_id": "NCT04326283", "intervention_name": "Riluzole (100 mg)", "condition_name": "Amyotrophic Lateral Sclerosis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL1-1319", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Investigational Agent\nCondition: Solid Tumor\nPhase: phase_2\nBlinding: NONE\nEnrollment: 45\np-value: 0.966\nInterpretation: definitive_negative", "metadata": {"result_id": 32579, "source_trial_id": "NCT04111107", "intervention_name": "Investigational Agent", "condition_name": "Solid Tumor", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL1-1320", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Hydroxychloroquine Sulfate\nCondition: Diffuse Parenchymal Lung Disease\nPhase: phase_2\nBlinding: QUADRUPLE\nEnrollment: 35\nPrimary endpoint met: 1.0\np-value: 0.01\nEffect size (Mean Difference (Net)): -1.3\nInterpretation: definitive_negative", "metadata": {"result_id": 585, "source_trial_id": "NCT02615938", "intervention_name": "Hydroxychloroquine Sulfate", "condition_name": "Diffuse Parenchymal Lung Disease", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1321", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: F-18 16 Alpha-Fluoroestradiol\nCondition: Deep Fibromatosis/Desmoid Tumor\nPhase: early_phase_1\nEnrollment: 3\nTermination reason: \"PI left institution\"\nDetail: PI left institution", "metadata": {"result_id": 14364, "source_trial_id": "NCT02374931", "intervention_name": "F-18 16 Alpha-Fluoroestradiol", "condition_name": "Deep Fibromatosis/Desmoid Tumor", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1322", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: LY3410738\nCondition: Healthy\nPhase: phase_1\nEnrollment: 27\nTermination reason: \"Data from part 2 no longer deemed necessary for this program.\"\nDetail: Data from part 2 no longer deemed necessary for this program.", "metadata": {"result_id": 23432, "source_trial_id": "NCT05205447", "intervention_name": "LY3410738", "condition_name": "Healthy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1323", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "hard", "context_text": "Drug: Nicorette Lozenge Product\nCondition: Smoking Cessation\nPhase: phase_3\nEnrollment: 4\nTermination reason: \"BIDI product received a market denial letter from the FDA\"\nDetail: BIDI product received a market denial letter from the FDA", "metadata": {"result_id": 7551, "source_trial_id": "NCT06088862", "intervention_name": "Nicorette Lozenge Product", "condition_name": "Smoking Cessation", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1324", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Chronic salsalate\nCondition: Obesity\nPhase: phase_1\nEnrollment: 16\nTermination reason: \"Preliminary results indicated no measurable benefit.\"\nDetail: Preliminary results indicated no measurable benefit.", "metadata": {"result_id": 61071, "source_trial_id": "NCT00837590", "intervention_name": "Chronic salsalate", "condition_name": "Obesity", "confidence_tier": "bronze", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-1325", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)\nCondition: Idiopathic Pulmonary Fibrosis (IPF)\nPhase: phase_1\nEnrollment: 9\nTermination reason: \"Study completed\"\nDetail: Study completed", "metadata": {"result_id": 55225, "source_trial_id": "NCT02013700", "intervention_name": "Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)", "condition_name": "Idiopathic Pulmonary Fibrosis (IPF)", "confidence_tier": "bronze", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-1326", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: Niferex\nCondition: Anemia\nPhase: phase_4\nBlinding: QUADRUPLE\nEnrollment: 22\nPrimary endpoint met: 1.0\np-value: 0.02\nEffect size (Mean Difference (Net)): 1.7\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 7016, "source_trial_id": "NCT00511901", "intervention_name": "Niferex", "condition_name": "Anemia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1327", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Brand-name latanoprost\nCondition: Primary Open Angle Glaucoma\nPhase: phase_4\nEnrollment: 60\nTermination reason: \"Problem with IP supply\"\nDetail: Problem with IP supply", "metadata": {"result_id": 32337, "source_trial_id": "NCT02047630", "intervention_name": "Brand-name latanoprost", "condition_name": "Primary Open Angle Glaucoma", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1328", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Intraperitoneal Gemcitabine\nCondition: Pancreatic Adenocarcinoma\nPhase: phase_2\nEnrollment: 9\nTermination reason: \"Study suspended\"\nDetail: Study suspended", "metadata": {"result_id": 3741, "source_trial_id": "NCT01206296", "intervention_name": "Intraperitoneal Gemcitabine", "condition_name": "Pancreatic Adenocarcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1329", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Laxabon\nCondition: Bowel Preparation\nEnrollment: 47\nTermination reason: \"The bowel was not clean when the colonoscopy was performed\"\nDetail: The bowel was not clean when the colonoscopy was performed", "metadata": {"result_id": 18723, "source_trial_id": "NCT00675324", "intervention_name": "Laxabon", "condition_name": "Bowel Preparation", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1330", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Intravitreal Bevacizumab\nCondition: Proliferative Diabetic Retinopathy\nPhase: phase_2_3\nTermination reason: \"Undefined\"\nDetail: Undefined", "metadata": {"result_id": 5912, "source_trial_id": "NCT00600262", "intervention_name": "Intravitreal Bevacizumab", "condition_name": "Proliferative Diabetic Retinopathy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1331", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Lidocaine in SphenoCath device\nCondition: Concussion\nPhase: phase_2\nEnrollment: 2\nTermination reason: \"Reassignment of PI to more intense clinical obligations prevents continuation of the trial.\"\nDetail: Reassignment of PI to more intense clinical obligations prevents continuation of the trial.", "metadata": {"result_id": 8039, "source_trial_id": "NCT04650282", "intervention_name": "Lidocaine in SphenoCath device", "condition_name": "Concussion", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1332", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Relugolix Pill\nCondition: Prostate Cancer\nPhase: phase_1\nEnrollment: 60\nTermination reason: \"Terminated by the PI\"\nDetail: Terminated by the PI", "metadata": {"result_id": 6324, "source_trial_id": "NCT05679388", "intervention_name": "Relugolix Pill", "condition_name": "Prostate Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1333", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: TSX-011\nCondition: Hypogonadism\nPhase: phase_1_2\nEnrollment: 9\nTermination reason: \"Incomplete effect\"\nDetail: Incomplete effect", "metadata": {"result_id": 63021, "source_trial_id": "NCT03335254", "intervention_name": "TSX-011", "condition_name": "Hypogonadism", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1334", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: BVD-523\nCondition: Uveal Melanoma\nPhase: phase_2\nEnrollment: 13\nTermination reason: \"This was a Simon two stage design trial that terminated after the first stage due to lack of response.\"\nDetail: This was a Simon two stage design trial that terminated after the first stage due to lack of response.", "metadata": {"result_id": 62185, "source_trial_id": "NCT03417739", "intervention_name": "BVD-523", "condition_name": "Uveal Melanoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1335", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Promitil\nCondition: Gastro-Intestinal Intraepithelial Neoplasia\nPhase: phase_1\nEnrollment: 9\nTermination reason: \"Investigational drug not available\"\nDetail: Investigational drug not available", "metadata": {"result_id": 890, "source_trial_id": "NCT04729205", "intervention_name": "Promitil", "condition_name": "Gastro-Intestinal Intraepithelial Neoplasia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1336", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: recombinant interleukin-12\nDrug type: peptide\nCondition: Stage IV Skin Melanoma\nPhase: phase_2\nEnrollment: 10\nTermination reason: \"Due to lack of clinical efficacy and lack of drug supply, trial was closed early and correlative studies were not pursued further.\"\nDetail: Due to lack of clinical efficacy and lack of drug supply, trial was closed early and correlative studies were not pursued further.", "metadata": {"result_id": 44230, "source_trial_id": "NCT01307618", "intervention_name": "recombinant interleukin-12", "condition_name": "Stage IV Skin Melanoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1337", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Infigratinib\nCondition: GBM\nPhase: early_phase_1\nEnrollment: 7\nTermination reason: \"Study drug no longer available.\"\nDetail: Study drug no longer available.", "metadata": {"result_id": 14991, "source_trial_id": "NCT04424966", "intervention_name": "Infigratinib", "condition_name": "GBM", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1338", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Open-label Nexagon® (lufepirsen)\nCondition: Corneal Persistent Epithelial Defect\nPhase: phase_2\nEnrollment: 35\nTermination reason: \"The study was stopped early (n=35) enabling the data to guide design of the subsequent clinical study.\"\nDetail: The study was stopped early (n=35) enabling the data to guide design of the subsequent clinical study.", "metadata": {"result_id": 48995, "source_trial_id": "NCT04081103", "intervention_name": "Open-label Nexagon® (lufepirsen)", "condition_name": "Corneal Persistent Epithelial Defect", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1339", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Investigational Agent\nCondition: Mutation Abnormality\nPhase: phase_2\nBlinding: NONE\nEnrollment: 45\np-value: 0.966\nInterpretation: definitive_negative", "metadata": {"result_id": 32588, "source_trial_id": "NCT04111107", "intervention_name": "Investigational Agent", "condition_name": "Mutation Abnormality", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1340", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Bezlotoxumab\nDrug type: monoclonal_antibody\nCondition: Clostridia Difficile Colitis\nPhase: phase_4\nEnrollment: 5\nTermination reason: \"Difficulties with enrollment and inability to guarantee further study drug supply after current supply expired.\"\nDetail: Difficulties with enrollment and inability to guarantee further study drug supply after current supply expired.", "metadata": {"result_id": 17132, "source_trial_id": "NCT03756454", "intervention_name": "Bezlotoxumab", "condition_name": "Clostridia Difficile Colitis", "confidence_tier": "bronze", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL1-1341", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Temozolomide (TMZ)\nCondition: Glioblastoma\nPhase: phase_1_2\nEnrollment: 53\nTermination reason: \"Unable to supply investigational agent, Zotiraciclib (TG02).\"\nDetail: Unable to supply investigational agent, Zotiraciclib (TG02).", "metadata": {"result_id": 54623, "source_trial_id": "NCT02942264", "intervention_name": "Temozolomide (TMZ)", "condition_name": "Glioblastoma", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1342", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Sterile Normal Saline (0.9% NaCl)\nCondition: Antitrypsin Deficiency Liver Disease\nPhase: phase_1\nEnrollment: 26\nTermination reason: \"Observation of low incidence of asymptomatic, transiently elevated liver enzymes in a subset of study subjects\"\nDetail: Observation of low incidence of asymptomatic, transiently elevated liver enzymes in a subset of study subjects", "metadata": {"result_id": 19033, "source_trial_id": "NCT02503683", "intervention_name": "Sterile Normal Saline (0.9% NaCl)", "condition_name": "Antitrypsin Deficiency Liver Disease", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1343", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: RRx-001\nCondition: Advanced Cancer\nPhase: phase_1\nEnrollment: 28\nTermination reason: \"Sufficient patients enrolled to end study\"\nDetail: Sufficient patients enrolled to end study", "metadata": {"result_id": 23475, "source_trial_id": "NCT02801097", "intervention_name": "RRx-001", "condition_name": "Advanced Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1344", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: duramorph\nCondition: Postoperative Pain Management\nPhase: phase_4\nEnrollment: 13\nTermination reason: \"feasibility of population needed to complete study\"\nDetail: feasibility of population needed to complete study", "metadata": {"result_id": 28743, "source_trial_id": "NCT02143141", "intervention_name": "duramorph", "condition_name": "Postoperative Pain Management", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1345", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "hard", "context_text": "Drug: Omegaven\nDrug type: unknown\nCondition: Cholestasis\nPhase: phase_2\nEnrollment: 62\nTermination reason: \"study intervention was approved by the FDA\"\nDetail: study intervention was approved by the FDA", "metadata": {"result_id": 23575, "source_trial_id": "NCT00969332", "intervention_name": "Omegaven", "condition_name": "Cholestasis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1346", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: leucovorin calcium\nCondition: Unresectable Gallbladder Cancer\nPhase: phase_2\nEnrollment: 14\nTermination reason: \"Lack of Drug Supply\"\nDetail: Lack of Drug Supply", "metadata": {"result_id": 46600, "source_trial_id": "NCT01229111", "intervention_name": "leucovorin calcium", "condition_name": "Unresectable Gallbladder Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1347", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: isosulfan blue based lymphatic mapping\nCondition: Breast Cancer\nPhase: phase_1_2\nBlinding: DOUBLE\nEnrollment: 39\np-value: 0.45\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 50822, "source_trial_id": "NCT00932035", "intervention_name": "isosulfan blue based lymphatic mapping", "condition_name": "Breast Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1348", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "medium", "context_text": "Drug: LQT-1213\nCondition: Long QT Syndrome\nPhase: phase_1_2\nBlinding: DOUBLE\nEnrollment: 42\nPrimary endpoint met: 1.0\np-value: 0.0016\nEffect size (Mean Difference (Net)): -53.42\nInterpretation: definitive_negative", "metadata": {"result_id": 26710, "source_trial_id": "NCT05906732", "intervention_name": "LQT-1213", "condition_name": "Long QT Syndrome", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1349", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: rhDNase I\nCondition: Dry Eye\nPhase: phase_1_2\nBlinding: QUADRUPLE\nEnrollment: 58\nPrimary endpoint met: 1.0\np-value: 0.001\nInterpretation: definitive_negative", "metadata": {"result_id": 25093, "source_trial_id": "NCT02702518", "intervention_name": "rhDNase I", "condition_name": "Dry Eye", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1350", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Tissue Plasminogen Activator\nCondition: Abscess\nPhase: phase_2_3\nEnrollment: 35\nTermination reason: \"Change in patient population no longer fit study criteria.\"\nDetail: Change in patient population no longer fit study criteria.", "metadata": {"result_id": 48160, "source_trial_id": "NCT00417768", "intervention_name": "Tissue Plasminogen Activator", "condition_name": "Abscess", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1351", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: 5-aminolevulinic acid\nCondition: Astrocytoma\nPhase: phase_1\nEnrollment: 6\nTermination reason: \"PI leaving institution\"\nDetail: PI leaving institution", "metadata": {"result_id": 60865, "source_trial_id": "NCT01502605", "intervention_name": "5-aminolevulinic acid", "condition_name": "Astrocytoma", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1352", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: brilliant blue G\nCondition: Epiretinal Membrane\nPhase: phase_3\nEnrollment: 22\nTermination reason: \"Undefined\"\nDetail: Undefined", "metadata": {"result_id": 46070, "source_trial_id": "NCT01820520", "intervention_name": "brilliant blue G", "condition_name": "Epiretinal Membrane", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1353", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Osmotic Release Oral System (OROS) hydromorphone\nCondition: Pain\nPhase: phase_4\nEnrollment: 20\nTermination reason: \"the study was stopped due to non-availability of 4mg\"\nDetail: the study was stopped due to non-availability of 4mg", "metadata": {"result_id": 57068, "source_trial_id": "NCT01648699", "intervention_name": "Osmotic Release Oral System (OROS) hydromorphone", "condition_name": "Pain", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1354", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: MCS\nCondition: Benign Prostatic Hyperplasia\nPhase: phase_3\nEnrollment: 85\nTermination reason: \"Study terminated for re-design. A new IND study (US FDA, July 2009) will be conducted in US and Taiwan. Termination not related to safety concerns.\"\nDetail: Study terminated for re-design. A new IND study (US FDA, July 2009) will be conducted in US and Taiwan. Termination not related to safety concerns.", "metadata": {"result_id": 9665, "source_trial_id": "NCT00501371", "intervention_name": "MCS", "condition_name": "Benign Prostatic Hyperplasia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1355", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Dextroamphetamine SR\nCondition: Attention Deficit Disorder With Hyperactivity\nPhase: phase_2\nEnrollment: 5\nTermination reason: \"Investigator left UTHSC-Houston\"\nDetail: Investigator left UTHSC-Houston", "metadata": {"result_id": 28226, "source_trial_id": "NCT00514202", "intervention_name": "Dextroamphetamine SR", "condition_name": "Attention Deficit Disorder With Hyperactivity", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1356", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "hard", "context_text": "Drug: Infanrix hexa\nCondition: Diphtheria\nPhase: phase_2\nEnrollment: 16\nTermination reason: \"Study stopped due to non-approval of IEC to proposed change in locations. Study discontinuation not due to safety/efficacy reasons related to the vaccine.\"\nDetail: Study stopped due to non-approval of IEC to proposed change in locations. Study discontinuation not due to safety/efficacy reasons related to the vaccine.", "metadata": {"result_id": 48112, "source_trial_id": "NCT00871741", "intervention_name": "Infanrix hexa", "condition_name": "Diphtheria", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1357", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Dose-Establishing Study 1 Niacin 250mg\nCondition: Growth Hormone Deficiency\nPhase: phase_1_2\nBlinding: QUADRUPLE\nEnrollment: 37\nPrimary endpoint met: 1.0\np-value: 0.016\nInterpretation: definitive_negative", "metadata": {"result_id": 58059, "source_trial_id": "NCT01237041", "intervention_name": "Dose-Establishing Study 1 Niacin 250mg", "condition_name": "Growth Hormone Deficiency", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1358", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: PBSC\nCondition: Neuroblastoma\nPhase: phase_2\nEnrollment: 4\nTermination reason: \"Voluntarily closed and terminated by the PI due to lack of feasibility\"\nDetail: Voluntarily closed and terminated by the PI due to lack of feasibility", "metadata": {"result_id": 61245, "source_trial_id": "NCT00808899", "intervention_name": "PBSC", "condition_name": "Neuroblastoma", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1359", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: URG101\nCondition: Painful Bladder Syndrome\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 28\nPrimary endpoint met: 1.0\np-value: 0.0363\nEffect size (Mean Difference (Final Values)): -21.14\n95% CI: [-44.43, 2.16]\nInterpretation: definitive_negative", "metadata": {"result_id": 10322, "source_trial_id": "NCT00517868", "intervention_name": "URG101", "condition_name": "Painful Bladder Syndrome", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1360", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Ad4-mgag\nCondition: HIV Vaccine\nPhase: phase_1\nEnrollment: 20\nTermination reason: \"Study endpoints not met.\"\nDetail: Study endpoints not met.", "metadata": {"result_id": 19477, "source_trial_id": "NCT02771730", "intervention_name": "Ad4-mgag", "condition_name": "HIV Vaccine", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-1361", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: oral Diclofenac\nCondition: Pain\nPhase: phase_4\nEnrollment: 8\nTermination reason: \"See termination reason in detailed description.\"\nDetail: See termination reason in detailed description.", "metadata": {"result_id": 17246, "source_trial_id": "NCT00894790", "intervention_name": "oral Diclofenac", "condition_name": "Pain", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1362", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Medium SLS toothpaste\nCondition: Oral Mucosal Disorder\nBlinding: SINGLE\nEnrollment: 53\np-value: 0.916\nInterpretation: definitive_negative", "metadata": {"result_id": 14986, "source_trial_id": "NCT04601103", "intervention_name": "Medium SLS toothpaste", "condition_name": "Oral Mucosal Disorder", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1363", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Maraviroc\nCondition: HIV-1\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 813\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (Mean Difference (Final Values)): -2.3\n95% CI: [-3.1, -1.5]\nSerious adverse events: 188.0\nInterpretation: definitive_negative", "metadata": {"result_id": 12178, "source_trial_id": "NCT01345630", "intervention_name": "Maraviroc", "condition_name": "HIV-1", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-1364", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: donepezil\nCondition: Dementia, Mixed\nPhase: phase_3\nBlinding: NONE\nEnrollment: 149\nPrimary endpoint met: 1.0\np-value: 0.004\nSerious adverse events: 56.0\nInterpretation: definitive_negative", "metadata": {"result_id": 40663, "source_trial_id": "NCT00174382", "intervention_name": "donepezil", "condition_name": "Dementia, Mixed", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-1365", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Ropivacaine\nCondition: Quality of Life\nPhase: phase_3\nEnrollment: 18\nTermination reason: \"Poor accrual due to change in standard of care procedure.\"\nDetail: Poor accrual due to change in standard of care procedure.", "metadata": {"result_id": 36376, "source_trial_id": "NCT02161705", "intervention_name": "Ropivacaine", "condition_name": "Quality of Life", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1366", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Dermaprazole 1%\nCondition: Radiation Dermatitis\nPhase: phase_1_2\nEnrollment: 3\nTermination reason: \"PI is leaving institution and this protocol will not be further pursued at this institution.\"\nDetail: PI is leaving institution and this protocol will not be further pursued at this institution.", "metadata": {"result_id": 45609, "source_trial_id": "NCT05269160", "intervention_name": "Dermaprazole 1%", "condition_name": "Radiation Dermatitis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1367", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Betamarc\nCondition: Carcinoma, Non-Small-Cell Lung\nPhase: phase_2\nEnrollment: 70\nTermination reason: \"Objectives of study could not be met within a reasonable timeframe.\"\nDetail: Objectives of study could not be met within a reasonable timeframe.", "metadata": {"result_id": 32427, "source_trial_id": "NCT00535015", "intervention_name": "Betamarc", "condition_name": "Carcinoma, Non-Small-Cell Lung", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1368", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Chloroquine, sulphadoxine-pyrimethamine\nCondition: Fever\nEnrollment: 1314\nTermination reason: \"Study never started\"\nDetail: Study never started", "metadata": {"result_id": 55052, "source_trial_id": "NCT00259142", "intervention_name": "Chloroquine, sulphadoxine-pyrimethamine", "condition_name": "Fever", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1369", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Prednisone/prednisolone\nCondition: Lymphoma, Follicular\nPhase: phase_3\nBlinding: NONE\nEnrollment: 29\nPrimary endpoint met: 1.0\np-value: 0.0358\nEffect size (Hazard Ratio (HR)): 0.19\n95% CI: [0.04, 1.02]\nSerious adverse events: 38.0\nInterpretation: definitive_negative", "metadata": {"result_id": 28720, "source_trial_id": "NCT00562965", "intervention_name": "Prednisone/prednisolone", "condition_name": "Lymphoma, Follicular", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1370", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Dexamethasone 8mg iv x1\nCondition: Post Operative Pain\nPhase: phase_4\nBlinding: QUADRUPLE\nEnrollment: 82\nPrimary endpoint met: 1.0\np-value: 0.006\nInterpretation: definitive_negative", "metadata": {"result_id": 19823, "source_trial_id": "NCT01149616", "intervention_name": "Dexamethasone 8mg iv x1", "condition_name": "Post Operative Pain", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1371", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Transdermal estradiol\nCondition: Aging\nEnrollment: 4\nTermination reason: \"PI left institution prior to completion of study. Data unavailable..\"\nDetail: PI left institution prior to completion of study. Data unavailable..", "metadata": {"result_id": 7762, "source_trial_id": "NCT01633814", "intervention_name": "Transdermal estradiol", "condition_name": "Aging", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1372", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: methylene blue\nCondition: Stage IA Breast Cancer\nPhase: phase_2\nEnrollment: 4\nTermination reason: \"P.I. left\"\nDetail: P.I. left", "metadata": {"result_id": 11238, "source_trial_id": "NCT01276054", "intervention_name": "methylene blue", "condition_name": "Stage IA Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1373", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: Chlorhexidine\nCondition: Hysterectomy\nPhase: phase_4\nBlinding: NONE\nEnrollment: 94\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Odds Ratio (OR)): 10.6\n95% CI: [3.02, 37.34]\nInterpretation: definitive_negative", "metadata": {"result_id": 58470, "source_trial_id": "NCT03412734", "intervention_name": "Chlorhexidine", "condition_name": "Hysterectomy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1374", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: No SLS toothpaste\nCondition: Oral Mucosal Disorder\nBlinding: SINGLE\nEnrollment: 53\np-value: 0.916\nInterpretation: definitive_negative", "metadata": {"result_id": 14985, "source_trial_id": "NCT04601103", "intervention_name": "No SLS toothpaste", "condition_name": "Oral Mucosal Disorder", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1375", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: LY2606368\nCondition: Ovarian Cancer\nPhase: phase_2\nEnrollment: 111\nTermination reason: \"Eli Lilly prematurely terminated the study.\"\nDetail: Eli Lilly prematurely terminated the study.", "metadata": {"result_id": 56332, "source_trial_id": "NCT02203513", "intervention_name": "LY2606368", "condition_name": "Ovarian Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1376", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: fenretinide\nCondition: Stage I Small Lymphocytic Lymphoma\nPhase: phase_1_2\nEnrollment: 32\nTermination reason: \"NCI stopped supplying fenretinide in November of 2012.\"\nDetail: NCI stopped supplying fenretinide in November of 2012.", "metadata": {"result_id": 17624, "source_trial_id": "NCT00288067", "intervention_name": "fenretinide", "condition_name": "Stage I Small Lymphocytic Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1377", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: Guanfacine extended-release tablets\nCondition: Attention Deficit Disorder\nPhase: phase_4\nBlinding: QUADRUPLE\nEnrollment: 29\nPrimary endpoint met: 1.0\np-value: 0.001\nInterpretation: definitive_negative", "metadata": {"result_id": 21158, "source_trial_id": "NCT01156051", "intervention_name": "Guanfacine extended-release tablets", "condition_name": "Attention Deficit Disorder", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1378", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: '2-0453\nCondition: Obesity\nPhase: phase_1\nEnrollment: 117\nTermination reason: \"See detailed description\"\nDetail: See detailed description", "metadata": {"result_id": 50962, "source_trial_id": "NCT01044108", "intervention_name": "'2-0453", "condition_name": "Obesity", "confidence_tier": "bronze", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-1379", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Lilly Bamlanivimab + Etesevimab\nCondition: Covid19\nPhase: phase_4\nEnrollment: 4571\nTermination reason: \"Emergency Use Authorizations for monoclonal antibodies withdrawn\"\nDetail: Emergency Use Authorizations for monoclonal antibodies withdrawn", "metadata": {"result_id": 48152, "source_trial_id": "NCT04790786", "intervention_name": "Lilly Bamlanivimab + Etesevimab", "condition_name": "Covid19", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-1380", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: AS703569\nCondition: Haematological Malignancies\nPhase: phase_1\nEnrollment: 124\nTermination reason: \"Please see Purpose Statement below\"\nDetail: Please see Purpose Statement below", "metadata": {"result_id": 51063, "source_trial_id": "NCT01080664", "intervention_name": "AS703569", "condition_name": "Haematological Malignancies", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1381", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Retosiban\nCondition: Obstetric Labour, Premature\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 97\np-value: 0.1432\nEffect size (Odds Ratio (OR)): 2.3\n95% CI: [0.75, 7.24]\nSerious adverse events: 100.0\nInterpretation: definitive_negative", "metadata": {"result_id": 17260, "source_trial_id": "NCT02292771", "intervention_name": "Retosiban", "condition_name": "Obstetric Labour, Premature", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1382", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Vyxeos\nCondition: AML, Adult\nPhase: phase_2\nEnrollment: 2\nTermination reason: \"Original investigator for the trial has left\"\nDetail: Original investigator for the trial has left", "metadata": {"result_id": 19430, "source_trial_id": "NCT04425655", "intervention_name": "Vyxeos", "condition_name": "AML, Adult", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1383", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Polyethylene glycol\nCondition: Bowel Preparation\nPhase: phase_4\nEnrollment: 5\nTermination reason: \"Significant changes to protocol and study design, study stopped to further enrollment and new study designed.\"\nDetail: Significant changes to protocol and study design, study stopped to further enrollment and new study designed.", "metadata": {"result_id": 652, "source_trial_id": "NCT02070341", "intervention_name": "Polyethylene glycol", "condition_name": "Bowel Preparation", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1384", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: recombinant human BNP(1-32)\nDrug type: unknown\nCondition: Metabolism\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 5\np-value: 0.063\nInterpretation: definitive_negative", "metadata": {"result_id": 8368, "source_trial_id": "NCT03397966", "intervention_name": "recombinant human BNP(1-32)", "condition_name": "Metabolism", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1385", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose\nCondition: Diabetic Nephropathy Type 2\nPhase: phase_1\nEnrollment: 2\nTermination reason: \"Principal Investigator relocation\"\nDetail: Principal Investigator relocation", "metadata": {"result_id": 54015, "source_trial_id": "NCT03840343", "intervention_name": "Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose", "condition_name": "Diabetic Nephropathy Type 2", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1386", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Humatrope\nDrug type: peptide\nCondition: Burns\nPhase: phase_2_3\nEnrollment: 1126\nTermination reason: \"At the request of the study site, this study has been closed and access to study-related data is unavailable. We are unable to submit the results-data.\"\nDetail: At the request of the study site, this study has been closed and access to study-related data is unavailable. We are unable to submit the results-data.", "metadata": {"result_id": 3767, "source_trial_id": "NCT00675714", "intervention_name": "Humatrope", "condition_name": "Burns", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1387", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Dexamethasone tablets\nCondition: Carcinoma, Non-Small-Cell Lung\nPhase: phase_1_2\nEnrollment: 42\nTermination reason: \"Premature closure - investigator left the National Institutes of Health.\"\nDetail: Premature closure - investigator left the National Institutes of Health.", "metadata": {"result_id": 46126, "source_trial_id": "NCT00923273", "intervention_name": "Dexamethasone tablets", "condition_name": "Carcinoma, Non-Small-Cell Lung", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1388", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: eptacog alfa (activated)\nDrug type: peptide\nCondition: Acquired Bleeding Disorder\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 554\nPrimary endpoint met: 1.0\np-value: 0.03\nEffect size (Hodges-Lehmann shift estimate): 2.0\nSerious adverse events: 1168.0\nInterpretation: definitive_negative", "metadata": {"result_id": 53883, "source_trial_id": "NCT00184548", "intervention_name": "eptacog alfa (activated)", "condition_name": "Acquired Bleeding Disorder", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1389", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: VXA-CoV2-1.1-S\nCondition: COVID-19\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 66\np-value: 0.257\nInterpretation: definitive_negative", "metadata": {"result_id": 22976, "source_trial_id": "NCT05067933", "intervention_name": "VXA-CoV2-1.1-S", "condition_name": "COVID-19", "confidence_tier": "silver", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-1390", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Milciclib Maleate\nCondition: Malignant Thymoma\nPhase: phase_2\nBlinding: NONE\nEnrollment: 30\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Single proportion): 0.54\n95% CI: [0.33, 0.74]\nSerious adverse events: 57.0\nInterpretation: definitive_negative", "metadata": {"result_id": 11766, "source_trial_id": "NCT01301391", "intervention_name": "Milciclib Maleate", "condition_name": "Malignant Thymoma", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1391", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: veledimex\nCondition: Metastatic Breast Cancer\nPhase: phase_1_2\nEnrollment: 9\nTermination reason: \"The study was terminated after 9 subjects had enrolled under Protocol Amend 1 because of slower than expected accrual. Protocol Amendment 2 (16 May 2016) was submitted to the FDA and, based on the decision of the PI, was not submitted to the IRB.\"\nDetail: The study was terminated after 9 subjects had enrolled under Protocol Amend 1 because of slower than expected accrual. Protocol Amendment 2 (16 May 2016) was submitted to the FDA and, based on the decision of the PI, was not submitted to the IRB.", "metadata": {"result_id": 9585, "source_trial_id": "NCT02423902", "intervention_name": "veledimex", "condition_name": "Metastatic Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1392", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: ARM 2\nCondition: Primary Open Angle Glaucoma (POAG)\nPhase: phase_1\nEnrollment: 12\nTermination reason: \"Study terminated early due to manufacturer not replenishing study site supply of inserts, despite repeated requests for more inserts.\"\nDetail: Study terminated early due to manufacturer not replenishing study site supply of inserts, despite repeated requests for more inserts.", "metadata": {"result_id": 34166, "source_trial_id": "NCT01180062", "intervention_name": "ARM 2", "condition_name": "Primary Open Angle Glaucoma (POAG)", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1393", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Ropivacine 0.2%\nCondition: Lumbar Plexus Nerve Block\nEnrollment: 10\nTermination reason: \"The computer is crushed and all data is lost (IT was not able to recover it. Last data was collected 6.17.14)\"\nDetail: The computer is crushed and all data is lost (IT was not able to recover it. Last data was collected 6.17.14)", "metadata": {"result_id": 11825, "source_trial_id": "NCT02161484", "intervention_name": "Ropivacine 0.2%", "condition_name": "Lumbar Plexus Nerve Block", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1394", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: BEAM\nCondition: Hodgkin Lymphoma\nPhase: phase_1_2\nEnrollment: 6\nTermination reason: \"Poor enrollment and ability to radioconjugate Daclizumab. Neither Center for Cancer Research (CCR) or Nuclear Medicine/Radiology wanted to do the facilities upgrade and hire personnel needed to radioconjugate the drug at the Clinical Center.\"\nDetail: Poor enrollment and ability to radioconjugate Daclizumab. Neither Center for Cancer Research (CCR) or Nuclear Medicine/Radiology wanted to do the facilities upgrade and hire personnel needed to radioconjugate the drug at the Clinical Center.", "metadata": {"result_id": 17711, "source_trial_id": "NCT01468311", "intervention_name": "BEAM", "condition_name": "Hodgkin Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1395", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Alprostadil (Prostaglandin E1)\nCondition: Macular Degeneration\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 37\np-value: 0.122\nEffect size (Mean Difference (Final Values)): 0.94\n95% CI: [-0.674, 2.55]\nInterpretation: definitive_negative", "metadata": {"result_id": 18261, "source_trial_id": "NCT00619229", "intervention_name": "Alprostadil (Prostaglandin E1)", "condition_name": "Macular Degeneration", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1396", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Opioid-Free Postoperative Pain Regimen\nCondition: Spinal Diseases\nPhase: phase_4\nEnrollment: 8\nTermination reason: \"Limitations of the prospective study design revealed that a retrospective study design would be better suited.\"\nDetail: Limitations of the prospective study design revealed that a retrospective study design would be better suited.", "metadata": {"result_id": 9411, "source_trial_id": "NCT04990804", "intervention_name": "Opioid-Free Postoperative Pain Regimen", "condition_name": "Spinal Diseases", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1397", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Anakinra and Ruxolitinib (overcome stage 3)\nCondition: COVID-19\nPhase: phase_2\nEnrollment: 2\nTermination reason: \"investigator decision\"\nDetail: investigator decision", "metadata": {"result_id": 25074, "source_trial_id": "NCT04366232", "intervention_name": "Anakinra and Ruxolitinib (overcome stage 3)", "condition_name": "COVID-19", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-1398", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: PXD101with cisplatin+doxorubicin+cyclophosphamide\nCondition: Thymic Carcinoma\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 26\nPrimary endpoint met: 1.0\np-value: 0.0001\nSerious adverse events: 66.0\nInterpretation: definitive_negative", "metadata": {"result_id": 13575, "source_trial_id": "NCT01100944", "intervention_name": "PXD101with cisplatin+doxorubicin+cyclophosphamide", "condition_name": "Thymic Carcinoma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1399", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: masoprocol\nCondition: Prostate Cancer\nPhase: phase_1\nEnrollment: 15\nTermination reason: \"Ran out of drug\"\nDetail: Ran out of drug", "metadata": {"result_id": 32600, "source_trial_id": "NCT00313534", "intervention_name": "masoprocol", "condition_name": "Prostate Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1400", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: Rovalpituzumab tesirine\nDrug type: antibody_drug_conjugate\nCondition: Small Cell Lung Cancer\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 748\np-value: 0.237\nEffect size (Hazard Ratio (HR)): 1.12\n95% CI: [0.92, 1.36]\nSerious adverse events: 1112.0\nInterpretation: definitive_negative", "metadata": {"result_id": 46092, "source_trial_id": "NCT03033511", "intervention_name": "Rovalpituzumab tesirine", "condition_name": "Small Cell Lung Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1401", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Erlotinib\nCondition: Nonsmall Cell Lung Cancer\nPhase: phase_1\nEnrollment: 8\nTermination reason: \"Drug shortage\"\nDetail: Drug shortage", "metadata": {"result_id": 49810, "source_trial_id": "NCT02342353", "intervention_name": "Erlotinib", "condition_name": "Nonsmall Cell Lung Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1402", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: URG101\nCondition: Bladder Pain Syndrome\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 28\nPrimary endpoint met: 1.0\np-value: 0.0363\nEffect size (Mean Difference (Final Values)): -21.14\n95% CI: [-44.43, 2.16]\nInterpretation: definitive_negative", "metadata": {"result_id": 10320, "source_trial_id": "NCT00517868", "intervention_name": "URG101", "condition_name": "Bladder Pain Syndrome", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1403", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: RVM-V001 30 µg\nCondition: Infectious Disease\nPhase: phase_1\nEnrollment: 13\nTermination reason: \"The landscape of the study area changed, making it impossible to continue the study.\"\nDetail: The landscape of the study area changed, making it impossible to continue the study.", "metadata": {"result_id": 23810, "source_trial_id": "NCT05420077", "intervention_name": "RVM-V001 30 µg", "condition_name": "Infectious Disease", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1404", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Avelumab 1200 mg in combination with gemcitabine/cisplatin\nCondition: Urothelial Cancer\nPhase: phase_1_2\nEnrollment: 67\nTermination reason: \"The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522).\"\nDetail: The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522).", "metadata": {"result_id": 35676, "source_trial_id": "NCT03317496", "intervention_name": "Avelumab 1200 mg in combination with gemcitabine/cisplatin", "condition_name": "Urothelial Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1405", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Miltefosine\nCondition: Chronic Urticaria\nPhase: phase_2\nEnrollment: 76\nTermination reason: \"Study medication expired\"\nDetail: Study medication expired", "metadata": {"result_id": 33824, "source_trial_id": "NCT01170949", "intervention_name": "Miltefosine", "condition_name": "Chronic Urticaria", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1406", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: BMS-986242\nCondition: Cancer\nPhase: phase_1_2\nEnrollment: 7\nTermination reason: \"Inability to meet protocol objectives\"\nDetail: Inability to meet protocol objectives", "metadata": {"result_id": 42944, "source_trial_id": "NCT03351231", "intervention_name": "BMS-986242", "condition_name": "Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1407", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Ketamine-assisted psychotherapy\nCondition: Major Depressive Disorder\nPhase: phase_2\nEnrollment: 5\nTermination reason: \"Primary Investigator leaving institution\"\nDetail: Primary Investigator leaving institution", "metadata": {"result_id": 36392, "source_trial_id": "NCT05193318", "intervention_name": "Ketamine-assisted psychotherapy", "condition_name": "Major Depressive Disorder", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1408", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Iscomatrix adjuvant\nCondition: Thorasic Cancers\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 21\np-value: 0.36\nInterpretation: definitive_negative", "metadata": {"result_id": 6272, "source_trial_id": "NCT02054104", "intervention_name": "Iscomatrix adjuvant", "condition_name": "Thorasic Cancers", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1409", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "hard", "context_text": "Drug: Sotrovimab\nDrug type: monoclonal_antibody\nCondition: Hematopoietic and Lymphoid Cell Neoplasm\nPhase: phase_1\nEnrollment: 20\nTermination reason: \"Terminated due to FDA withdrawal of the emergency use authorization (EUA) for sotrovimab\"\nDetail: Terminated due to FDA withdrawal of the emergency use authorization (EUA) for sotrovimab", "metadata": {"result_id": 48613, "source_trial_id": "NCT05135650", "intervention_name": "Sotrovimab", "condition_name": "Hematopoietic and Lymphoid Cell Neoplasm", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1410", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Zotiraciclib (TG02)\nCondition: Astrocytoma\nPhase: phase_1_2\nEnrollment: 53\nTermination reason: \"Unable to supply investigational agent, Zotiraciclib (TG02).\"\nDetail: Unable to supply investigational agent, Zotiraciclib (TG02).", "metadata": {"result_id": 54630, "source_trial_id": "NCT02942264", "intervention_name": "Zotiraciclib (TG02)", "condition_name": "Astrocytoma", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1411", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: LDE225-800mg\nCondition: Pancreatic Ductal Adenocarcinoma\nPhase: phase_1_2\nEnrollment: 23\nTermination reason: \"Study was terminated due to cease in manufacturing of study drug.\"\nDetail: Study was terminated due to cease in manufacturing of study drug.", "metadata": {"result_id": 1658, "source_trial_id": "NCT01431794", "intervention_name": "LDE225-800mg", "condition_name": "Pancreatic Ductal Adenocarcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1412", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: Darbepoetin alfa\nDrug type: peptide\nCondition: Kidney Disease\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 116\nPrimary endpoint met: 1.0\np-value: 0.001\nSerious adverse events: 98.0\nInterpretation: definitive_negative", "metadata": {"result_id": 47125, "source_trial_id": "NCT00436748", "intervention_name": "Darbepoetin alfa", "condition_name": "Kidney Disease", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1413", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: URG101\nCondition: Interstitial Cystitis\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 28\nPrimary endpoint met: 1.0\np-value: 0.0363\nEffect size (Mean Difference (Final Values)): -21.14\n95% CI: [-44.43, 2.16]\nInterpretation: definitive_negative", "metadata": {"result_id": 10318, "source_trial_id": "NCT00517868", "intervention_name": "URG101", "condition_name": "Interstitial Cystitis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1414", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Ruxolitinib\nCondition: Myeloid Malignancy\nPhase: phase_2\nEnrollment: 3\nTermination reason: \"Principal Investigator left institution\"\nDetail: Principal Investigator left institution", "metadata": {"result_id": 58113, "source_trial_id": "NCT05579769", "intervention_name": "Ruxolitinib", "condition_name": "Myeloid Malignancy", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1415", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: ethyl chloride\nCondition: Shoulder Pain\nPhase: phase_4\nBlinding: NONE\nEnrollment: 19\nPrimary endpoint met: 1.0\np-value: 0.05\nInterpretation: definitive_negative", "metadata": {"result_id": 27561, "source_trial_id": "NCT02592629", "intervention_name": "ethyl chloride", "condition_name": "Shoulder Pain", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1416", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: PET/MRI with Gallium-68 labeled PSMA-HBED-CC\nCondition: Prostate Cancer\nPhase: phase_2\nBlinding: NONE\nEnrollment: 273\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (Risk Difference (RD)): 0.42\n95% CI: [0.3, 0.53]\nInterpretation: definitive_negative", "metadata": {"result_id": 14772, "source_trial_id": "NCT03439033", "intervention_name": "PET/MRI with Gallium-68 labeled PSMA-HBED-CC", "condition_name": "Prostate Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1417", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Erythropoiesis-Stimulating Agent (ESA)\nCondition: End Stage Renal Disease\nEnrollment: 88\nTermination reason: \"Standard clinical practice at site caused unforeseen issues for the use of the ACM\"\nDetail: Standard clinical practice at site caused unforeseen issues for the use of the ACM", "metadata": {"result_id": 50543, "source_trial_id": "NCT03214627", "intervention_name": "Erythropoiesis-Stimulating Agent (ESA)", "condition_name": "End Stage Renal Disease", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1418", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Capecitabine based chemoradiation\nCondition: Locally Advanced Rectal Cancer\nPhase: phase_1_2\nEnrollment: 10\nTermination reason: \"Due to the amended therapy strategies for rectal cancer recently, it was decided not to transfer the study to the phase II part, as superiority over standard chemoradiation and transfer to a new therapy standard are increasingly unlikely.\"\nDetail: Due to the amended therapy strategies for rectal cancer recently, it was decided not to transfer the study to the phase II part, as superiority over standard chemoradiation and transfer to a new therapy standard are increasingly unlikely.", "metadata": {"result_id": 46209, "source_trial_id": "NCT04177602", "intervention_name": "Capecitabine based chemoradiation", "condition_name": "Locally Advanced Rectal Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1419", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Fenofibrate capsule daily for 4 weeks\nCondition: Healthy\nBlinding: QUADRUPLE\nEnrollment: 11\nPrimary endpoint met: 1.0\np-value: 0.015\nEffect size (Ratio of mean effects): 1.27\n95% CI: [1.06, 1.52]\nInterpretation: definitive_negative", "metadata": {"result_id": 18995, "source_trial_id": "NCT00644592", "intervention_name": "Fenofibrate capsule daily for 4 weeks", "condition_name": "Healthy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1420", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Maltodextrin\nDrug type: unknown\nCondition: SARS-CoV-2\nPhase: phase_2\nEnrollment: 209\nTermination reason: \"The study was interrupted due to the arrival and distribution of the vaccine to hospital workers in Peru\"\nDetail: The study was interrupted due to the arrival and distribution of the vaccine to hospital workers in Peru", "metadata": {"result_id": 12985, "source_trial_id": "NCT04526821", "intervention_name": "Maltodextrin", "condition_name": "SARS-CoV-2", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1421", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Inhaled iloprost\nCondition: Pulmonary Hypertension\nPhase: phase_4\nEnrollment: 1\nTermination reason: \"Sub-Investigator left U of C\"\nDetail: Sub-Investigator left U of C", "metadata": {"result_id": 2646, "source_trial_id": "NCT00409526", "intervention_name": "Inhaled iloprost", "condition_name": "Pulmonary Hypertension", "confidence_tier": "bronze", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-1422", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Ibuprofen 2400mg\nCondition: Preterm Labor\nEnrollment: 11\nTermination reason: \"Investigative team moved institutions\"\nDetail: Investigative team moved institutions", "metadata": {"result_id": 16926, "source_trial_id": "NCT04726085", "intervention_name": "Ibuprofen 2400mg", "condition_name": "Preterm Labor", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1423", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: CP-751,871\nDrug type: monoclonal_antibody\nCondition: Advanced Cancer\nPhase: phase_1\nEnrollment: 45\nTermination reason: \"See termination reason in detailed description.\"\nDetail: See termination reason in detailed description.", "metadata": {"result_id": 53667, "source_trial_id": "NCT00729833", "intervention_name": "CP-751,871", "condition_name": "Advanced Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1424", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Misoprostol\nCondition: Pregnancy\nPhase: phase_4\nBlinding: NONE\nEnrollment: 34\nPrimary endpoint met: 1.0\np-value: 0.04\nInterpretation: definitive_negative", "metadata": {"result_id": 43276, "source_trial_id": "NCT02777190", "intervention_name": "Misoprostol", "condition_name": "Pregnancy", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1425", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Pemetrexed followed by Cisplatin\nCondition: Carcinoma, Non-Small-Cell Lung\nPhase: phase_2\nEnrollment: 31\nTermination reason: \"Study terminated due to reproducibility issues with genomics prediction model.\"\nDetail: Study terminated due to reproducibility issues with genomics prediction model.", "metadata": {"result_id": 43096, "source_trial_id": "NCT00545948", "intervention_name": "Pemetrexed followed by Cisplatin", "condition_name": "Carcinoma, Non-Small-Cell Lung", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1426", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: DS-8201a\nDrug type: antibody_drug_conjugate\nCondition: Breast Cancer\nPhase: phase_2\nEnrollment: 253\nTermination reason: \"The last participant was transitioned to alternative study.\"\nDetail: The last participant was transitioned to alternative study.", "metadata": {"result_id": 54410, "source_trial_id": "NCT03248492", "intervention_name": "DS-8201a", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1427", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Spartalizumab\nDrug type: monoclonal_antibody\nCondition: Metastatic Pancreatic Ductal Adenocarcinoma\nPhase: phase_2\nBlinding: NONE\nEnrollment: 164\np-value: 0.38\nEffect size (Hazard Ratio (HR)): 1.08\nInterpretation: definitive_negative", "metadata": {"result_id": 57932, "source_trial_id": "NCT04390763", "intervention_name": "Spartalizumab", "condition_name": "Metastatic Pancreatic Ductal Adenocarcinoma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1428", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "hard", "context_text": "Drug: IMTOX-25\nCondition: Adult T Cell Lymphoma\nPhase: phase_2\nEnrollment: 1\nTermination reason: \"IND withdrawn\"\nDetail: IND withdrawn", "metadata": {"result_id": 8340, "source_trial_id": "NCT01378871", "intervention_name": "IMTOX-25", "condition_name": "Adult T Cell Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1429", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Concept2 inhaler\nCondition: Chronic Obstructive Pulmonary Disease\nPhase: phase_3\nEnrollment: 7\nTermination reason: \"devices malfunctioned\"\nDetail: devices malfunctioned", "metadata": {"result_id": 29098, "source_trial_id": "NCT03379233", "intervention_name": "Concept2 inhaler", "condition_name": "Chronic Obstructive Pulmonary Disease", "confidence_tier": "bronze", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL1-1430", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Morphine, Parecoxib\nCondition: Pain, Postoperative\nPhase: phase_4\nBlinding: DOUBLE\nEnrollment: 105\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (LS mean difference (net)): -1.16\n95% CI: [-1.77, -0.56]\nSerious adverse events: 39.0\nInterpretation: definitive_negative", "metadata": {"result_id": 6477, "source_trial_id": "NCT00346268", "intervention_name": "Morphine, Parecoxib", "condition_name": "Pain, Postoperative", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1431", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: CUDC-907\nCondition: Thyroid Neoplasms\nPhase: phase_2\nEnrollment: 7\nTermination reason: \"Study was closed because investigator left the National Institutes of Health.\"\nDetail: Study was closed because investigator left the National Institutes of Health.", "metadata": {"result_id": 61687, "source_trial_id": "NCT03002623", "intervention_name": "CUDC-907", "condition_name": "Thyroid Neoplasms", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1432", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Double-dose Lopinavir/Ritonavir\nCondition: HIV Infection\nPhase: phase_2\nEnrollment: 71\nTermination reason: \"The study was stopped early due to feasibility concerns.\"\nDetail: The study was stopped early due to feasibility concerns.", "metadata": {"result_id": 44474, "source_trial_id": "NCT01601626", "intervention_name": "Double-dose Lopinavir/Ritonavir", "condition_name": "HIV Infection", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-1433", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Navelbine\nCondition: Lung Cancer\nPhase: phase_1_2\nEnrollment: 36\nTermination reason: \"Original Principal Investigator left the institution.\"\nDetail: Original Principal Investigator left the institution.", "metadata": {"result_id": 53515, "source_trial_id": "NCT00004093", "intervention_name": "Navelbine", "condition_name": "Lung Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1434", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Sutent®/Sunitinib\nCondition: NF1\nPhase: phase_2\nEnrollment: 19\nTermination reason: \"1 patient died of uncertain cause but possibly related to drug.\"\nDetail: 1 patient died of uncertain cause but possibly related to drug.", "metadata": {"result_id": 484, "source_trial_id": "NCT01402817", "intervention_name": "Sutent®/Sunitinib", "condition_name": "NF1", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1435", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: Apixaban\nCondition: Atrial Fibrillation\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 14830\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (Cox Proportional Hazard): 3.785\n95% CI: [2.457, 5.833]\nInterpretation: definitive_negative", "metadata": {"result_id": 10829, "source_trial_id": "NCT05643573", "intervention_name": "Apixaban", "condition_name": "Atrial Fibrillation", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-1436", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Omegaven\nDrug type: unknown\nCondition: Cancer\nPhase: phase_2\nBlinding: NONE\nEnrollment: 12\np-value: 0.07\nSerious adverse events: 1.0\nInterpretation: definitive_negative", "metadata": {"result_id": 44444, "source_trial_id": "NCT01325584", "intervention_name": "Omegaven", "condition_name": "Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1437", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: tanezumab 10 mg\nCondition: Osteoarthritis\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 614\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Least Squares (LS) Mean Difference): -0.96\n95% CI: [-1.49, -0.44]\nSerious adverse events: 35.0\nInterpretation: definitive_negative", "metadata": {"result_id": 61122, "source_trial_id": "NCT00985621", "intervention_name": "tanezumab 10 mg", "condition_name": "Osteoarthritis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1438", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Brexpiprazole, OPDC-34712\nCondition: Schizophrenia\nPhase: phase_1\nEnrollment: 22\nTermination reason: \"Part A of study was completed per protocol. Conduct of Part B of the study (confirmatory phase) was not necessary.\"\nDetail: Part A of study was completed per protocol. Conduct of Part B of the study (confirmatory phase) was not necessary.", "metadata": {"result_id": 62083, "source_trial_id": "NCT02968121", "intervention_name": "Brexpiprazole, OPDC-34712", "condition_name": "Schizophrenia", "confidence_tier": "bronze", "therapeutic_area": "psychiatry"}, "split": "test"}
+{"question_id": "CTL1-1439", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "hard", "context_text": "Drug: Peru-15 Vaccine\nCondition: Vibrio Infections\nPhase: phase_2\nEnrollment: 74\nTermination reason: \"one of site was not able to get an approval from the national regulatory authority.\"\nDetail: one of site was not able to get an approval from the national regulatory authority.", "metadata": {"result_id": 13392, "source_trial_id": "NCT00624975", "intervention_name": "Peru-15 Vaccine", "condition_name": "Vibrio Infections", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1440", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: vaccine\nCondition: Influenza Infection\nPhase: phase_3\nEnrollment: 140\nTermination reason: \"End of the study\"\nDetail: End of the study", "metadata": {"result_id": 55348, "source_trial_id": "NCT00647465", "intervention_name": "vaccine", "condition_name": "Influenza Infection", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-1441", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Visbiome\nCondition: HIV-1 Infection\nPhase: phase_2\nEnrollment: 1\nTermination reason: \"Recruitment potential impaired by shift in clinical care whereby practically all HIV patients receive standard treatment as soon as possible after HIV diagnosis\"\nDetail: Recruitment potential impaired by shift in clinical care whereby practically all HIV patients receive standard treatment as soon as possible after HIV diagnosis", "metadata": {"result_id": 42947, "source_trial_id": "NCT02441244", "intervention_name": "Visbiome", "condition_name": "HIV-1 Infection", "confidence_tier": "bronze", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL1-1442", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: tinzaparin sodium\nDrug type: other_biologic\nCondition: Cancer\nPhase: phase_2\nEnrollment: 131\nTermination reason: \"Tinzaparin will no longer be available in the United States\"\nDetail: Tinzaparin will no longer be available in the United States", "metadata": {"result_id": 49262, "source_trial_id": "NCT00981903", "intervention_name": "tinzaparin sodium", "condition_name": "Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1443", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: defined green tea catechin extract\nCondition: Stage II Colon Cancer\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 39\np-value: 0.1439\nInterpretation: definitive_negative", "metadata": {"result_id": 32815, "source_trial_id": "NCT01606124", "intervention_name": "defined green tea catechin extract", "condition_name": "Stage II Colon Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1444", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Gemcitabine Injection\nCondition: Metastatic Pancreatic Ductal Adenocarcinoma\nPhase: phase_1_2\nEnrollment: 6\nTermination reason: \"Changing treatment landscape: The availability of nab-paclitaxel with gemcitabine in the second-line setting has changed the feasibility of further recruitment and potential long-term development opportunities of SLC-0111 with gemcitabine alone.\"\nDetail: Changing treatment landscape: The availability of nab-paclitaxel with gemcitabine in the second-line setting has changed the feasibility of further recruitment and potential long-term development opportunities of SLC-0111 with gemcitabine alone.", "metadata": {"result_id": 56574, "source_trial_id": "NCT03450018", "intervention_name": "Gemcitabine Injection", "condition_name": "Metastatic Pancreatic Ductal Adenocarcinoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1445", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "hard", "context_text": "Drug: OSIRIS other concentration 2\nCondition: Allergic Rhinitis\nPhase: phase_2\nEnrollment: 210\nTermination reason: \"CA approval not obtained\"\nDetail: CA approval not obtained", "metadata": {"result_id": 17117, "source_trial_id": "NCT01240954", "intervention_name": "OSIRIS other concentration 2", "condition_name": "Allergic Rhinitis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1446", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Tarceva\nCondition: Non-Small Cell Lung Cancer\nPhase: phase_1\nEnrollment: 11\nTermination reason: \"Phase II not initiated due to cancellation of supply of Poly E by collaborator.\"\nDetail: Phase II not initiated due to cancellation of supply of Poly E by collaborator.", "metadata": {"result_id": 3753, "source_trial_id": "NCT00707252", "intervention_name": "Tarceva", "condition_name": "Non-Small Cell Lung Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1447", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: DC-006 vaccine\nCondition: Recurrent Epithelial Ovarian Cancer\nPhase: phase_1_2\nEnrollment: 5\nTermination reason: \"The study needed to be terminated due to new knowledge about cancer vaccines. A new protocol with an expected more efficient vaccine is currently being written.\"\nDetail: The study needed to be terminated due to new knowledge about cancer vaccines. A new protocol with an expected more efficient vaccine is currently being written.", "metadata": {"result_id": 38368, "source_trial_id": "NCT01334047", "intervention_name": "DC-006 vaccine", "condition_name": "Recurrent Epithelial Ovarian Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1448", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Exenatide once weekly (QW)\nCondition: Diabetes Mellitus, Type 2\nPhase: phase_4\nEnrollment: 192\nTermination reason: \"The trial was terminated per protocol because of lack of feasibility.\"\nDetail: The trial was terminated per protocol because of lack of feasibility.", "metadata": {"result_id": 35338, "source_trial_id": "NCT02072096", "intervention_name": "Exenatide once weekly (QW)", "condition_name": "Diabetes Mellitus, Type 2", "confidence_tier": "bronze", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-1449", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: H1299 Cell Lysates\nCondition: Sarcoma\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 21\np-value: 0.36\nInterpretation: definitive_negative", "metadata": {"result_id": 6259, "source_trial_id": "NCT02054104", "intervention_name": "H1299 Cell Lysates", "condition_name": "Sarcoma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1450", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: MEDI-507\nDrug type: monoclonal_antibody\nCondition: Multiple Myeloma\nPhase: phase_2\nEnrollment: 14\nTermination reason: \"Expiration of MEDI-507\"\nDetail: Expiration of MEDI-507", "metadata": {"result_id": 62300, "source_trial_id": "NCT00113646", "intervention_name": "MEDI-507", "condition_name": "Multiple Myeloma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1451", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: DMSO Instillation\nCondition: Overactive Bladder\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 25\nPrimary endpoint met: 1.0\np-value: 0.024\nSerious adverse events: 5.0\nInterpretation: definitive_negative", "metadata": {"result_id": 26381, "source_trial_id": "NCT00667095", "intervention_name": "DMSO Instillation", "condition_name": "Overactive Bladder", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1452", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Triamcinolone\nCondition: Nasal Polyps\nPhase: phase_1_2\nEnrollment: 1\nTermination reason: \"not enough particpants\"\nDetail: not enough particpants", "metadata": {"result_id": 15130, "source_trial_id": "NCT01222871", "intervention_name": "Triamcinolone", "condition_name": "Nasal Polyps", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1453", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "medium", "context_text": "Drug: NIS793\nDrug type: monoclonal_antibody\nCondition: Metastatic Pancreatic Ductal Adenocarcinoma\nPhase: phase_2\nBlinding: NONE\nEnrollment: 164\np-value: 0.38\nEffect size (Hazard Ratio (HR)): 1.08\nInterpretation: definitive_negative", "metadata": {"result_id": 57933, "source_trial_id": "NCT04390763", "intervention_name": "NIS793", "condition_name": "Metastatic Pancreatic Ductal Adenocarcinoma", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1454", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: MK-3475\nDrug type: monoclonal_antibody\nCondition: Lymphoma, T-Cell, Peripheral\nPhase: phase_1_2\nEnrollment: 17\nTermination reason: \"Merck no longer providing drug for study\"\nDetail: Merck no longer providing drug for study", "metadata": {"result_id": 15484, "source_trial_id": "NCT02535247", "intervention_name": "MK-3475", "condition_name": "Lymphoma, T-Cell, Peripheral", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1455", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: CP-751,871 (Figitumumab)\nDrug type: monoclonal_antibody\nCondition: Carcinoma, Adenosquamous\nPhase: phase_3\nBlinding: NONE\nEnrollment: 681\np-value: 0.064\nEffect size (Hazard Ratio (HR)): 1.179\n95% CI: [0.99, 1.404]\nSerious adverse events: 1081.0\nInterpretation: definitive_negative", "metadata": {"result_id": 13701, "source_trial_id": "NCT00596830", "intervention_name": "CP-751,871 (Figitumumab)", "condition_name": "Carcinoma, Adenosquamous", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1456", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Aminophylline\nDrug type: peptide\nCondition: Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan\nPhase: phase_4\nBlinding: QUADRUPLE\nEnrollment: 248\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Odds Ratio (OR)): 0.39\n95% CI: [0.2, 0.7]\nInterpretation: definitive_negative", "metadata": {"result_id": 10825, "source_trial_id": "NCT01250496", "intervention_name": "Aminophylline", "condition_name": "Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan", "confidence_tier": "silver", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL1-1457", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: DMSO Instillation\nCondition: Urinary Urge Incontinence\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 25\nPrimary endpoint met: 1.0\np-value: 0.024\nSerious adverse events: 5.0\nInterpretation: definitive_negative", "metadata": {"result_id": 26389, "source_trial_id": "NCT00667095", "intervention_name": "DMSO Instillation", "condition_name": "Urinary Urge Incontinence", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1458", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Dose-Establishing Study 1 Niacin 500mg\nCondition: Short Stature\nPhase: phase_1_2\nBlinding: QUADRUPLE\nEnrollment: 37\nPrimary endpoint met: 1.0\np-value: 0.016\nInterpretation: definitive_negative", "metadata": {"result_id": 58065, "source_trial_id": "NCT01237041", "intervention_name": "Dose-Establishing Study 1 Niacin 500mg", "condition_name": "Short Stature", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1459", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "medium", "context_text": "Drug: BIIB019 (Daclizumab)\nCondition: Relapsing-Remitting Multiple Sclerosis\nPhase: phase_3\nBlinding: NONE\nEnrollment: 1501\nPrimary endpoint met: 1.0\np-value: 0.0057\nSerious adverse events: 1034.0\nInterpretation: definitive_negative", "metadata": {"result_id": 32309, "source_trial_id": "NCT01797965", "intervention_name": "BIIB019 (Daclizumab)", "condition_name": "Relapsing-Remitting Multiple Sclerosis", "confidence_tier": "silver", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-1460", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Atosiban\nDrug type: peptide\nCondition: Obstetric Labour, Premature\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 97\np-value: 0.1432\nEffect size (Odds Ratio (OR)): 2.3\n95% CI: [0.75, 7.24]\nSerious adverse events: 100.0\nInterpretation: definitive_negative", "metadata": {"result_id": 17259, "source_trial_id": "NCT02292771", "intervention_name": "Atosiban", "condition_name": "Obstetric Labour, Premature", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1461", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: tanezumab\nDrug type: monoclonal_antibody\nCondition: Osteoarthritis\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 220\np-value: 0.434\nEffect size (Least squares (LS) mean difference): 0.29\n95% CI: [-0.44, 1.01]\nSerious adverse events: 8.0\nInterpretation: definitive_negative", "metadata": {"result_id": 49410, "source_trial_id": "NCT00863772", "intervention_name": "tanezumab", "condition_name": "Osteoarthritis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1462", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Fosciclopirox + Cytarabine\nCondition: Recurrent Acute Myeloid Leukemia\nPhase: phase_1_2\nEnrollment: 18\nTermination reason: \"Discontinued\"\nDetail: Discontinued", "metadata": {"result_id": 8910, "source_trial_id": "NCT04956042", "intervention_name": "Fosciclopirox + Cytarabine", "condition_name": "Recurrent Acute Myeloid Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1463", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: Lorcaserin\nCondition: Cocaine Use Disorder\nPhase: phase_2\nBlinding: TRIPLE\nEnrollment: 22\np-value: 0.32\nInterpretation: definitive_negative", "metadata": {"result_id": 9577, "source_trial_id": "NCT03192995", "intervention_name": "Lorcaserin", "condition_name": "Cocaine Use Disorder", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1464", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: recombinant human BNP(1-32)\nDrug type: unknown\nCondition: Cardiovascular Physiological Phenomena\nPhase: phase_4\nBlinding: TRIPLE\nEnrollment: 5\np-value: 0.063\nInterpretation: definitive_negative", "metadata": {"result_id": 8370, "source_trial_id": "NCT03397966", "intervention_name": "recombinant human BNP(1-32)", "condition_name": "Cardiovascular Physiological Phenomena", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1465", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: oprelvekin\nDrug type: peptide\nCondition: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\nPhase: phase_1_2\nEnrollment: 81\nTermination reason: \"Trial completed prematurely.\"\nDetail: Trial completed prematurely.", "metadata": {"result_id": 8087, "source_trial_id": "NCT00012298", "intervention_name": "oprelvekin", "condition_name": "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1466", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Vistusertib\nCondition: Stage III Lung Small Cell Carcinoma, by American Joint Committee on Cancer (AJCC) v7\nPhase: phase_1_2\nEnrollment: 15\nTermination reason: \"Drug supply issues\"\nDetail: Drug supply issues", "metadata": {"result_id": 62161, "source_trial_id": "NCT03366103", "intervention_name": "Vistusertib", "condition_name": "Stage III Lung Small Cell Carcinoma, by American Joint Committee on Cancer (AJCC) v7", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1467", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Cisplatin plus Epirubicin\nCondition: Germ Cell Tumor\nPhase: phase_2\nEnrollment: 37\nTermination reason: \"Accrual Goal Met\"\nDetail: Accrual Goal Met", "metadata": {"result_id": 35927, "source_trial_id": "NCT00198172", "intervention_name": "Cisplatin plus Epirubicin", "condition_name": "Germ Cell Tumor", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1468", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: G-CSF\nDrug type: peptide\nCondition: Leukemia\nPhase: phase_2\nEnrollment: 16\nTermination reason: \"Objectives not met.\"\nDetail: Objectives not met.", "metadata": {"result_id": 4749, "source_trial_id": "NCT01518153", "intervention_name": "G-CSF", "condition_name": "Leukemia", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1469", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Articaine Injection\nCondition: Apical Periodontitis\nPhase: phase_2\nEnrollment: 3\nTermination reason: \"Drug is no longer being manufactured\"\nDetail: Drug is no longer being manufactured", "metadata": {"result_id": 34272, "source_trial_id": "NCT03962634", "intervention_name": "Articaine Injection", "condition_name": "Apical Periodontitis", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1470", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: NSAID\nCondition: Arthritis\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 2720\nPrimary endpoint met: 1.0\np-value: 0.001\nEffect size (Least Square (LS) Mean Difference): -0.92\n95% CI: [-1.28, -0.57]\nSerious adverse events: 598.0\nInterpretation: definitive_negative", "metadata": {"result_id": 19397, "source_trial_id": "NCT00809354", "intervention_name": "NSAID", "condition_name": "Arthritis", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1471", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Investigational Agent\nCondition: Malignant Neoplasm\nPhase: phase_2\nBlinding: NONE\nEnrollment: 45\np-value: 0.966\nInterpretation: definitive_negative", "metadata": {"result_id": 32585, "source_trial_id": "NCT04111107", "intervention_name": "Investigational Agent", "condition_name": "Malignant Neoplasm", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1472", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: IL-2\nDrug type: peptide\nCondition: Leukemia, Myelogenous, Acute\nPhase: phase_2\nEnrollment: 15\nTermination reason: \"study drug (Ontak) no longer available\"\nDetail: study drug (Ontak) no longer available", "metadata": {"result_id": 41325, "source_trial_id": "NCT01106950", "intervention_name": "IL-2", "condition_name": "Leukemia, Myelogenous, Acute", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1473", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: PF-04447943\nCondition: Elderly\nPhase: phase_1\nEnrollment: 10\nTermination reason: \"See Detailed Description for termination reason.\"\nDetail: See Detailed Description for termination reason.", "metadata": {"result_id": 17490, "source_trial_id": "NCT00736528", "intervention_name": "PF-04447943", "condition_name": "Elderly", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1474", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Depakote ER\nCondition: Dementia\nPhase: phase_3\nEnrollment: 20\nTermination reason: \"Investigator closed study and left VAMC.\"\nDetail: Investigator closed study and left VAMC.", "metadata": {"result_id": 6843, "source_trial_id": "NCT00315900", "intervention_name": "Depakote ER", "condition_name": "Dementia", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-1475", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: CEM-102\nCondition: Prosthetic Joint Infections of Hip\nPhase: phase_2\nEnrollment: 14\nTermination reason: \"This study has been terminated; alternative study designs are being considered. Fusidic acid remains available under an Expanded Access Protocol.\"\nDetail: This study has been terminated; alternative study designs are being considered. Fusidic acid remains available under an Expanded Access Protocol.", "metadata": {"result_id": 54578, "source_trial_id": "NCT01756924", "intervention_name": "CEM-102", "condition_name": "Prosthetic Joint Infections of Hip", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1476", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: AG-024322\nCondition: Lymphoma, Non-Hodgkin\nPhase: phase_1\nEnrollment: 37\nTermination reason: \"See Detailed Description\"\nDetail: See Detailed Description", "metadata": {"result_id": 40047, "source_trial_id": "NCT00147485", "intervention_name": "AG-024322", "condition_name": "Lymphoma, Non-Hodgkin", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1477", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Dose-Establishing Study 2 Niacin 500mg\nCondition: Short Stature\nPhase: phase_1_2\nBlinding: QUADRUPLE\nEnrollment: 37\nPrimary endpoint met: 1.0\np-value: 0.016\nInterpretation: definitive_negative", "metadata": {"result_id": 58066, "source_trial_id": "NCT01237041", "intervention_name": "Dose-Establishing Study 2 Niacin 500mg", "condition_name": "Short Stature", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1478", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: H1299 Cell Lysates\nCondition: Thoracic Sarcomas\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 21\np-value: 0.36\nInterpretation: definitive_negative", "metadata": {"result_id": 6263, "source_trial_id": "NCT02054104", "intervention_name": "H1299 Cell Lysates", "condition_name": "Thoracic Sarcomas", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1479", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Cyclophosphamid\nCondition: Breast Cancer\nPhase: phase_2\nEnrollment: 21\nTermination reason: \"Therapy of HER2+ patients according to protocol was no longer appropriate. Patient enrolment behind planned schedule and challenges of site performance\"\nDetail: Therapy of HER2+ patients according to protocol was no longer appropriate. Patient enrolment behind planned schedule and challenges of site performance", "metadata": {"result_id": 42775, "source_trial_id": "NCT01690325", "intervention_name": "Cyclophosphamid", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1480", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Spheramine (BAY86-5280)\nCondition: Parkinson''s Disease\nPhase: phase_2\nEnrollment: 6\nTermination reason: \"Study was completed, only life long extended follow-up phase was discontinued after 12 years\"\nDetail: Study was completed, only life long extended follow-up phase was discontinued after 12 years", "metadata": {"result_id": 39440, "source_trial_id": "NCT00761436", "intervention_name": "Spheramine (BAY86-5280)", "condition_name": "Parkinson''s Disease", "confidence_tier": "bronze", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL1-1481", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: H1299 Cell Lysates\nCondition: Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura\nPhase: phase_1_2\nBlinding: NONE\nEnrollment: 21\np-value: 0.36\nInterpretation: definitive_negative", "metadata": {"result_id": 6267, "source_trial_id": "NCT02054104", "intervention_name": "H1299 Cell Lysates", "condition_name": "Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1482", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: 5-fluorouracil (5-FU)\nCondition: Metastatic Pancreatic Cancer\nPhase: phase_1\nEnrollment: 4\nTermination reason: \"NIS793 is no longer being developed\"\nDetail: NIS793 is no longer being developed", "metadata": {"result_id": 39951, "source_trial_id": "NCT05417386", "intervention_name": "5-fluorouracil (5-FU)", "condition_name": "Metastatic Pancreatic Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1483", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Topical Benzocaine\nCondition: Neonatal Tongue-tie\nPhase: phase_1_2\nEnrollment: 21\nTermination reason: \"The study ethics committee recommended concluding the study for longer crying time with benzocaine and very short crying time in all participants.\"\nDetail: The study ethics committee recommended concluding the study for longer crying time with benzocaine and very short crying time in all participants.", "metadata": {"result_id": 15088, "source_trial_id": "NCT01274247", "intervention_name": "Topical Benzocaine", "condition_name": "Neonatal Tongue-tie", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1484", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: insulin NPH\nDrug type: peptide\nCondition: Diabetes\nPhase: phase_4\nEnrollment: 23\nTermination reason: \"See detailed description\"\nDetail: See detailed description", "metadata": {"result_id": 61356, "source_trial_id": "NCT00509925", "intervention_name": "insulin NPH", "condition_name": "Diabetes", "confidence_tier": "bronze", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL1-1485", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: doxorubicin/cyclophosphamide\nCondition: Stage III Breast Cancer\nPhase: phase_2\nEnrollment: 34\nTermination reason: \"The Principal Investigator left Johns Hopkins\"\nDetail: The Principal Investigator left Johns Hopkins", "metadata": {"result_id": 41343, "source_trial_id": "NCT02096588", "intervention_name": "doxorubicin/cyclophosphamide", "condition_name": "Stage III Breast Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1486", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: BIIB092\nDrug type: monoclonal_antibody\nCondition: Frontotemporal Lobar Degeneration With Tau Inclusions\nPhase: phase_1\nEnrollment: 22\nTermination reason: \"BIIB092 program discontinued\"\nDetail: BIIB092 program discontinued", "metadata": {"result_id": 20627, "source_trial_id": "NCT03658135", "intervention_name": "BIIB092", "condition_name": "Frontotemporal Lobar Degeneration With Tau Inclusions", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1487", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: CC-292\nCondition: Lymphoma, Large B-Cell, Diffuse\nPhase: phase_1\nEnrollment: 174\nTermination reason: \"Replaced with another clinical trial.\"\nDetail: Replaced with another clinical trial.", "metadata": {"result_id": 55529, "source_trial_id": "NCT02031419", "intervention_name": "CC-292", "condition_name": "Lymphoma, Large B-Cell, Diffuse", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1488", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "hard", "context_text": "Drug: Efalizumab - anti CD11a recombinant human monoclonal antibody\nCondition: Chronic Plaque Psoriasis\nPhase: phase_4\nEnrollment: 76\nTermination reason: \"The study was terminated after the European Medicines Agency recommended to suspend the marketing authorisation of Raptiva in the European Union\"\nDetail: The study was terminated after the European Medicines Agency recommended to suspend the marketing authorisation of Raptiva in the European Union", "metadata": {"result_id": 57644, "source_trial_id": "NCT00739882", "intervention_name": "Efalizumab - anti CD11a recombinant human monoclonal antibody", "condition_name": "Chronic Plaque Psoriasis", "confidence_tier": "bronze", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL1-1489", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: cinacalcet capsule\nCondition: Chronic Kidney Disease\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 43\nPrimary endpoint met: 1.0\np-value: 0.017\nEffect size (Difference (Cinacalcet - Placebo)): 35.5\n95% CI: [8.76, 62.24]\nSerious adverse events: 83.0\nInterpretation: definitive_negative", "metadata": {"result_id": 37078, "source_trial_id": "NCT01277510", "intervention_name": "cinacalcet capsule", "condition_name": "Chronic Kidney Disease", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1490", "task": "CT-L1", "gold_answer": "E", "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: Guanfacine extended-release tablets\nCondition: Attention-deficit/Hyperactivity Disorder\nPhase: phase_4\nBlinding: QUADRUPLE\nEnrollment: 29\nPrimary endpoint met: 1.0\np-value: 0.001\nInterpretation: definitive_negative", "metadata": {"result_id": 21162, "source_trial_id": "NCT01156051", "intervention_name": "Guanfacine extended-release tablets", "condition_name": "Attention-deficit/Hyperactivity Disorder", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1491", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Tozuleristide\nDrug type: peptide\nCondition: Stage IVA Lip and Oral Cavity Cancer AJCC v8\nPhase: phase_1_2\nEnrollment: 8\nTermination reason: \"Terminated due to suboptimal delineation of fluorescence between tumor and native oral cavity mucosa.\"\nDetail: Terminated due to suboptimal delineation of fluorescence between tumor and native oral cavity mucosa.", "metadata": {"result_id": 60763, "source_trial_id": "NCT05316688", "intervention_name": "Tozuleristide", "condition_name": "Stage IVA Lip and Oral Cavity Cancer AJCC v8", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1492", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: nicotinic acid\nCondition: Central Retinal Vein Occlusion\nPhase: phase_2_3\nEnrollment: 36\nTermination reason: \"The PI retired/left the institution. Efforts were made to contact the PI but were unsuccessful.\"\nDetail: The PI retired/left the institution. Efforts were made to contact the PI but were unsuccessful.", "metadata": {"result_id": 24449, "source_trial_id": "NCT00500045", "intervention_name": "nicotinic acid", "condition_name": "Central Retinal Vein Occlusion", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1493", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Onalespib\nCondition: Recurrent Mantle Cell Lymphoma\nPhase: phase_2\nEnrollment: 25\nTermination reason: \"Drug supply issues\"\nDetail: Drug supply issues", "metadata": {"result_id": 25388, "source_trial_id": "NCT02572453", "intervention_name": "Onalespib", "condition_name": "Recurrent Mantle Cell Lymphoma", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1494", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: defined green tea catechin extract\nCondition: Stage III Colon Cancer\nPhase: phase_2\nBlinding: DOUBLE\nEnrollment: 39\np-value: 0.1439\nInterpretation: definitive_negative", "metadata": {"result_id": 32819, "source_trial_id": "NCT01606124", "intervention_name": "defined green tea catechin extract", "condition_name": "Stage III Colon Cancer", "confidence_tier": "silver", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1495", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Proflavine Hemisulfate\nCondition: Anal Dysplasia\nPhase: early_phase_1\nEnrollment: 183\nTermination reason: \"Study is closed as the PI transferred to another institution.\"\nDetail: Study is closed as the PI transferred to another institution.", "metadata": {"result_id": 28972, "source_trial_id": "NCT01384240", "intervention_name": "Proflavine Hemisulfate", "condition_name": "Anal Dysplasia", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1496", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: DMSO Instillation\nCondition: Detrusor Hyperreflexia\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 25\nPrimary endpoint met: 1.0\np-value: 0.024\nSerious adverse events: 5.0\nInterpretation: definitive_negative", "metadata": {"result_id": 26387, "source_trial_id": "NCT00667095", "intervention_name": "DMSO Instillation", "condition_name": "Detrusor Hyperreflexia", "confidence_tier": "silver", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1497", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "hard", "context_text": "Drug: [15O]water\nCondition: Brain Cancer\nPhase: phase_1\nEnrollment: 2\nTermination reason: \"PI retired, study closed\"\nDetail: PI retired, study closed", "metadata": {"result_id": 13377, "source_trial_id": "NCT01246869", "intervention_name": "[15O]water", "condition_name": "Brain Cancer", "confidence_tier": "bronze", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL1-1498", "task": "CT-L1", "gold_answer": "E", "gold_category": "design", "difficulty": "hard", "context_text": "Drug: Flurbiprofen Axetil\nCondition: Surgery--Complications\nPhase: phase_4\nEnrollment: 126\nTermination reason: \"Protocol violation occurred frequently during the postoperative period.\"\nDetail: Protocol violation occurred frequently during the postoperative period.", "metadata": {"result_id": 6398, "source_trial_id": "NCT03200600", "intervention_name": "Flurbiprofen Axetil", "condition_name": "Surgery--Complications", "confidence_tier": "bronze", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL1-1499", "task": "CT-L1", "gold_answer": "E", "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Leflunomide\nCondition: Rheumatoid Arthritis\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 836\nPrimary endpoint met: 1.0\np-value: 0.0001\nEffect size (Weighted Difference): 20.4\n95% CI: [12.8, 27.9]\nSerious adverse events: 693.0\nInterpretation: definitive_negative", "metadata": {"result_id": 33187, "source_trial_id": "NCT00476996", "intervention_name": "Leflunomide", "condition_name": "Rheumatoid Arthritis", "confidence_tier": "silver", "therapeutic_area": "autoimmune"}, "split": "test"}